0000875320-23-000031.txt : 20231107 0000875320-23-000031.hdr.sgml : 20231107 20231107161657 ACCESSION NUMBER: 0000875320-23-000031 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 77 CONFORMED PERIOD OF REPORT: 20230930 FILED AS OF DATE: 20231107 DATE AS OF CHANGE: 20231107 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 231384166 BUSINESS ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6173416393 MAIL ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 10-Q 1 vrtx-20230930.htm 10-Q vrtx-20230930
VERTEX PHARMACEUTICALS INC / MA000087532012/312023Q3falseP1M25237065035035700008753202023-01-012023-09-3000008753202023-10-31xbrli:shares00008753202023-07-012023-09-30iso4217:USD00008753202022-07-012022-09-3000008753202022-01-012022-09-30iso4217:USDxbrli:shares00008753202023-09-3000008753202022-12-310000875320us-gaap:CommonStockMember2022-06-300000875320us-gaap:AdditionalPaidInCapitalMember2022-06-300000875320us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-300000875320us-gaap:RetainedEarningsMember2022-06-3000008753202022-06-300000875320us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-300000875320us-gaap:RetainedEarningsMember2022-07-012022-09-300000875320us-gaap:CommonStockMember2022-07-012022-09-300000875320us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300000875320us-gaap:CommonStockMember2022-09-300000875320us-gaap:AdditionalPaidInCapitalMember2022-09-300000875320us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-300000875320us-gaap:RetainedEarningsMember2022-09-3000008753202022-09-300000875320us-gaap:CommonStockMember2023-06-300000875320us-gaap:AdditionalPaidInCapitalMember2023-06-300000875320us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300000875320us-gaap:RetainedEarningsMember2023-06-3000008753202023-06-300000875320us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300000875320us-gaap:RetainedEarningsMember2023-07-012023-09-300000875320us-gaap:CommonStockMember2023-07-012023-09-300000875320us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300000875320us-gaap:CommonStockMember2023-09-300000875320us-gaap:AdditionalPaidInCapitalMember2023-09-300000875320us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300000875320us-gaap:RetainedEarningsMember2023-09-300000875320us-gaap:CommonStockMember2021-12-310000875320us-gaap:AdditionalPaidInCapitalMember2021-12-310000875320us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310000875320us-gaap:RetainedEarningsMember2021-12-3100008753202021-12-310000875320us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-09-300000875320us-gaap:RetainedEarningsMember2022-01-012022-09-300000875320us-gaap:CommonStockMember2022-01-012022-09-300000875320us-gaap:AdditionalPaidInCapitalMember2022-01-012022-09-300000875320us-gaap:CommonStockMember2022-12-310000875320us-gaap:AdditionalPaidInCapitalMember2022-12-310000875320us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310000875320us-gaap:RetainedEarningsMember2022-12-310000875320us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-09-300000875320us-gaap:RetainedEarningsMember2023-01-012023-09-300000875320us-gaap:CommonStockMember2023-01-012023-09-300000875320us-gaap:AdditionalPaidInCapitalMember2023-01-012023-09-30vrtx:segment0000875320vrtx:TRIKAFTAKAFTRIOMember2023-07-012023-09-300000875320vrtx:TRIKAFTAKAFTRIOMember2022-07-012022-09-300000875320vrtx:TRIKAFTAKAFTRIOMember2023-01-012023-09-300000875320vrtx:TRIKAFTAKAFTRIOMember2022-01-012022-09-300000875320vrtx:KalydecoMember2023-07-012023-09-300000875320vrtx:KalydecoMember2022-07-012022-09-300000875320vrtx:KalydecoMember2023-01-012023-09-300000875320vrtx:KalydecoMember2022-01-012022-09-300000875320vrtx:ORKAMBIMember2023-07-012023-09-300000875320vrtx:ORKAMBIMember2022-07-012022-09-300000875320vrtx:ORKAMBIMember2023-01-012023-09-300000875320vrtx:ORKAMBIMember2022-01-012022-09-300000875320vrtx:SYMDEKOSYMKEVIMember2023-07-012023-09-300000875320vrtx:SYMDEKOSYMKEVIMember2022-07-012022-09-300000875320vrtx:SYMDEKOSYMKEVIMember2023-01-012023-09-300000875320vrtx:SYMDEKOSYMKEVIMember2022-01-012022-09-300000875320country:US2023-07-012023-09-300000875320country:US2022-07-012022-09-300000875320country:US2023-01-012023-09-300000875320country:US2022-01-012022-09-300000875320srt:EuropeMember2023-07-012023-09-300000875320srt:EuropeMember2022-07-012022-09-300000875320srt:EuropeMember2023-01-012023-09-300000875320srt:EuropeMember2022-01-012022-09-300000875320vrtx:OtherNonU.S.Member2023-07-012023-09-300000875320vrtx:OtherNonU.S.Member2022-07-012022-09-300000875320vrtx:OtherNonU.S.Member2023-01-012023-09-300000875320vrtx:OtherNonU.S.Member2022-01-012022-09-300000875320us-gaap:NonUsMember2023-07-012023-09-300000875320us-gaap:NonUsMember2022-07-012022-09-300000875320us-gaap:NonUsMember2023-01-012023-09-300000875320us-gaap:NonUsMember2022-01-012022-09-300000875320vrtx:CRISPRTherapeuticsAGMember2019-01-012019-12-31vrtx:target0000875320vrtx:CRSIPRJDCAMember2021-01-012021-12-310000875320vrtx:CRSIPRJDCAMember2021-12-31xbrli:pure0000875320vrtx:CRISPRMembervrtx:CRSIPRJDCAMember2021-12-310000875320vrtx:CRSIPRJDCAMember2023-07-012023-09-300000875320vrtx:CRSIPRJDCAMember2022-07-012022-09-300000875320vrtx:CRSIPRJDCAMember2023-01-012023-09-300000875320vrtx:CRSIPRJDCAMember2022-01-012022-09-300000875320vrtx:CRISPRT1DMember2023-03-012023-03-310000875320vrtx:CRISPRT1DMember2023-07-012023-09-300000875320vrtx:CRISPRT1DMember2023-01-012023-09-300000875320vrtx:EntradaTherapeuticsMember2023-02-012023-02-280000875320vrtx:VerveMember2022-07-012022-07-310000875320vrtx:SepternaIncMember2023-09-012023-09-300000875320vrtx:CatalystBiosciencesMember2022-05-012022-05-310000875320us-gaap:EmployeeStockOptionMember2023-07-012023-09-300000875320us-gaap:EmployeeStockOptionMember2022-07-012022-09-300000875320us-gaap:EmployeeStockOptionMember2023-01-012023-09-300000875320us-gaap:EmployeeStockOptionMember2022-01-012022-09-300000875320us-gaap:RestrictedStockUnitsRSUMember2023-07-012023-09-300000875320us-gaap:RestrictedStockUnitsRSUMember2022-07-012022-09-300000875320us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-09-300000875320us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-09-300000875320us-gaap:EmployeeStockOptionMember2023-07-012023-09-300000875320us-gaap:EmployeeStockOptionMember2022-07-012022-09-300000875320us-gaap:EmployeeStockOptionMember2023-01-012023-09-300000875320us-gaap:EmployeeStockOptionMember2022-01-012022-09-300000875320us-gaap:RestrictedStockUnitsRSUMember2023-07-012023-09-300000875320us-gaap:RestrictedStockUnitsRSUMember2022-07-012022-09-300000875320us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-09-300000875320us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-09-300000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2023-09-300000875320us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2023-09-300000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2023-09-300000875320us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2023-09-300000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2022-12-310000875320us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2022-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2022-12-310000875320us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2022-12-310000875320us-gaap:BankTimeDepositsMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300000875320us-gaap:BankTimeDepositsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300000875320us-gaap:BankTimeDepositsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-09-300000875320us-gaap:BankTimeDepositsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300000875320us-gaap:BankTimeDepositsMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000875320us-gaap:BankTimeDepositsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000875320us-gaap:BankTimeDepositsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-12-310000875320us-gaap:BankTimeDepositsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2023-09-300000875320us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2023-09-300000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMember2023-09-300000875320us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2023-09-300000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2022-12-310000875320us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2022-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMember2022-12-310000875320us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2022-12-310000875320us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300000875320us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300000875320us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-09-300000875320us-gaap:FairValueInputsLevel3Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300000875320us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000875320us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000875320us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-12-310000875320us-gaap:FairValueInputsLevel3Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000875320us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300000875320us-gaap:FairValueInputsLevel1Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300000875320us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-09-300000875320us-gaap:FairValueInputsLevel3Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300000875320us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000875320us-gaap:FairValueInputsLevel1Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000875320us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-12-310000875320us-gaap:FairValueInputsLevel3Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:EquitySecuritiesMember2023-09-300000875320us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EquitySecuritiesMember2023-09-300000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel2Member2023-09-300000875320us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EquitySecuritiesMember2023-09-300000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:EquitySecuritiesMember2022-12-310000875320us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EquitySecuritiesMember2022-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel2Member2022-12-310000875320us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EquitySecuritiesMember2022-12-310000875320us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300000875320us-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300000875320us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-09-300000875320us-gaap:FairValueInputsLevel3Memberus-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300000875320us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000875320us-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000875320us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-12-310000875320us-gaap:FairValueInputsLevel3Memberus-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000875320us-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300000875320us-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300000875320us-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-09-300000875320us-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300000875320us-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000875320us-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000875320us-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-12-310000875320us-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMember2023-09-300000875320us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMember2023-09-300000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CertificatesOfDepositMember2023-09-300000875320us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMember2023-09-300000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMember2022-12-310000875320us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMember2022-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CertificatesOfDepositMember2022-12-310000875320us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMember2022-12-310000875320us-gaap:FairValueMeasurementsRecurringMember2023-09-300000875320us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-09-300000875320us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300000875320us-gaap:FairValueMeasurementsRecurringMember2022-12-310000875320us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-12-310000875320us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000875320us-gaap:EquitySecuritiesMember2023-09-300000875320us-gaap:FairValueInputsLevel3Member2023-09-300000875320us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountRateMembersrt:MinimumMember2023-09-300000875320srt:MaximumMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountRateMember2023-09-300000875320us-gaap:MoneyMarketFundsMember2023-09-300000875320us-gaap:MoneyMarketFundsMember2022-12-310000875320us-gaap:BankTimeDepositsMember2023-09-300000875320us-gaap:BankTimeDepositsMember2022-12-310000875320us-gaap:USTreasurySecuritiesMember2023-09-300000875320us-gaap:USTreasurySecuritiesMember2022-12-310000875320us-gaap:CorporateDebtSecuritiesMember2023-09-300000875320us-gaap:CorporateDebtSecuritiesMember2022-12-310000875320us-gaap:CommercialPaperMember2023-09-300000875320us-gaap:CommercialPaperMember2022-12-310000875320us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember2023-09-300000875320us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember2022-12-310000875320us-gaap:AssetBackedSecuritiesMember2023-09-300000875320us-gaap:AssetBackedSecuritiesMember2022-12-310000875320us-gaap:CertificatesOfDepositMember2023-09-300000875320us-gaap:CertificatesOfDepositMember2022-12-310000875320us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember2023-09-300000875320us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember2022-12-310000875320vrtx:MarketableSecuritiesAndOtherNoncurrentAssetsMember2023-09-300000875320vrtx:MarketableSecuritiesAndOtherNoncurrentAssetsMember2022-12-3100008753202022-01-012022-12-310000875320us-gaap:CashAndCashEquivalentsMember2023-09-300000875320us-gaap:CashAndCashEquivalentsMember2022-12-310000875320vrtx:MarketableSecuritiesMember2023-09-300000875320vrtx:MarketableSecuritiesMember2022-12-310000875320vrtx:MarketableSecuritiesNoncurrentMember2023-09-300000875320vrtx:MarketableSecuritiesNoncurrentMember2022-12-310000875320vrtx:PubliclyTradedCompaniesSaleMember2023-01-012023-09-300000875320vrtx:PubliclyTradedCompaniesSaleMember2023-09-300000875320vrtx:PubliclyTradedCompaniesSaleMember2022-01-012022-09-300000875320us-gaap:OtherAssetsMember2023-09-300000875320us-gaap:AccumulatedTranslationAdjustmentMember2022-12-310000875320us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-12-310000875320us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-12-310000875320us-gaap:AccumulatedTranslationAdjustmentMember2023-01-012023-09-300000875320us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-01-012023-09-300000875320us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-01-012023-09-300000875320us-gaap:AccumulatedTranslationAdjustmentMember2023-09-300000875320us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-09-300000875320us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-09-300000875320us-gaap:AccumulatedTranslationAdjustmentMember2021-12-310000875320us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-12-310000875320us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-12-310000875320us-gaap:AccumulatedTranslationAdjustmentMember2022-01-012022-09-300000875320us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-01-012022-09-300000875320us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-01-012022-09-300000875320us-gaap:AccumulatedTranslationAdjustmentMember2022-09-300000875320us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-09-300000875320us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-09-300000875320us-gaap:CashFlowHedgingMembersrt:MinimumMemberus-gaap:ForeignExchangeForwardMember2023-01-012023-09-300000875320srt:MaximumMemberus-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMember2023-01-012023-09-300000875320currency:EURus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMember2023-09-300000875320currency:EURus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMember2022-12-310000875320us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMembercurrency:CADus-gaap:ForeignExchangeForwardMember2023-09-300000875320us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMembercurrency:CADus-gaap:ForeignExchangeForwardMember2022-12-310000875320currency:GBPus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMember2023-09-300000875320currency:GBPus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMember2022-12-310000875320currency:AUDus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMember2023-09-300000875320currency:AUDus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMember2022-12-310000875320us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMembercurrency:CHF2023-09-300000875320us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMembercurrency:CHF2022-12-310000875320us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMember2023-09-300000875320us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMember2022-12-310000875320us-gaap:NondesignatedMemberus-gaap:ForeignExchangeForwardMember2023-01-012023-09-300000875320us-gaap:NondesignatedMemberus-gaap:ForeignExchangeForwardMember2023-09-300000875320us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedTranslationAdjustmentMemberus-gaap:ForeignExchangeForwardMember2023-07-012023-09-300000875320us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedTranslationAdjustmentMemberus-gaap:ForeignExchangeForwardMember2022-07-012022-09-300000875320us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedTranslationAdjustmentMemberus-gaap:ForeignExchangeForwardMember2023-01-012023-09-300000875320us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedTranslationAdjustmentMemberus-gaap:ForeignExchangeForwardMember2022-01-012022-09-300000875320us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:NondesignatedMemberus-gaap:AccumulatedTranslationAdjustmentMemberus-gaap:ForeignExchangeForwardMember2023-07-012023-09-300000875320us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:NondesignatedMemberus-gaap:AccumulatedTranslationAdjustmentMemberus-gaap:ForeignExchangeForwardMember2022-07-012022-09-300000875320us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:NondesignatedMemberus-gaap:AccumulatedTranslationAdjustmentMemberus-gaap:ForeignExchangeForwardMember2023-01-012023-09-300000875320us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:NondesignatedMemberus-gaap:AccumulatedTranslationAdjustmentMemberus-gaap:ForeignExchangeForwardMember2022-01-012022-09-300000875320us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:ForeignExchangeForwardMember2023-09-300000875320us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMemberus-gaap:OtherCurrentLiabilitiesMember2023-09-300000875320us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMemberus-gaap:OtherAssetsMemberus-gaap:ForeignExchangeForwardMember2023-09-300000875320us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMemberus-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:ForeignExchangeForwardMember2023-09-300000875320us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:ForeignExchangeForwardMember2022-12-310000875320us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMemberus-gaap:OtherCurrentLiabilitiesMember2022-12-310000875320us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMemberus-gaap:OtherAssetsMemberus-gaap:ForeignExchangeForwardMember2022-12-310000875320us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMemberus-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:ForeignExchangeForwardMember2022-12-310000875320us-gaap:RestrictedStockMember2023-07-012023-09-300000875320us-gaap:RestrictedStockMember2022-07-012022-09-300000875320us-gaap:RestrictedStockMember2023-01-012023-09-300000875320us-gaap:RestrictedStockMember2022-01-012022-09-300000875320us-gaap:EmployeeStockMember2023-07-012023-09-300000875320us-gaap:EmployeeStockMember2022-07-012022-09-300000875320us-gaap:EmployeeStockMember2023-01-012023-09-300000875320us-gaap:EmployeeStockMember2022-01-012022-09-300000875320us-gaap:CostOfSalesMember2023-07-012023-09-300000875320us-gaap:CostOfSalesMember2022-07-012022-09-300000875320us-gaap:CostOfSalesMember2023-01-012023-09-300000875320us-gaap:CostOfSalesMember2022-01-012022-09-300000875320us-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300000875320us-gaap:ResearchAndDevelopmentExpenseMember2022-07-012022-09-300000875320us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-300000875320us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-09-300000875320us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-07-012023-09-300000875320us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-07-012022-09-300000875320us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-09-300000875320us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-09-3000008753202023-02-280000875320us-gaap:RevolvingCreditFacilityMember2022-07-310000875320us-gaap:LetterOfCreditMember2022-07-310000875320us-gaap:RevolvingCreditFacilityMembersrt:MinimumMemberus-gaap:BaseRateMember2022-07-012022-07-310000875320us-gaap:RevolvingCreditFacilityMembersrt:MaximumMemberus-gaap:BaseRateMember2022-07-012022-07-310000875320srt:MinimumMembervrtx:SecuredOvernightFinancingRateSOFRMember2022-07-012022-07-310000875320srt:MaximumMembervrtx:SecuredOvernightFinancingRateSOFRMember2022-07-012022-07-310000875320us-gaap:RevolvingCreditFacilityMember2022-07-012022-07-310000875320vrtx:EMorrowMorreyAtkinsonIIIMember2023-07-012023-09-300000875320vrtx:EMorrowMorreyAtkinsonIIIMember2023-09-300000875320vrtx:ReshmaKewalramaniMember2023-07-012023-09-300000875320vrtx:ReshmaKewalramaniMember2023-09-300000875320vrtx:JeffreyMLeidenMember2023-07-012023-09-300000875320vrtx:JeffreyMLeidenMember2023-09-300000875320vrtx:BastianoSannaMember2023-07-012023-09-300000875320vrtx:BastianoSannaMember2023-09-300000875320vrtx:CharlesFWagnerJrMember2023-07-012023-09-300000875320vrtx:CharlesFWagnerJrMember2023-09-30
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
________________________________________________________
FORM 10-Q
☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2023
or
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD FROM    TO   
Commission file number 000-19319
____________________________________________
Vertex Pharmaceuticals Incorporated
(Exact name of registrant as specified in its charter)

Massachusetts
(State or other jurisdiction of incorporation or organization)

50 Northern Avenue, Boston, Massachusetts
(Address of principal executive offices)

04-3039129
(I.R.S. Employer Identification No.)

02210
(Zip Code)

Registrant’s telephone number, including area code (617) 341-6100
____________________________________________
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol
Name of each exchange on which registered
Common Stock, $0.01 Par Value Per Share
VRTX
The Nasdaq Global Select Market
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer ☒ Accelerated filer ☐ Non-accelerated filer ☐ Smaller reporting company ☐ Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒ 
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.
Common Stock, par value $0.01 per share
257,683,184
Outstanding at October 31, 2023

VERTEX PHARMACEUTICALS INCORPORATED
FORM 10-Q
FOR THE QUARTER ENDED SEPTEMBER 30, 2023

TABLE OF CONTENTS
Page
Condensed Consolidated Statements of Income - Three and Nine Months Ended September 30, 2023 and 2022
Condensed Consolidated Statements of Comprehensive Income - Three and Nine Months Ended September 30, 2023 and 2022
Condensed Consolidated Balance Sheets - September 30, 2023 and December 31, 2022
Condensed Consolidated Statements of Shareholders' Equity - Three and Nine Months Ended September 30, 2023 and 2022
Condensed Consolidated Statements of Cash Flows - Nine Months Ended September 30, 2023 and 2022
Item 1A.

“Vertex,” “we,” “us,” and “our” as used in this Quarterly Report on Form 10-Q refer to Vertex Pharmaceuticals Incorporated, a Massachusetts corporation, and its subsidiaries.
“Vertex®,” “KALYDECO®,” “ORKAMBI®,” “SYMDEKO®,” “SYMKEVI®,” “TRIKAFTA®” and “KAFTRIO®” are registered trademarks of Vertex. Other brands, names and trademarks contained in this Quarterly Report on Form 10-Q are the property of their respective owners.
We use the brand name for our products when we refer to the product that has been approved and with respect to the indications on the approved label. Otherwise, including in discussions of our development programs, we refer to our compounds by their scientific (or generic) name or VX developmental designation.


Part I. Financial Information

Item 1.  Financial Statements
VERTEX PHARMACEUTICALS INCORPORATED
Condensed Consolidated Statements of Income
(in millions, except per share amounts)(unaudited)

Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Product revenues, net$2,483.5 $2,334.3 $7,351.5 $6,628.0 
Costs and expenses:
Cost of sales318.7 289.4 894.2 797.0 
Research and development expenses810.0 645.0 2,338.3 1,846.2 
Acquired in-process research and development expenses51.7 29.0 509.3 92.9 
Selling, general and administrative expenses263.8 246.8 767.5 677.3 
Change in fair value of contingent consideration1.2 (2.6)(1.3)(59.3)
Total costs and expenses1,445.4 1,207.6 4,508.0 3,354.1 
Income from operations1,038.1 1,126.7 2,843.5 3,273.9 
Interest income167.9 46.2 435.2 58.6 
Interest expense(10.9)(13.7)(33.5)(43.2)
Other (expense) income, net(15.9)17.2 (13.0)(133.7)
Income before provision for income taxes1,179.2 1,176.4 3,232.2 3,155.6 
Provision for income taxes143.9 245.9 581.4 652.5 
Net income$1,035.3 $930.5 $2,650.8 $2,503.1 
Net income per common share:
Basic$4.01 $3.63 $10.29 $9.78 
Diluted$3.97 $3.59 $10.18 $9.68 
Shares used in per share calculations:
Basic258.0 256.5 257.7 255.8 
Diluted260.6 259.5 260.4 258.7 
The accompanying notes are an integral part of these condensed consolidated financial statements.

2
VERTEX PHARMACEUTICALS INCORPORATED
Condensed Consolidated Statements of Comprehensive Income
(in millions)(unaudited)
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Net income$1,035.3 $930.5 $2,650.8 $2,503.1 
Other comprehensive income (loss):
Unrealized holding losses on marketable securities, net of tax of $1.7, zero, $5.2 and zero, respectively
(6.2)(0.6)(18.8)(3.6)
Unrealized gains on foreign currency forward contracts, net of tax of $(13.2), $(16.0), $(1.6) and $(34.3), respectively
48.0 58.8 5.9 128.1 
Foreign currency translation adjustment(5.0)(18.1)9.1 (42.8)
Total other comprehensive income (loss)
36.8 40.1 (3.8)81.7 
Comprehensive income$1,072.1 $970.6 $2,647.0 $2,584.8 
The accompanying notes are an integral part of these condensed consolidated financial statements.

3
VERTEX PHARMACEUTICALS INCORPORATED
Condensed Consolidated Balance Sheets
(in millions, except share data)(unaudited)
September 30, 2023December 31, 2022
Assets
Current assets:
Cash and cash equivalents$11,110.2 $10,504.0 
Marketable securities818.0 274.5 
Accounts receivable, net1,538.7 1,442.2 
Inventories688.7 460.6 
Prepaid expenses and other current assets
540.2 553.5 
Total current assets
14,695.8 13,234.8 
Property and equipment, net1,124.0 1,108.4 
Goodwill1,088.0 1,088.0 
Intangible assets
603.6 603.6 
Deferred tax assets
1,729.1 1,246.9 
Operating lease assets
310.5 347.4 
Long-term marketable securities1,700.0 112.2 
Other assets
475.2 409.6 
Total assets
$21,726.2 $18,150.9 
Liabilities and Shareholders’ Equity
Current liabilities:
Accounts payable$375.9 $303.9 
Accrued expenses2,907.3 2,126.7 
Other current liabilities
316.2 311.5 
Total current liabilities
3,599.4 2,742.1 
Long-term finance lease liabilities390.3 430.8 
Long-term operating lease liabilities354.4 379.5 
Other long-term liabilities
869.3 685.8 
Total liabilities
5,213.4 4,238.2 
Commitments and contingencies— — 
Shareholders’ equity:
Preferred stock, $0.01 par value; 1,000,000 shares authorized; none issued and outstanding
— — 
Common stock, $0.01 par value; 500,000,000 shares authorized, 257,828,508 and 257,011,628 shares issued and outstanding, respectively
2.6 2.6 
Additional paid-in capital7,339.6 7,386.5 
Accumulated other comprehensive (loss) income(3.0)0.8 
Retained earnings
9,173.6 6,522.8 
Total shareholders’ equity
16,512.8 13,912.7 
Total liabilities and shareholders’ equity
$21,726.2 $18,150.9 
The accompanying notes are an integral part of these condensed consolidated financial statements.

4
VERTEX PHARMACEUTICALS INCORPORATED
Condensed Consolidated Statements of Shareholders’ Equity
(in millions)(unaudited)
Three Months Ended
Common StockAdditional Paid-in CapitalAccumulated Other Comprehensive Income (Loss)Retained EarningsTotal Shareholders’ Equity
SharesAmount
Balance at June 30, 2022256.0 $2.6 $7,100.0 $57.5 $4,773.4 $11,933.5 
Other comprehensive income, net of tax— — — 40.1 — 40.1 
Net income— — — — 930.5 930.5 
Common stock withheld for employee tax obligations(0.2)(0.0)(48.0)— — (48.0)
Issuance of common stock under benefit plans0.8 0.0 38.2 — — 38.2 
Stock-based compensation expense
— — 135.3 — — 135.3 
Balance at September 30, 2022256.6 $2.6 $7,225.5 $97.6 $5,703.9 $13,029.6 
Balance at June 30, 2023257.8 $2.6 $7,369.1 $(39.8)$8,138.3 $15,470.2 
Other comprehensive income, net of tax— — — 36.8 — 36.8 
Net income— — — — 1,035.3 1,035.3 
Repurchase of common stock(0.4)(0.0)(123.0)— — (123.0)
Common stock withheld for employee tax obligations(0.1)(0.0)(53.2)— — (53.2)
Issuance of common stock under benefit plans0.5 0.0 15.0 — — 15.0 
Stock-based compensation expense
— — 131.7 — — 131.7 
Balance at September 30, 2023257.8 $2.6 $7,339.6 $(3.0)$9,173.6 $16,512.8 
Nine Months Ended
Common StockAdditional Paid-in CapitalAccumulated Other Comprehensive Income (Loss)Retained EarningsTotal Shareholders’ Equity
SharesAmount
Balance at December 31, 2021254.5 $2.5 $6,880.8 $15.9 $3,200.8 $10,100.0 
Other comprehensive income, net of tax— — — 81.7 — 81.7 
Net income
— — — — 2,503.1 2,503.1 
Common stock withheld for employee tax obligations(0.7)(0.0)(169.9)— — (169.9)
Issuance of common stock under benefit plans2.8 0.1 135.2 — — 135.3 
Stock-based compensation expense
— — 379.4 — — 379.4 
Balance at September 30, 2022256.6 $2.6 $7,225.5 $97.6 $5,703.9 $13,029.6 
Balance at December 31, 2022257.0 $2.6 $7,386.5 $0.8 $6,522.8 $13,912.7 
Other comprehensive loss, net of tax— — — (3.8)— (3.8)
Net income
— — — — 2,650.8 2,650.8 
Repurchase of common stock(0.9)(0.0)(284.1)— — (284.1)
Common stock withheld for employee tax obligations(0.7)(0.0)(222.9)— — (222.9)
Issuance of common stock under benefit plans2.4 0.0 85.7 — — 85.7 
Stock-based compensation expense
— — 374.4 — — 374.4 
Balance at September 30, 2023257.8 $2.6 $7,339.6 $(3.0)$9,173.6 $16,512.8 
The accompanying notes are an integral part of these condensed consolidated financial statements.

5
VERTEX PHARMACEUTICALS INCORPORATED
Condensed Consolidated Statements of Cash Flows
(in millions)(unaudited)
Nine Months Ended September 30,
20232022
Cash flows from operating activities:
Net income
$2,650.8 $2,503.1 
Adjustments to reconcile net income to net cash provided by operating activities:
Stock-based compensation expense372.6 379.8 
Depreciation expense122.3 109.9 
Deferred income taxes(405.5)(424.0)
Losses on equity securities0.2 143.1 
Decrease in fair value of contingent consideration(1.3)(59.3)
Other non-cash items, net(9.6)(32.8)
Changes in operating assets and liabilities:
Accounts receivable, net(99.5)(368.8)
Inventories(252.9)(58.1)
Prepaid expenses and other assets(94.4)(41.9)
Accounts payable80.5 (39.1)
Accrued expenses786.1 980.3 
Other liabilities153.4 (40.7)
Net cash provided by operating activities
3,302.7 3,051.5 
Cash flows from investing activities:
Purchases of available-for-sale debt securities(2,798.0)(417.8)
Sales and maturities of available-for-sale debt securities621.0 435.9 
Purchases of property and equipment(142.3)(171.1)
Sale of equity securities95.1 — 
Investment in equity securities and notes receivable(31.0)(47.8)
Payment to acquire ViaCyte, Inc., net of cash acquired— (295.9)
Net cash used in investing activities
(2,255.2)(496.7)
Cash flows from financing activities:
Issuances of common stock under benefit plans88.2 134.7 
Repurchases of common stock
(278.1)— 
Payments in connection with common stock withheld for employee tax obligations
(222.9)(169.9)
Payments on finance leases
(32.9)(75.1)
Other financing activities3.3 2.4 
Net cash used in financing activities
(442.4)(107.9)
Effect of changes in exchange rates on cash
(0.5)(70.0)
Net increase in cash, cash equivalents and restricted cash604.6 2,376.9 
Cash, cash equivalents and restricted cash—beginning of period
10,512.0 6,800.1 
Cash, cash equivalents and restricted cash—end of period
$11,116.6 $9,177.0 
Supplemental disclosure of cash flow information:
Cash paid for income taxes
$919.1 $840.1 
Cash paid for interest
$32.6 $41.1 
The accompanying notes are an integral part of these condensed consolidated financial statements.
6
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)

A.Basis of Presentation and Accounting Policies
Basis of Presentation
The accompanying condensed consolidated financial statements are unaudited and have been prepared by Vertex Pharmaceuticals Incorporated (“Vertex,” “we,” “us” or “our”) in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).
The condensed consolidated financial statements reflect the operations of Vertex and our wholly-owned subsidiaries. All material intercompany balances and transactions have been eliminated. We have reclassified certain items from the prior year’s condensed consolidated balance sheet to conform to the current year’s presentation. We operate in one segment, pharmaceuticals.
Certain information and footnote disclosures normally included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 (the “2022 Annual Report on Form 10-K”) have been condensed or omitted. These interim financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the financial position and results of income for the interim periods ended September 30, 2023 and 2022.
The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full fiscal year. These interim financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2022, which are contained in our 2022 Annual Report on Form 10-K.
Use of Estimates
The preparation of condensed consolidated financial statements in accordance with U.S. GAAP requires us to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of our condensed consolidated financial statements, and the amounts of revenues and expenses during the reported periods. We base our estimates on historical experience and various other assumptions, including in certain circumstances future projections that we believe to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.
Recently Adopted and Issued Accounting Standards
For a discussion of recently adopted accounting pronouncements please refer to Note A, “Nature of Business and Accounting Policies,” in our 2022 Annual Report on Form 10-K. We do not expect any recently issued accounting standards to have a significant impact on our condensed consolidated financial statements.
Summary of Significant Accounting Policies
Our significant accounting policies are described in Note A, “Nature of Business and Accounting Policies,” in our 2022 Annual Report on Form 10-K.


7
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)
B.Revenue Recognition
Disaggregation of Revenue
Revenues by Product
“Product revenues, net” consisted of the following:
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
(in millions)
TRIKAFTA/KAFTRIO$2,274.3 $2,010.5 $6,611.4 $5,665.3 
KALYDECO112.8 139.4 363.1 417.1 
ORKAMBI63.0 146.2 281.8 399.9 
SYMDEKO/SYMKEVI33.4 38.2 95.2 145.7 
Total product revenues, net$2,483.5 $2,334.3 $7,351.5 $6,628.0 
Product Revenues by Geographic Location
“Product revenues, net” by geographic region, based on the location of the customer, consisted of the following:
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
(in millions)
United States$1,554.2 $1,455.6 $4,465.8 $4,238.9 
Outside of the United States
Europe766.5 730.5 2,373.7 2,018.3 
Other
162.8 148.2 512.0 370.8 
Total product revenues outside of the United States929.3 878.7 2,885.7 2,389.1 
Total product revenues, net
$2,483.5 $2,334.3 $7,351.5 $6,628.0 
Contract Liabilities
We had contract liabilities of $157.1 million and $159.6 million as of September 30, 2023 and December 31, 2022, respectively, related to annual contracts with government-owned and supported customers in international markets that limit the amount of annual reimbursement we can receive. Upon exceeding the annual reimbursement amount, products are provided free of charge, which is a material right. These contracts include upfront payments and fees. We defer a portion of the consideration received for shipments made up to the annual reimbursement limit as a portion of “Other current liabilities.” The deferred amount is recognized as revenue when the free products are shipped. Our product revenue contracts include performance obligations that are one year or less.
Our contract liabilities at the end of each fiscal year relate to contracts with annual reimbursement limits in international markets in which the annual period associated with the contract is not the same as our fiscal year. In these markets, we recognize revenues related to performance obligations satisfied in previous years; however, these revenues do not relate to any performance obligations that were satisfied more than 12 months prior to the beginning of the current year.


8
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)
C.Acquired In-Process Research and Development and Other Arrangements
We have entered into numerous agreements with third parties to collaborate on research, development and commercialization programs, license technologies, or acquire assets. Our “Acquired in-process research and development expenses” included $51.7 million and $509.3 million for the three and nine months ended September 30, 2023, respectively, and $29.0 million and $92.9 million, for the three and nine months ended September 30, 2022, respectively, related to upfront, contingent milestone, or other payments pursuant to our business development transactions, including collaborations, licenses of third-party technologies, and asset acquisitions that qualify as in-process research and development.
Our collaboration, licensing and asset acquisition agreements that had a significant impact on our financial statements for the three and nine months ended September 30, 2023 and 2022, or were new or materially revised during the three and nine months ended September 30, 2023, are described below. Additional agreements were described in Note B, “Acquired In-Process Research and Development and Other Arrangements,” of our 2022 Annual Report on Form 10-K.
In-license Agreements
We have entered into several in-license agreements to advance and obtain access to technologies and services related to our research and early-development activities. We are generally required to make an upfront payment upon execution of our license agreements; development, regulatory and commercialization milestones payments upon the achievement of certain product research, development and commercialization objectives; and royalty payments on future sales, if any, of commercial products resulting from our collaborations.
Pursuant to the terms of our in-license agreements, our collaborators typically lead the discovery efforts and we lead all preclinical, development and commercialization activities associated with the advancement of any product candidates and fund all expenses.
We typically can terminate our in-license agreements by providing advance notice to our collaborators. Our license agreements may be terminated by either party for a material breach by the other, subject to notice and cure provisions. Unless earlier terminated, these license agreements generally remain in effect until the date on which the royalty term and all payment obligations with respect to all products in all countries have expired.
CRISPR Therapeutics AG
CRISPR-Cas9 Gene-editing Therapies Agreements
In 2015, we entered into a strategic collaboration, option, and license agreement (the “CRISPR Agreement”) with CRISPR Therapeutics AG and its affiliates (“CRISPR”) to collaborate on the discovery and development of potential new treatments aimed at the underlying genetic causes of human diseases using CRISPR-Cas9 gene-editing technology. We had the exclusive right to license certain targets. In 2019, we elected to exclusively license three targets, including cystic fibrosis, pursuant to the CRISPR Agreement. For each of the three targets that we elected to license, CRISPR has the potential to receive up to an additional $410.0 million in development, regulatory and commercial milestones as well as royalties on resulting net product sales.
In 2017, we entered into a joint development and commercialization agreement with CRISPR (the “CRISPR JDCA”), which we amended and restated in 2021, pursuant to the terms of the CRISPR Agreement. Under the CRISPR JDCA, we and CRISPR are co-developing and preparing to co-commercialize exagamglogene autotemcel (“exa-cel”), for the treatment of hemoglobinopathies, including treatments for sickle cell disease and transfusion-dependent beta thalassemia. Pursuant to the CRISPR JDCA, we lead global development, manufacturing, and commercialization of exa-cel, with support from CRISPR. We also conduct all research, development, manufacturing, and commercialization activities relating to other product candidates and products under the CRISPR JDCA throughout the world subject to CRISPR’s reserved right to conduct certain activities.
In connection with the CRISPR JDCA, CRISPR has the potential to receive a one-time $200.0 million milestone payment upon receipt of the first marketing approval of exa-cel from the U.S. Food and Drug Administration or the European Commission.
We account for the CRISPR JDCA as a cost-sharing arrangement, with costs incurred related to exa-cel allocated 60% to us and 40% to CRISPR, subject to certain adjustments. We recognized the net impact of the CRISPR JDCA as “Research and

9
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)
development expenses” of $74.9 million and $45.5 million during the three months ended September 30, 2023 and 2022, respectively, and $193.2 million and $120.6 million during the nine months ended September 30, 2023 and 2022, respectively; and as “Selling, general and administrative expenses” of $26.0 million and $13.5 million during the three months ended September 30, 2023 and 2022, respectively, and $66.1 million and $35.3 million during the nine months ended September 30, 2023 and 2022, respectively.
In March 2023, we entered into a non-exclusive license agreement (“the CRISPR T1D Agreement”) for the use of CRISPR’s CRISPR-Cas9 gene-editing technology to accelerate the development of our hypoimmune cell therapies for type 1 diabetes. Pursuant to the CRISPR T1D Agreement, we made a $100.0 million upfront payment to CRISPR. In the second quarter of 2023, we achieved a research milestone that resulted in a $70.0 million payment to CRISPR in the third quarter of 2023. CRISPR is eligible to receive up to an additional $160.0 million in research, development, regulatory and commercial milestones for any products that may result from the agreement, as well as royalties on resulting net product sales. We determined that substantially all the fair value of the collaboration agreement was attributable to in-process research and development and no substantive processes were acquired that would constitute a business. We concluded that there is no alternative future use for the acquired in-process research and development and recorded the upfront payment and the research milestone to “Acquired in-process research and development expenses” in the first and second quarters of 2023, respectively, resulting in $170.0 million of “Acquired in-process research and development expenses” in the nine months ended September 30, 2023.
Entrada Therapeutics, Inc.
In February 2023, we closed a strategic collaboration and license agreement (the “Entrada Agreement”) with Entrada Therapeutics, Inc. (“Entrada”) focused on discovering and developing intracellular Endosomal Escape Vehicle (EEV) therapeutics for myotonic dystrophy type 1 (“DM1”). Upon closing, we made an upfront payment of $225.1 million to Entrada, and purchased $24.9 million of Entrada’s common stock in connection with the Entrada Agreement. Entrada is eligible to receive up to an additional $485.0 million in research, development, regulatory and commercial milestones for any products that may result from the Entrada Agreement, as well as royalties on resulting net product sales. We determined that substantially all the fair value of the collaboration agreement was attributable to in-process research and development and no substantive processes were acquired that would constitute a business. We concluded that there is no alternative future use for the acquired in-process research and development and recorded the upfront payment to “Acquired in-process research and development expenses” in the first quarter of 2023. The investment in Entrada’s common stock is recorded at fair value on our condensed consolidated balance sheet within “Marketable securities.”
Verve Therapeutics, Inc.
In July 2022, we entered into a research collaboration with Verve Therapeutics, Inc. (“Verve”) focused on discovering and developing an in vivo gene-editing program for a liver disease. Under the terms of the agreement, we made a $25.0 million upfront payment to Verve and purchased $35.0 million of Verve’s common stock. We concluded that there is no alternative future use for the acquired in-process research and development and recorded the upfront payment to “Acquired in-process research and development expenses.” The investment in Verve’s common stock is recorded at fair value on our condensed consolidated balance sheet within “Marketable securities.”
Asset Acquisitions
Septerna, Inc. - Novel G Protein-coupled Receptor Program
In September 2023, pursuant to an asset purchase agreement, we acquired a novel G protein-coupled receptor (“GPCR”) program from Septerna, Inc. We determined that substantially all the fair value acquired is concentrated in the GPCR in-process research and development asset, which does not constitute a business, and for which we determined there is no alternative future use. As a result, we recorded $47.5 million to “Acquired in-process research and development expenses” in the three and nine months ended September 30, 2023.
Catalyst Biosciences, Inc. - Complement 3 Degrader Program
In May 2022, pursuant to an asset purchase agreement, we acquired Catalyst Biosciences, Inc.’s portfolio of protease medicines that target the complement system (the “complement portfolio”) and related intellectual property, including CB 2782-PEG, which is a pre-clinical complement component 3 degrader program for geographic atrophy in dry age-related macular degeneration. We determined that substantially all the fair value acquired is concentrated in the CB-2782 PEG in-

10
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)
process research and development assets, which do not constitute a business, and for which we determined there is no alternative future use. As a result, we recorded our $60.0 million upfront payment to “Acquired in-process research and development expenses” in the three and nine months ended September 30, 2022.
Cystic Fibrosis Foundation
In 2004, we entered into a collaboration agreement with the Cystic Fibrosis Foundation, as successor in interest to the Cystic Fibrosis Foundation Therapeutics, Inc., to support research and development activities. Pursuant to the collaboration agreement, as amended, we have agreed to pay tiered royalties ranging from single digits to sub-teens on covered compounds first synthesized and/or tested during a research term on or before February 28, 2014, including ivacaftor, lumacaftor and tezacaftor and royalties ranging from low-single digits to mid-single digits on potential net sales of certain compounds first synthesized and/or tested between March 1, 2014 and August 31, 2016, including elexacaftor. We do not have any royalty obligations on compounds first synthesized and tested on or after September 1, 2016. For combination products, such as ORKAMBI, SYMDEKO/SYMKEVI and TRIKAFTA/KAFTRIO, sales are allocated equally to each of the active pharmaceutical ingredients in the combination product. We record expenses related to these royalty obligations to “Cost of sales.”

D.Earnings Per Share
The following table sets forth the computation of basic and diluted net income per common share for the periods ended:
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
(in millions, except per share amounts)
Net income$1,035.3 $930.5 $2,650.8 $2,503.1 
Basic weighted-average common shares outstanding258.0 256.5 257.7 255.8 
Effect of potentially dilutive securities:
Stock options1.2 1.4 1.2 1.4 
Restricted stock units (including PSUs)
1.4 1.6 1.5 1.4 
Employee stock purchase program
0.0 0.0 0.0 0.1 
Diluted weighted-average common shares outstanding260.6 259.5 260.4 258.7 
Basic net income per common share$4.01 $3.63 $10.29 $9.78 
Diluted net income per common share$3.97 $3.59 $10.18 $9.68 
We did not include the securities in the following table in the computation of the diluted net income per common share because the effect would have been anti-dilutive during each period:
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
(in millions)
Stock options— — 0.0 0.0 
Unvested restricted stock units (including PSUs)— 0.0 0.2 0.2 


11
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)
E.Fair Value Measurements
The following fair value hierarchy is used to classify assets and liabilities based on observable inputs and unobservable inputs used in order to determine the fair value of our financial assets and liabilities:
Level 1:
Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.
Level 2:
Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.
Level 3:
Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability.
Our investment strategy is focused on capital preservation. We invest in instruments that meet the credit quality standards outlined in our investment policy, which also limits the amount of credit exposure to any one issue or type of instrument. We maintain strategic equity investments separately from the investment policy that governs our other cash, cash equivalents and marketable securities as described in Note F, “Marketable Securities and Equity Investments.” Additionally, we utilize foreign currency forward contracts intended to mitigate the effect of changes in foreign exchange rates on our condensed consolidated statement of income.

12
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)
The following tables set forth our financial assets and liabilities subject to fair value measurements by level within the fair value hierarchy (and does not include $5.5 billion and $3.1 billion of cash as of September 30, 2023 and December 31, 2022, respectively):
As of September 30, 2023As of December 31, 2022
Total
Level 1
Level 2
Level 3
Total
Level 1
Level 2
Level 3
(in millions)
Financial instruments carried at fair value (asset positions):
Cash equivalents:
Money market funds$3,753.4 $3,753.4 $— $— $5,162.6 $5,162.6 $— $— 
Time deposits1,550.0 — 1,550.0 — 2,000.0 — 2,000.0 — 
U.S. Treasury securities236.8 236.8 — — — — — — 
Corporate debt securities— — — — 5.8 — 5.8 — 
Commercial paper96.5 — 96.5 — 204.5 — 204.5 — 
Marketable securities:
Corporate equity securities46.4 46.4 — — 116.8 88.8 28.0 — 
U.S. Treasury securities408.2 408.2 — — — — — — 
Government-sponsored enterprise securities421.0 421.0 — — 127.1 127.1 — — 
Asset-backed securities237.8 — 237.8 — — — — — 
Certificates of deposit31.7 — 31.7 — — — — — 
Corporate debt securities1,214.2 — 1,214.2 — 87.0 — 87.0 — 
Commercial paper158.7 — 158.7 — 55.8 — 55.8 — 
Prepaid expenses and other current assets:
Foreign currency forward contracts37.8 — 37.8 — 47.5 — 47.5 — 
Other assets:
Foreign currency forward contracts3.4 — 3.4 — 0.8 — 0.8 — 
Total financial assets
$8,195.9 $4,865.8 $3,330.1 $— $7,807.9 $5,378.5 $2,429.4 $— 
Financial instruments carried at fair value (liability positions):
Other current liabilities:
Foreign currency forward contracts
$(0.7)$— $(0.7)$— $(14.3)$— $(14.3)$— 
Contingent consideration(15.0)— — (15.0)(14.6)— — (14.6)
Other long-term liabilities:
Foreign currency forward contracts— — — — (0.9)— (0.9)— 
Contingent consideration(112.7)— — (112.7)(114.4)— — (114.4)
Total financial liabilities
$(128.4)$— $(0.7)$(127.7)$(144.2)$— $(15.2)$(129.0)
Please refer to Note F, “Marketable Securities and Equity Investments,” for the carrying amount and related unrealized gains (losses) by type of investment.
Fair Value of Corporate Equity Securities
We classify our investments in publicly traded corporate equity securities as “Marketable securities” on our condensed consolidated balance sheets. Generally, our investments in the common stock of publicly traded companies are valued based on Level 1 inputs because they have readily determinable fair values. However, certain of our investments in publicly traded companies have been or continue to be valued based on Level 2 inputs due to transfer restrictions associated with these investments.
As of September 30, 2023, one of our investments in publicly traded corporate equity securities was subject to a contractual sales restriction expiring partially in 2024 and partially in 2025 with a total fair value of $25.5 million. We purchased this investment directly from the publicly traded company in the first quarter of 2023, and do not anticipate any circumstances that would cause this restriction to lapse prior to the periods listed above.
Please refer to Note F, “Marketable Securities and Equity Investments,” for further information on these investments.

13
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)
Fair Value of Contingent Consideration
In 2019, we acquired Exonics Therapeutics, Inc. (“Exonics”), a privately-held company focused on creating transformative gene-editing therapies to repair mutations that cause Duchenne muscular dystrophy (“DMD”) and other severe neuromuscular diseases, including DM1. Our Level 3 contingent consideration liabilities are related to $678.3 million of development and regulatory milestones potentially payable to former Exonics equity holders. We base our estimates of the probability of achieving the milestones relevant to the fair value of contingent payments, which could include milestone, royalty and option payments, on industry data attributable to rare diseases and our knowledge of the progress and viability of the programs. The discount rates used in the valuation model for contingent payments, which were between 5.5% and 6.5% as of September 30, 2023, represent a measure of credit risk and market risk associated with settling the liabilities. Significant judgment is used in determining the appropriateness of these assumptions at each reporting period.
The following table represents a rollforward of the fair value of our contingent consideration liabilities:
Nine Months Ended September 30, 2023
(in millions)
Balance at December 31, 2022$129.0 
Decrease in fair value of contingent payments
(1.3)
Balance at September 30, 2023$127.7 
In November 2023, we determined that additional pre-clinical studies of the delivery system for our gene-editing components for DMD will be required. Any potential impact on the fair value of our contingent consideration liabilities will be recognized as of December 31, 2023.



14
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)
F.Marketable Securities and Equity Investments
A summary of our cash equivalents and marketable securities, which are recorded at fair value (and do not include $5.5 billion and $3.1 billion of cash as of September 30, 2023 and December 31, 2022, respectively), is shown below:
As of September 30, 2023As of December 31, 2022
Amortized Cost
Gross
Unrealized
Gains
Gross
Unrealized
Losses
Fair
Value
Amortized Cost
Gross
Unrealized
Gains
Gross
Unrealized
Losses
Fair
Value
(in millions)
Cash equivalents:
Money market funds$3,753.4 $— $— $3,753.4 $5,162.6 $— $— $5,162.6 
Time deposits1,550.0 — — 1,550.0 2,000.0 — — 2,000.0 
U.S. Treasury securities236.8 — — 236.8 — — — — 
Corporate debt securities— — — — 5.8 — — 5.8 
Commercial paper96.5 — — 96.5 204.5 — — 204.5 
Total cash equivalents
$5,636.7 $— $— $5,636.7 $7,372.9 $— $— $7,372.9 
Marketable securities:
U.S. Treasury securities$414.6 $0.1 $(6.5)$408.2 $— $— $— $— 
Government-sponsored enterprise securities
422.9 — (1.9)421.0 127.0 0.2 (0.1)127.1 
Asset-backed securities239.3 0.0 (1.5)237.8 — — — — 
Certificates of deposit31.7 0.0 — 31.7 — — — — 
Corporate debt securities
1,228.4 0.0 (14.2)1,214.2 87.2 — (0.2)87.0 
Commercial paper
158.8 0.0 (0.1)158.7 55.8 — — 55.8 
Total marketable debt securities
2,495.7 0.1 (24.2)2,471.6 270.0 0.2 (0.3)269.9 
Corporate equity securities
72.1 0.5 (26.2)46.4 104.4 30.9 (18.5)116.8 
Total marketable securities
$2,567.8 $0.6 $(50.4)$2,518.0 $374.4 $31.1 $(18.8)$386.7 
Available-for-sale debt securities were classified on our condensed consolidated balance sheets at fair value as follows:
As of September 30, 2023As of December 31, 2022
(in millions)
Cash and cash equivalents$4,086.7 $5,372.9 
Marketable securities
771.6 157.7 
Long-term marketable securities1,700.0 112.2 
Total
$6,558.3 $5,642.8 
Available-for-sale debt securities by contractual maturity were as follows:
As of September 30, 2023As of December 31, 2022
(in millions)
Matures within one year$4,858.3 $5,530.6 
Matures after one year through five years
1,700.0 112.2 
Total
$6,558.3 $5,642.8 
We did not record any allowances for credit losses to adjust the fair value of available-for-sale debt securities or gross realized gains or losses in the three and nine months ended September 30, 2023 and 2022. As of September 30, 2023, we held available-for-sale debt securities with a total fair value of $2.28 billion that were in unrealized loss positions totaling $24.2 million; however, none of these investments had been in an unrealized loss position for greater than twelve months.

15
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)
We record changes in the fair value of our investments in corporate equity securities to “Other (expense) income, net” in our condensed consolidated statements of income. During the three and nine months ended September 30, 2023 and 2022, our net unrealized (losses) gains on corporate equity securities held at the conclusion of each period were as follows:
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
(in millions)
Net unrealized (losses) gains
$(6.2)$16.7 $(7.1)$(143.1)
        
During the nine months ended September 30, 2023, we received proceeds of $95.1 million related to the sale of the common stock of a publicly traded company, which had a total original cost basis of $57.3 million. There were no sales of the common stock of publicly traded companies during the nine months ended September 30, 2022.
As of September 30, 2023, the carrying value of our equity investments without readily determinable fair values, which are recorded in “Other assets” on our condensed consolidated balance sheets, was $98.6 million.

G.Accumulated Other Comprehensive Income (Loss)
The following table summarizes the changes in accumulated other comprehensive income (loss) by component:
Unrealized Holding Gains (Losses), Net of Tax
Foreign Currency Translation AdjustmentOn Available-For-Sale Debt SecuritiesOn Foreign Currency Forward ContractsTotal
(in millions)
Balance at December 31, 2022$(25.0)$(0.1)$25.9 $0.8 
Other comprehensive income (loss) before reclassifications9.1 (18.8)31.8 22.1 
Amounts reclassified from accumulated other comprehensive income (loss)— — (25.9)(25.9)
Net current period other comprehensive income (loss)9.1 (18.8)5.9 (3.8)
Balance at September 30, 2023$(15.9)$(18.9)$31.8 $(3.0)
Balance at December 31, 2021$(13.6)$(0.5)$30.0 $15.9 
Other comprehensive (loss) income before reclassifications(42.8)(3.6)230.2 183.8 
Amounts reclassified from accumulated other comprehensive income (loss)— — (102.1)(102.1)
Net current period other comprehensive (loss) income(42.8)(3.6)128.1 81.7 
Balance at September 30, 2022$(56.4)$(4.1)$158.1 $97.6 

H.Hedging
Foreign currency forward contracts - Designated as hedging instruments
We maintain a hedging program intended to mitigate the effect of changes in foreign exchange rates for a portion of our forecasted product revenues denominated in certain foreign currencies. The program includes foreign currency forward contracts that are designated as cash flow hedges under U.S. GAAP having contractual durations from one to eighteen months. We recognize realized gains and losses for the effective portion of such contracts in “Product revenues, net” in our

16
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)
condensed consolidated statements of income in the same period that we recognize the product revenues that were impacted by the hedged foreign exchange rate changes.
We formally document the relationship between foreign currency forward contracts (hedging instruments) and forecasted product revenues (hedged items), as well as our risk management objective and strategy for undertaking various hedging activities, which includes matching all foreign currency forward contracts that are designated as cash flow hedges to forecasted transactions. We also formally assess, both at the hedge’s inception and on an ongoing basis, whether the foreign currency forward contracts are highly effective in offsetting changes in cash flows of hedged items on a prospective and retrospective basis. If we were to determine that a (i) foreign currency forward contract is not highly effective as a cash flow hedge, (ii) foreign currency forward contract has ceased to be a highly effective hedge or (iii) forecasted transaction is no longer probable of occurring, we would discontinue hedge accounting treatment prospectively. We measure effectiveness based on the change in fair value of the forward contracts and the fair value of the hypothetical foreign currency forward contracts with terms that match the critical terms of the risk being hedged. As of September 30, 2023, all hedges were determined to be highly effective.
We consider the impact of our counterparties’ credit risk on the fair value of the foreign currency forward contracts. As of September 30, 2023 and December 31, 2022, credit risk did not change the fair value of our foreign currency forward contracts.
The following table summarizes the notional amount in U.S. dollars of our outstanding foreign currency forward contracts designated as cash flow hedges under U.S. GAAP:
As of September 30, 2023As of December 31, 2022
Foreign Currency(in millions)
Euro$1,343.3 $1,497.7 
Canadian dollar
192.6 216.3 
British pound sterling
191.9 247.4 
Australian dollar
136.2 174.9 
Swiss Franc51.7 65.2 
Total foreign currency forward contracts
$1,915.7 $2,201.5 
Foreign currency forward contracts - Not designated as hedging instruments
We also enter into foreign currency forward contracts with contractual maturities of less than one month, which are designed to mitigate the effect of changes in foreign exchange rates on monetary assets and liabilities, including intercompany balances. These contracts are not designated as hedging instruments under U.S. GAAP. We recognize realized gains and losses for such contracts in “Other (expense) income, net” in our condensed consolidated statements of income each period. As of September 30, 2023, the notional amount of our outstanding foreign currency forward contracts where hedge accounting under U.S. GAAP is not applied was $922.8 million.

17
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)
During the three and nine months ended September 30, 2023 and 2022, we recognized the following related to foreign currency forward contracts in our condensed consolidated statements of income:
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
(in millions)
Designated as hedging instruments - Reclassified from AOCI
Product revenues, net$2.8 $65.2 $33.0 $130.3 
Not designated as hedging instruments
Other (expense) income, net$(22.0)$(22.1)$(17.8)$(38.9)
Total reported in the Condensed Consolidated Statements of Income
Product revenues, net$2,483.5 $2,334.3 $7,351.5 $6,628.0 
Other (expense) income, net$(15.9)$17.2 $(13.0)$(133.7)
The following table summarizes the fair value of our outstanding foreign currency forward contracts designated as cash flow hedges under U.S. GAAP included on our condensed consolidated balance sheets:
As of September 30, 2023
AssetsLiabilities
ClassificationFair ValueClassificationFair Value
(in millions)
Prepaid expenses and other current assets$37.8 Other current liabilities$(0.7)
Other assets3.4 Other long-term liabilities— 
Total assets
$41.2 
Total liabilities
$(0.7)
As of December 31, 2022
AssetsLiabilities
ClassificationFair ValueClassificationFair Value
(in millions)
Prepaid expenses and other current assets$47.5 Other current liabilities$(14.3)
Other assets0.8 Other long-term liabilities(0.9)
Total assets
$48.3 
Total liabilities
$(15.2)
As of September 30, 2023, we expect the amounts that are related to foreign exchange forward contracts designated as cash flow hedges under U.S. GAAP recorded in “Prepaid expenses and other current assets” and “Other current liabilities” to be reclassified to earnings within twelve months.

18
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)
We present the fair value of our foreign currency forward contracts on a gross basis within our condensed consolidated balance sheets. The following table summarizes the potential effect of offsetting derivatives by type of financial instrument designated as cash flow hedges under U.S. GAAP on our condensed consolidated balance sheets:

As of September 30, 2023
Gross Amounts RecognizedGross Amounts OffsetGross Amounts PresentedGross Amounts Not OffsetLegal Offset
Foreign currency forward contracts(in millions)
Total assets$41.2 $— $41.2 $(0.7)$40.5 
Total liabilities(0.7)— (0.7)0.7 — 
As of December 31, 2022
Gross Amounts RecognizedGross Amounts OffsetGross Amounts PresentedGross Amounts Not OffsetLegal Offset
Foreign currency forward contracts(in millions)
Total assets$48.3 $— $48.3 $(15.2)$33.1 
Total liabilities(15.2)— (15.2)15.2 — 

I.Inventories
Inventories consisted of the following:
As of September 30, 2023As of December 31, 2022
(in millions)
Raw materials$77.5 $38.1 
Work-in-process498.3 260.7 
Finished goods
112.9 161.8 
Total
$688.7 $460.6 


19
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)
J.Stock-based Compensation Expense and Share Repurchase Programs
Stock-based compensation expense
During the three and nine months ended September 30, 2023 and 2022, we recognized the following stock-based compensation expense:
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
(in millions)
Stock-based compensation expense by type of award:
Restricted stock units (including PSUs)$129.1 $130.3 $358.6 $351.5 
Stock options0.2 3.1 4.0 14.9 
ESPP share issuances2.4 1.9 11.8 13.0 
Stock-based compensation expense related to inventories
(0.8)0.3 (1.8)0.4 
Total stock-based compensation expense included in “Total costs and expenses”
$130.9 $135.6 $372.6 $379.8 
Stock-based compensation expense by line item:
Cost of sales$1.7 $2.4 $5.4 $7.0 
Research and development expenses81.1 80.0 231.9 229.9 
Selling, general and administrative expenses48.1 53.2 135.3 142.9 
Total stock-based compensation expense included in costs and expenses
130.9 135.6 372.6 379.8 
Income tax effect(37.1)(38.8)(109.0)(101.3)
Total stock-based compensation expense, net of tax
$93.8 $96.8 $263.6 $278.5 
Share repurchase program
In February 2023, our Board of Directors approved a share repurchase program (our “Share Repurchase Program”), pursuant to which we are authorized to repurchase up to $3.0 billion of our common stock. Our Share Repurchase Program does not have an expiration date and can be discontinued at any time. During the nine months ended September 30, 2023, we repurchased 891,060 shares of our common stock under our Share Repurchase Program for an aggregate of $284.1 million. As of September 30, 2023, a total of $2.7 billion remained authorized for future repurchases.

K.Income Taxes
We are subject to U.S. federal, state, and foreign income taxes. During the three and nine months ended September 30, 2023 and 2022, we recorded the following provisions for income taxes and effective tax rates as compared to our income before provision for income taxes:
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
(in millions, except percentages)
Income before provision for income taxes$1,179.2 $1,176.4 $3,232.2 $3,155.6 
Provision for income taxes$143.9 $245.9 $581.4 $652.5 
Effective tax rate12.2 %20.9 %18.0 %20.7 %

20
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)
Our effective tax rate for each of the three and nine months ended September 30, 2023 was lower than the U.S. statutory rate primarily due to a benefit from a research and development tax credit study that was completed in the third quarter of 2023 and excess tax benefits related to stock-based compensation, partially offset by changes in uncertain tax positions.
Our effective tax rate was similar to the U.S. statutory rate for each of the three and nine months ended September 30, 2022.
We have reviewed the tax positions taken, or to be taken, in our tax returns for all tax years currently open to examination by a taxing authority. As of September 30, 2023 and December 31, 2022, we had $245.4 million and $208.5 million, respectively, of net unrecognized tax benefits, which would affect our tax rate if recognized.
We file U.S. federal income tax returns and income tax returns in various state, local and foreign jurisdictions. We have various income tax audits ongoing at any time throughout the world. Except for jurisdictions where we have net operating losses or tax credit carryforwards, we are no longer subject to any tax assessment from tax authorities for years prior to 2014 in jurisdictions that have a material impact on our consolidated financial statements.

L.Commitments and Contingencies
2022 Credit Facility
In July 2022, Vertex and certain of its subsidiaries entered into a $500.0 million unsecured revolving facility (the “Credit Agreement”) with Bank of America, N.A., as administrative agent and the lenders referred to therein (the “Lenders”), which matures on July 1, 2027. The Credit Agreement was not drawn upon at closing and we have not drawn upon it to date. Amounts drawn pursuant to the Credit Agreement, if any, will be used for general corporate purposes. Subject to satisfaction of certain conditions, we may request that the borrowing capacity for the Credit Agreement be increased by an additional $500.0 million. Additionally, the Credit Agreement provides a sublimit of $100.0 million for letters of credit.
Any amounts borrowed under the Credit Agreement will bear interest, at our option, at either a base rate or a Secured Overnight Financing Rate (“SOFR”), in each case plus an applicable margin. Under the Credit Agreement, the applicable margins on base rate loans range from 0.000% to 0.500% and the applicable margins on SOFR loans range from 1.000% to 1.500%, in each case based on our consolidated leverage ratio (the ratio of our total consolidated funded indebtedness to our consolidated EBITDA for the most recently completed four fiscal quarter period).
Any amounts borrowed pursuant to the Credit Agreement are guaranteed by certain of our existing and future domestic subsidiaries, subject to certain exceptions.
The Credit Agreement contains customary representations and warranties and affirmative and negative covenants, including a financial covenant to maintain subject to certain limited exceptions, a consolidated leverage ratio of 3.50 to 1.00, subject to an increase to 4.00 to 1.00 following a material acquisition. As of September 30, 2023, we were in compliance with the covenants described above. The Credit Agreement also contains customary events of default. In the case of a continuing event of default, the administrative agent would be entitled to exercise various remedies, including the acceleration of amounts due under outstanding loans.
Direct costs related to the Credit Agreement are recorded over its term and were not material to our financial statements.
Guaranties and Indemnifications
As permitted under Massachusetts law, our Articles of Organization and By-laws provide that we will indemnify certain of our officers and directors for certain claims asserted against them in connection with their service as an officer or director. The maximum potential amount of future payments that we could be required to make under these indemnification provisions is unlimited. However, we have purchased directors’ and officers’ liability insurance policies that could reduce our monetary exposure and enable us to recover a portion of any future amounts paid. No indemnification claims currently are outstanding, and we believe the estimated fair value of these indemnification arrangements is minimal.
We customarily agree in the ordinary course of our business to indemnification provisions in agreements with clinical trial investigators and sites in our product development programs, sponsored research agreements with academic and not-for-profit institutions, various comparable agreements involving parties performing services for us, and our real estate leases. We

21
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)
also customarily agree to certain indemnification provisions in our drug discovery, development and commercialization collaboration agreements. With respect to our clinical trials and sponsored research agreements, these indemnification provisions typically apply to any claim asserted against the investigator or the investigator’s institution relating to personal injury or property damage, violations of law or certain breaches of our contractual obligations arising out of the research or clinical testing of our compounds or product candidates. With respect to lease agreements, the indemnification provisions typically apply to claims asserted against the landlord relating to personal injury or property damage caused by us, to violations of law by us or to certain breaches of our contractual obligations. The indemnification provisions appearing in our collaboration agreements are similar to those for the other agreements discussed above, but in addition provide some limited indemnification for our collaborator in the event of third-party claims alleging infringement of intellectual property rights. In each of the cases above, the indemnification obligation generally survives the termination of the agreement for some extended period, although we believe the obligation typically has the most relevance during the contract term and for a short period of time thereafter. The maximum potential amount of future payments that we could be required to make under these provisions is generally unlimited. We have purchased insurance policies covering personal injury, property damage and general liability that reduce our exposure for indemnification and would enable us in many cases to recover all or a portion of any future amounts paid. We have never paid any material amounts to defend lawsuits or settle claims related to these indemnification provisions. Accordingly, we believe the estimated fair value of these indemnification arrangements is minimal.
Other Contingencies
We have certain contingent liabilities that arise in the ordinary course of our business activities. We accrue for such contingent liabilities when it is probable that future expenditures will be made, and such expenditures can be reasonably estimated. Other than our contingent consideration liabilities discussed in Note E, “Fair Value Measurements,” there were no material contingent liabilities accrued as of September 30, 2023 or December 31, 2022.

M.Additional Cash Flow Information
The cash, cash equivalents and restricted cash at the beginning and ending of each period presented in our condensed consolidated statements of cash flows consisted of the following:
Nine Months Ended September 30,
20232022
Beginning of periodEnd of periodBeginning of periodEnd of period
(in millions)
Cash and cash equivalents$10,504.0 $11,110.2 $6,795.0 $9,171.5 
Prepaid expenses and other current assets
8.0 6.4 5.1 5.5 
Cash, cash equivalents and restricted cash per condensed consolidated statement of cash flows$10,512.0 $11,116.6 $6,800.1 $9,177.0 


22
Item 2.     Management’s Discussion and Analysis of Financial Condition and Results of Operations
OVERVIEW
We are a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. We have four approved medicines that treat the underlying cause of cystic fibrosis (“CF”), a life-threatening genetic disease, and we continue to focus on developing additional treatments for CF. Beyond CF, we have a pipeline that includes mid- and late-stage clinical programs in sickle cell disease, beta thalassemia, acute and neuropathic pain, APOL1-mediated kidney disease, type 1 diabetes, and alpha-1 antitrypsin deficiency, and earlier-stage programs in diseases such as muscular dystrophies.
Our triple combination regimen, TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), was approved in 2019 in the United States (“U.S.”) and in 2020 in the European Union (“E.U.”). Collectively, our four medicines are being used to treat more than two-thirds of the approximately 88,000 people with CF in North America, Europe, and Australia. We are evaluating our medicines in additional patient populations, including younger children, with the goal of having small molecule treatments for all people who have at least one mutation in their cystic fibrosis transmembrane conductance regulator (“CFTR”) gene that is responsive to our CFTR modulators. We also are pursuing messenger ribonucleic acid (“mRNA”) and genetic therapies for people with CF who do not make CFTR protein and, as a result, cannot benefit from our current CF medicines.
In addition, we are preparing for near-term launches of potential new products in sickle cell disease (“SCD”), beta thalassemia, CF and acute pain. We completed regulatory submissions in the U.S., E.U. and the United Kingdom (“U.K.”) for exagamglogene autotemcel (“exa-cel”) for the treatment of SCD and transfusion-dependent beta thalassemia (“TDT”). The exa-cel regulatory submissions for SCD and TDT are under review by the U.S. Food and Drug Administration (“FDA”), the European Medicines Agency (“EMA”) and the Medicines and Healthcare products Regulatory Agency (“MHRA”).
Financial Highlights
Revenues
In the third quarter of 2023, our net product revenues increased to $2.5 billion as compared to $2.3 billion in the third quarter of 2022. The increase was primarily due to the continued performance of TRIKAFTA in the U.S., following the launch of TRIKAFTA in children with CF 2 to 5 years of age and strong uptake of TRIKAFTA/KAFTRIO in ex-U.S. markets with recently achieved reimbursements and label extensions in younger age groups.
Expenses
Our total research and development (“R&D”), acquired in-process research and development (“AIPR&D”), and selling, general and administrative (“SG&A”) expenses increased to $1.1 billion in the third quarter of 2023 as compared to $920.8 million in the third quarter of 2022. The increase was primarily due to the progression of several product candidates in mid- to late-stage clinical development, increased AIPR&D and costs to support global launches. Cost of sales was 13% and 12% of our net product revenues in the third quarter of 2023 and 2022, respectively.
Cash
Our total cash, cash equivalents and marketable securities increased to $13.6 billion as of September 30, 2023 as compared to $10.9 billion as of December 31, 2022 primarily due to our net product revenues and operating cash flows partially offset by our upfront payments to Entrada Therapeutics, Inc. (“Entrada”) and CRISPR Therapeutics AG (“CRISPR”), repurchases of our common stock, and income tax payments.

23
MDA chart.gif
Note: Charts above may not add due to rounding.
Business Updates
Marketed Products
We expect to grow our CF business with (i) continued uptake by patients in countries where we are early in our launch, such as those with recently achieved reimbursement agreements, (ii) label expansions, including into younger patient groups, (iii) the development of mRNA therapies for people with CF who are not eligible for our approved CFTR modulators, and (iv) growth in the number of people living with CF. Recent progress in activities supporting continued uptake and label expansions is included below.
•Health Canada granted market authorization for the use of TRIKAFTA in children with CF 2 to 5 years of age who have at least one F508del mutation in the CFTR gene.
•The EMA’s Committee for Medicinal Products for Human Use adopted a positive opinion for the use of KAFTRIO in children with CF 2 to 5 years of age who have at least one F508del mutation in the CFTR gene.
•The European Commission approved ORKAMBI in children with CF 1 year to less than 2 years of age with two copies of the F508del mutation in the CFTR gene.
Potential Near-Term Launch Opportunities
We are preparing for the following near-term launches of potential new products:
Exa-cel in SCD and TDT
•In the U.S., the FDA’s Cellular, Tissue and Gene Therapies Advisory Committee meeting to discuss exa-cel in people with SCD has completed. The FDA has assigned exa-cel Prescription Drug User Fee Act action dates of December 8, 2023 for SCD and March 30, 2024 for TDT. The FDA granted Priority Review for the BLA for exa-cel in SCD. Exa-cel has been granted Fast Track, Regenerative Medicine Advanced Therapy, Orphan Drug and Rare Pediatric Disease designations in the U.S.
•The EMA and MHRA are reviewing the marketing authorization applications (each, an “MAA”) for exa-cel in SCD and TDT in the E.U. and U.K, and we expect regulatory decisions in the coming months. In the E.U., exa-cel has been granted Priority Medicines (“PRIME”) and Orphan Drug designations. In the U.K., exa-cel has been granted an Innovation Passport under the Innovative Licensing and Access Pathway from the MHRA.
•We submitted a MAA for exa-cel in SCD and TDT to the Saudi Food and Drug Authority (the “SFDA”). Exa-cel has been granted Breakthrough designation by the SFDA in the Kingdom of Saudi Arabia.

24
Vanzacaftor/tezacaftor/deutivacaftor in CF
•We expect to complete the pivotal SKYLINE 102 and SKYLINE 103 clinical trials, which evaluate the efficacy and safety of our new once-daily investigational triple combination vanzacaftor/tezacaftor/deutivacaftor relative to TRIKAFTA in people with CF 12 years of age and older, and the RIDGELINE clinical trial of vanzacaftor/tezacaftor/deutivacaftor in children with CF 6 to 11 years of age, by the end of 2023.
•We expect to share the results of all three clinical trials in early 2024.
VX-548 in Acute Pain
•We have completed the randomized controlled Phase 3 pivotal trial in abdominoplasty and we continue to enroll the randomized, controlled Phase 3 clinical trial in bunionectomy and a single-arm safety and effectiveness clinical trial, evaluating our lead compound, VX-548, for the treatment of moderate to severe acute pain. We expect to complete the pivotal program for acute pain in late 2023. We expect to share results from the three clinical trials in early 2024.
•In the U.S., VX-548 has been granted Breakthrough Therapy and Fast Track designations for moderate to severe acute pain.
Pipeline
We continue to advance a diversified pipeline of potentially transformative medicines for serious diseases utilizing a range of modalities. Recent and anticipated progress in activities supporting these efforts is included below.
Cystic Fibrosis
•In collaboration with Moderna, we are developing VX-522, a CFTR mRNA therapeutic for the treatment of people with CF who do not produce any CFTR protein. We are enrolling people with CF in a single-ascending dose clinical trial for VX-522. We expect to complete this single-ascending dose clinical trial and initiate a multiple-ascending dose clinical trial by the end of 2023. In the U.S., the FDA has granted Fast Track designation for VX-522.
•In addition, we are advancing additional CFTR potentiators and correctors through clinical development with the goal of bringing more patients to carrier levels of CFTR function. We are also advancing additional research-stage CFTR modulators and genetic therapies for CF.
Sickle Cell Disease and Beta Thalassemia
•We continue to enroll and dose patients in two global Phase 3 clinical trials evaluating exa-cel in children with SCD or TDT 5 to 11 years of age.
•We continue to work on preclinical assets for gentler conditioning for exa-cel, which could broaden the eligible patient population.
Acute and Neuropathic Pain
•We have discovered multiple selective small molecule inhibitors of NaV1.8, with the objective of creating a new class of pain medicines that provide effective pain relief without the limitations of other pain medicines, such as the abuse potential of opioids.
•We have completed the Phase 2 dose-ranging clinical trial evaluating VX-548 in patients with diabetic peripheral neuropathy, a common form of chronic peripheral neuropathic pain. We expect to share results from this clinical trial in late 2023.
•We expect to initiate another Phase 2 clinical trial evaluating VX-548 in patients with peripheral neuropathic pain in late 2023. This clinical trial will evaluate VX-548 in patients with lumbosacral radiculopathy, a second type of peripheral neuropathic pain.
•We are advancing multiple NaV1.8 inhibitors and NaV1.7 inhibitors through research and earlier stages of development for pain.

25
APOL1-Mediated Kidney Disease
•Inaxaplin is our small molecule for the treatment of APOL1-mediated kidney disease (“AMKD”), including APOL1-mediated focal segmental glomerulosclerosis (“FSGS”). We continue to enroll and dose patients in the pivotal program for inaxaplin, a single Phase 2/3 clinical trial in patients with AMKD, and we expect to complete enrollment in the Phase 2B dose-ranging portion of the trial in 2023.
•The FDA granted Breakthrough Therapy designation to inaxaplin for APOL1-mediated FSGS and the EMA granted Orphan Drug and PRIME designations to inaxaplin for AMKD.
Type 1 Diabetes
•VX-880 is a stem cell-derived, fully differentiated, insulin-producing islet cell replacement therapy, using standard immunosuppression to protect the implanted cells. Proof-of-concept for VX-880 was achieved in 2022. We are evaluating VX-880 as a potential treatment for type 1 diabetes (“T1D”) in a sequential, three-part Phase 1/2 clinical trial. We have completed enrollment in Part C of the clinical trial.
•We continue to advance additional programs in T1D, in which these same stem cell-derived, fully differentiated, insulin-producing islet cells are encapsulated and implanted in an immunoprotective device or are modified to produce hypoimmune cells with the goal of eliminating the need for immunosuppression. We are evaluating VX-264, the cells and device program, in a sequential, multi-part Phase 1/2 clinical trial.
•Our hypoimmune cell program uses CRISPR/Cas9 technology to gene-edit the same stem cell-derived, fully differentiated islets used in the VX-880 and VX-264 programs. The goal is to cloak the cells from the immune system to explore another possible path to eliminate the need for immunosuppressive therapy. This program continues to progress through the research stage.
Alpha-1 Antitrypsin Deficiency
•We are working to address the underlying genetic cause of alpha-1 antitrypsin (“AAT”) deficiency (“AATD”). We are developing novel small molecule correctors of Z-AAT protein folding, with the goal of enabling the secretion of functional AAT into the blood and addressing both the lung and the liver aspects of AATD. We continue to enroll and dose healthy volunteers in Phase 1 clinical trials evaluating VX-634 and VX-668, our next-wave investigational molecule AAT correctors with significantly improved potency and drug-like properties as compared to the first-generation AATD correctors.
•We have discontinued development of VX-864, a first generation AATD corrector, due to non-serious rash events in some patients.
Duchenne Muscular Dystrophy
•We are pursuing preclinical research in Duchenne muscular dystrophy (“DMD”) using innovative approaches to target the underlying cause of disease, with the goal of restoring near-full-length dystrophin and muscle function.
•Based on pre-clinical data generated to date, we have determined that additional in vitro and animal studies of the delivery system for our gene editing components will be required prior to advancing the program into clinical development.
•We are using the learnings from our first-generation vectors to design next-generation delivery systems for in vivo gene editing in DMD.
Our Business Environment
Our net product revenues come from the sale of our medicines for the treatment of CF. Our CF strategy involves continuing to develop and obtain approval and reimbursement for treatment regimens that will provide benefits to all people with CF and increasing the number of people with CF eligible and able to receive our medicines, including through label expansions, expanded reimbursement, and the development of new medicines. We are advancing our pipeline of product candidates for the treatment of serious diseases outside of CF. Our strategy is to combine transformative advances in the understanding of causal human biology and the science of therapeutics to discover and develop innovative medicines. This

26
approach includes advancing multiple compounds from each program, spanning multiple modalities, into early clinical trials to obtain patient data that can inform selection of the most promising compounds for later-stage development, and to inform discovery and development of additional compounds. We aim to rapidly follow our first-in-class therapies that achieve proof-of-concept with potential best-in-class candidates to provide durable clinical and commercial success.
In pursuit of new product candidates and therapies in specialty markets, we invest in research and development. We believe that pursuing research in diverse areas allows us to balance the risks inherent in product development and may provide product candidates that will form our pipeline in future years. To supplement our internal research programs, we acquire technologies and programs and collaborate with biopharmaceutical and technology companies, leading academic research institutions, government laboratories, foundations and other organizations, as needed, to advance research in our areas of therapeutic interest and to access technologies needed to execute on our strategy.
Discovery and development of a new pharmaceutical or biological product is a difficult and lengthy process that requires significant financial resources along with extensive technical and regulatory expertise. Across the industry, most potential drug or biological products never progress into development, and most products that do advance into development never receive marketing approval. Our investments in product candidates are subject to considerable risks. We closely monitor the results of our discovery, research, clinical trials and nonclinical studies and frequently evaluate our product development programs in light of new data and scientific, business and commercial insights, with the objective of balancing risk and potential. This process can result in rapid changes in focus and priorities as new information becomes available and as we gain additional understanding of our ongoing programs and potential new programs, as well as those of our competitors.
Our business also requires ensuring appropriate manufacturing and reimbursement of our products. As we advance our product candidates through clinical development toward commercialization and market and sell our approved products, we build and maintain our supply chain and quality assurance resources. We rely on a global network of third parties and our internal capabilities to manufacture and distribute our products for commercial sale and post-approval clinical trials and to manufacture and distribute our product candidates for clinical trials. In addition to establishing supply chains for each new approved product, we adapt our supply chain for existing products to include additional formulations or to increase scale of production for existing products as needed. The processes for cell and genetic therapies can be more complex than those required for small molecule drugs and require additional investments in different systems, equipment, facilities and expertise. We are focused on ensuring the stability of the supply chains for our current products, as well as for our pipeline programs.
Sales of our products depend, to a large degree, on the extent to which our products are reimbursed by third-party payors, such as government health programs, commercial insurance and managed health care organizations. Reimbursement for our products, including our potential pipeline therapies, cannot be assured and may take significant periods of time to obtain. We dedicate substantial management and other resources to obtain and maintain appropriate levels of reimbursement for our products from third-party payors, including governmental organizations in the U.S. and ex-U.S. markets.
In the U.S., we have worked successfully with third-party payors to promptly obtain appropriate levels of reimbursement for our CF medicines. We plan to continue to engage in discussions with numerous commercial insurers and managed health care organizations, along with government health programs that are typically managed by authorities in the individual states, to ensure that payors recognize the significant benefits that our medicines provide and provide patients with appropriate levels of access to our medicines now and in the future. We cannot, however, predict how recent changes in the law, including through the Inflation Reduction Act of 2022 and passage of state laws (e.g., transparency laws and prescription drug affordability boards), will affect our ability to negotiate successfully with third-party payors and distribute our products. In ex-U.S. markets, we seek government reimbursement for our medicines on a country-by-country or region-by-region basis, as required. This is necessary for each new medicine, as well as for label expansions for our current medicines. We expect to continue to focus significant resources to obtain expanded reimbursement for our CF medicines and, ultimately, pipeline therapies, in U.S. and ex-U.S. markets.
Strategic Transactions
Acquisitions
As part of our business strategy, we seek to acquire technologies, products, product candidates and other businesses that are aligned with our corporate and research and development strategies and complement and advance our ongoing research and development efforts. During 2022 and 2023, we have completed several acquisitions, including:

27
•In the second quarter of 2022, we acquired Catalyst Biosciences, Inc.’s (“Catalyst”), portfolio of protease medicines that target the complement system and related intellectual property for $60.0 million.
•In the third quarter of 2022, we acquired ViaCyte, a privately held biotechnology company with intellectual property, tools, technologies and assets with potential to accelerate development of our T1D programs, for $315.0 million.
•In the third quarter of 2023, we acquired a novel G protein-coupled receptor (“GPCR”) program from Septerna, Inc. for $47.5 million.
We expect to continue to identify and evaluate potential acquisitions and may include larger transactions or later-stage assets.
Collaboration and In-Licensing Arrangements
We enter into arrangements with third parties, including collaboration and licensing arrangements, for the development, manufacture and commercialization of products, product candidates and other technologies that have the potential to complement our ongoing research and development efforts. Over the last several years, we entered into collaboration agreements with a number of companies, including Arbor Biotechnologies, Inc., CRISPR, Entrada, ImmunoGen, Inc., Mammoth Biosciences, Inc., Moderna, Inc., Obsidian Therapeutics, Inc., and Verve Therapeutics, Inc. Generally, when we in-license a technology or product candidate, we make upfront payments to the collaborator, assume the costs of the program and/or agree to make contingent payments, which could consist of milestone, royalty and option payments. Most of these collaboration payments are expensed as AIPR&D; however, depending on many factors, including the structure of the collaboration, the stage of development of the acquired technology, the significance of the in-licensed product candidate to the collaborator’s operations and the other activities in which our collaborators are engaged, the accounting for these transactions can vary significantly. We expect to continue to identify and evaluate collaboration and licensing opportunities that may be similar to or different from the collaborations and licenses that we have engaged in previously.
In February 2023, we closed our strategic collaboration and licensing agreement with Entrada. Upon closing, we made an upfront payment of $225.1 million to Entrada, and purchased $24.9 million of Entrada’s common stock.
In March 2023, we entered into a non-exclusive license agreement for the use of CRISPR’s CRISPR-Cas9 gene-editing technology to accelerate the development of our hypoimmune cell therapies for T1D and made a $100.0 million upfront payment to CRISPR. In the second quarter of 2023, we achieved a research milestone that resulted in a $70.0 million payment to CRISPR in the third quarter of 2023.
Acquired In-Process Research and Development Expenses
In the nine months ended September 30, 2023 and 2022, our AIPR&D included $509.3 million and $92.9 million, respectively, related to upfront, contingent milestone, or other payments pursuant to our business development transactions, including the collaborations, licenses of third-party technologies, and asset acquisitions described above.
Out-License Agreements
We also have out-licensed internally developed programs to collaborators who are leading the development of these programs. Pursuant to these out-licensing arrangements, our collaborators are responsible for the research, development, and commercialization costs associated with these programs, and we are entitled to receive contingent milestone and/or royalty payments. As a result, we do not expect to incur significant expenses in connection with these programs and have the potential for future collaborative and royalty revenues resulting from these programs. None of our out-license agreements had a significant impact on our condensed consolidated statement of income during the nine months ended September 30, 2023 and 2022.
Strategic Equity Investments
In connection with our business development activities, we have periodically made equity investments in our collaborators. As of September 30, 2023, we held strategic equity investments in certain public and private companies, and we expect to make additional strategic equity investments in the future. We invest the majority of our cash, cash equivalents and marketable securities in instruments that meet specific credit quality standards and limit our exposure to any one issue or

28
type of instrument. Our strategic equity investments are maintained and managed separately from our other cash, cash equivalents and marketable securities. As discussed below in “Other Income (Expense), Net” in our Results of Operations, any changes in the fair value of equity investments with readily determinable fair values (including publicly traded securities) are recorded to other income (expense), net in our condensed consolidated statements of income.


29
RESULTS OF OPERATIONS
Three Months Ended September 30,Nine Months Ended September 30,
20232022Change20232022Change
(in millions, except percentages and per share amounts)
Product revenues, net
$2,483.5 $2,334.3 6%$7,351.5 $6,628.0 11%
Operating costs and expenses1,445.4 1,207.6 20%4,508.0 3,354.1 34%
Income from operations
1,038.1 1,126.7 (8)%2,843.5 3,273.9 (13)%
Other non-operating income (expense), net141.1 49.7 184%388.7 (118.3)**
Provision for income taxes
143.9 245.9 (41)%581.4 652.5 (11)%
Net income
$1,035.3 $930.5 11%$2,650.8 $2,503.1 6%
Net income per diluted common share$3.97 $3.59 $10.18 $9.68 
Diluted shares used in per share calculations
260.6 259.5 260.4 258.7 
** Not meaningful
Product Revenues, net
Three Months Ended September 30,Nine Months Ended September 30,
20232022Change20232022Change
(in millions, except percentages)
TRIKAFTA/KAFTRIO$2,274.3 $2,010.5 13%$6,611.4 $5,665.3 17%
KALYDECO112.8 139.4 (19)%363.1 417.1 (13)%
ORKAMBI63.0 146.2 (57)%281.8 399.9 (30)%
SYMDEKO/SYMKEVI33.4 38.2 (13)%95.2 145.7 (35)%
Product revenues, net$2,483.5 $2,334.3 6%$7,351.5 $6,628.0 11%
In the third quarter and nine months ended September 30, 2023, our net product revenues increased by $149.2 million and $723.5 million, or 6% and 11%, as compared to the third quarter and nine months ended September 30, 2022, respectively. These increases were primarily due to the continued strong uptake of TRIKAFTA/KAFTRIO in ex-U.S. markets with recently achieved reimbursements and label extensions in younger age groups and the performance of TRIKAFTA in the U.S., following the launch of TRIKAFTA in children with CF 2 to 5 years of age. Decreases in revenues for our products other than TRIKAFTA/KAFTRIO were primarily the result of patients switching from these medicines to TRIKAFTA/KAFTRIO.
Our net product revenues from the U.S. and from ex-U.S. markets were as follows:
Three Months Ended September 30,Nine Months Ended September 30,
20232022Change20232022Change
(in millions, except percentages)
United States$1,554.2 $1,455.6 7%$4,465.8 $4,238.9 5%
ex-U.S.929.3 878.7 6%2,885.7 2,389.1 21%
Product revenues, net$2,483.5 $2,334.3 6%$7,351.5 $6,628.0 11%

30
Operating Costs and Expenses

Three Months Ended September 30,Nine Months Ended September 30,
20232022Change20232022Change
(in millions, except percentages)
Cost of sales$318.7 $289.4 10%$894.2 $797.0 12%
Research and development expenses810.0 645.0 26%2,338.3 1,846.2 27%
Acquired in-process research and development expenses51.7 29.0 78%509.3 92.9 448%
Selling, general and administrative expenses263.8 246.8 7%767.5 677.3 13%
Change in fair value of contingent consideration1.2 (2.6)**(1.3)(59.3)**
Total costs and expenses$1,445.4 $1,207.6 20%$4,508.0 $3,354.1 34%
** Not meaningful
Cost of Sales
Our cost of sales primarily consists of third-party royalties payable on net sales of our products as well as the cost of producing inventories. Pursuant to our agreement with the Cystic Fibrosis Foundation our tiered third-party royalties on sales of TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, KALYDECO, and ORKAMBI, calculated as a percentage of net sales, range from the single digits to the sub-teens, with lower royalties on sales of TRIKAFTA/KAFTRIO than for our other products. Over the last several years, our cost of sales has been increasing due to increased net product revenues. Our cost of sales as a percentage of our net product revenues was 13% and 12% in the third quarter of 2023 and 2022, respectively, and 12% in each of the nine months ended September 30, 2023 and 2022.
Research and Development Expenses
Three Months Ended September 30,Nine Months Ended September 30,
20232022Change20232022Change
(in millions, except percentages)
Research expenses$173.9 $160.2 9%$511.4 $464.9 10%
Development expenses
636.1 484.8 31%1,826.9 1,381.3 32%
Total research and development expenses
$810.0 $645.0 26%$2,338.3 $1,846.2 27%
Our research and development expenses include internal and external costs incurred for research and development of our products and product candidates. We do not assign our internal costs, such as salary and benefits, stock-based compensation expense, laboratory supplies and other direct expenses and infrastructure costs, to individual products or product candidates, because the employees within our research and development groups typically are deployed across multiple research and development programs. We assign external costs of services provided to us by clinical research organizations and other outsourced research by individual program. Our internal costs are greater than our external costs. All research and development costs for our products and product candidates are expensed as incurred.
Since January 2021, we have incurred approximately $8.6 billion in total research and development and AIPR&D expenses associated with product discovery and development. The successful development of our product candidates is highly uncertain and subject to a number of risks. In addition, the duration of clinical trials may vary substantially according to the type, complexity and novelty of the product candidate and the disease indication being targeted. The FDA and comparable agencies in foreign countries impose substantial requirements on the introduction of therapeutic pharmaceutical products, typically requiring lengthy and detailed laboratory and clinical testing procedures, sampling activities and other costly and time-consuming procedures. Data obtained from nonclinical and clinical activities at any step in the testing process may be adverse and lead to discontinuation or redirection of development activities. Data obtained from these activities also are susceptible to varying interpretations, which could delay, limit or prevent regulatory approval. The duration and cost of discovery, nonclinical studies and clinical trials may vary significantly over the life of a project and are difficult to predict.

31
Therefore, accurate and meaningful estimates of the ultimate costs to bring our product candidates to market are not available.
Any estimates regarding development and regulatory timelines for our product candidates are highly subjective and subject to change. Therefore, we cannot make a meaningful estimate regarding when, or if, a clinical development program will generate revenues and cash flows.
Research Expenses
Three Months Ended September 30,Nine Months Ended September 30,
20232022Change20232022Change
(in millions, except percentages)
Research Expenses:
Salary and benefits$46.3 $40.7 14%$137.5 $119.0 16%
Stock-based compensation expense20.5 23.3 (12)%59.2 65.7 (10)%
Outsourced services and other direct expenses61.8 49.2 26%176.0 132.7 33%
Intangible asset impairment charge— — **— 13.0 **
Infrastructure costs
45.3 47.0 (4)%138.7 134.5 3%
Total research expenses
$173.9 $160.2 9%$511.4 $464.9 10%
** Not meaningful
Our research expenses have been increasing over the last several years as we have invested in our pipeline and expanded our cell and genetic therapy capabilities, resulting in increased headcount, outside services and other direct expenses and infrastructure costs associated with our research facilities. We expect to continue to invest in our research programs with a focus on creating transformative medicines for serious diseases.
Development Expenses
Three Months Ended September 30,Nine Months Ended September 30,
20232022Change20232022Change
(in millions, except percentages)
Development Expenses:
Salary and benefits$152.3 $133.5 14%$438.8 $344.4 27%
Stock-based compensation expense60.6 56.7 7%172.7 164.2 5%
Outsourced services and other direct expenses332.6 215.9 54%957.0 639.2 50%
Infrastructure costs
90.6 78.7 15%258.4 233.5 11%
Total development expenses
$636.1 $484.8 31%$1,826.9 $1,381.3 32%
Our development expenses increased by $151.3 million and $445.6 million, or 31% and 32%, in the three and nine months ended September 30, 2023 as compared to the three and nine months ended September 30, 2022, respectively, primarily due to increased costs to support clinical trials and drug supply associated with our advancing pipeline programs, including in pain, exa-cel and T1D. We are investing significantly in internal headcount, leveraging outsourced services, and in infrastructure to support these programs.

32
Acquired In-process Research and Development Expenses
Three Months Ended September 30,Nine Months Ended September 30,
20232022Change20232022Change
(in millions, except percentages)
Acquired in-process research and development expenses$51.7 $29.0 78%$509.3 $92.9 448%
AIPR&D in the third quarter of 2023 was primarily related to our $47.5 million acquisition of a novel GPCR program from Septerna. AIPR&D in the nine months ended September 30, 2023 also included our $225.1 million upfront payment to Entrada, and our $100.0 million upfront payment and $70.0 million T1D research milestone to CRISPR. AIPR&D in the third quarter of 2022 was primarily related to a $25.0 million upfront payment pursuant to our license agreement with Verve. AIPR&D in the nine months ended September 30, 2022 was primarily related to our payment to Verve and a $60.0 million payment to Catalyst to acquire their complement portfolio and related intellectual property. Our AIPR&D has historically fluctuated, and is expected to continue to fluctuate, from one period to another due to upfront, contingent milestone, and other payments pursuant to our existing and future business development transactions, including collaborations, licenses of third-party technologies, and asset acquisitions.
Selling, General and Administrative Expenses
Three Months Ended September 30,Nine Months Ended September 30,
20232022Change20232022Change
(in millions, except percentages)
Selling, general and administrative expenses$263.8 $246.8 7%$767.5 $677.3 13%
Selling, general and administrative expenses increased by 7% and 13% in the third quarter and nine months ended September 30, 2023 as compared to the third quarter and nine months ended September 30, 2022, respectively, primarily due to the continued investment to support the commercialization of our medicines and increased support for our pipeline product candidates.
Contingent Consideration
The fair value of our contingent consideration increased by $1.2 million and decreased by $1.3 million in the third quarter and nine months ended September 30, 2023, respectively. The fair value of our contingent consideration decreased by $2.6 million and $59.3 million in the third quarter and nine months ended September 30, 2022, respectively. The fair value of contingent consideration decreased in the nine months ended September 30, 2022 primarily as a result of a revision to the scope of certain gene-editing programs in the second quarter of 2022.
As of September 30, 2023, the fair value of our contingent consideration liabilities of $127.7 million related to development and regulatory milestones associated with our genetic therapy program for DMD. In November 2023, we determined that additional pre-clinical studies of the delivery system for our gene-editing components for DMD will be required. Any potential impact on the fair value of our contingent consideration liabilities will be recognized as of December 31, 2023.
Other Non-Operating Income (Expense), Net
Interest Income
Interest income increased to $167.9 million and $435.2 million in the third quarter and nine months ended September 30, 2023, respectively, as compared to $46.2 million and $58.6 million in the third quarter and nine months ended September 30, 2022, respectively, primarily due to increased market interest rates and increased cash equivalents and available-for-sale debt securities. Our future interest income is dependent on the amount of, and prevailing market interest rates on, our outstanding cash equivalents and available-for-sale debt securities.

33
Interest Expense
Interest expense was $10.9 million and $13.7 million in the third quarter of 2023 and 2022, respectively, and $33.5 million and $43.2 million in the nine months ended September 30, 2023 and 2022, respectively. The majority of our interest expense in these periods was related to imputed interest expense associated with our leased corporate headquarters in Boston.
Other Income (Expense), Net
Other income (expense), net was expense of $15.9 million and income of $17.2 million in the third quarter of 2023 and 2022, respectively, and expense of $13.0 million and $133.7 million in the nine months ended September 30, 2023 and 2022, respectively. These amounts related primarily to net unrealized gains or losses resulting from changes in the fair value of our strategic equity investments. As of September 30, 2023, the fair value of our investments in publicly traded companies was $46.4 million. To the extent that we continue to hold strategic equity investments in publicly traded companies, we will record other income (expense) related to these investments on a quarterly basis. We expect that due to the volatility of the stock price of biotechnology companies, our other income (expense), net will fluctuate in future periods based on increases or decreases in the fair value of our strategic equity investments.
Income Taxes
Our effective tax rate fluctuates from period to period due to the global nature of our operations. The factors that most significantly impact our effective tax rate include changes in tax laws, variability in the allocation of our taxable earnings among multiple jurisdictions, the amount and characterization of our research and development expenses, the levels of certain deductions and credits, adjustments to the value of our uncertain tax positions, acquisitions and third-party collaboration and licensing transactions.
We recorded provisions for income taxes of $143.9 million and $245.9 million in the third quarter of 2023 and 2022, respectively, and $581.4 million and $652.5 million in the nine months ended September 30, 2023 and 2022, respectively. Our effective tax rate of 18.0% in the nine months ended September 30, 2023 was lower than the U.S. statutory rate primarily due to a benefit from a research and development tax credit study that was completed during the third quarter of 2023 and excess tax benefits related to stock-based compensation, partially offset by changes in uncertain tax positions. Our effective tax rate of 20.7% in the nine months ended September 30, 2022 was similar to the U.S. statutory rate.


34
LIQUIDITY AND CAPITAL RESOURCES
The following table summarizes the components of our financial condition as of September 30, 2023 and December 31, 2022:
As of September 30, 2023As of December 31, 2022Change
(in millions, except percentages)
Cash, cash equivalents and marketable securities:
Cash and cash equivalents$11,110.2 $10,504.0 6%
Marketable securities818.0 274.5 198%
Long-term marketable securities1,700.0 112.2 1,415%
Total cash, cash equivalents and marketable securities$13,628.2 $10,890.7 25%
Working Capital:
Total current assets$14,695.8 $13,234.8 11%
Total current liabilities(3,599.4)(2,742.1)31%
Total working capital$11,096.4 $10,492.7 6%
Working Capital
As of September 30, 2023, total working capital was $11.1 billion, which represented an increase of $603.7 million from $10.5 billion as of December 31, 2022. The increase in total working capital during the nine months ended September 30, 2023 was primarily due to $3.3 billion of cash provided by operations partially offset by increased investment in long-term marketable securities and repurchases of our common stock.
Cash Flows
Nine Months Ended September 30,
20232022
(in millions)
Net cash provided by (used in):
Operating activities$3,302.7 $3,051.5 
Investing activities$(2,255.2)$(496.7)
Financing activities$(442.4)$(107.9)
Operating Activities
Cash provided by operating activities were $3.3 billion in the nine months ended September 30, 2023 as compared to $3.1 billion in the nine months ended September 30, 2022. The increase in cash provided by operating activities was primarily due to increased net income in the nine months ended September 30, 2023 as compared to the nine months ended September 30, 2022.
Investing Activities
Cash used in investing activities were $2.3 billion and $496.7 million in the nine months ended September 30, 2023 and 2022, respectively. In the nine months ended September 30, 2023, our investing activities primarily related to net purchases of marketable securities. In the nine months ended September 30, 2022, our investing activities primarily related to a net payment of $295.9 million to acquire ViaCyte, Inc. and purchases of property and equipment.
Financing Activities
Cash used in financing activities were $442.4 million and $107.9 million in the nine months ended September 30, 2023 and 2022, respectively. In the nine months ended September 30, 2023, our financing activities primarily related to

35
repurchases of our common stock pursuant to our Share Repurchase Program and payments related to our employee stock benefit plans. In the nine months ended September 30, 2022, the largest portion of our financing activities were payments related to our employee stock benefit plans.
Sources and Uses of Liquidity
As of September 30, 2023, we had total cash, cash equivalents and marketable securities of $13.6 billion, which represented an increase of $2.7 billion from $10.9 billion as of December 31, 2022. We intend to rely on our existing cash, cash equivalents and marketable securities together with cash flows from product sales as our primary source of liquidity.
We expect that cash flows from our product sales together with our current cash, cash equivalents and marketable securities will be sufficient to fund our operations for at least the next twelve months. The adequacy of our available funds to meet our future operating and capital requirements will depend on many factors, including our future product sales, and the potential introduction of one or more of our other product candidates to the market, our business development activities, and the number, breadth, cost and prospects of our research and development programs.
Credit Facilities & Financing Strategy
We may borrow up to a total of $500.0 million pursuant to a revolving credit facility that we entered into in July 2022 and could repay and reborrow amounts under this revolving credit agreement without penalty. Subject to certain conditions, we could request that the borrowing capacity be increased by an additional $500.0 million, for a total of $1.0 billion. Negative covenants in our credit agreement could prohibit or limit our ability to access this source of liquidity. As of September 30, 2023, the facility was undrawn, and we were in compliance with these covenants.
We may also raise additional capital by borrowing under credit agreements, through public offerings or private placements of our securities or securing new collaborative agreements or other methods of financing. We will continue to manage our capital structure and will consider all financing opportunities, whenever they may occur, that could strengthen our long-term liquidity profile. There can be no assurance that any such financing opportunities will be available on acceptable terms, if at all.
Future Capital Requirements
We have significant future capital requirements, including:
•Expected operating expenses to conduct research and development activities, manufacture and commercialize our existing and future products, and to operate our organization.
•Facility, operating and finance lease obligations.
•Royalties we pay related to sales of our CF products.
•Cash paid for income taxes.
In addition, we have significant potential future capital requirements including:
•We have entered into certain business development-related and strategic agreements with third parties that include the funding of certain research, development, manufacturing and commercialization efforts. Certain of our transactions, including collaborations, licensing arrangements, and asset acquisitions, include the potential for future milestone and royalty payments by us upon the achievement of pre-established developmental and regulatory targets and/or commercial targets. Other transactions include the potential for future lease-related expenses and other costs. Our obligation to fund these research and development and commercialization efforts and to pay these potential milestones, expenses and royalties is contingent upon continued involvement in the programs and/or the lack of any adverse events that could cause their discontinuance. We may enter into additional business development transactions and strategic agreements, including acquisitions, collaborations, licensing arrangements and equity investments, that require additional capital.
•To the extent we borrow amounts under our existing credit agreement, we would be required to repay any outstanding principal amounts in 2027.

36
•As of September 30, 2023, we had $2.7 billion remaining authorization available under our Share Repurchase Program.
There have not been any material changes to our future capital requirements disclosed in our Annual Report on Form 10-K for the year ended December 31, 2022, which was filed with the Securities and Exchange Commission, or SEC, on February 10, 2023.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES
Our discussion and analysis of our financial condition and results of operations are based upon our condensed consolidated financial statements prepared in accordance with generally accepted accounting principles in the U.S. The preparation of these financial statements requires us to make certain estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reported periods. These items are monitored and analyzed by management for changes in facts and circumstances, and material changes in these estimates could occur in the future. Changes in estimates are reflected in reported results for the period in which the change occurs. We base our estimates on historical experience and various other assumptions that we believe to be reasonable under the circumstances. Actual results may differ from our estimates if past experience or other assumptions do not turn out to be substantially accurate. During the nine months ended September 30, 2023, there were no material changes to our critical accounting policies as reported in our Annual Report on Form 10-K for the year ended December 31, 2022, which was filed with the SEC on February 10, 2023.

RECENT ACCOUNTING PRONOUNCEMENTS
For a discussion of recent accounting pronouncements, please refer to Note A, “Basis of Presentation and Accounting Policies.”

Item 3.    Quantitative and Qualitative Disclosures About Market Risk
Information required by this item is incorporated by reference from the discussion in Part II, Item 7A, “Quantitative and Qualitative Disclosures About Market Risk,” of our Annual Report on Form 10-K for the year ended December 31, 2022, which was filed with the SEC on February 10, 2023.

Item 4.    Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Our management (under the supervision and with the participation of our chief executive officer and chief financial officer), after evaluating the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this Quarterly Report on Form 10-Q, has concluded that, based on such evaluation, as of September 30, 2023 our disclosure controls and procedures were effective and designed to provide reasonable assurance that the information required to be disclosed is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. In designing and evaluating our disclosure controls and procedures, our management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.
Changes in Internal Controls Over Financial Reporting
No change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934, as amended) occurred during the three months ended September 30, 2023 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

37

PART II. Other Information

Item 1. Legal Proceedings
We are not currently subject to any material legal proceedings.

Item 1A. Risk Factors
Information regarding risk factors appears in Part I, Item 1A. “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2022, which was filed with the SEC on February 10, 2023. There have been no material changes from the risk factors previously disclosed in the Annual Report on Form 10-K.
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q and, in particular, our Management’s Discussion and Analysis of Financial Condition and Results of Operations set forth in Part I, Item 2, contain a number of forward-looking statements. Forward-looking statements are not purely historical and may be accompanied by words such as “anticipates,” “may,” “forecasts,” “expects,” “intends,” “plans,” “potentially,” “believes,” “seeks,” “estimates,” and other words and terms of similar meaning. Such statements may relate to:
•our expectations regarding the amount of, timing of, and trends with respect to our financial performance, including revenues, costs and expenses, and other gains and losses;
•our expectations regarding our clinical trials and pipeline programs, including expectations for patient enrollment, development timelines, the expected timing of data from our ongoing and planned clinical trials, regulatory authority filings and other submissions for our therapies, communications with regulatory authorities and anticipated regulatory approvals;
•our ability to maintain and obtain adequate reimbursement for our products, our ability to launch, commercialize and market our products or any of our other therapies for which we obtain regulatory approval and our ability to obtain label expansions for existing therapies;
•our expectations regarding our ability to continue to grow our CF business by increasing the number of people with CF eligible and able to receive our medicines, providing improved treatment options for people who are already eligible for one of our medicines, and pursuing genetic therapies for people with CF who cannot currently benefit from our medicines;
•the data that will be generated by ongoing and planned clinical trials and the ability to use that data to advance compounds, continue development or support regulatory filings;
•our beliefs regarding the support provided by clinical trials and preclinical and nonclinical studies of our therapies for further investigation, clinical trials or potential use as a treatment;
•our plans to continue investing in our research and development programs, including anticipated timelines for our programs, and our strategy to develop our pipeline programs, alone or with third party-collaborators;
•our beliefs regarding the approximate patient populations for the disease areas on which we focus;
•the potential benefits and therapeutic scope of our acquisitions and collaborations;
•the establishment, development and maintenance of collaborative relationships, including potential milestone payments or other obligations;
•potential business development activities, including the identification of potential collaborative partners or acquisition targets;

38
•our ability to expand and protect our intellectual property portfolio and otherwise maintain exclusive rights to products;
•potential fluctuations in foreign currency exchange rates and the effectiveness of our foreign currency management program;
•our expectations regarding cash generated by operations, our cash balance and expected generation and interest income;
•our expectations regarding our provision for or benefit from income taxes and the utilization of our deferred tax assets;
•our ability to use our research programs to identify and develop new product candidates to address serious diseases and significant unmet medical needs;
•our plans to expand, strengthen, and invest in our global supply chains and manufacturing infrastructure and capabilities, including for cell and gene therapies; and
•our liquidity and our expectations regarding the possibility of raising additional capital.
Forward-looking statements are subject to certain risks, uncertainties, or other factors that are difficult to predict and could cause actual events or results to differ materially from those indicated in any such statements. These risks, uncertainties, and other factors include, but are not limited to, those described in our “Risk Factors” in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2022, which was filed with the SEC on February 10, 2023, and those described from time to time in our future reports filed with the Securities and Exchange Commission.
Any such forward-looking statements are made on the basis of our views and assumptions as of the date of the filing and are not estimates of future performance. Except as required by law, we undertake no obligation to publicly update any forward-looking statements. The reader is cautioned not to place undue reliance on any such statements.

Item 2.     Unregistered Sales of Equity Securities and Use of Proceeds
Issuer Repurchases of Equity Securities
In February 2023, our Board of Directors approved a share repurchase program (our “Share Repurchase Program”), pursuant to which we are authorized to repurchase up to $3.0 billion of our common stock. Our Share Repurchase Program does not have an expiration date and can be discontinued at any time. The table set forth below shows repurchases of securities by us during the three months ended September 30, 2023 under our Share Repurchase Program.
PeriodTotal Number
of Shares Purchased		Average Price
Paid per Share		Total Number of Shares
Purchased as Part of
Publicly Announced
Plans or Programs (1)		Approximate Dollar Value
 of Shares that May Yet be
Purchased Under the
Plans or Programs (1)
July 1, 2023 to July 31, 2023
— $— — $2,838,895,548 
August 1, 2023 to August 31, 2023
179,355 $347.96 179,355 $2,776,487,068 
September 1, 2023 to September 30, 2023
173,200 $349.65 173,200 $2,715,927,898 
Total352,555 $348.79 352,555 $2,715,927,898 
(1) Under our Share Repurchase Program, we are authorized to purchase shares from time to time through open market or privately negotiated transactions. Such purchases may be pursuant to Rule 10b5-1 plans or other means as determined by our management and in accordance with the requirements of the Securities and Exchange Commission.


39
Item 5.     Other Information
Rule 10b5-1 Trading Plans
Our policy governing transactions in our securities by our directors, officers, and employees permits our officers, directors and employees to enter into trading plans complying with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. The following table describes the written plans for the sale of our securities adopted by our executive officers and directors during the third quarter of 2023, each of which is intended to satisfy the affirmative defense conditions of Rule 10b5-1 (each, a “Trading Plan”).
Name and TitleDate of Adoption of Trading PlanScheduled Expiration Date of Trading Plan (1)Maximum Shares Subject to Trading Plan
E. Morrow “Morrey” Atkinson III
EVP, Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations
8/22/20234/30/2024
9,224(2)
Reshma Kewalramani
President, Chief Executive Officer and Director
8/11/20238/15/2024
27,330
Jeffrey M. Leiden
Executive Chairman
8/4/20235/15/2025
40,454(2)
Bastiano Sanna
EVP, Chief of Cell and Genetic Therapies
8/25/20238/9/2024
32,833(2)
Charles F. Wagner, Jr.
EVP, Chief Financial Officer
8/18/20238/9/2024
6,000
(1) A Trading Plan may expire on an earlier date if all contemplated transactions are completed before such Trading Plan’s expiration date, upon termination by broker or the holder of the Trading Plan, or as otherwise provided in the Trading Plan.
(2) The maximum shares listed has not been reduced by the number of shares of common stock that will be withheld to satisfy tax withholding obligations at future vesting dates because such number of shares is not yet determinable.

Item 6.    Exhibits
Exhibit Number
Exhibit Description
31.1
31.2
32.1
101.INSXBRL Instance - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCHXBRL Taxonomy Extension Schema
101.CALXBRL Taxonomy Extension Calculation
101.LABXBRL Taxonomy Extension Labels
101.PREXBRL Taxonomy Extension Presentation
101.DEFXBRL Taxonomy Extension Definition
104Cover Page Interactive Data File––the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

40
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Vertex Pharmaceuticals Incorporated
November 7, 2023
By:
/s/ Charles F. Wagner, Jr.
Charles F. Wagner, Jr.
Executive Vice President, Chief Financial Officer
(principal financial officer and
duly authorized officer)

41
 EX-31.1 2 a2023q310-qexhibit311.htm EX-31.1 Document

Exhibit 31.1
CERTIFICATION
I, Reshma Kewalramani, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of Vertex Pharmaceuticals Incorporated;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: November 7, 2023/s/ Reshma Kewalramani
Reshma Kewalramani
Chief Executive Officer and President


 EX-31.2 3 a2023q310-qexhibit312.htm EX-31.2 Document

Exhibit 31.2
CERTIFICATION
I, Charles F. Wagner, Jr., certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of Vertex Pharmaceuticals Incorporated;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: November 7, 2023/s/ Charles F. Wagner, Jr.
Charles F. Wagner, Jr.
Executive Vice President and Chief Financial Officer

 EX-32.1 4 a2023q310-qexhibit321.htm EX-32.1 Document

Exhibit 32.1
SECTION 906 CEO/CFO CERTIFICATION
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) each of the undersigned officers of Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (the “Company”), does hereby certify, to such officer’s knowledge, that the Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 (the “Form 10-Q”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: November 7, 2023
/s/ Reshma Kewalramani
Reshma Kewalramani
Chief Executive Officer and President
Date: November 7, 2023
/s/ Charles F. Wagner, Jr.
Charles F. Wagner, Jr.
Executive Vice President and Chief Financial Officer



 EX-101.SCH 5 vrtx-20230930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - Condensed Consolidated Statements of Income link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - Condensed Consolidated Statements of Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - Condensed Consolidated Statements of Comprehensive Income (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - Condensed Consolidated Statements of Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 0000008 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Basis of Presentation and Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Revenue Recognition link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Acquired In-Process Research and Development and Other Arrangements link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Earnings Per Share link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Marketable Securities and Equity Investments link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Accumulated Other Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Hedging link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Stock-based Compensation Expense and Share Repurchase Programs link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Additional Cash Flow Information link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - Basis of Presentation and Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - Revenue Recognition (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - Earnings Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - Marketable Securities and Equity Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - Hedging (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - Stock-based Compensation Expense and Share Repurchase Programs (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - Additional Cash Flow Information (Tables) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - Basis of Presentation and Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - Revenue Recognition - Disaggregation of Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - Revenue Recognition - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - Acquired In-Process Research and Development and Other Arrangements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - Earnings Per Share - Schedule of Computation (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - Earnings Per Share - Anti-dilutive Securities (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - Fair Value Measurements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Subject to Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Fair Value Measurements - Fair Value of Contingent Consideration Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Marketable Securities and Equity Investments - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Marketable Securities and Equity Investments - Summary of Cash Equivalents and Marketable Securities (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Marketable Securities and Equity Investments - Summary of Cash Equivalents and Marketable Securities (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - Marketable Securities and Equity Investments - Available-for-Sale Debt Securities at Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Marketable Securities and Equity Investments - Available-for-Sale Debt Securities by Contractual Maturity (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Marketable Securities and Equity Investments - Net Unrealized Gains (Losses) (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - Hedging - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - Hedging - Notional Amount (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - Hedging - Cash Flow Hedging Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - Hedging - Derivative Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - Hedging - Offsetting Derivatives (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - Stock-based Compensation Expense and Share Repurchase Programs - Stock-based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - Stock-based Compensation Expense and Share Repurchase Programs - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954505 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 9954506 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 9954507 - Disclosure - Additional Cash Flow Information (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 vrtx-20230930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 vrtx-20230930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 vrtx-20230930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Variable Rate [Domain] Variable Rate [Domain] Pay vs Performance Disclosure [Line Items] Accrued expenses Accrued Liabilities, Current Other long-term liabilities Other Noncurrent Liabilities [Member] Statistical Measurement [Domain] Statistical Measurement [Domain] Line of credit facility, maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Research and development expenses Research and Development Expense Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Debt covenant, consolidated leverage ratio Debt Covenant, Consolidated Leverage Ratio Consolidated leverage ratio that must be maintained in order to be in compliance with debt covenants. Award Type [Domain] Award Type [Domain] Fair Value as of Grant Date Award Grant Date Fair Value Acquired in-process research and development expenses Research and Development Asset Acquired Other than Through Business Combination, Writeoff Other current liabilities Other Current Liabilities [Member] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Investments, Debt and Equity Securities [Abstract] Investments, Debt and Equity Securities [Abstract] Revolving Credit Facility Revolving Credit Facility [Member] Schedule of Cash Equivalents and Marketable Securities Cash, Cash Equivalents and Investments [Table Text Block] Effect of changes in exchange rates on cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Accounts payable Accounts Payable, Current Prepaid expenses and other current assets Prepaid Expenses and Other Current Assets [Member] Restatement Determination Date: Restatement Determination Date [Axis] Corporate debt securities Corporate Debt Securities [Member] Commitments and contingencies Commitments and Contingencies Insider Trading Policies and Procedures [Line Items] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Prepaid expenses and other current assets, foreign currency forward contracts Derivative Asset, Current Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Line of Credit Facility [Line Items] Line of Credit Facility [Line Items] Geographical [Axis] Geographical [Axis] Income Taxes Income Tax Disclosure [Text Block] Canadian dollar Canada, Dollars Total financial liabilities Financial Liabilities Fair Value Disclosure Current liabilities: Liabilities, Current [Abstract] Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, $0.01 par value; 1,000,000 shares authorized; none issued and outstanding Preferred Stock, Value, Issued Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Diluted (in dollars per share) Diluted net income per common share (in dollars per share) Earnings Per Share, Diluted Total liabilities Gross Amounts Recognized Derivative Liability, Subject to Master Netting Arrangement, before Offset Net unrealized (losses) gains Unrealized Gain (Loss) on Investments PEO Total Compensation Amount PEO Total Compensation Amount Hedging Relationship [Axis] Hedging Relationship [Axis] Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Collaborative Arrangements by Agreement [Domain] Collaborative Arrangements by Agreement [Domain] Collaborative Arrangements by Agreement [Domain] Unrealized gains on foreign currency forward contracts, net of tax of $(13.2), $(16.0), $(1.6) and $(34.3), respectively Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Level 3 Fair Value, Inputs, Level 3 [Member] Trading Symbol Trading Symbol Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Interest income Investment Income, Interest and Dividend Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Unrealized holding losses on marketable securities, tax OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax Net income Net income Net income Net income Net Income (Loss) Total current liabilities Liabilities, Current Derivative Contract [Domain] Derivative Contract [Domain] Schedule of Cash Flow Hedging Instruments Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Company Selected Measure Name Company Selected Measure Name All Currencies [Domain] All Currencies [Domain] Property and equipment, net Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization Liabilities and Shareholders’ Equity Liabilities and Equity [Abstract] ESPP share issuances Employee Stock [Member] Repurchase of common stock Value of shares repurchased Stock Repurchased During Period, Value Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Table] Amounts reclassified from accumulated other comprehensive income (loss) Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent Unrealized loss Gross Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Contract liabilities Contract with Customer, Liability Schedule of Earnings Per Share, Basic and Diluted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Cost of sales Cost of Goods and Services Sold Executive Category: Executive Category [Axis] Level 1 Fair Value, Inputs, Level 1 [Member] Name Measure Name Marketable securities Marketable Securities, Current Name Forgone Recovery, Individual Name British pound sterling United Kingdom, Pounds Goodwill Goodwill Equity Components [Axis] Equity Components [Axis] Equity Components [Axis] Financial Instruments [Domain] Financial Instruments [Domain] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Hedging Relationship [Domain] Hedging Relationship [Domain] Certificates of deposit Certificates of Deposit [Member] Asset Acquisition [Domain] Asset Acquisition [Domain] Underlying Securities Award Underlying Securities Amount Entity Small Business Entity Small Business Accumulated Other Comprehensive Income (Loss) Comprehensive Income (Loss) Note [Text Block] Local Phone Number Local Phone Number Accounts receivable, net Increase (Decrease) in Accounts Receivable Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Letters of Credit Letter of Credit [Member] Verve Verve [Member] Verve Selling, general and administrative expenses Selling, General and Administrative Expenses [Member] Notional amount of foreign currency forward contract Derivative, Notional Amount Fair Value by Measurement Frequency [Axis] Measurement Frequency [Axis] Long-term operating lease liabilities Operating Lease, Liability, Noncurrent Restricted stock units (including PSUs) Unvested restricted stock units (including PSUs) Restricted Stock Units (RSUs) [Member] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Purchase of common stock Payment To Acquire Common Stock Payment To Acquire Common Stock Schedule of Foreign Exchange Contracts Schedule of Foreign Exchange Contracts, Statement of Financial Position [Table Text Block] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Reclassification out of Accumulated Other Comprehensive Income [Axis] Reclassification out of Accumulated Other Comprehensive Income [Axis] Line of Credit Facility [Table] Line of Credit Facility [Table] Income Statement Location [Axis] Income Statement Location [Axis] Research and development expenses Research and Development Expense (Excluding Acquired in Process Cost) Issuance of common stock under benefit plans (in shares) Stock Issued During Period, Shares, Employee Benefit Plan Total stock-based compensation expense, net of tax Share-Based Payment Arrangement, Expense, after Tax Common stock withheld for employee tax obligations Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation Foreign currency forward contracts Foreign Exchange Forward [Member] Europe Europe [Member] SYMDEKO/SYMKEVI SYMDEKO/SYMKEVI [Member] SYMDEKO/SYMKEVI [Member] Product and Service [Domain] Product and Service [Domain] Schedule of Potential Gross Common Equivalent Shares Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Other Performance Measure, Amount Other Performance Measure, Amount Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Inventories Increase (Decrease) in Inventories Unrealized holding losses on marketable securities, net of tax of $1.7, zero, $5.2 and zero, respectively Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent Research and development expenses Research and Development Expense [Member] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Antidilutive securities excluded from computation of earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Award Type [Axis] Award Type [Axis] Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Unrealized gains (losses) on foreign currency forward contracts, tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax, Parent Document Quarterly Report Document Quarterly Report Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair Value Hierarchy and NAV [Domain] Additional Cash Flow Information Additional Financial Information Disclosure [Text Block] Hedging Designation [Axis] Hedging Designation [Axis] Trading Arrangement: Trading Arrangement [Axis] Contingent consideration, measurement input (as a percent) Business Combination, Contingent Consideration, Liability, Measurement Input Publicly Traded Companies Sale Publicly Traded Companies Sale [Member] Publicly Traded Companies Sale Use of Estimates Use of Estimates, Policy [Policy Text Block] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Corporate equity securities Equity Securities, FV-NI and without Readily Determinable Fair Value [Abstract] Schedule of Provision for (Benefits from) Income Taxes and Effective Tax rates Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Stock-based compensation expense: Share-based Compensation Allocation [Abstract] -- None. No documentation exists for this element. -- Total marketable debt securities Debt Securities, Available-for-Sale [Abstract] Entity File Number Entity File Number Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Amortized Cost Cash Equivalents And Debt Securities, Available for Sale Cash Equivalents And Debt Securities, Available for Sale Offsetting Derivative Liabilities [Abstract] Offsetting Derivative Liabilities [Abstract] Discount Rate Measurement Input, Discount Rate [Member] Derivative term Derivative, Term of Contract On Available-For-Sale Debt Securities AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member] Allowance for credit loss for available-for-sale debt securities Debt Securities, Available-for-Sale, Allowance for Credit Loss Sales and maturities of available-for-sale debt securities Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale Entity Shell Company Entity Shell Company Bastiano Sanna [Member] Bastiano Sanna [Member] Other comprehensive income (loss) before reclassifications OCI, before Reclassifications, Net of Tax, Attributable to Parent Restatement Determination Date Restatement Determination Date Schedule of Offsetting Liabilities Offsetting Liabilities [Table Text Block] KALYDECO KALYDECO [Member] KALYDECO inventories, net Other liabilities Increase (Decrease) in Other Operating Liabilities Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Cash, cash equivalents and restricted cash—beginning of period Cash, cash equivalents and restricted cash—end of period Cash, cash equivalents and restricted cash per condensed consolidated statement of cash flows Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Government-sponsored enterprise securities Government-sponsored enterprise securities US Government-sponsored Enterprises Debt Securities [Member] Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] ORKAMBI ORKAMBI [Member] ORKAMBI [Member] Unrealized loss position for greater than twelve months Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer Common stock, shares issued (in shares) Common Stock, Shares, Issued Schedule of Company's Net Unrealized (Losses) Gains on Corporate Equity Securities Unrealized Gain (Loss) on Investments [Table Text Block] Security Exchange Name Security Exchange Name Total financial assets Assets, Fair Value Disclosure Selling, general and administrative expenses Selling, General and Administrative Expense Accumulated other comprehensive (loss) income Accumulated Other Comprehensive Income (Loss), Net of Tax Swiss Franc Switzerland, Francs Acquired In-Process Research and Development and Other Arrangements Collaborative Arrangement Disclosure [Text Block] Foreign Currency Translation Adjustment Foreign Currency Forward Contract Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Stock options Stock options Employee Stock Option [Member] Hedging Derivative Instruments and Hedging Activities Disclosure [Text Block] CRISPR T1D CRISPR T1D [Member] CRISPR T1D Gross Amounts Not Offset Derivative Liability, Subject to Master Netting Arrangement, Deduction of Financial Instrument Not Offset Legal Offset Derivative Liability, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election Collaborative arrangement, development and regulatory potential milestone payments maximum Collaborative Arrangement Development And Regulatory Potential Milestone Payments Maximum Represents the potential milestone amount to be paid by the entity under the collaboration agreement if drug candidates are approved and commercialized. Total costs and expenses Costs and Expenses Other financing activities Proceeds from (Payments for) Other Financing Activities Maximum Maximum [Member] Comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Document Type Document Type Reshma Kewalramani [Member] Reshma Kewalramani [Member] Tabular List, Table Tabular List [Table Text Block] Entity Address, Address Line One Entity Address, Address Line One Long-term marketable securities Marketable Securities, Noncurrent Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Other current liabilities, foreign currency forward contracts Derivative Liability, Current Stock-based Compensation Expense and Share Repurchase Programs Share-Based Payment Arrangement [Text Block] Up-front payment Collaborative Arrangement Up-front License Fee Collaborative Arrangement Up-front License Fee Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Other non-cash items, net Other Noncash Income (Expense) Purchases of available-for-sale debt securities Payments to Acquire Debt Securities, Available-for-Sale Gross Unrealized Losses Equity Securities, FV-NI, Unrealized Loss Derivative [Table] Derivative [Table] Other current liabilities Other Liabilities, Current Variable Rate [Axis] Variable Rate [Axis] Income Statement [Abstract] Income Statement [Abstract] Raw materials Inventory, Raw Materials, Net of Reserves Costs and expenses: Costs and Expenses [Abstract] Title of 12(b) Security Title of 12(b) Security Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Cash equivalents: Cash and Cash Equivalents, Fair Value Disclosure Gross Amounts Presented Derivative Liability Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Amortized Cost Debt and Equity Securities, Cost Debt and Equity Securities, Cost Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Collaborative Arrangements by Agreement [Axis] Collaborative Arrangements by Agreement [Axis] Significant terms of collaboration arrangements, by individual agreement. Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Entity Tax Identification Number Entity Tax Identification Number Inventories Total Inventory, Net Stock-based compensation expense related to inventories Share-Based Payment Arrangement, Amount Capitalized Statistical Measurement [Axis] Statistical Measurement [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Financial Instrument [Axis] Financial Instrument [Axis] Entity Interactive Data Current Entity Interactive Data Current Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-Sale [Table] Adjustments to reconcile net income to net cash provided by operating activities: Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Total Shareholder Return Amount Total Shareholder Return Amount Repurchases of common stock Payments for Repurchase of Common Stock Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Other Assets Other assets Other Assets [Member] E. Morrow "Morrey" Atkinson III [Member] Morrey Atkinson [Member] Share-based Compensation Arrangement by Share-based Payment Award Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Retained earnings Retained Earnings (Accumulated Deficit) Measure: Measure [Axis] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Name Outstanding Recovery, Individual Name Gross Amounts Not Offset Derivative Asset, Subject to Master Netting Arrangement, Deduction of Financial Instrument Not Offset Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Current assets: Assets, Current [Abstract] Entity Address, State or Province Entity Address, State or Province Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Antidilutive Securities Excluded from Computation of Earnings Per Share Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Common stock, shares outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding PEO PEO [Member] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Total assets Gross Amounts Recognized Derivative Asset, Subject to Master Netting Arrangement, before Offset Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Remaining milestone payment Business Combination, Remaining Milestone Payment Business Combination, Remaining Milestone Payment Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Fair Value Equity Securities, FV-NI, Current Schedule of Inventories by Type Schedule of Inventory, Current [Table Text Block] Schedule of Foreign Exchange Contracts, Condensed Consolidated Statements of Operations Reclassification out of Accumulated Other Comprehensive Income [Table Text Block] Other long-term liabilities, foreign currency forward contracts Derivative Liability, Noncurrent Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Effective tax rate Effective Income Tax Rate Reconciliation, Percent Measurement Input Type [Domain] Measurement Input Type [Domain] Milestone payment Collaborative Arrangement, Milestone Payment Collaborative Arrangement, Milestone Payment Credit Facility [Axis] Credit Facility [Axis] Total liabilities Liabilities Asset Acquisition [Axis] Asset Acquisition [Axis] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Accumulated Other Comprehensive Income (Loss) Total AOCI Attributable to Parent [Member] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Debt securities fair value, unrealized loss position Debt Securities, Available-for-Sale, Unrealized Loss Position Measurement Frequency [Domain] Measurement Frequency [Domain] All Executive Categories All Executive Categories [Member] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Income tax effect Share-Based Payment Arrangement, Expense, Tax Benefit Net income per common share: Earnings Per Share [Abstract] Common stock, $0.01 par value; 500,000,000 shares authorized, 257,828,508 and 257,011,628 shares issued and outstanding, respectively Common Stock, Value, Issued Matures after one year through five years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Deferred income taxes Increase (Decrease) in Other Deferred Liability Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Total current assets Assets, Current Fair Value Cash Equivalents And Debt Securities, Available for Sale, Fair Value Disclosure Cash Equivalents And Debt Securities, Available for Sale, Fair Value Disclosure Payments on finance leases Finance Lease, Principal Payments Beginning balance Ending balance Business Combination, Contingent Consideration, Liability Corporate equity securities Equity Securities [Member] Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] All Individuals All Individuals [Member] Supplemental disclosure of cash flow information: Supplemental Cash Flow Information [Abstract] Other (expense) income, net Other (expense) income, net Other Nonoperating Income (Expense) Entity Filer Category Entity Filer Category Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Statement [Table] Statement [Table] Contingent consideration Business Combination, Contingent Consideration, Liability, Noncurrent Current Fiscal Year End Date Current Fiscal Year End Date Number of shares authorized to be repurchased Stock Repurchase Program, Authorized Amount Repurchase of common stock (in shares) Shares repurchased (in shares) Stock Repurchased During Period, Shares Contingent liabilities Contingent Liabilities Contingent Liabilities Marketable Securities and Equity Investments Cash, Cash Equivalents, and Marketable Securities [Text Block] PEO Name PEO Name Entrada Therapeutics Entrada Therapeutics [Member] Entrada Therapeutics Schedule of Accumulated Other Comprehensive Income (Loss) Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Base Rate Base Rate [Member] Issuance of common stock under benefit plans Stock Issued During Period, Value, Employee Benefit Plan Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Charles F. Wagner, Jr. [Member] Charles F. Wager, Jr. [Member] Asset-backed securities Asset-Backed Securities [Member] Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Other current liabilities, contingent consideration Business Combination, Contingent Consideration, Liability, Current Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] CRISPR JDCA CRSIPR JDCA [Member] CRISPR Amended and restated the Original CTX001 JDCA Depreciation expense Depreciation, Depletion and Amortization Euro Euro Member Countries, Euro Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Total shareholders’ equity Beginning balance Ending balance Equity, Attributable to Parent Indemnification claims Indemnification Claims Amount of indemnification claims currently outstanding Commercial paper Commercial Paper [Member] Net unrecognized tax benefits which would affect the tax rate if recognized Unrecognized Tax Benefits that Would Impact Effective Tax Rate Restricted stock units (including PSUs) Restricted Stock [Member] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Prepaid expenses and other current assets Restricted Cash and Cash Equivalents Debt covenant, increase in consolidated leverage ratio Debt Covenant, Increase In Consolidated Leverage Ratio Debt Covenant, Increase In Consolidated Leverage Ratio Schedule of Cash, Cash Equivalents and Available-for-sale Securities [Table] Schedule of Cash, Cash Equivalents and Available-for-sale Securities [Table] Schedule of the cash and cash equivalents and available-for-sale investments held by the entity. Catalyst Biosciences Catalyst Biosciences [Member] Catalyst Biosciences On Foreign Currency Forward Contracts Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] Long-term marketable securities Marketable Securities, Noncurrent [Member] Marketable Securities, Noncurrent Income before provision for income taxes Income before provision for income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Schedule of Additional Cash Flow Information Condensed Cash Flow Statement [Table Text Block] Equity securities without readily determinable fair value, amount Equity Securities without Readily Determinable Fair Value, Amount Not Designated as Hedging Instrument Not designated as hedging instruments Not Designated as Hedging Instrument [Member] Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Hedging Designation [Domain] Hedging Designation [Domain] Level 2 Fair Value, Inputs, Level 2 [Member] Entity Emerging Growth Company Entity Emerging Growth Company Investment in equity securities and notes receivable Payments to Acquire Equity Securities, FV-NI Intangible assets Intangible Assets, Net (Excluding Goodwill) Increase (Decrease) in Stockholders' Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Document Fiscal Period Focus Document Fiscal Period Focus Accrued expenses Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Title Trading Arrangement, Individual Title Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Common Stock Common Stock [Member] Individual: Individual [Axis] City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Product and Service [Axis] Product and Service [Axis] Earnings Per Share Earnings Per Share [Text Block] Income Statement Location [Domain] Income Statement Location [Domain] Other assets, foreign currency forward contracts Derivative Asset, Noncurrent Document Fiscal Year Focus Document Fiscal Year Focus Geographical [Domain] Geographical [Domain] Minimum Minimum [Member] Shares used in per share calculations: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Basis of Presentation and Accounting Policies Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Exercise Price Award Exercise Price Cash Cash CRISPR CRISPR [Member] CRISPR Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Assets Assets [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Payments in connection with common stock withheld for employee tax obligations Payment, Tax Withholding, Share-Based Payment Arrangement U.S. Treasury securities US Treasury Securities [Member] Cash paid for income taxes Income Taxes Paid, Net Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Deferred tax assets Deferred Income Tax Assets, Net Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Retained Earnings Retained Earnings [Member] Summary of cash, cash equivalents and marketable securities Schedule of Cash, Cash Equivalents and Available-for-sale Securities [Line Items] -- None. No documentation exists for this element. -- Schedule of Stock-based Compensation Expense by Line Item Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Total liabilities and shareholders’ equity Liabilities and Equity Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost Other assets Other Assets, Noncurrent Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Operating lease assets Operating Lease, Right-of-Use Asset Basic (in dollars per share) Basic net income per common share (in dollars per share) Earnings Per Share, Basic Accounting Policies [Abstract] Accounting Policies [Abstract] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Currency [Axis] Currency [Axis] Arrangement Duration Trading Arrangement Duration Entity Address, City or Town Entity Address, City or Town Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Total marketable debt securities Marketable Securities And Other Noncurrent Assets [Member] Marketable Securities And Other Noncurrent Assets Schedule of Fair Value of Our Contingent Consideration Liabilities Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block] Document Transition Report Document Transition Report Award Timing Predetermined Award Timing Predetermined [Flag] SOFR Loan Secured Overnight Financing Rate (SOFR) [Member] Secured Overnight Financing Rate (SOFR) Stock repurchase program, remaining amount Stock Repurchase Program, Remaining Authorized Repurchase Amount Termination Date Trading Arrangement Termination Date Proceeds received Proceeds from Sale and Maturity of Marketable Securities Accounts payable Increase (Decrease) in Accounts Payable Common stock, shares authorized (in shares) Common Stock, Shares Authorized Fair Value Debt securities Total Debt Securities, Available-for-Sale Gross Unrealized Gains Equity Securities, FV-NI, Unrealized Gain Gross Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] CRISPR Therapeutics CRISPR Therapeutics AG [Member] CRISPR Therapeutics AG Derivative Instrument [Axis] Derivative Instrument [Axis] Allocation of net profits and net losses, percent Collaborative Arrangement, Allocation Of Net Profits And Losses, Percent Collaborative Arrangement, Allocation Of Net Profits And Losses, Percent Gross Unrealized Gains Debt and Equity Securities, Unrealized Gain Debt and Equity Securities, Unrealized Gain All Trading Arrangements All Trading Arrangements [Member] Measurement Input Type [Axis] Measurement Input Type [Axis] All Adjustments to Compensation All Adjustments to Compensation [Member] Derivative [Line Items] Derivative [Line Items] Award Timing Disclosures [Line Items] Compensation Amount Outstanding Recovery Compensation Amount Marketable securities Marketable Securities [Member] Marketable Securities [Member] Gross Amounts Presented Derivative Asset Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract] Statement of Comprehensive Income [Abstract] Australian dollar Australia, Dollars TRIKAFTA/KAFTRIO TRIKAFTA/KAFTRIO [Member] TRIKAFTA/KAFTRIO [Member] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Insider Trading Arrangements [Line Items] AOCI Attributable to Parent, Net of Tax [Roll Forward] AOCI Attributable to Parent, Net of Tax [Roll Forward] Entity Registrant Name Entity Registrant Name Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Award Timing Method Award Timing Method [Text Block] Share-based payment arrangements (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Losses on equity securities Equity Securities, FV-NI, Unrealized Gain (Loss) Adjustment to Compensation, Amount Adjustment to Compensation Amount Cost of sales Cost of Sales [Member] Change in fair value of contingent consideration Decrease in fair value of contingent consideration Decrease in fair value of contingent payments Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Document Period End Date Document Period End Date Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Adoption Date Trading Arrangement Adoption Date Schedule of Financial Assets Subject to Fair Value Measurements Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Long-term finance lease liabilities Finance Lease, Liability, Noncurrent Entity Central Index Key Entity Central Index Key Reclassification out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income [Member] Financial instruments carried at fair value (liability positions): Liabilities, Fair Value Disclosure [Abstract] Total stock-based compensation expense included in costs and expenses Share-Based Payment Arrangement, Expense Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Provision for income taxes Income Tax Expense (Benefit) Finished goods Inventory, Finished Goods, Net of Reserves Total product revenues outside of the United States Non-US [Member] Designated as Hedging Instruments Designated as hedging instruments Designated as Hedging Instrument [Member] Fair Value Measurements Fair Value Disclosures [Text Block] Number of operating segments Number of Operating Segments Name Trading Arrangement, Individual Name Cash equivalents: Cash and Cash Equivalents [Abstract] Total other comprehensive income (loss) Other comprehensive income (loss), net of tax Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Schedule of Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] Equity [Abstract] Equity [Abstract] Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Inventories Inventory Disclosure [Text Block] Product revenues, net Revenue from Contract with Customer, Excluding Assessed Tax Entity [Domain] Entity [Domain] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Amendment Flag Amendment Flag Other Other, Non U.S. [Member] Other, Non U.S. [Member] Legal Entity [Axis] Legal Entity [Axis] Gross Amounts Offset Derivative Liability, Subject to Master Netting Arrangement, Asset Offset Money market funds Money Market Funds [Member] Jeffrey M. Leiden [Member] Jeffrey M. Leiden [Member] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Payment to acquire ViaCyte, Inc., net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Common stock withheld for employee tax obligations (in shares) Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Interest expense Interest Income (Expense), Net Matures within one year Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One Financial instruments carried at fair value (asset positions): Assets, Fair Value Disclosure [Abstract] Credit Facility [Domain] Credit Facility [Domain] Time deposits Bank Time Deposits [Member] Basis spread on variable rate (as a percent) Debt Instrument, Basis Spread on Variable Rate Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Fair Value Debt and Equity Securities, Fair Value Debt and Equity Securities, Fair Value Diluted (in shares) Diluted weighted-average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Diluted Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Revenue Recognition Revenue from Contract with Customer [Text Block] Offsetting Derivative Assets [Abstract] Offsetting Derivative Assets [Abstract] Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Company Selected Measure Amount Company Selected Measure Amount Additional paid-in capital Additional Paid in Capital, Common Stock Legal Offset Derivative Asset, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election Investments with restrictions Restricted Investments, at Fair Value Additional Paid-in Capital Additional Paid-in Capital [Member] Sale of equity securities Proceeds from Sale of Equity Securities, FV-NI Effect of potentially dilutive securities: Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract] Balance Sheet Location [Axis] Balance Sheet Location [Axis] Total assets Assets Name Awards Close in Time to MNPI Disclosures, Individual Name Employee stock purchase program (in shares) Incremental Common Shares Attributable to Dilutive Effect of Equity Unit Purchase Agreements Gross Unrealized Losses Debt and Equity Securities, Unrealized Loss Debt and Equity Securities, Unrealized Loss Cover [Abstract] Cover [Abstract] Commercial paper Commercial Paper, Not Included with Cash and Cash Equivalents [Member] Stock-based compensation expense APIC, Share-Based Payment Arrangement, Increase for Cost Recognition United States UNITED STATES Recurring Basis Fair Value, Recurring [Member] Other long-term liabilities Other Liabilities, Noncurrent Non-NEOs Non-NEOs [Member] Cash Flow Hedging Cash Flow Hedging [Member] Asset acquisition, consideration transferred Asset Acquisition, Consideration Transferred Net increase in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Non-PEO NEO Non-PEO NEO [Member] Marketable securities: Marketable Securities Equity Component [Domain] Equity Component [Domain] Line of credit facility additional borrowing capacity Line Of Credit Facility Additional Borrowing Capacity Amount of increased borrowing capacity available in the future. Adjustment to Compensation: Adjustment to Compensation [Axis] Original cost Amortized Cost Equity Securities, FV-NI, Cost Schedule of Offsetting Assets Offsetting Assets [Table Text Block] Work-in-process Inventory, Work in Process, Net of Reserves Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Gross Amounts Offset Derivative Asset, Subject to Master Netting Arrangement, Liability Offset Basic (in shares) Basic weighted-average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Entity Current Reporting Status Entity Current Reporting Status Collaborative arrangement, right to exclusively license, number of targets Collaborative Arrangement, Right To License, Number Of Targets Collaborative Arrangement, Right To License, Number Of Targets Income from operations Operating Income (Loss) Cash and cash equivalents Cash and Cash Equivalents [Member] Issuances of common stock under benefit plans Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Statement Statement [Line Items] Other comprehensive income (loss): Other Comprehensive Income (Loss), Net of Tax [Abstract] Total stock-based compensation expense included in “Total costs and expenses” Share-Based Payment Arrangement, Expensed and Capitalized, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Septerna, Inc Septerna, Inc [Member] Septerna, Inc Shareholders’ equity: Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Reclassification out of Accumulated Other Comprehensive Income [Domain] Reclassification out of Accumulated Other Comprehensive Income [Domain] EX-101.PRE 9 vrtx-20230930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 10 vrtx-20230930_g1.gif GRAPHIC begin 644 vrtx-20230930_g1.gif M1TE&.#EA801U 7< "'Y! $ + !A!'4!A_\ _P !$1$2,C(S0T M-$='1U(4Q5=75VGM,TXF)B8UDV9B8F)UYWIVQSZ>GIZFZU:J, MX[..]+3$VK6UM;:;YKR<];[,W\&JZL/#P\6I]\?3Y,JW[Z]G+\MK(^MSC[MW=W=_/^N#5]>'G\.36^^7K\N;=]^C<_.GN].OA M_.SE^>SL[.WQ]N[F_?'K_?'T^/+M^_3O_?3V^O?S_OCV_?CY^_GW_OO\_?S[ M_____P M M M M M M M M M M M M C^ (,('$BPH,&# M"!,J7,BPH<.'$"-*G$BQHL6+&#-JW,BQH\>/($.*'$FRI,F3*%.J7,FRIO8,.*'4NVK-FS:-.J7//JW/'D"-+GDRYLN7+F#-KWLRY,\X" 4('B# P@N@ M*"H..'UZ@T84IU.#!,U:- .I#$078%B[-L?+WZ\5#:\=H>CG%U0$&#"5N'+I) M^ ' !TF@7V&$_@2)EIIX[F%$VW$5_9<0?,*))]]3V*4&6H$'!4"=>.N9YI"" M#(D'X':A/1B$;0=%&,2$R(6V'('V<9:;0/3)-D!WUS5$'(4$-2=B@9@$)L@O@E!I&F1JM*-.N"> H4:E-ZDF::FI@6^M"N=]I9D)XB*DI0 ML$$,FZ)R ]$7)JN1.>L0B@Q%^J=HR%V:[+4'T1>NI[TN].MZH[9T:D7OHI&K$ 8-FDE"N*AMN^ITBE+T)D"P8?@ MO0+=&X!VXJEI;<8&PT==GPG0%R6+ XG'L$+TY89@LNW>ZU[$PFE,T*=\OJLG MCBT[/&V!\+5+;[:U%H0?>*RYAU]WWA:$\K))GC:<>ANHZ>&MR;Y9'LC@/LR? MU<%AW>B0E6IMVY85@VMEP:&=V-J(;;.]<8 $L[VD;L")F#3^V_MU:?! >+^+ ML'KS#FU@OX7J"Z*?V+FV Y[;8:UW$*%WKCB*-F>9N%ZKDD: S MIRT XB(D'4#DZW0Y 2EOGB;F9JX MFHB0+ZYWW04!WW!W@Q)$6ZJ&,Z8MX%SBOEW3L&G7G,I?7W7NTHPUN MG'@-G3^\P\NC*9^TP:,&/T*A.FI0;O+I$YKB!I\!^LEM[:L8X$8G/+B)"'-; M6D_+B'.;#30M-Z[!U[(Z!9Q$V8:"*:/6O5Z6/2:%,#014-QJQ(>OYGVI-OJY M50+D,[M=@1"!LOF9J3;^!ZL4"@=VH5XMB8>ERM<0@:,FVRTN0_59 MC6LXYRN_M6QP02R1L1Y&'1X&#VESFU+S^B2U"J&&1 ,[6/5.Z+L20F9[P>-: M:BYH'"<*48.1$]<+M=,DXK@F F#CD@OSN)!"]1%/@/3A%_FWMZDEL("4BZ0D M'9BQF@6G:1"+6WTBY:VF@68];X(?CV!4ODX*KW!NG$B!K%0 #W:J.8K\W95, M%[T MT-FQ:9'^$YHM;S,E^!3H1X/DWB\3$LXK^?-FQAPG OE)H0Y.$I*0+.<)7>,> MXJ DP0#S8.&R,GRW7%F16/.GD;YT9+.4TVH?"=$*/2VQ;%F0 J%F\]H>4 # MTFYNS<3A+G5J1X1*3)A<.NA (J:^MBV)C%YJ9DZA:2PKC2=V[:*-+8,ST_D- M%'%J@B3.R"B;,3ZI3P>3JMRV]#)V(E"?*CT,'$\U2GS*38(>A5-<%<)5@?H, MH#&=JC9=.M/8*-*%H4(!A8P448C6,J*V0P&1&N:>4^&'1!W%%SZGIY"ED9): MWLII2M/:$ I]#)G _&GD2#A)OBWN-IJ]D@[G.-=8F@]/5\3^ZK080*R>#G6) M0T2F'0M'GRS*KYRB10CQN);5;Z;+HN(,+K-B=YS?'NU_<^479^$94F\^2)>3 MW=@]6\NUFB($N;,,WH/P&ER1UO*[QEF5@_ZJT'7!*'.]*BP!#WO>W_;+57%U M['DONQM3FK-/'\(=22.[G-16=;HKK9.RWK4>A\KRP#8MWBWQA,N=ZK2?X77F M#^UT+]=M,4I=XQ[S9+O4VADKIXK-EXPZ!=1?TJ=[Z+GJ'8O;X'05RF*N?=:[ M:// I]X13R#5('".*&,$"P:.V+GNE>)JN4V9U""_NIEL;GPE*!Z0O,+Q(I0; MF+(ISPW'?9LG>\L;983],;?R/6#^FG.TQ7EN8& B"8MQ1!8 M4]JX)M$AI%2AY^Q,TN04;GS<8M=J7# :0QD16Z'I4 M8TY5T[W^DG,WZ>;N;^4Z#;$\K1"B]NA>;?S5]6(D'?V\^.-^??'*>_5KP;TP M@0+_2V]H"G275IQTB9UT](3IB=R M!6#W> 3FU)MYUF#5PX^\&ZYTI5<<89\U+VI"U7;@01PTI VZWATS@+SO_>\: MZ;M2V WXPAN^)P70X^$7ORW% X7PC(^\Y%E2WLE;WB"5'PKD+\_YSGO^\VY! MJM]!3_K2F_[TJ$^]ZE?/^M:[_O6PC[WL9T_[VMO^]KC/O>YWS_O>^_[WP ^^ M\(=/_.(;?_&P 9!3PU8<2Q9'T 8LNMQ8@U:--$R?L4FQW(W^2=J-,T1#"WDL M$)W"I=Q4_UO<[1=Y2+2V@F710.\__E<:MM\?I[]8&=Y(PUQ=]0U9!]0G@1WB M BCRMTY%1CD'DW5,9BP 5B']E5M I2;]]Q&V94T#1"/FTFLDM#YPHWB@$7_1 MDR[8 8)#@3^;MQ#1)DDD!4DIB!'04X!A825!-$,^)R;Y]WWDDF/"1H+0-3(W M*!*"0VJE!H.1$V@0*%->9B=#)FPX8GY8]%I )UT@48%/."=,4X-X)U(%QFQY M']..$]=5$L?"!+F1(1=$7'F9"$U&!%_5B M)X9T,S6C]Q$"N"_$0H!$.')0F(#^!I5;2\@U[K0_H&&$0!=U(4&%;D,C6U-. M600;954?)I(0^\<;L%5!?-@3L %]$=&"YK6&WB42N>%X<$@5K22%$5 06(1 M=ZACF3=1TS**=X0@)>,2Q,&+Q5< ZT53B.@S)K=%A6: RN$_D%A;4LB,=?,= M_==;;79"[4)I)?(R.C)###$ M'%^_))";&8;'Z0;UR-W7M> ?<8A+G4V(R3\,IRL%.\*%D+%9 )I,S.F,;X/R8<-!,[ON,A4GAJ&/-@M'*$P)4:)/./P#4P\F$=KY9"&RDX'71^ ML"=8<6?^0,<(4P.UB)1X+Q)8-&+36V/S0H1B5+7D1^74+C>'(,EQ+&CT7#E" M6R'F-US"A3]V4C7*:O1 M6 2S@A/F:_5X)1W6' V"&N%#-\*(D$W1.7&# O?S+G793<&3 #1(&E/R(CYS4]AW&LQ3AW5"B]*E;T:3 M/M*'>:Q!),SB.YD%6T,4B!=6'WJ2&OI"-DX8G(I?QQC6J MJ)M[5#"[0S9L>1LK,T NB9=/<6E+1$VP4D>4RK]7-'A5L;=8W%EITINIU$B7,LQE;" TE,Q6)B-4HDU:+29HKL*17[ M22T'U)#V-)\_=2 ,H)SF&3>9@CD2%4N0U$P]6J->ET#;F3[N]*3TB(];"*%X M,CN?Y%)WN7KDF*$,5W35)6S:04S^7M-K S"+JMEK86(SVO:=H.4TN.@P(^1( MR*A!K2%H_*&!"C&.C()/W4F=M?$@/VI_W55&+W80WAEGFD;#I[R^=S(OJ#B\AC*RH;?2)H8M.0&^0G)BI(O:*=!RAX "D< MU>@EGW6JBD9]FQJ*&7,C.[E&J3$TEMRJ:@S84LD10-TA-IOF2+<18KB)0.)I.BQ5 M4W#V, ZCZ1M/,4GZCA9'HX5:D18@R&.,HD4[K8 M@;*EL75R,$HR28G6,>6ZH'/J2 BKBP$K/L*1I[>7?*'E7=NZ:,ZT)#@Y?53# MFW^*4B!9;+0E5B]K)]#B?<+4FP=CMS#+D.D(,*;N,:)B&3KN"DW7Y:YEDT:J^SCH'#IMG[^YIYV.;=7 31 MUY!@ZJO]REK,1#:DEFD\,HO^^4K3F%N_2T(5]D+%]K7]%C>M-)X#R6B?:B$* M0EB<"#(PM:>E1W\N:B'9N@'BMXJ_5D1;%Y0[-AWA%[IM,YDMU2=I"&7V1UJ_ M9A :'TPPL+W%YH*UW=U1Z2P MD3_@H79DQ JG!T5A[0UW"G\430'J;U007#]\L/E V!R0G_$0G\,XU?)L4K1 MJUVK=G)QI3&D^W"+L=^_,?^");'>ER<4"''@'S(B)Q*1*&)2K2>2DLG3OBY[>0C+OOS+?-&5+/L0+7BLC[277E@1N@/, MS-S,?I$;Q%+!Q(R&OY13$=6&'E&7TV4 W-S-WOS-X.S-DDP!Y%S.YGS.Z'S. MSKQ[V881@LRO)^@1([C-X5S/]CS.Z9S/^DP!ZZQ[WD,Y);PQ]PBY^KAUQ>4G M)#E/&H23]E4_03JQ]&+/$@W.^+S/%EW._8Q[0JFJ95FZ/W8;=0%0Z0'C=U$XMT0FQ 5G='Q%P LQ V\R ^ 8!#/@ % M '4]$3.@U0Y! C!V:X1Q:3-&5]MT?$3 !:@P4 7 DDMP[)]&YOMUAMX #/ MEVM=$&T-KFT] +U=$)A=(#.;UX&QUY2TJDG:MDL:V,<\V(/^*M@D!H&VJMB< MU=B.G1"Y(0##O1V*AZB-0BAP71&BW2VF23O@00"-#!FKO<_?!QJ4O4'9V;,! MT-O,I@!:S6($\-U)S&:I#64-A=S)'5[JRKP'2UPB3=W(5-C0O;M%%['>M-@M MHMWWS-V<+0"??8D'$0("0"?.J$1,72$C+A SP-X(42:VU,N.\=[Z?"0A\-OT M'2#= 1KN6H9$HAPS()@ILF7O%^+Y0N"!H=,1*,0;C67 M!4:T7.$6'LXM5S6=7=>7&./JL=M9S<4AKM]P+=/Z_=HHT-8!H-8$H0 "( "D M"3?H1CVKT=]!P-[)I'B^;P0(; ;%A Y9TS]3T0[(W?#UF M#G#6?A(J9-[FW<'H7?TXK<3>,R, !*!]^;(\KQT$%C WJT 0EX4++W<*TNI MC9;D#&Y')5U+AXU2V!OEV5WE%,W=GY;F75PI!R"2 K >;%H J9WA,P#9LTL M=/W6E4( M!5N3X#=!S:NLIB"M#NP%XP*"D : MCZY86;WMEOWO=H(=,++MV]'M0> E,V7D@X5E)[.UZ$F M!&>/XEPO[HC74; M(2##!)'^[[^$V;I]6[\Y-J?1'9Q-V;_N."JRUOI-&F?.[=J1U0, UYE.&B$P M #,P P= '0.OV2;BW?E"X<->$_\,7#3,=3XV-3@J[9(YE^1!]+XQ(B".ZZ&AYB B[ *A %.Y?K)A*5L)..CI,Q$@UFYS M[Z+!]@*1Z?ZBV:J[UJ%=H,)LF(=_0/K-&OF2\O+(%1>/SBPC(OJM'QTOFJO1 M[9]]&@30ZS>CVUEXXI^M1"LOX .QZJ=> !O.;)F]^&5DJ14D>"E6^"T_(@VR M]$2QS%@QS],>]MU\Y9X^&EN3> [(/V93XP5" &%)XW7_)>'^-OKVWH6?MN[% M0R<),-_EC9\&:)&8IH0'1/P%D>G=_H=6$?GJS-VU$267?][8YMKKI.$]I #] M8>I"$E4%TB/8L>D@TAWZ?2*, OL $02%@ '-@0)LB$ 0H8("00@$*'A1(H5 M+5[$F%'C1HX=/7X$&5+D2)(E39Y$F3(C@P 25;Y\B2) I@U;=[$&=+ 3IX] M??[LB9'!080S'B9@@+! @8H!F%9<6E%A4J4$&D9EV3 5:<,MR9L2;' 0JD! MB!8@,(,A P%J*5H(@ *% X0*B39D231KD+P(]T:EN.% @+ Y#9NDD%CQ8L:- M&6,Z\6G@C8XH'!=Z>N'1 :M%;0 MFE$D($C3\L09# 9 E'Q8^'#BQ8T?1YYV>$ Q0$<<"PD++Q1KQQ5+87HBF"L >0BR$Z:& BTPR;7 MO.E$71^3"D+>\B.J18;P$U+. (H-<( K'WJOM['T"R("EP;C4##@*IJ!SX8V M("!"!HN:M#.%:AT4Q%CO+-3&=-_; -I!$1J5U/ "H N_!''%-U]]]^6W7W__ M#=--@?\C=:((, OA(0'=*K" X%BR4T^% A@ X4@/*#,$5T.H6"V.9PKPPT(5 M(&A3A+@;X%XG"_:+,*9FN/A>F3*%EZ!N*R1L@[%R#F)491G^*.#*A/-+0"T$ MQW(8X)-V99J"L@C#;&*H25UH9YX9LEH^J06*-**$!A. 7:KS.\#%TL8F+#:( M#[)Z X4.^(V !(=>>&6GI"Y@ PN^2YDADB&ZD@&V!#!;:<,/1SQQQ1=G7#F! MW0PIN,8GI[SI72D7Z37,-^>\<\\_!SWTB1YO4W33-[=.&')QY7VZTK/OGH=C>1=JGU5#YZZ:>GOGKK MK\<^>^VWY[Y[[[\'/WSQQR>_?///1S]]]==GOWWWWX<_?OGGI[]^^^_'/W_] M]^>_?___!V !3A A;0@ =$8 +^%;A !C;0@0^$8 0E.$$*5M""%\3@B""P M00YVT(,?[& &13A"$I;P@"!$80HA8$(6MM"%+W2?"F480AC6T(8WQ"'U9KA# MX\S 6A26JN@ET,B%M&("=SA#"^2-5*=YR-LD0]#I&8G @P1(3]T2IG(,[8" M*$"+)VE7C&X$M@:MJ"X'($C'SH/% GQQ(@I1F8S0%L4CUM&.=\1<$F5XD4,I MY2D;^-1%9N!$O-"1(8,Y&;,H4B!$W8HA\7%)"!)5.)/,0(P.*5JT/M.0^(C, MAS[J42,Q\IW?561+#(%9FO"X2E:V,E]Z5"&+CVH(E!4 M5%T2D+>'S(9D^KED@ KR1=]M!#^?ZZE.[>5)2%,(AF02T-P0A7,N&^!T._58A V+ <-O#(;A,%4 75<],S.B? M4 :A4W9B"H7VPH #J"4"!XE7P0 )HM6ZUK[W_1]L8ZN1<,JF(2)RTFP<]1NJ M[+:05=DJ5<;2TUI:LTK@'19NY)/<038;!@1D;A&]Z%^@9 M9:Y82ZZA,F+=HEMSFD8A M+F))IKYSJVK1<9B2ZU"?D&L?Q-[EF+.QI$M84LOU!D#1!;D10D0[D=H2K,GA M&60(N).6-0NUKK]Q@%JF1%9=\@5$(EJ2>!(B)2KAV=>_;I^>-ZB1;/7I1@(@ MEYKSQ)(0G'4K$3I5108C&99X,0APZ9M@?E,TF%VQ,)+,SSX9-0.?FL4"ENR3 M)9N%;$3^Y4>[;^O,;5B-D._<;#ODQ;:XX :R;H>HE.:=YZ4\C4I:%"DG: M6+9, "'!A502B7;/*,.76K&FH:32C;NH"6R.=YQ\PE[A5BK"UB 8(H8)R6=!G>[DTQCC% N-?=[OZ3NQ'I?G>^]YU^>2_B0R#M=\(7_GR SZ'5#+]X MQC?>\8^'?.0E/WG*5][RE\=\YC6_>]?H[7NQE/WO:UWY@K\=][K-G>][WWO>_]XGNK0I\XA??^,<7/DZ.OWSF M&S_Y5&U^]*4__3<]'R;4QW[V;V?]@6K?^]^G/?>O#W[R3U_\ BU_^M7_D_.K M9/WO)W[[MPE_^H-?_BBI?_[#?W]7ZM__TN<_D_B_ ;R] %PE D3 ^#/ D4C M!@R^!<0C!Y3 _8- D)A !ZS .[K #22=#+1 #B1 #ZPC$"1!Y!'!CBC!_SM! M(TK!%N2)%>0(%\P_&"0B&6S!XK!!^NN?'(0_&LPA'B1!' 1"]=O!(4P_'\0A M(]Q (51"^^.?)B0_)+PA*)1 )J3^PNPKPBO$0BFL(2U,0"OT0@!\PC"D/B[L M0C)40>) 0_,;PS5L/C.$(3?4/S"4P^++PCIT/CAT(3S4037DPSSLO6\41GD$1WJ< M('ND0.'^\$=]S$=^E"!_1$5X+$>!]$6"+$B#C#U\7$AUG$>&?""'?,AS3$B) MW$>*=""+/!Z(W$6%#$F.[$B/7$6 M$>1Q$62+$F3+$"4=$>5I$66;""7?!R0 M7$F-'$B:5"";?$EB3$F=C$B>3""?Y$6$[$:9C$6B[$FCK$68C$>A'$FF/""G M?$J@C$FIS$FJ-""K-$&DK$:E=$6NK$JO! J]4T1U'T4=4D;M44O% M/TQM'TT5/D]%#CO]5$CM3E!U/5(]#E,]"5&-4U5M/58U#E<50%E5'UC-/5H= M3EQE0%]%'UW%/5X]4YOLU4Z\360-0&*]3Z,\5DU,5FA=5DXM4F;5"6 ]'V%] M/6O]4Z]\5DN,5G"=5DJM4VZM'6PU'VUMC@VH+_PRUQ.EUA^5U/I15^1PJK2Q M-E1"*VS^:@@+B#%M>M<+C==#157YJ5?CP \'8%=NP8RY> A^O:+!:-P /L,$UP3;!L0@#(YB)K<&2=1R;Q0B<+1_U:P 50 @<$($% MX D$* &$<($':).J90BLC<0U*9""&#RA+0NB_4&C30[]VUDT_-9)#%?;:X @ MT("=?0 9X-F=D $7\ "MY5J@6 <<(&_+0$BQ)6A82=UBEF_TD"S+57Z:]JG MC=J>0( +P(&]W0FJ10@5D-HV00 -<($@<($^;%8T#='O*P'^&3" M%V NKT M#> )#0@"%;".$F@ T%T3;B&(PA%;$"/;)%3<5H6_MXU;#YC;NC6 != &0@" MRC4 %[B G0T"T[V.!L !'O" V:7=;@700/4^IUV M#6 "=@)XMT)OZV.M\6! M$LAS=6H6_TCU=GDU=G_" Y.V)![!> ZC:__V)!N ! M&4" .2S6K4Q3ZIN (, !#Q!?H' !V 4*#\ !AF!=]:W=I& DPZTFQ+4CI'W4 M]>->[P7?GMA?Y47A(#A@H$ 'L"!%I[!!%[+!::^"[A<&?X)!.!?ZT #^"! M(+@ #1:3 7'9^- BH4VM=HI?&Q+^X4M]OP9^X CFB12V#KR-72%.P]"=/N]U MP;;EO09 7AP0X)[0 IN$P+F 2(.DP(X@!!@UP@(&S%##800@(U[I.#JO_E= M6^##X=?5X2KN89]X@+_U81[@ 0VX8!P8XNM]T_)K7 =^W)UH@,X- O3U8:W% MW$-,S^*;VR!NY)Y8 !<(9.MP7176/I_=-X@PFY?[+V/;NK@Z0#ZF8>H38P% MWB/L9.+;6>F59LA5@6FN#AY&Y5+YPE 7BHV -&5_#^LU_4K5O9Y0FGS6!"_M\ 9N,D3;^TQ6'*Y6?2>>&!%I/!N[-S?M7\ MV^;IU>%==F$>^-R?:&#Q15Y[%ECP*^&Z/6'QI6=XYF5P)N?1];[ O=]X#H+T M%8%<-@ $ &<-,.F47E,S;=-TYMF#9N?K*(&,]HFW96EJ7N,>K&7CDV((+IU_ MON*;QFF"_KX);H"=O0 >$('*G6 (AN 2:&1$IN0@$($#UH"B[MKUI&4NICZ6 M3EO735]='F2@6.;*E6$7Z.:=P&J/MMCR^^-OMHX)N.OJ*&2AQF9<&8K02;\) M4($+?MY01MZ)N&L9@%X$L&3F->9Q9=,^53^JMNJ\[@FG#67^ Q !1IYI:.X) ML*9D9Z;ITD7I34SJX[ME,JX.%7#JG]A?JVWM,O393B$ G7NDE&L[OTBC,MOI M\O/B&\1LG=;LQ%YLA)"!T ;F7N:)"6!LR^X)R>Z)2@X"U:Z_8[8]=0[MG9@ ML_[K=V9H+QF4A95C$H,6W"@F]2"7.BYN\LOM"S1 B+[5^CMN+?3NVIOHP#: M!B#OZWAAPG9",P&TPWXO44N/ 7 BN$B0 G#?^=;2G";3]LR_^A["_J8]@QYD M!/!KT@GJ\^X2>SKL&2"*44D0ZJ*(7NL1[0J8E34]_$99&F>(]&-KGG7KRBV! M::;IZICKLQZ342F !."2AR@D2AK^B\HXEC4159"#\BB7M%[=$>XA\V\ ,WD^\0(ZV3+HH8%1=Y&R>'TBFW\SO' M*N5$SG]%B7=:SR M]%!OU$_WB/?3\"HT=;TIC]\H)%=O"(LRGCJ?]6-']F_:?)Z M=WA-OW?ESO=QEU=!_1('D'#"&#-06:EC$Q*6< ]KGWB+GXB'-_D[C_@+IW#: M?&WC-&QL7YR&/_F91[S&U'=RIWB"U?8O<6C,D7F:!WK82GF67WEO;7GUM&$P MO8B@9WI:7W9\?_6<'V&2CU2J9XBFQWH]&GJC+WJK_',^!&-&W(BL)_L]>GJ) MCWJHOV>K-UAC+_NWWR]PK[\TI\(R57GLE/<4A76XY_MA.WOUL^#+#>_4/6K( M%8$@[O%,MEJ9%O*11_NU1U"ICGR*Z/N^WWJ0EH%1_N$@R&[^(.9\GW"!S$< M1-]A&>AQJN4!QE=SQ[_[/E=Z[]#[\ MJ<5HO\?Z)W;_NPC< ', !H"!?GA#H MR^YZ/S]ZW-0(YU]^C?AY\V=ZZ-<^Y!6!:Z[^SZ]MVH5:_8LVI(V7[)MZ_:M0IMI MY]*MNQ8NWKQZ'Y+MZ_ 3YK7LC[K_/IU,?&YUB]>QI8<_N[KTA:^WBP7+_;O[\P.OJ MU[./.;ZX 1%!/ !'BG$!X^+-05X(4F)\>SR]-R!I[1%XH$_EH;=@=^$A^*!I M-#$XH7;EH(S^+M)H(X]MK?@CD%QI]\ %%Q''PW^-:=3?4PT$4>1%4FDD% \-O!>D M:#EJ^1.,6[:X8X]APM23EU^>)B::+V&Y)ILRB?< #Q<@X,("*O @95#)X7F1 M#+XMT"=&3JIPGP8C6GEEFR>5N2A(73)*()AI2AH7F8]">N:DF8*7**=LBH> M"$<%@>2>ADE$'T8(E#"J""DNP -B!O2F08H =LJ9I;D:X*BN*F*J*; (X=AK M=9$&J^FMR?ZH(;$D*6M?LXOR&NUSQAX[Z;#4OO;KM=<^^^VTV=6J+4?/DNME MN.>.9FVW:&:K[F?LMALFN/5>!Z^,YN(;8[K[$B;OO#R^ZZ_^7=P&G*F]"6=( M\(/Z,HQ@OP^C!?#!% XL\5D45\R@PAUKAO&ER8( [37"Q[-[-GM9MGXWVBTK#'6_.$U[P>H<[B_??#?ZLN'4\-VZQX)5C!_G.MV(^ M5]B8^STY7GLK_OE>-Y1M.>K0;BZ6S:L'7;?KY3(.^FJ/QWX1Z7!) ,,/0?P M0P<%@7##"@QE (/I J=>^>VO&][^O%>=0YX[[;39?COU;4G0 PP2W% !#PA(MFFR*(],D*.+.4= MCPB]/T*D VWL61_GQDJ(F*X"GX2 (4%YQ5'&#)6IK*,O=Z7*YLW2>.4+0@]: M,,6!G$"0-\B 0E80Q0_:*)9P*V8TEVFZ#&RPD+<4R#()XL-J\K*7P>R;W,XY MHV%B#Y-ZX>8)7-D!'?!0FL'C73@+ @,=3%&#:TS@3$Z(S82L0 T)UYV2!\]F2ASUX(PB" -$ M_H"B6&/BZ@:*D./I0"(]6(%+(5 1@K3@!^&\ 44Z"5"+V@O^HQA)X4;9*4./ MXJ5\%7"E!P6BOI7"( CY%$A5">*_$[3/DBUD:NE.1U2%&15WZ30J1\L(UK>D M]*:OK"E!5M#-@@#5I05L05<#*DG)V2BGL!QKPLHJ3(VB,JU^7.M;_!<$&N0T M)0.1ZRLAH+Y_%I &>1W<)?E*R=H!MEZ"16IAE=I$Q+XE S7MP4H=*Q#(&J2& M/PA>!LH7V?-8$VTR56)GBUI6T);2L+(D[5OFV;LUJA8"K#6(:9&Y J!2\Z5> M12)P-]O#W(+KLV?%J&^O&=VVN#(#/6@I! 09UR T%R&V[$%%]9K9F4C7;-3] MEG4)VUO1QG2[;(&J_^ZI4H=:=2'^0!6J<]7[5]NKZO.[-K6OBPA M)%0U.,62#N1W Y& 7R%0U7\.U3U[96^!4W-@WC*2Q"6F[^9N:Y ;T" #KB3! M#_ JU1]D8'<^K? /+DP"':AQEP*&+H%##)<1*SB8)K8C@\6F8N'10)!!T &' MC=L[&N13!PHU+C*5";/GKM+!0A8(D>5[8C&/N60?EDF/H'JUVBK9RU\.\RFQ M6V0CH]AS;F9)AE_&YJ\M&7]P[E1\XRSG+PX8Q%^^$4Q3?.<0_YE3@0;THZ,C MT$47>,]9=) /7D7XT2<:MIV-LV-+MO3>X5 MZ3I(O$XRGZ>]64M3#=.TFW>YT3KGI!(:R/".-T3X[31_@P[@]$9WIR'^:76? M!.%C^O92PVWQ@C@<0_4&TKVUG4>-;SP][A[YP4L^[H[CN]38/F?+^ZUO2BI\ M:0R?',LM]/& "[S@+@>VRKU-:FF37.4Y#]#.'R[QA?T:UD$7.F8+#?2G4^KH M/J>SLN<8\X7/?(\U1]K-&V=UD1?QR%HGNUJ+7O*O RWL?QO^^]4)_G*L^UKJ M3J=ZU8<.[I3CG>-PCV3/YRYWP-M]W7T?X\D[JO:-_YWPVTZ M&I_NP)^;\YLO?,4/+ZS$IYWOJ*$ ZE.O^M6SOO6N?WWK*Z3YB7L^XK6G M/>AWVAW8\[[WOE\]T4A_V,6[Y/?&/W[L'3=[5]^>U4MG?NXIXAWD4__XPR7WYHDNYQ\4N'XKJ?3??3[_KKZSWCIM]+[T?P O4;__O@_]CS MK9W_S8#Z_7KI_0N, /UYG_U%G<%-76S W@?8@$3X0 QP@.JQ@ \$00Y\ .^9 M0 [,'^\5X/T!!OGIW ?V1?\AH&K^P)X)[(!$[ +8$ $3F %PMX(H* /F #L ML9\!_MS=R<;K?4 0L(#\Q: &4L + ($ U@ 00*#KL0 #!N'K<6 'SLS^@5P( MDL4(YF ")B$1!F *$&'J#6$1'J'KC4 /4D *! $-KI\3*HKY2=_NN5X-[ % MR!\%<( &$3'LV@"5YHQ9W[D6!JO)X#"J$ IH SB$? MHEX>NEXDHIX1LF#R*5_[99__Y<7K,2 'R"$%G&$,!($%4F(0(&'KB2$3HN%L M_*%@3"':"9'D@=W,O1X0^( B4@ &-.(HEB(%U, ILIX)C"'JE6$*L&(K"M]O MT<0 JM_^,/K "ZPB"JK>"P3!,8;A(S:C^KEB8, B(0YBW1V@%9:@ZXUB#M1 M(Z;>-':A-;+>**:C&-8 ,KH7]M47,VIC]Y5A$-B ):*>1%!C-K*>*N+C-G)C M^34?LD7A*Z[A1! D]P%C0%+ /[+C*E) #@0!/%*@0U*?Y=V,36QD]7V #/KB M1*)>-59DZ@TD2'*D04(A0NK?2_(?0Y;D2OZ>"0 !!?8C39XDZUUD1NIA3?I> M1]+,1P:E\<4@3E[C3D:DZJFD40IE2XJ@0BI=3))% %PE5F:E5FXE5W:E5WXE M6(:E6(XE69:E69[E60+@10)!*2YE1?ID2FIDZZ$E7=:E7=[^)5[FI5[N)5_& MWPM\@ \ 0M.($">82HR)>OQY5E&94YX8S@^7F@HIF1.)F56IF4"X @,(U 2 M)CL:9NH!8T;&@.M9)FF6IFF>)FJ6I5^2(4;^(BFFGB>^GE.^7FINY=_5)F[F MIF[N)F_VIF_^YE@R9IM@IFN:HB_&YNJ5(0ND'@NT8^L)IT6]GCS&X?PU)P3: M81 "P73J8C^BWFRZ'G1J!G".)WF6IWF>)WKZ9GABB72:I #: "XZ8G9N)RI2 MP"12 'R^WGJ.TNOE@ U\@/QMH6BB7@RP)088(2H" 1"L7G-NIW[N)X1&J(1. MZ(_HYPO0H0E4HV$6Z <<*!A2 _^VD#J#>,Q-J=GKAZ%*M#KF0!\IN U=B%. MVD!][@ >E32B29>LR9_EZ: MMJF;OJFFK6GOP:F]R.FYJF>8I&=PMZ>_BF@!JJ@#BJA%JJA'BJB)JJB M+BJC-JJC/BJD1BJD1D !,("DU@2E6NJELL<,, !7"4!,, ,5$0(%$ "( " MC&I,S$ "7&4!;$!%H, !G*JF3@0#"$ #$ $5(0%# "MJNJF\@0*)("O!D ! M["JIFBK^J@+K293J528 "E3$!GSJ %A 1=QJKB*KK>(J )$K_YJO=YKODZ$O-+K1#"LP[;D!HCK MQ5H 0C Q08!"A2 !6S K!YL3!! I;9J /3K# A LQ "*#J1"A P2H KM:J M!:#JP!KKM^Z$ P0 N0;!#$2 ! L)YLRJYL3* S3* L@+K!@2 P0!NEJK M1.@L _"LPG8M VR T@I QPYMLEC 56)LJPJ MEY(V :& HS^;=EVK 4H@-#> MA-0F -6>*K#>*JPF@-E.A,LR ,SV:^$>[IH(+JPFK;CV1"6Z][VK0 :^5>;N9&90CD[<8. ,E*1 0 MJ^S&1 1DK404[0%,A."J*KK"JJQB[*E.1 &HZ@SX:LFB+4T4K;H&P>LR+>W: MK@#$1 *4[*SJ;A , +Q*Q.^:;.]*Q.M6+])J*[IJ+_,FR]I2!+K&[(I,KE\D M[42<[TG ;DU<[T1DKT2@0-QR+^UJ+^_^[T0$<)"\[MMN0/=NQ:M*[O/VQ0:4 M;*M"<.K2KOO2Q/'ZJ_+N;_]V+_[^2H3^!L$#^VX +*\K9G!%H&L"4T0!M.Y) M/*__(FT A*_)SJO6=FRK[N_;!F_ZT@3_DF]%M&H#!\$*QX2Z\J^FJJWVHNNN M1H -!P!*7"W7[O"MK*_HYNK[!C%@0'']IC!-%''8XBT$!T"TNG#WDC&67.WS MLJQ6%&W ^@7\"L;E(F\,/RP-SP0*Y' %@[$(CS%%&#%*Q+''6O%)S,!5GNW, MMK%,%$#XJJVZ"O*U^K"TCK 4R\3E)@!*J.T #+( ('),8&W75C (U_$C_S$7 M3W*;4/'&7N7%S@#8MJN_!FVU4H2]YJKNAH#@!H$#X.K!AL"G%H##IFL(6*PL M$ZSN;L#^[YIJ%),R2MBO3GAR$'QJ%;^M\RK MKGXR5C9N*WNK+5=O+ALM]/;R+S- ,!MKR;(RMWJK,:I1K/A /(,&0?M6.+[P P:^R2,$MS-!9?9;]NMCK7Q %H M;TE/Q$DW:VD7-E8. &JG]H\HMFIK+0NKK26CJZJJK;7RKQQG\F,'@*I>K1J[ M;&*#MCHCM[\*LJF>;21?I6Y?-4_$=F-7<0-_=DR(-YMT*JY.]0PGMT04P'8' M@=JV+ES3;G#7,2"'\G,GL%XO]\%&P'Q;,D=C=Q6[JJJ&MF_+1/*6+"J'M@>C M[W(+>$M>-DJ8ZMLZ;EB?Q,G^[>3^*C:^8C1!IW9F=_)';ZS25CBO^O=Z@W)M M5_-NA\"L5C9O6XAOP_2L:B6\4C9*%*UM+C=MQZVI)G:M$C*\XKA6GKA-L#@S M'[6+RT0W\[-C*_B%4_4%)PHK/^ONRY4:SE%YX0"O&V"P^^27_*:&Z3:0C*3HS:8&_@WLV^&L[#W[K;6 M,OB+XRTU[SB>2\2>QX0M_S"*O[;O"CJ1OSB6*#8A?[2-GT2F7^MH"_2.:[:8 M-S*\7BYF=WHB=_J1UT2C4T26"W0RY[1I^VN?WPHONR^I1W@*IWE\"[%&WWHH M@[J/\W/^C6MTFM?$S'8ONC8RH--$[E9$JVMY,J_ZJCYN2^(J(JNM1H>T]9(P M_\KPZYHX+G)8D/X 2CW M_'(TL^YJT78LLOKZHA=[AEORO[/OI-L$NG(W3L"ZHV-OB ?ZMK<)V?*JPA[\ MOO.Z"I/OKN?["6OYIX=YL">V)7L\PG,T3KRK!GN[*-.$M(LPQ#NLP\^$RK?D M>S/K#'SJ;D>T3"C ;J\TQFNMN(= 9]=[$. MN=_L;7LU)R-MS:+$"Y>YO@O] M8B>YT4>'2Z/K[.*R*(= UA:MB4> M48O\K*LP/-XJ.\XK)+^O;^R;+%7//; 7=*U>+:P> MOOCJ[MO31$J3KE4'_4P0/57'[=W[Z]-3/D*#'[JZLLBZ+>$NL*QB\0PH,@.T MON$BZ]Z"<.<>?:BZ/EO3;L&Z/M4:?:LV;/D*0'L_,^HG-:,/P-RZ_@&$[$!S M?10K0.VW_NW_K*@"-X!?O7JH[5;;\JG&\Z>&*F,C;2\;;@*WJO%[:KF:ZL6B M:_@F;XCG*JQ^K!J3_]P20+3FO%O'A/2/*G^?+>![\/+;-D H8#"0P8$008(H M$!!B1@(!*!#.*'" ((,$$8)(I$C^\")"CQ]!AA0YDB3(#0$*6$"X@0"!&0@3 M!!@@D #$( 4".,CH\&40"P$N1IA!( !!@H*>,1Y,$B$ Q9Q?)7$ !!](;7CX0NB%F!;T9(&>:>J!JU5E$K*^BKJQ3SSWYM"V"R]CJ4]!!"2W4T.HB M /)0+=U<%+9$'8V42[-DBH R23'-E$P4X$HI3TU!#57446EC8$92J9M!JD]% M-1755VV;P8$"!% .UEMQ90P%I +(U==?@0U6V*O8&];88Y%635;999EMUMEG MH8U6VFFIK=;::['-5MMMN>W6VV_!#5?<< XML 11 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover - shares
 9 Months Ended
Sep. 30, 2023
Oct. 31, 2023
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2023  
Document Transition Report false  
Entity File Number 000-19319  
Entity Registrant Name VERTEX PHARMACEUTICALS INC / MA  
Entity Incorporation, State or Country Code MA  
Entity Tax Identification Number 04-3039129  
Entity Address, Address Line One 50 Northern Avenue  
Entity Address, City or Town Boston  
Entity Address, State or Province MA  
Entity Address, Postal Zip Code 02210  
City Area Code 617  
Local Phone Number 341-6100  
Title of 12(b) Security Common Stock, $0.01 Par Value Per Share  
Trading Symbol VRTX  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   257,683,184
Entity Central Index Key 0000875320  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2023  
Document Fiscal Period Focus Q3  
Amendment Flag false  
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statements of Income - USD ($)
shares in Millions, $ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Income Statement [Abstract]        
Product revenues, net $ 2,483.5 $ 2,334.3 $ 7,351.5 $ 6,628.0
Costs and expenses:        
Cost of sales 318.7 289.4 894.2 797.0
Research and development expenses 810.0 645.0 2,338.3 1,846.2
Acquired in-process research and development expenses 51.7 29.0 509.3 92.9
Selling, general and administrative expenses 263.8 246.8 767.5 677.3
Change in fair value of contingent consideration 1.2 (2.6) (1.3) (59.3)
Total costs and expenses 1,445.4 1,207.6 4,508.0 3,354.1
Income from operations 1,038.1 1,126.7 2,843.5 3,273.9
Interest income 167.9 46.2 435.2 58.6
Interest expense (10.9) (13.7) (33.5) (43.2)
Other (expense) income, net (15.9) 17.2 (13.0) (133.7)
Income before provision for income taxes 1,179.2 1,176.4 3,232.2 3,155.6
Provision for income taxes 143.9 245.9 581.4 652.5
Net income $ 1,035.3 $ 930.5 $ 2,650.8 $ 2,503.1
Net income per common share:        
Basic (in dollars per share) $ 4.01 $ 3.63 $ 10.29 $ 9.78
Diluted (in dollars per share) $ 3.97 $ 3.59 $ 10.18 $ 9.68
Shares used in per share calculations:        
Basic (in shares) 258.0 256.5 257.7 255.8
Diluted (in shares) 260.6 259.5 260.4 258.7
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statements of Comprehensive Income - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Statement of Comprehensive Income [Abstract]        
Net income $ 1,035.3 $ 930.5 $ 2,650.8 $ 2,503.1
Other comprehensive income (loss):        
Unrealized holding losses on marketable securities, net of tax of $1.7, zero, $5.2 and zero, respectively (6.2) (0.6) (18.8) (3.6)
Unrealized gains on foreign currency forward contracts, net of tax of $(13.2), $(16.0), $(1.6) and $(34.3), respectively 48.0 58.8 5.9 128.1
Foreign currency translation adjustment (5.0) (18.1) 9.1 (42.8)
Total other comprehensive income (loss) 36.8 40.1 (3.8) 81.7
Comprehensive income $ 1,072.1 $ 970.6 $ 2,647.0 $ 2,584.8
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Statement of Comprehensive Income [Abstract]        
Unrealized holding losses on marketable securities, tax $ 1.7 $ 0.0 $ 5.2 $ 0.0
Unrealized gains (losses) on foreign currency forward contracts, tax $ (13.2) $ (16.0) $ (1.6) $ (34.3)
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Balance Sheets - USD ($)
$ in Millions
Sep. 30, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 11,110.2 $ 10,504.0
Marketable securities 818.0 274.5
Accounts receivable, net 1,538.7 1,442.2
Inventories 688.7 460.6
Prepaid expenses and other current assets 540.2 553.5
Total current assets 14,695.8 13,234.8
Property and equipment, net 1,124.0 1,108.4
Goodwill 1,088.0 1,088.0
Intangible assets 603.6 603.6
Deferred tax assets 1,729.1 1,246.9
Operating lease assets 310.5 347.4
Long-term marketable securities 1,700.0 112.2
Other assets 475.2 409.6
Total assets 21,726.2 18,150.9
Current liabilities:    
Accounts payable 375.9 303.9
Accrued expenses 2,907.3 2,126.7
Other current liabilities 316.2 311.5
Total current liabilities 3,599.4 2,742.1
Long-term finance lease liabilities 390.3 430.8
Long-term operating lease liabilities 354.4 379.5
Other long-term liabilities 869.3 685.8
Total liabilities 5,213.4 4,238.2
Commitments and contingencies 0.0 0.0
Shareholders’ equity:    
Preferred stock, $0.01 par value; 1,000,000 shares authorized; none issued and outstanding 0.0 0.0
Common stock, $0.01 par value; 500,000,000 shares authorized, 257,828,508 and 257,011,628 shares issued and outstanding, respectively 2.6 2.6
Additional paid-in capital 7,339.6 7,386.5
Accumulated other comprehensive (loss) income (3.0) 0.8
Retained earnings 9,173.6 6,522.8
Total shareholders’ equity 16,512.8 13,912.7
Total liabilities and shareholders’ equity $ 21,726.2 $ 18,150.9
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
Sep. 30, 2023
Dec. 31, 2022
Statement of Financial Position [Abstract]    
Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01
Preferred stock, shares authorized (in shares) 1,000,000 1,000,000
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, shares authorized (in shares) 500,000,000 500,000,000
Common stock, shares issued (in shares) 257,828,508 257,011,628
Common stock, shares outstanding (in shares) 257,828,508 257,011,628
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statements of Shareholders' Equity - USD ($)
$ in Millions
Total
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Income (Loss)
Retained Earnings
Beginning balance (in shares) at Dec. 31, 2021   254,500,000      
Beginning balance at Dec. 31, 2021 $ 10,100.0 $ 2.5 $ 6,880.8 $ 15.9 $ 3,200.8
Increase (Decrease) in Stockholders' Equity          
Other comprehensive income (loss), net of tax 81.7     81.7  
Net income 2,503.1       2,503.1
Common stock withheld for employee tax obligations (in shares)   (700,000)      
Common stock withheld for employee tax obligations (169.9) $ (0.0) (169.9)    
Issuance of common stock under benefit plans (in shares)   2,800,000      
Issuance of common stock under benefit plans 135.3 $ 0.1 135.2    
Stock-based compensation expense 379.4   379.4    
Ending balance (in shares) at Sep. 30, 2022   256,600,000      
Ending balance at Sep. 30, 2022 13,029.6 $ 2.6 7,225.5 97.6 5,703.9
Beginning balance (in shares) at Jun. 30, 2022   256,000,000.0      
Beginning balance at Jun. 30, 2022 11,933.5 $ 2.6 7,100.0 57.5 4,773.4
Increase (Decrease) in Stockholders' Equity          
Other comprehensive income (loss), net of tax 40.1     40.1  
Net income 930.5       930.5
Common stock withheld for employee tax obligations (in shares)   (200,000)      
Common stock withheld for employee tax obligations (48.0) $ (0.0) (48.0)    
Issuance of common stock under benefit plans (in shares)   800,000      
Issuance of common stock under benefit plans 38.2 $ 0.0 38.2    
Stock-based compensation expense 135.3   135.3    
Ending balance (in shares) at Sep. 30, 2022   256,600,000      
Ending balance at Sep. 30, 2022 $ 13,029.6 $ 2.6 7,225.5 97.6 5,703.9
Beginning balance (in shares) at Dec. 31, 2022 257,011,628 257,000,000.0      
Beginning balance at Dec. 31, 2022 $ 13,912.7 $ 2.6 7,386.5 0.8 6,522.8
Increase (Decrease) in Stockholders' Equity          
Other comprehensive income (loss), net of tax (3.8)     (3.8)  
Net income $ 2,650.8       2,650.8
Repurchase of common stock (in shares) (891,060) (900,000)      
Repurchase of common stock $ (284.1) $ (0.0) (284.1)    
Common stock withheld for employee tax obligations (in shares)   (700,000)      
Common stock withheld for employee tax obligations (222.9) $ (0.0) (222.9)    
Issuance of common stock under benefit plans (in shares)   2,400,000      
Issuance of common stock under benefit plans 85.7 $ 0.0 85.7    
Stock-based compensation expense $ 374.4   374.4    
Ending balance (in shares) at Sep. 30, 2023 257,828,508 257,800,000      
Ending balance at Sep. 30, 2023 $ 16,512.8 $ 2.6 7,339.6 (3.0) 9,173.6
Beginning balance (in shares) at Jun. 30, 2023   257,800,000      
Beginning balance at Jun. 30, 2023 15,470.2 $ 2.6 7,369.1 (39.8) 8,138.3
Increase (Decrease) in Stockholders' Equity          
Other comprehensive income (loss), net of tax 36.8     36.8  
Net income 1,035.3       1,035.3
Repurchase of common stock (in shares)   (400,000)      
Repurchase of common stock (123.0) $ (0.0) (123.0)    
Common stock withheld for employee tax obligations (in shares)   (100,000)      
Common stock withheld for employee tax obligations (53.2) $ (0.0) (53.2)    
Issuance of common stock under benefit plans (in shares)   500,000      
Issuance of common stock under benefit plans 15.0 $ 0.0 15.0    
Stock-based compensation expense $ 131.7   131.7    
Ending balance (in shares) at Sep. 30, 2023 257,828,508 257,800,000      
Ending balance at Sep. 30, 2023 $ 16,512.8 $ 2.6 $ 7,339.6 $ (3.0) $ 9,173.6
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Millions
 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Cash flows from operating activities:    
Net income $ 2,650.8 $ 2,503.1
Adjustments to reconcile net income to net cash provided by operating activities:    
Stock-based compensation expense 372.6 379.8
Depreciation expense 122.3 109.9
Deferred income taxes (405.5) (424.0)
Losses on equity securities 0.2 143.1
Decrease in fair value of contingent consideration (1.3) (59.3)
Other non-cash items, net (9.6) (32.8)
Changes in operating assets and liabilities:    
Accounts receivable, net (99.5) (368.8)
Inventories (252.9) (58.1)
Prepaid expenses and other assets (94.4) (41.9)
Accounts payable 80.5 (39.1)
Accrued expenses 786.1 980.3
Other liabilities 153.4 (40.7)
Net cash provided by operating activities 3,302.7 3,051.5
Cash flows from investing activities:    
Purchases of available-for-sale debt securities (2,798.0) (417.8)
Sales and maturities of available-for-sale debt securities 621.0 435.9
Purchases of property and equipment (142.3) (171.1)
Sale of equity securities 95.1 0.0
Investment in equity securities and notes receivable (31.0) (47.8)
Payment to acquire ViaCyte, Inc., net of cash acquired 0.0 (295.9)
Net cash used in investing activities (2,255.2) (496.7)
Cash flows from financing activities:    
Issuances of common stock under benefit plans 88.2 134.7
Repurchases of common stock (278.1) 0.0
Payments in connection with common stock withheld for employee tax obligations (222.9) (169.9)
Payments on finance leases (32.9) (75.1)
Other financing activities 3.3 2.4
Net cash used in financing activities (442.4) (107.9)
Effect of changes in exchange rates on cash (0.5) (70.0)
Net increase in cash, cash equivalents and restricted cash 604.6 2,376.9
Cash, cash equivalents and restricted cash—beginning of period 10,512.0 6,800.1
Cash, cash equivalents and restricted cash—end of period 11,116.6 9,177.0
Supplemental disclosure of cash flow information:    
Cash paid for income taxes 919.1 840.1
Cash paid for interest $ 32.6 $ 41.1
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.23.3
Basis of Presentation and Accounting Policies
 9 Months Ended
Sep. 30, 2023
Accounting Policies [Abstract]  
Basis of Presentation and Accounting Policies Basis of Presentation and Accounting Policies
Basis of Presentation
The accompanying condensed consolidated financial statements are unaudited and have been prepared by Vertex Pharmaceuticals Incorporated (“Vertex,” “we,” “us” or “our”) in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).
The condensed consolidated financial statements reflect the operations of Vertex and our wholly-owned subsidiaries. All material intercompany balances and transactions have been eliminated. We have reclassified certain items from the prior year’s condensed consolidated balance sheet to conform to the current year’s presentation. We operate in one segment, pharmaceuticals.
Certain information and footnote disclosures normally included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 (the “2022 Annual Report on Form 10-K”) have been condensed or omitted. These interim financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the financial position and results of income for the interim periods ended September 30, 2023 and 2022.
The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full fiscal year. These interim financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2022, which are contained in our 2022 Annual Report on Form 10-K.
Use of Estimates
The preparation of condensed consolidated financial statements in accordance with U.S. GAAP requires us to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of our condensed consolidated financial statements, and the amounts of revenues and expenses during the reported periods. We base our estimates on historical experience and various other assumptions, including in certain circumstances future projections that we believe to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.
Recently Adopted and Issued Accounting Standards
For a discussion of recently adopted accounting pronouncements please refer to Note A, “Nature of Business and Accounting Policies,” in our 2022 Annual Report on Form 10-K. We do not expect any recently issued accounting standards to have a significant impact on our condensed consolidated financial statements.
Summary of Significant Accounting Policies
Our significant accounting policies are described in Note A, “Nature of Business and Accounting Policies,” in our 2022 Annual Report on Form 10-K.
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.23.3
Revenue Recognition
 9 Months Ended
Sep. 30, 2023
Revenue from Contract with Customer [Abstract]  
Revenue Recognition Revenue Recognition
Disaggregation of Revenue
Revenues by Product
“Product revenues, net” consisted of the following:
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
(in millions)
TRIKAFTA/KAFTRIO$2,274.3 $2,010.5 $6,611.4 $5,665.3 
KALYDECO112.8 139.4 363.1 417.1 
ORKAMBI63.0 146.2 281.8 399.9 
SYMDEKO/SYMKEVI33.4 38.2 95.2 145.7 
Total product revenues, net$2,483.5 $2,334.3 $7,351.5 $6,628.0 
Product Revenues by Geographic Location
“Product revenues, net” by geographic region, based on the location of the customer, consisted of the following:
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
(in millions)
United States$1,554.2 $1,455.6 $4,465.8 $4,238.9 
Outside of the United States
Europe766.5 730.5 2,373.7 2,018.3 
Other
162.8 148.2 512.0 370.8 
Total product revenues outside of the United States929.3 878.7 2,885.7 2,389.1 
Total product revenues, net
$2,483.5 $2,334.3 $7,351.5 $6,628.0 
Contract Liabilities
We had contract liabilities of $157.1 million and $159.6 million as of September 30, 2023 and December 31, 2022, respectively, related to annual contracts with government-owned and supported customers in international markets that limit the amount of annual reimbursement we can receive. Upon exceeding the annual reimbursement amount, products are provided free of charge, which is a material right. These contracts include upfront payments and fees. We defer a portion of the consideration received for shipments made up to the annual reimbursement limit as a portion of “Other current liabilities.” The deferred amount is recognized as revenue when the free products are shipped. Our product revenue contracts include performance obligations that are one year or less.
Our contract liabilities at the end of each fiscal year relate to contracts with annual reimbursement limits in international markets in which the annual period associated with the contract is not the same as our fiscal year. In these markets, we recognize revenues related to performance obligations satisfied in previous years; however, these revenues do not relate to any performance obligations that were satisfied more than 12 months prior to the beginning of the current year.
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.23.3
Acquired In-Process Research and Development and Other Arrangements
 9 Months Ended
Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Acquired In-Process Research and Development and Other Arrangements Acquired In-Process Research and Development and Other Arrangements
We have entered into numerous agreements with third parties to collaborate on research, development and commercialization programs, license technologies, or acquire assets. Our “Acquired in-process research and development expenses” included $51.7 million and $509.3 million for the three and nine months ended September 30, 2023, respectively, and $29.0 million and $92.9 million, for the three and nine months ended September 30, 2022, respectively, related to upfront, contingent milestone, or other payments pursuant to our business development transactions, including collaborations, licenses of third-party technologies, and asset acquisitions that qualify as in-process research and development.
Our collaboration, licensing and asset acquisition agreements that had a significant impact on our financial statements for the three and nine months ended September 30, 2023 and 2022, or were new or materially revised during the three and nine months ended September 30, 2023, are described below. Additional agreements were described in Note B, “Acquired In-Process Research and Development and Other Arrangements,” of our 2022 Annual Report on Form 10-K.
In-license Agreements
We have entered into several in-license agreements to advance and obtain access to technologies and services related to our research and early-development activities. We are generally required to make an upfront payment upon execution of our license agreements; development, regulatory and commercialization milestones payments upon the achievement of certain product research, development and commercialization objectives; and royalty payments on future sales, if any, of commercial products resulting from our collaborations.
Pursuant to the terms of our in-license agreements, our collaborators typically lead the discovery efforts and we lead all preclinical, development and commercialization activities associated with the advancement of any product candidates and fund all expenses.
We typically can terminate our in-license agreements by providing advance notice to our collaborators. Our license agreements may be terminated by either party for a material breach by the other, subject to notice and cure provisions. Unless earlier terminated, these license agreements generally remain in effect until the date on which the royalty term and all payment obligations with respect to all products in all countries have expired.
CRISPR Therapeutics AG
CRISPR-Cas9 Gene-editing Therapies Agreements
In 2015, we entered into a strategic collaboration, option, and license agreement (the “CRISPR Agreement”) with CRISPR Therapeutics AG and its affiliates (“CRISPR”) to collaborate on the discovery and development of potential new treatments aimed at the underlying genetic causes of human diseases using CRISPR-Cas9 gene-editing technology. We had the exclusive right to license certain targets. In 2019, we elected to exclusively license three targets, including cystic fibrosis, pursuant to the CRISPR Agreement. For each of the three targets that we elected to license, CRISPR has the potential to receive up to an additional $410.0 million in development, regulatory and commercial milestones as well as royalties on resulting net product sales.
In 2017, we entered into a joint development and commercialization agreement with CRISPR (the “CRISPR JDCA”), which we amended and restated in 2021, pursuant to the terms of the CRISPR Agreement. Under the CRISPR JDCA, we and CRISPR are co-developing and preparing to co-commercialize exagamglogene autotemcel (“exa-cel”), for the treatment of hemoglobinopathies, including treatments for sickle cell disease and transfusion-dependent beta thalassemia. Pursuant to the CRISPR JDCA, we lead global development, manufacturing, and commercialization of exa-cel, with support from CRISPR. We also conduct all research, development, manufacturing, and commercialization activities relating to other product candidates and products under the CRISPR JDCA throughout the world subject to CRISPR’s reserved right to conduct certain activities.
In connection with the CRISPR JDCA, CRISPR has the potential to receive a one-time $200.0 million milestone payment upon receipt of the first marketing approval of exa-cel from the U.S. Food and Drug Administration or the European Commission.
We account for the CRISPR JDCA as a cost-sharing arrangement, with costs incurred related to exa-cel allocated 60% to us and 40% to CRISPR, subject to certain adjustments. We recognized the net impact of the CRISPR JDCA as “Research and
development expenses” of $74.9 million and $45.5 million during the three months ended September 30, 2023 and 2022, respectively, and $193.2 million and $120.6 million during the nine months ended September 30, 2023 and 2022, respectively; and as “Selling, general and administrative expenses” of $26.0 million and $13.5 million during the three months ended September 30, 2023 and 2022, respectively, and $66.1 million and $35.3 million during the nine months ended September 30, 2023 and 2022, respectively.
In March 2023, we entered into a non-exclusive license agreement (“the CRISPR T1D Agreement”) for the use of CRISPR’s CRISPR-Cas9 gene-editing technology to accelerate the development of our hypoimmune cell therapies for type 1 diabetes. Pursuant to the CRISPR T1D Agreement, we made a $100.0 million upfront payment to CRISPR. In the second quarter of 2023, we achieved a research milestone that resulted in a $70.0 million payment to CRISPR in the third quarter of 2023. CRISPR is eligible to receive up to an additional $160.0 million in research, development, regulatory and commercial milestones for any products that may result from the agreement, as well as royalties on resulting net product sales. We determined that substantially all the fair value of the collaboration agreement was attributable to in-process research and development and no substantive processes were acquired that would constitute a business. We concluded that there is no alternative future use for the acquired in-process research and development and recorded the upfront payment and the research milestone to “Acquired in-process research and development expenses” in the first and second quarters of 2023, respectively, resulting in $170.0 million of “Acquired in-process research and development expenses” in the nine months ended September 30, 2023.
Entrada Therapeutics, Inc.
In February 2023, we closed a strategic collaboration and license agreement (the “Entrada Agreement”) with Entrada Therapeutics, Inc. (“Entrada”) focused on discovering and developing intracellular Endosomal Escape Vehicle (EEV) therapeutics for myotonic dystrophy type 1 (“DM1”). Upon closing, we made an upfront payment of $225.1 million to Entrada, and purchased $24.9 million of Entrada’s common stock in connection with the Entrada Agreement. Entrada is eligible to receive up to an additional $485.0 million in research, development, regulatory and commercial milestones for any products that may result from the Entrada Agreement, as well as royalties on resulting net product sales. We determined that substantially all the fair value of the collaboration agreement was attributable to in-process research and development and no substantive processes were acquired that would constitute a business. We concluded that there is no alternative future use for the acquired in-process research and development and recorded the upfront payment to “Acquired in-process research and development expenses” in the first quarter of 2023. The investment in Entrada’s common stock is recorded at fair value on our condensed consolidated balance sheet within “Marketable securities.”
Verve Therapeutics, Inc.
In July 2022, we entered into a research collaboration with Verve Therapeutics, Inc. (“Verve”) focused on discovering and developing an in vivo gene-editing program for a liver disease. Under the terms of the agreement, we made a $25.0 million upfront payment to Verve and purchased $35.0 million of Verve’s common stock. We concluded that there is no alternative future use for the acquired in-process research and development and recorded the upfront payment to “Acquired in-process research and development expenses.” The investment in Verve’s common stock is recorded at fair value on our condensed consolidated balance sheet within “Marketable securities.”
Asset Acquisitions
Septerna, Inc. - Novel G Protein-coupled Receptor Program
In September 2023, pursuant to an asset purchase agreement, we acquired a novel G protein-coupled receptor (“GPCR”) program from Septerna, Inc. We determined that substantially all the fair value acquired is concentrated in the GPCR in-process research and development asset, which does not constitute a business, and for which we determined there is no alternative future use. As a result, we recorded $47.5 million to “Acquired in-process research and development expenses” in the three and nine months ended September 30, 2023.
Catalyst Biosciences, Inc. - Complement 3 Degrader Program
In May 2022, pursuant to an asset purchase agreement, we acquired Catalyst Biosciences, Inc.’s portfolio of protease medicines that target the complement system (the “complement portfolio”) and related intellectual property, including CB 2782-PEG, which is a pre-clinical complement component 3 degrader program for geographic atrophy in dry age-related macular degeneration. We determined that substantially all the fair value acquired is concentrated in the CB-2782 PEG in-
process research and development assets, which do not constitute a business, and for which we determined there is no alternative future use. As a result, we recorded our $60.0 million upfront payment to “Acquired in-process research and development expenses” in the three and nine months ended September 30, 2022.
Cystic Fibrosis Foundation
In 2004, we entered into a collaboration agreement with the Cystic Fibrosis Foundation, as successor in interest to the Cystic Fibrosis Foundation Therapeutics, Inc., to support research and development activities. Pursuant to the collaboration agreement, as amended, we have agreed to pay tiered royalties ranging from single digits to sub-teens on covered compounds first synthesized and/or tested during a research term on or before February 28, 2014, including ivacaftor, lumacaftor and tezacaftor and royalties ranging from low-single digits to mid-single digits on potential net sales of certain compounds first synthesized and/or tested between March 1, 2014 and August 31, 2016, including elexacaftor. We do not have any royalty obligations on compounds first synthesized and tested on or after September 1, 2016. For combination products, such as ORKAMBI, SYMDEKO/SYMKEVI and TRIKAFTA/KAFTRIO, sales are allocated equally to each of the active pharmaceutical ingredients in the combination product. We record expenses related to these royalty obligations to “Cost of sales.”
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.23.3
Earnings Per Share
 9 Months Ended
Sep. 30, 2023
Earnings Per Share [Abstract]  
Earnings Per Share Earnings Per Share
The following table sets forth the computation of basic and diluted net income per common share for the periods ended:
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
(in millions, except per share amounts)
Net income$1,035.3 $930.5 $2,650.8 $2,503.1 
Basic weighted-average common shares outstanding258.0 256.5 257.7 255.8 
Effect of potentially dilutive securities:
Stock options1.2 1.4 1.2 1.4 
Restricted stock units (including PSUs)
1.4 1.6 1.5 1.4 
Employee stock purchase program
0.0 0.0 0.0 0.1 
Diluted weighted-average common shares outstanding260.6 259.5 260.4 258.7 
Basic net income per common share$4.01 $3.63 $10.29 $9.78 
Diluted net income per common share$3.97 $3.59 $10.18 $9.68 
We did not include the securities in the following table in the computation of the diluted net income per common share because the effect would have been anti-dilutive during each period:
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
(in millions)
Stock options— — 0.0 0.0 
Unvested restricted stock units (including PSUs)— 0.0 0.2 0.2 
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.23.3
Fair Value Measurements
 9 Months Ended
Sep. 30, 2023
Fair Value Disclosures [Abstract]  
Fair Value Measurements Fair Value Measurements
The following fair value hierarchy is used to classify assets and liabilities based on observable inputs and unobservable inputs used in order to determine the fair value of our financial assets and liabilities:
Level 1:
Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.
Level 2:
Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.
Level 3:
Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability.
Our investment strategy is focused on capital preservation. We invest in instruments that meet the credit quality standards outlined in our investment policy, which also limits the amount of credit exposure to any one issue or type of instrument. We maintain strategic equity investments separately from the investment policy that governs our other cash, cash equivalents and marketable securities as described in Note F, “Marketable Securities and Equity Investments.” Additionally, we utilize foreign currency forward contracts intended to mitigate the effect of changes in foreign exchange rates on our condensed consolidated statement of income.
The following tables set forth our financial assets and liabilities subject to fair value measurements by level within the fair value hierarchy (and does not include $5.5 billion and $3.1 billion of cash as of September 30, 2023 and December 31, 2022, respectively):
As of September 30, 2023As of December 31, 2022
Total
Level 1
Level 2
Level 3
Total
Level 1
Level 2
Level 3
(in millions)
Financial instruments carried at fair value (asset positions):
Cash equivalents:
Money market funds$3,753.4 $3,753.4 $— $— $5,162.6 $5,162.6 $— $— 
Time deposits1,550.0 — 1,550.0 — 2,000.0 — 2,000.0 — 
U.S. Treasury securities236.8 236.8 — — — — — — 
Corporate debt securities— — — — 5.8 — 5.8 — 
Commercial paper96.5 — 96.5 — 204.5 — 204.5 — 
Marketable securities:
Corporate equity securities46.4 46.4 — — 116.8 88.8 28.0 — 
U.S. Treasury securities408.2 408.2 — — — — — — 
Government-sponsored enterprise securities421.0 421.0 — — 127.1 127.1 — — 
Asset-backed securities237.8 — 237.8 — — — — — 
Certificates of deposit31.7 — 31.7 — — — — — 
Corporate debt securities1,214.2 — 1,214.2 — 87.0 — 87.0 — 
Commercial paper158.7 — 158.7 — 55.8 — 55.8 — 
Prepaid expenses and other current assets:
Foreign currency forward contracts37.8 — 37.8 — 47.5 — 47.5 — 
Other assets:
Foreign currency forward contracts3.4 — 3.4 — 0.8 — 0.8 — 
Total financial assets
$8,195.9 $4,865.8 $3,330.1 $— $7,807.9 $5,378.5 $2,429.4 $— 
Financial instruments carried at fair value (liability positions):
Other current liabilities:
Foreign currency forward contracts
$(0.7)$— $(0.7)$— $(14.3)$— $(14.3)$— 
Contingent consideration(15.0)— — (15.0)(14.6)— — (14.6)
Other long-term liabilities:
Foreign currency forward contracts— — — — (0.9)— (0.9)— 
Contingent consideration(112.7)— — (112.7)(114.4)— — (114.4)
Total financial liabilities
$(128.4)$— $(0.7)$(127.7)$(144.2)$— $(15.2)$(129.0)
Please refer to Note F, “Marketable Securities and Equity Investments,” for the carrying amount and related unrealized gains (losses) by type of investment.
Fair Value of Corporate Equity Securities
We classify our investments in publicly traded corporate equity securities as “Marketable securities” on our condensed consolidated balance sheets. Generally, our investments in the common stock of publicly traded companies are valued based on Level 1 inputs because they have readily determinable fair values. However, certain of our investments in publicly traded companies have been or continue to be valued based on Level 2 inputs due to transfer restrictions associated with these investments.
As of September 30, 2023, one of our investments in publicly traded corporate equity securities was subject to a contractual sales restriction expiring partially in 2024 and partially in 2025 with a total fair value of $25.5 million. We purchased this investment directly from the publicly traded company in the first quarter of 2023, and do not anticipate any circumstances that would cause this restriction to lapse prior to the periods listed above.
Please refer to Note F, “Marketable Securities and Equity Investments,” for further information on these investments.
Fair Value of Contingent Consideration
In 2019, we acquired Exonics Therapeutics, Inc. (“Exonics”), a privately-held company focused on creating transformative gene-editing therapies to repair mutations that cause Duchenne muscular dystrophy (“DMD”) and other severe neuromuscular diseases, including DM1. Our Level 3 contingent consideration liabilities are related to $678.3 million of development and regulatory milestones potentially payable to former Exonics equity holders. We base our estimates of the probability of achieving the milestones relevant to the fair value of contingent payments, which could include milestone, royalty and option payments, on industry data attributable to rare diseases and our knowledge of the progress and viability of the programs. The discount rates used in the valuation model for contingent payments, which were between 5.5% and 6.5% as of September 30, 2023, represent a measure of credit risk and market risk associated with settling the liabilities. Significant judgment is used in determining the appropriateness of these assumptions at each reporting period.
The following table represents a rollforward of the fair value of our contingent consideration liabilities:
Nine Months Ended September 30, 2023
(in millions)
Balance at December 31, 2022$129.0 
Decrease in fair value of contingent payments
(1.3)
Balance at September 30, 2023$127.7 
In November 2023, we determined that additional pre-clinical studies of the delivery system for our gene-editing components for DMD will be required. Any potential impact on the fair value of our contingent consideration liabilities will be recognized as of December 31, 2023.
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.23.3
Marketable Securities and Equity Investments
 9 Months Ended
Sep. 30, 2023
Investments, Debt and Equity Securities [Abstract]  
Marketable Securities and Equity Investments Marketable Securities and Equity Investments
A summary of our cash equivalents and marketable securities, which are recorded at fair value (and do not include $5.5 billion and $3.1 billion of cash as of September 30, 2023 and December 31, 2022, respectively), is shown below:
As of September 30, 2023As of December 31, 2022
Amortized Cost
Gross
Unrealized
Gains
Gross
Unrealized
Losses
Fair
Value
Amortized Cost
Gross
Unrealized
Gains
Gross
Unrealized
Losses
Fair
Value
(in millions)
Cash equivalents:
Money market funds$3,753.4 $— $— $3,753.4 $5,162.6 $— $— $5,162.6 
Time deposits1,550.0 — — 1,550.0 2,000.0 — — 2,000.0 
U.S. Treasury securities236.8 — — 236.8 — — — — 
Corporate debt securities— — — — 5.8 — — 5.8 
Commercial paper96.5 — — 96.5 204.5 — — 204.5 
Total cash equivalents
$5,636.7 $— $— $5,636.7 $7,372.9 $— $— $7,372.9 
Marketable securities:
U.S. Treasury securities$414.6 $0.1 $(6.5)$408.2 $— $— $— $— 
Government-sponsored enterprise securities
422.9 — (1.9)421.0 127.0 0.2 (0.1)127.1 
Asset-backed securities239.3 0.0 (1.5)237.8 — — — — 
Certificates of deposit31.7 0.0 — 31.7 — — — — 
Corporate debt securities
1,228.4 0.0 (14.2)1,214.2 87.2 — (0.2)87.0 
Commercial paper
158.8 0.0 (0.1)158.7 55.8 — — 55.8 
Total marketable debt securities
2,495.7 0.1 (24.2)2,471.6 270.0 0.2 (0.3)269.9 
Corporate equity securities
72.1 0.5 (26.2)46.4 104.4 30.9 (18.5)116.8 
Total marketable securities
$2,567.8 $0.6 $(50.4)$2,518.0 $374.4 $31.1 $(18.8)$386.7 
Available-for-sale debt securities were classified on our condensed consolidated balance sheets at fair value as follows:
As of September 30, 2023As of December 31, 2022
(in millions)
Cash and cash equivalents$4,086.7 $5,372.9 
Marketable securities
771.6 157.7 
Long-term marketable securities1,700.0 112.2 
Total
$6,558.3 $5,642.8 
Available-for-sale debt securities by contractual maturity were as follows:
As of September 30, 2023As of December 31, 2022
(in millions)
Matures within one year$4,858.3 $5,530.6 
Matures after one year through five years
1,700.0 112.2 
Total
$6,558.3 $5,642.8 
We did not record any allowances for credit losses to adjust the fair value of available-for-sale debt securities or gross realized gains or losses in the three and nine months ended September 30, 2023 and 2022. As of September 30, 2023, we held available-for-sale debt securities with a total fair value of $2.28 billion that were in unrealized loss positions totaling $24.2 million; however, none of these investments had been in an unrealized loss position for greater than twelve months.
We record changes in the fair value of our investments in corporate equity securities to “Other (expense) income, net” in our condensed consolidated statements of income. During the three and nine months ended September 30, 2023 and 2022, our net unrealized (losses) gains on corporate equity securities held at the conclusion of each period were as follows:
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
(in millions)
Net unrealized (losses) gains
$(6.2)$16.7 $(7.1)$(143.1)
        
During the nine months ended September 30, 2023, we received proceeds of $95.1 million related to the sale of the common stock of a publicly traded company, which had a total original cost basis of $57.3 million. There were no sales of the common stock of publicly traded companies during the nine months ended September 30, 2022.
As of September 30, 2023, the carrying value of our equity investments without readily determinable fair values, which are recorded in “Other assets” on our condensed consolidated balance sheets, was $98.6 million.
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.23.3
Accumulated Other Comprehensive Income (Loss)
 9 Months Ended
Sep. 30, 2023
Equity [Abstract]  
Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss)
The following table summarizes the changes in accumulated other comprehensive income (loss) by component:
Unrealized Holding Gains (Losses), Net of Tax
Foreign Currency Translation AdjustmentOn Available-For-Sale Debt SecuritiesOn Foreign Currency Forward ContractsTotal
(in millions)
Balance at December 31, 2022$(25.0)$(0.1)$25.9 $0.8 
Other comprehensive income (loss) before reclassifications9.1 (18.8)31.8 22.1 
Amounts reclassified from accumulated other comprehensive income (loss)— — (25.9)(25.9)
Net current period other comprehensive income (loss)9.1 (18.8)5.9 (3.8)
Balance at September 30, 2023$(15.9)$(18.9)$31.8 $(3.0)
Balance at December 31, 2021$(13.6)$(0.5)$30.0 $15.9 
Other comprehensive (loss) income before reclassifications(42.8)(3.6)230.2 183.8 
Amounts reclassified from accumulated other comprehensive income (loss)— — (102.1)(102.1)
Net current period other comprehensive (loss) income(42.8)(3.6)128.1 81.7 
Balance at September 30, 2022$(56.4)$(4.1)$158.1 $97.6 
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.23.3
Hedging
 9 Months Ended
Sep. 30, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Hedging Hedging
Foreign currency forward contracts - Designated as hedging instruments
We maintain a hedging program intended to mitigate the effect of changes in foreign exchange rates for a portion of our forecasted product revenues denominated in certain foreign currencies. The program includes foreign currency forward contracts that are designated as cash flow hedges under U.S. GAAP having contractual durations from one to eighteen months. We recognize realized gains and losses for the effective portion of such contracts in “Product revenues, net” in our
condensed consolidated statements of income in the same period that we recognize the product revenues that were impacted by the hedged foreign exchange rate changes.
We formally document the relationship between foreign currency forward contracts (hedging instruments) and forecasted product revenues (hedged items), as well as our risk management objective and strategy for undertaking various hedging activities, which includes matching all foreign currency forward contracts that are designated as cash flow hedges to forecasted transactions. We also formally assess, both at the hedge’s inception and on an ongoing basis, whether the foreign currency forward contracts are highly effective in offsetting changes in cash flows of hedged items on a prospective and retrospective basis. If we were to determine that a (i) foreign currency forward contract is not highly effective as a cash flow hedge, (ii) foreign currency forward contract has ceased to be a highly effective hedge or (iii) forecasted transaction is no longer probable of occurring, we would discontinue hedge accounting treatment prospectively. We measure effectiveness based on the change in fair value of the forward contracts and the fair value of the hypothetical foreign currency forward contracts with terms that match the critical terms of the risk being hedged. As of September 30, 2023, all hedges were determined to be highly effective.
We consider the impact of our counterparties’ credit risk on the fair value of the foreign currency forward contracts. As of September 30, 2023 and December 31, 2022, credit risk did not change the fair value of our foreign currency forward contracts.
The following table summarizes the notional amount in U.S. dollars of our outstanding foreign currency forward contracts designated as cash flow hedges under U.S. GAAP:
As of September 30, 2023As of December 31, 2022
Foreign Currency(in millions)
Euro$1,343.3 $1,497.7 
Canadian dollar
192.6 216.3 
British pound sterling
191.9 247.4 
Australian dollar
136.2 174.9 
Swiss Franc51.7 65.2 
Total foreign currency forward contracts
$1,915.7 $2,201.5 
Foreign currency forward contracts - Not designated as hedging instruments
We also enter into foreign currency forward contracts with contractual maturities of less than one month, which are designed to mitigate the effect of changes in foreign exchange rates on monetary assets and liabilities, including intercompany balances. These contracts are not designated as hedging instruments under U.S. GAAP. We recognize realized gains and losses for such contracts in “Other (expense) income, net” in our condensed consolidated statements of income each period. As of September 30, 2023, the notional amount of our outstanding foreign currency forward contracts where hedge accounting under U.S. GAAP is not applied was $922.8 million.
During the three and nine months ended September 30, 2023 and 2022, we recognized the following related to foreign currency forward contracts in our condensed consolidated statements of income:
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
(in millions)
Designated as hedging instruments - Reclassified from AOCI
Product revenues, net$2.8 $65.2 $33.0 $130.3 
Not designated as hedging instruments
Other (expense) income, net$(22.0)$(22.1)$(17.8)$(38.9)
Total reported in the Condensed Consolidated Statements of Income
Product revenues, net$2,483.5 $2,334.3 $7,351.5 $6,628.0 
Other (expense) income, net$(15.9)$17.2 $(13.0)$(133.7)
The following table summarizes the fair value of our outstanding foreign currency forward contracts designated as cash flow hedges under U.S. GAAP included on our condensed consolidated balance sheets:
As of September 30, 2023
AssetsLiabilities
ClassificationFair ValueClassificationFair Value
(in millions)
Prepaid expenses and other current assets$37.8 Other current liabilities$(0.7)
Other assets3.4 Other long-term liabilities— 
Total assets
$41.2 
Total liabilities
$(0.7)
As of December 31, 2022
AssetsLiabilities
ClassificationFair ValueClassificationFair Value
(in millions)
Prepaid expenses and other current assets$47.5 Other current liabilities$(14.3)
Other assets0.8 Other long-term liabilities(0.9)
Total assets
$48.3 
Total liabilities
$(15.2)
As of September 30, 2023, we expect the amounts that are related to foreign exchange forward contracts designated as cash flow hedges under U.S. GAAP recorded in “Prepaid expenses and other current assets” and “Other current liabilities” to be reclassified to earnings within twelve months.
We present the fair value of our foreign currency forward contracts on a gross basis within our condensed consolidated balance sheets. The following table summarizes the potential effect of offsetting derivatives by type of financial instrument designated as cash flow hedges under U.S. GAAP on our condensed consolidated balance sheets:

As of September 30, 2023
Gross Amounts RecognizedGross Amounts OffsetGross Amounts PresentedGross Amounts Not OffsetLegal Offset
Foreign currency forward contracts(in millions)
Total assets$41.2 $— $41.2 $(0.7)$40.5 
Total liabilities(0.7)— (0.7)0.7 — 
As of December 31, 2022
Gross Amounts RecognizedGross Amounts OffsetGross Amounts PresentedGross Amounts Not OffsetLegal Offset
Foreign currency forward contracts(in millions)
Total assets$48.3 $— $48.3 $(15.2)$33.1 
Total liabilities(15.2)— (15.2)15.2 — 
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.23.3
Inventories
 9 Months Ended
Sep. 30, 2023
Inventory Disclosure [Abstract]  
Inventories Inventories
Inventories consisted of the following:
As of September 30, 2023As of December 31, 2022
(in millions)
Raw materials$77.5 $38.1 
Work-in-process498.3 260.7 
Finished goods
112.9 161.8 
Total
$688.7 $460.6 
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.23.3
Stock-based Compensation Expense and Share Repurchase Programs
 9 Months Ended
Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]  
Stock-based Compensation Expense and Share Repurchase Programs Stock-based Compensation Expense and Share Repurchase Programs
Stock-based compensation expense
During the three and nine months ended September 30, 2023 and 2022, we recognized the following stock-based compensation expense:
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
(in millions)
Stock-based compensation expense by type of award:
Restricted stock units (including PSUs)$129.1 $130.3 $358.6 $351.5 
Stock options0.2 3.1 4.0 14.9 
ESPP share issuances2.4 1.9 11.8 13.0 
Stock-based compensation expense related to inventories
(0.8)0.3 (1.8)0.4 
Total stock-based compensation expense included in “Total costs and expenses”
$130.9 $135.6 $372.6 $379.8 
Stock-based compensation expense by line item:
Cost of sales$1.7 $2.4 $5.4 $7.0 
Research and development expenses81.1 80.0 231.9 229.9 
Selling, general and administrative expenses48.1 53.2 135.3 142.9 
Total stock-based compensation expense included in costs and expenses
130.9 135.6 372.6 379.8 
Income tax effect(37.1)(38.8)(109.0)(101.3)
Total stock-based compensation expense, net of tax
$93.8 $96.8 $263.6 $278.5 
Share repurchase program
In February 2023, our Board of Directors approved a share repurchase program (our “Share Repurchase Program”), pursuant to which we are authorized to repurchase up to $3.0 billion of our common stock. Our Share Repurchase Program does not have an expiration date and can be discontinued at any time. During the nine months ended September 30, 2023, we repurchased 891,060 shares of our common stock under our Share Repurchase Program for an aggregate of $284.1 million. As of September 30, 2023, a total of $2.7 billion remained authorized for future repurchases.
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.23.3
Income Taxes
 9 Months Ended
Sep. 30, 2023
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes
We are subject to U.S. federal, state, and foreign income taxes. During the three and nine months ended September 30, 2023 and 2022, we recorded the following provisions for income taxes and effective tax rates as compared to our income before provision for income taxes:
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
(in millions, except percentages)
Income before provision for income taxes$1,179.2 $1,176.4 $3,232.2 $3,155.6 
Provision for income taxes$143.9 $245.9 $581.4 $652.5 
Effective tax rate12.2 %20.9 %18.0 %20.7 %
Our effective tax rate for each of the three and nine months ended September 30, 2023 was lower than the U.S. statutory rate primarily due to a benefit from a research and development tax credit study that was completed in the third quarter of 2023 and excess tax benefits related to stock-based compensation, partially offset by changes in uncertain tax positions.
Our effective tax rate was similar to the U.S. statutory rate for each of the three and nine months ended September 30, 2022.
We have reviewed the tax positions taken, or to be taken, in our tax returns for all tax years currently open to examination by a taxing authority. As of September 30, 2023 and December 31, 2022, we had $245.4 million and $208.5 million, respectively, of net unrecognized tax benefits, which would affect our tax rate if recognized.
We file U.S. federal income tax returns and income tax returns in various state, local and foreign jurisdictions. We have various income tax audits ongoing at any time throughout the world. Except for jurisdictions where we have net operating losses or tax credit carryforwards, we are no longer subject to any tax assessment from tax authorities for years prior to 2014 in jurisdictions that have a material impact on our consolidated financial statements.
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.23.3
Commitments and Contingencies
 9 Months Ended
Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
2022 Credit Facility
In July 2022, Vertex and certain of its subsidiaries entered into a $500.0 million unsecured revolving facility (the “Credit Agreement”) with Bank of America, N.A., as administrative agent and the lenders referred to therein (the “Lenders”), which matures on July 1, 2027. The Credit Agreement was not drawn upon at closing and we have not drawn upon it to date. Amounts drawn pursuant to the Credit Agreement, if any, will be used for general corporate purposes. Subject to satisfaction of certain conditions, we may request that the borrowing capacity for the Credit Agreement be increased by an additional $500.0 million. Additionally, the Credit Agreement provides a sublimit of $100.0 million for letters of credit.
Any amounts borrowed under the Credit Agreement will bear interest, at our option, at either a base rate or a Secured Overnight Financing Rate (“SOFR”), in each case plus an applicable margin. Under the Credit Agreement, the applicable margins on base rate loans range from 0.000% to 0.500% and the applicable margins on SOFR loans range from 1.000% to 1.500%, in each case based on our consolidated leverage ratio (the ratio of our total consolidated funded indebtedness to our consolidated EBITDA for the most recently completed four fiscal quarter period).
Any amounts borrowed pursuant to the Credit Agreement are guaranteed by certain of our existing and future domestic subsidiaries, subject to certain exceptions.
The Credit Agreement contains customary representations and warranties and affirmative and negative covenants, including a financial covenant to maintain subject to certain limited exceptions, a consolidated leverage ratio of 3.50 to 1.00, subject to an increase to 4.00 to 1.00 following a material acquisition. As of September 30, 2023, we were in compliance with the covenants described above. The Credit Agreement also contains customary events of default. In the case of a continuing event of default, the administrative agent would be entitled to exercise various remedies, including the acceleration of amounts due under outstanding loans.
Direct costs related to the Credit Agreement are recorded over its term and were not material to our financial statements.
Guaranties and Indemnifications
As permitted under Massachusetts law, our Articles of Organization and By-laws provide that we will indemnify certain of our officers and directors for certain claims asserted against them in connection with their service as an officer or director. The maximum potential amount of future payments that we could be required to make under these indemnification provisions is unlimited. However, we have purchased directors’ and officers’ liability insurance policies that could reduce our monetary exposure and enable us to recover a portion of any future amounts paid. No indemnification claims currently are outstanding, and we believe the estimated fair value of these indemnification arrangements is minimal.
We customarily agree in the ordinary course of our business to indemnification provisions in agreements with clinical trial investigators and sites in our product development programs, sponsored research agreements with academic and not-for-profit institutions, various comparable agreements involving parties performing services for us, and our real estate leases. We
also customarily agree to certain indemnification provisions in our drug discovery, development and commercialization collaboration agreements. With respect to our clinical trials and sponsored research agreements, these indemnification provisions typically apply to any claim asserted against the investigator or the investigator’s institution relating to personal injury or property damage, violations of law or certain breaches of our contractual obligations arising out of the research or clinical testing of our compounds or product candidates. With respect to lease agreements, the indemnification provisions typically apply to claims asserted against the landlord relating to personal injury or property damage caused by us, to violations of law by us or to certain breaches of our contractual obligations. The indemnification provisions appearing in our collaboration agreements are similar to those for the other agreements discussed above, but in addition provide some limited indemnification for our collaborator in the event of third-party claims alleging infringement of intellectual property rights. In each of the cases above, the indemnification obligation generally survives the termination of the agreement for some extended period, although we believe the obligation typically has the most relevance during the contract term and for a short period of time thereafter. The maximum potential amount of future payments that we could be required to make under these provisions is generally unlimited. We have purchased insurance policies covering personal injury, property damage and general liability that reduce our exposure for indemnification and would enable us in many cases to recover all or a portion of any future amounts paid. We have never paid any material amounts to defend lawsuits or settle claims related to these indemnification provisions. Accordingly, we believe the estimated fair value of these indemnification arrangements is minimal.
Other Contingencies
We have certain contingent liabilities that arise in the ordinary course of our business activities. We accrue for such contingent liabilities when it is probable that future expenditures will be made, and such expenditures can be reasonably estimated. Other than our contingent consideration liabilities discussed in Note E, “Fair Value Measurements,” there were no material contingent liabilities accrued as of September 30, 2023 or December 31, 2022.
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.23.3
Additional Cash Flow Information
 9 Months Ended
Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Additional Cash Flow Information Additional Cash Flow Information
The cash, cash equivalents and restricted cash at the beginning and ending of each period presented in our condensed consolidated statements of cash flows consisted of the following:
Nine Months Ended September 30,
20232022
Beginning of periodEnd of periodBeginning of periodEnd of period
(in millions)
Cash and cash equivalents$10,504.0 $11,110.2 $6,795.0 $9,171.5 
Prepaid expenses and other current assets
8.0 6.4 5.1 5.5 
Cash, cash equivalents and restricted cash per condensed consolidated statement of cash flows$10,512.0 $11,116.6 $6,800.1 $9,177.0 
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.23.3
Pay vs Performance Disclosure - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Pay vs Performance Disclosure        
Net income $ 1,035.3 $ 930.5 $ 2,650.8 $ 2,503.1
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.23.3
Insider Trading Arrangements
 3 Months Ended 9 Months Ended
Sep. 30, 2023
shares
Sep. 30, 2023
shares
Trading Arrangements, by Individual    
Material Terms of Trading Arrangement   The following table describes the written plans for the sale of our securities adopted by our executive officers and directors during the third quarter of 2023, each of which is intended to satisfy the affirmative defense conditions of Rule 10b5-1 (each, a “Trading Plan”).
Name and TitleDate of Adoption of Trading PlanScheduled Expiration Date of Trading Plan (1)Maximum Shares Subject to Trading Plan
E. Morrow “Morrey” Atkinson III
EVP, Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations
8/22/20234/30/2024
9,224(2)
Reshma Kewalramani
President, Chief Executive Officer and Director
8/11/20238/15/2024
27,330
Jeffrey M. Leiden
Executive Chairman
8/4/20235/15/2025
40,454(2)
Bastiano Sanna
EVP, Chief of Cell and Genetic Therapies
8/25/20238/9/2024
32,833(2)
Charles F. Wagner, Jr.
EVP, Chief Financial Officer
8/18/20238/9/2024
6,000
(1) A Trading Plan may expire on an earlier date if all contemplated transactions are completed before such Trading Plan’s expiration date, upon termination by broker or the holder of the Trading Plan, or as otherwise provided in the Trading Plan.
(2) The maximum shares listed has not been reduced by the number of shares of common stock that will be withheld to satisfy tax withholding obligations at future vesting dates because such number of shares is not yet determinable.
Non-Rule 10b5-1 Arrangement Adopted false  
Rule 10b5-1 Arrangement Terminated false  
Non-Rule 10b5-1 Arrangement Terminated false  
E. Morrow "Morrey" Atkinson III [Member]    
Trading Arrangements, by Individual    
Name E. Morrow “Morrey” Atkinson III  
Title EVP, Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations  
Rule 10b5-1 Arrangement Adopted true  
Adoption Date 8/22/2023  
Arrangement Duration 252 days  
Aggregate Available 9,224 9,224
Reshma Kewalramani [Member]    
Trading Arrangements, by Individual    
Name Reshma Kewalramani  
Title President, Chief Executive Officer and Director  
Rule 10b5-1 Arrangement Adopted true  
Adoption Date 8/11/2023  
Arrangement Duration 370 days  
Aggregate Available 27,330 27,330
Jeffrey M. Leiden [Member]    
Trading Arrangements, by Individual    
Name Jeffrey M. Leiden  
Title Executive Chairman  
Rule 10b5-1 Arrangement Adopted true  
Adoption Date 8/4/2023  
Arrangement Duration 650 days  
Aggregate Available 40,454 40,454
Bastiano Sanna [Member]    
Trading Arrangements, by Individual    
Name Bastiano Sanna  
Title EVP, Chief of Cell and Genetic Therapies  
Rule 10b5-1 Arrangement Adopted true  
Adoption Date 8/25/2023  
Arrangement Duration 350 days  
Aggregate Available 32,833 32,833
Charles F. Wagner, Jr. [Member]    
Trading Arrangements, by Individual    
Name Charles F. Wagner, Jr.  
Title EVP, Chief Financial Officer  
Rule 10b5-1 Arrangement Adopted true  
Adoption Date 8/18/2023  
Arrangement Duration 357 days  
Aggregate Available 6,000 6,000
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.23.3
Basis of Presentation and Accounting Policies (Policies)
 9 Months Ended
Sep. 30, 2023
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
The accompanying condensed consolidated financial statements are unaudited and have been prepared by Vertex Pharmaceuticals Incorporated (“Vertex,” “we,” “us” or “our”) in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).
The condensed consolidated financial statements reflect the operations of Vertex and our wholly-owned subsidiaries. All material intercompany balances and transactions have been eliminated. We have reclassified certain items from the prior year’s condensed consolidated balance sheet to conform to the current year’s presentation. We operate in one segment, pharmaceuticals.
Certain information and footnote disclosures normally included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 (the “2022 Annual Report on Form 10-K”) have been condensed or omitted. These interim financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the financial position and results of income for the interim periods ended September 30, 2023 and 2022.
The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full fiscal year. These interim financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2022, which are contained in our 2022 Annual Report on Form 10-K.
Use of Estimates
Use of Estimates
The preparation of condensed consolidated financial statements in accordance with U.S. GAAP requires us to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of our condensed consolidated financial statements, and the amounts of revenues and expenses during the reported periods. We base our estimates on historical experience and various other assumptions, including in certain circumstances future projections that we believe to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.23.3
Revenue Recognition (Tables)
 9 Months Ended
Sep. 30, 2023
Revenue from Contract with Customer [Abstract]  
Schedule of Disaggregation of Revenue
“Product revenues, net” consisted of the following:
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
(in millions)
TRIKAFTA/KAFTRIO$2,274.3 $2,010.5 $6,611.4 $5,665.3 
KALYDECO112.8 139.4 363.1 417.1 
ORKAMBI63.0 146.2 281.8 399.9 
SYMDEKO/SYMKEVI33.4 38.2 95.2 145.7 
Total product revenues, net$2,483.5 $2,334.3 $7,351.5 $6,628.0 
“Product revenues, net” by geographic region, based on the location of the customer, consisted of the following:
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
(in millions)
United States$1,554.2 $1,455.6 $4,465.8 $4,238.9 
Outside of the United States
Europe766.5 730.5 2,373.7 2,018.3 
Other
162.8 148.2 512.0 370.8 
Total product revenues outside of the United States929.3 878.7 2,885.7 2,389.1 
Total product revenues, net
$2,483.5 $2,334.3 $7,351.5 $6,628.0 
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.23.3
Earnings Per Share (Tables)
 9 Months Ended
Sep. 30, 2023
Earnings Per Share [Abstract]  
Schedule of Earnings Per Share, Basic and Diluted
The following table sets forth the computation of basic and diluted net income per common share for the periods ended:
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
(in millions, except per share amounts)
Net income$1,035.3 $930.5 $2,650.8 $2,503.1 
Basic weighted-average common shares outstanding258.0 256.5 257.7 255.8 
Effect of potentially dilutive securities:
Stock options1.2 1.4 1.2 1.4 
Restricted stock units (including PSUs)
1.4 1.6 1.5 1.4 
Employee stock purchase program
0.0 0.0 0.0 0.1 
Diluted weighted-average common shares outstanding260.6 259.5 260.4 258.7 
Basic net income per common share$4.01 $3.63 $10.29 $9.78 
Diluted net income per common share$3.97 $3.59 $10.18 $9.68 
Schedule of Potential Gross Common Equivalent Shares
We did not include the securities in the following table in the computation of the diluted net income per common share because the effect would have been anti-dilutive during each period:
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
(in millions)
Stock options— — 0.0 0.0 
Unvested restricted stock units (including PSUs)— 0.0 0.2 0.2 
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.23.3
Fair Value Measurements (Tables)
 9 Months Ended
Sep. 30, 2023
Fair Value Disclosures [Abstract]  
Schedule of Financial Assets Subject to Fair Value Measurements
The following tables set forth our financial assets and liabilities subject to fair value measurements by level within the fair value hierarchy (and does not include $5.5 billion and $3.1 billion of cash as of September 30, 2023 and December 31, 2022, respectively):
As of September 30, 2023As of December 31, 2022
Total
Level 1
Level 2
Level 3
Total
Level 1
Level 2
Level 3
(in millions)
Financial instruments carried at fair value (asset positions):
Cash equivalents:
Money market funds$3,753.4 $3,753.4 $— $— $5,162.6 $5,162.6 $— $— 
Time deposits1,550.0 — 1,550.0 — 2,000.0 — 2,000.0 — 
U.S. Treasury securities236.8 236.8 — — — — — — 
Corporate debt securities— — — — 5.8 — 5.8 — 
Commercial paper96.5 — 96.5 — 204.5 — 204.5 — 
Marketable securities:
Corporate equity securities46.4 46.4 — — 116.8 88.8 28.0 — 
U.S. Treasury securities408.2 408.2 — — — — — — 
Government-sponsored enterprise securities421.0 421.0 — — 127.1 127.1 — — 
Asset-backed securities237.8 — 237.8 — — — — — 
Certificates of deposit31.7 — 31.7 — — — — — 
Corporate debt securities1,214.2 — 1,214.2 — 87.0 — 87.0 — 
Commercial paper158.7 — 158.7 — 55.8 — 55.8 — 
Prepaid expenses and other current assets:
Foreign currency forward contracts37.8 — 37.8 — 47.5 — 47.5 — 
Other assets:
Foreign currency forward contracts3.4 — 3.4 — 0.8 — 0.8 — 
Total financial assets
$8,195.9 $4,865.8 $3,330.1 $— $7,807.9 $5,378.5 $2,429.4 $— 
Financial instruments carried at fair value (liability positions):
Other current liabilities:
Foreign currency forward contracts
$(0.7)$— $(0.7)$— $(14.3)$— $(14.3)$— 
Contingent consideration(15.0)— — (15.0)(14.6)— — (14.6)
Other long-term liabilities:
Foreign currency forward contracts— — — — (0.9)— (0.9)— 
Contingent consideration(112.7)— — (112.7)(114.4)— — (114.4)
Total financial liabilities
$(128.4)$— $(0.7)$(127.7)$(144.2)$— $(15.2)$(129.0)
Schedule of Fair Value of Our Contingent Consideration Liabilities
The following table represents a rollforward of the fair value of our contingent consideration liabilities:
Nine Months Ended September 30, 2023
(in millions)
Balance at December 31, 2022$129.0 
Decrease in fair value of contingent payments
(1.3)
Balance at September 30, 2023$127.7 
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.23.3
Marketable Securities and Equity Investments (Tables)
 9 Months Ended
Sep. 30, 2023
Investments, Debt and Equity Securities [Abstract]  
Schedule of Cash Equivalents and Marketable Securities
A summary of our cash equivalents and marketable securities, which are recorded at fair value (and do not include $5.5 billion and $3.1 billion of cash as of September 30, 2023 and December 31, 2022, respectively), is shown below:
As of September 30, 2023As of December 31, 2022
Amortized Cost
Gross
Unrealized
Gains
Gross
Unrealized
Losses
Fair
Value
Amortized Cost
Gross
Unrealized
Gains
Gross
Unrealized
Losses
Fair
Value
(in millions)
Cash equivalents:
Money market funds$3,753.4 $— $— $3,753.4 $5,162.6 $— $— $5,162.6 
Time deposits1,550.0 — — 1,550.0 2,000.0 — — 2,000.0 
U.S. Treasury securities236.8 — — 236.8 — — — — 
Corporate debt securities— — — — 5.8 — — 5.8 
Commercial paper96.5 — — 96.5 204.5 — — 204.5 
Total cash equivalents
$5,636.7 $— $— $5,636.7 $7,372.9 $— $— $7,372.9 
Marketable securities:
U.S. Treasury securities$414.6 $0.1 $(6.5)$408.2 $— $— $— $— 
Government-sponsored enterprise securities
422.9 — (1.9)421.0 127.0 0.2 (0.1)127.1 
Asset-backed securities239.3 0.0 (1.5)237.8 — — — — 
Certificates of deposit31.7 0.0 — 31.7 — — — — 
Corporate debt securities
1,228.4 0.0 (14.2)1,214.2 87.2 — (0.2)87.0 
Commercial paper
158.8 0.0 (0.1)158.7 55.8 — — 55.8 
Total marketable debt securities
2,495.7 0.1 (24.2)2,471.6 270.0 0.2 (0.3)269.9 
Corporate equity securities
72.1 0.5 (26.2)46.4 104.4 30.9 (18.5)116.8 
Total marketable securities
$2,567.8 $0.6 $(50.4)$2,518.0 $374.4 $31.1 $(18.8)$386.7 
Available-for-sale debt securities were classified on our condensed consolidated balance sheets at fair value as follows:
As of September 30, 2023As of December 31, 2022
(in millions)
Cash and cash equivalents$4,086.7 $5,372.9 
Marketable securities
771.6 157.7 
Long-term marketable securities1,700.0 112.2 
Total
$6,558.3 $5,642.8 
Available-for-sale debt securities by contractual maturity were as follows:
As of September 30, 2023As of December 31, 2022
(in millions)
Matures within one year$4,858.3 $5,530.6 
Matures after one year through five years
1,700.0 112.2 
Total
$6,558.3 $5,642.8 
Schedule of Company's Net Unrealized (Losses) Gains on Corporate Equity Securities During the three and nine months ended September 30, 2023 and 2022, our net unrealized (losses) gains on corporate equity securities held at the conclusion of each period were as follows:
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
(in millions)
Net unrealized (losses) gains
$(6.2)$16.7 $(7.1)$(143.1)
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.23.3
Accumulated Other Comprehensive Income (Loss) (Tables)
 9 Months Ended
Sep. 30, 2023
Equity [Abstract]  
Schedule of Accumulated Other Comprehensive Income (Loss)
The following table summarizes the changes in accumulated other comprehensive income (loss) by component:
Unrealized Holding Gains (Losses), Net of Tax
Foreign Currency Translation AdjustmentOn Available-For-Sale Debt SecuritiesOn Foreign Currency Forward ContractsTotal
(in millions)
Balance at December 31, 2022$(25.0)$(0.1)$25.9 $0.8 
Other comprehensive income (loss) before reclassifications9.1 (18.8)31.8 22.1 
Amounts reclassified from accumulated other comprehensive income (loss)— — (25.9)(25.9)
Net current period other comprehensive income (loss)9.1 (18.8)5.9 (3.8)
Balance at September 30, 2023$(15.9)$(18.9)$31.8 $(3.0)
Balance at December 31, 2021$(13.6)$(0.5)$30.0 $15.9 
Other comprehensive (loss) income before reclassifications(42.8)(3.6)230.2 183.8 
Amounts reclassified from accumulated other comprehensive income (loss)— — (102.1)(102.1)
Net current period other comprehensive (loss) income(42.8)(3.6)128.1 81.7 
Balance at September 30, 2022$(56.4)$(4.1)$158.1 $97.6 
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.23.3
Hedging (Tables)
 9 Months Ended
Sep. 30, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Cash Flow Hedging Instruments
The following table summarizes the notional amount in U.S. dollars of our outstanding foreign currency forward contracts designated as cash flow hedges under U.S. GAAP:
As of September 30, 2023As of December 31, 2022
Foreign Currency(in millions)
Euro$1,343.3 $1,497.7 
Canadian dollar
192.6 216.3 
British pound sterling
191.9 247.4 
Australian dollar
136.2 174.9 
Swiss Franc51.7 65.2 
Total foreign currency forward contracts
$1,915.7 $2,201.5 
Schedule of Foreign Exchange Contracts, Condensed Consolidated Statements of Operations
During the three and nine months ended September 30, 2023 and 2022, we recognized the following related to foreign currency forward contracts in our condensed consolidated statements of income:
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
(in millions)
Designated as hedging instruments - Reclassified from AOCI
Product revenues, net$2.8 $65.2 $33.0 $130.3 
Not designated as hedging instruments
Other (expense) income, net$(22.0)$(22.1)$(17.8)$(38.9)
Total reported in the Condensed Consolidated Statements of Income
Product revenues, net$2,483.5 $2,334.3 $7,351.5 $6,628.0 
Other (expense) income, net$(15.9)$17.2 $(13.0)$(133.7)
Schedule of Foreign Exchange Contracts
The following table summarizes the fair value of our outstanding foreign currency forward contracts designated as cash flow hedges under U.S. GAAP included on our condensed consolidated balance sheets:
As of September 30, 2023
AssetsLiabilities
ClassificationFair ValueClassificationFair Value
(in millions)
Prepaid expenses and other current assets$37.8 Other current liabilities$(0.7)
Other assets3.4 Other long-term liabilities— 
Total assets
$41.2 
Total liabilities
$(0.7)
As of December 31, 2022
AssetsLiabilities
ClassificationFair ValueClassificationFair Value
(in millions)
Prepaid expenses and other current assets$47.5 Other current liabilities$(14.3)
Other assets0.8 Other long-term liabilities(0.9)
Total assets
$48.3 
Total liabilities
$(15.2)
Schedule of Offsetting Assets The following table summarizes the potential effect of offsetting derivatives by type of financial instrument designated as cash flow hedges under U.S. GAAP on our condensed consolidated balance sheets:

As of September 30, 2023
Gross Amounts RecognizedGross Amounts OffsetGross Amounts PresentedGross Amounts Not OffsetLegal Offset
Foreign currency forward contracts(in millions)
Total assets$41.2 $— $41.2 $(0.7)$40.5 
Total liabilities(0.7)— (0.7)0.7 — 
As of December 31, 2022
Gross Amounts RecognizedGross Amounts OffsetGross Amounts PresentedGross Amounts Not OffsetLegal Offset
Foreign currency forward contracts(in millions)
Total assets$48.3 $— $48.3 $(15.2)$33.1 
Total liabilities(15.2)— (15.2)15.2 — 
Schedule of Offsetting Liabilities The following table summarizes the potential effect of offsetting derivatives by type of financial instrument designated as cash flow hedges under U.S. GAAP on our condensed consolidated balance sheets:

As of September 30, 2023
Gross Amounts RecognizedGross Amounts OffsetGross Amounts PresentedGross Amounts Not OffsetLegal Offset
Foreign currency forward contracts(in millions)
Total assets$41.2 $— $41.2 $(0.7)$40.5 
Total liabilities(0.7)— (0.7)0.7 — 
As of December 31, 2022
Gross Amounts RecognizedGross Amounts OffsetGross Amounts PresentedGross Amounts Not OffsetLegal Offset
Foreign currency forward contracts(in millions)
Total assets$48.3 $— $48.3 $(15.2)$33.1 
Total liabilities(15.2)— (15.2)15.2 — 
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.23.3
Inventories (Tables)
 9 Months Ended
Sep. 30, 2023
Inventory Disclosure [Abstract]  
Schedule of Inventories by Type
Inventories consisted of the following:
As of September 30, 2023As of December 31, 2022
(in millions)
Raw materials$77.5 $38.1 
Work-in-process498.3 260.7 
Finished goods
112.9 161.8 
Total
$688.7 $460.6 
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.23.3
Stock-based Compensation Expense and Share Repurchase Programs (Tables)
 9 Months Ended
Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]  
Schedule of Stock-based Compensation Expense by Line Item
During the three and nine months ended September 30, 2023 and 2022, we recognized the following stock-based compensation expense:
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
(in millions)
Stock-based compensation expense by type of award:
Restricted stock units (including PSUs)$129.1 $130.3 $358.6 $351.5 
Stock options0.2 3.1 4.0 14.9 
ESPP share issuances2.4 1.9 11.8 13.0 
Stock-based compensation expense related to inventories
(0.8)0.3 (1.8)0.4 
Total stock-based compensation expense included in “Total costs and expenses”
$130.9 $135.6 $372.6 $379.8 
Stock-based compensation expense by line item:
Cost of sales$1.7 $2.4 $5.4 $7.0 
Research and development expenses81.1 80.0 231.9 229.9 
Selling, general and administrative expenses48.1 53.2 135.3 142.9 
Total stock-based compensation expense included in costs and expenses
130.9 135.6 372.6 379.8 
Income tax effect(37.1)(38.8)(109.0)(101.3)
Total stock-based compensation expense, net of tax
$93.8 $96.8 $263.6 $278.5 
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.23.3
Income Taxes (Tables)
 9 Months Ended
Sep. 30, 2023
Income Tax Disclosure [Abstract]  
Schedule of Provision for (Benefits from) Income Taxes and Effective Tax rates During the three and nine months ended September 30, 2023 and 2022, we recorded the following provisions for income taxes and effective tax rates as compared to our income before provision for income taxes:
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
(in millions, except percentages)
Income before provision for income taxes$1,179.2 $1,176.4 $3,232.2 $3,155.6 
Provision for income taxes$143.9 $245.9 $581.4 $652.5 
Effective tax rate12.2 %20.9 %18.0 %20.7 %
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.23.3
Additional Cash Flow Information (Tables)
 9 Months Ended
Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Additional Cash Flow Information
The cash, cash equivalents and restricted cash at the beginning and ending of each period presented in our condensed consolidated statements of cash flows consisted of the following:
Nine Months Ended September 30,
20232022
Beginning of periodEnd of periodBeginning of periodEnd of period
(in millions)
Cash and cash equivalents$10,504.0 $11,110.2 $6,795.0 $9,171.5 
Prepaid expenses and other current assets
8.0 6.4 5.1 5.5 
Cash, cash equivalents and restricted cash per condensed consolidated statement of cash flows$10,512.0 $11,116.6 $6,800.1 $9,177.0 
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.23.3
Basis of Presentation and Accounting Policies (Details)
 9 Months Ended
Sep. 30, 2023
segment
Accounting Policies [Abstract]  
Number of operating segments 1
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.23.3
Revenue Recognition - Disaggregation of Revenue (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Disaggregation of Revenue [Line Items]        
Product revenues, net $ 2,483.5 $ 2,334.3 $ 7,351.5 $ 6,628.0
United States        
Disaggregation of Revenue [Line Items]        
Product revenues, net 1,554.2 1,455.6 4,465.8 4,238.9
Total product revenues outside of the United States        
Disaggregation of Revenue [Line Items]        
Product revenues, net 929.3 878.7 2,885.7 2,389.1
Europe        
Disaggregation of Revenue [Line Items]        
Product revenues, net 766.5 730.5 2,373.7 2,018.3
Other        
Disaggregation of Revenue [Line Items]        
Product revenues, net 162.8 148.2 512.0 370.8
TRIKAFTA/KAFTRIO        
Disaggregation of Revenue [Line Items]        
Product revenues, net 2,274.3 2,010.5 6,611.4 5,665.3
KALYDECO        
Disaggregation of Revenue [Line Items]        
Product revenues, net 112.8 139.4 363.1 417.1
ORKAMBI        
Disaggregation of Revenue [Line Items]        
Product revenues, net 63.0 146.2 281.8 399.9
SYMDEKO/SYMKEVI        
Disaggregation of Revenue [Line Items]        
Product revenues, net $ 33.4 $ 38.2 $ 95.2 $ 145.7
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.23.3
Revenue Recognition - Additional Information (Details) - USD ($)
$ in Millions
Sep. 30, 2023
Dec. 31, 2022
Revenue from Contract with Customer [Abstract]    
Contract liabilities $ 157.1 $ 159.6
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.23.3
Acquired In-Process Research and Development and Other Arrangements - Additional Information (Details)
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2023
USD ($)
Mar. 31, 2023
USD ($)
Feb. 28, 2023
USD ($)
Jul. 31, 2022
USD ($)
May 31, 2022
USD ($)
Sep. 30, 2023
USD ($)
Sep. 30, 2022
USD ($)
Sep. 30, 2023
USD ($)
Sep. 30, 2022
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2019
USD ($)
target
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Acquired in-process research and development expenses           $ 51,700,000 $ 29,000,000 $ 509,300,000 $ 92,900,000    
Selling, general and administrative expenses           263,800,000 246,800,000 767,500,000 677,300,000    
Septerna, Inc                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Asset acquisition, consideration transferred $ 47,500,000                    
Catalyst Biosciences                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Asset acquisition, consideration transferred         $ 60,000,000            
CRISPR Therapeutics                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Collaborative arrangement, right to exclusively license, number of targets | target                     3
Collaborative arrangement, development and regulatory potential milestone payments maximum                     $ 410,000,000
CRISPR JDCA                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Collaborative arrangement, development and regulatory potential milestone payments maximum                   $ 200,000,000  
Allocation of net profits and net losses, percent                   60.00%  
Research and development expenses           74,900,000 45,500,000 193,200,000 120,600,000    
Selling, general and administrative expenses           26,000,000 $ 13,500,000 66,100,000 $ 35,300,000    
CRISPR JDCA | CRISPR                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Allocation of net profits and net losses, percent                   40.00%  
CRISPR T1D                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Acquired in-process research and development expenses               170,000,000      
Collaborative arrangement, development and regulatory potential milestone payments maximum               $ 160,000,000      
Up-front payment   $ 100,000,000                  
Milestone payment           $ 70,000,000          
Entrada Therapeutics                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Collaborative arrangement, development and regulatory potential milestone payments maximum     $ 485,000,000                
Up-front payment     225,100,000                
Purchase of common stock     $ 24,900,000                
Verve                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Up-front payment       $ 25,000,000              
Purchase of common stock       $ 35,000,000              
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.23.3
Earnings Per Share - Schedule of Computation (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share        
Net income $ 1,035.3 $ 930.5 $ 2,650.8 $ 2,503.1
Basic weighted-average common shares outstanding (in shares) 258.0 256.5 257.7 255.8
Effect of potentially dilutive securities:        
Employee stock purchase program (in shares) 0.0 0.0 0.0 0.1
Diluted weighted-average common shares outstanding (in shares) 260.6 259.5 260.4 258.7
Basic net income per common share (in dollars per share) $ 4.01 $ 3.63 $ 10.29 $ 9.78
Diluted net income per common share (in dollars per share) $ 3.97 $ 3.59 $ 10.18 $ 9.68
Stock options        
Effect of potentially dilutive securities:        
Share-based payment arrangements (in shares) 1.2 1.4 1.2 1.4
Restricted stock units (including PSUs)        
Effect of potentially dilutive securities:        
Share-based payment arrangements (in shares) 1.4 1.6 1.5 1.4
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.23.3
Earnings Per Share - Anti-dilutive Securities (Details) - shares
shares in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Stock options        
Antidilutive Securities Excluded from Computation of Earnings Per Share        
Antidilutive securities excluded from computation of earnings per share (in shares) 0.0 0.0 0.0 0.0
Unvested restricted stock units (including PSUs)        
Antidilutive Securities Excluded from Computation of Earnings Per Share        
Antidilutive securities excluded from computation of earnings per share (in shares) 0.0 0.0 0.2 0.2
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.23.3
Fair Value Measurements - Additional Information (Details)
$ in Millions
Sep. 30, 2023
USD ($)
Dec. 31, 2022
USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash $ 5,500.0 $ 3,100.0
Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Remaining milestone payment $ 678.3  
Level 3 | Minimum | Discount Rate    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration, measurement input (as a percent) 0.055  
Level 3 | Maximum | Discount Rate    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration, measurement input (as a percent) 0.065  
Corporate equity securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments with restrictions $ 25.5  
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.23.3
Fair Value Measurements - Financial Assets and Liabilities Subject to Fair Value Measurements (Details) - Recurring Basis - USD ($)
$ in Millions
Sep. 30, 2023
Dec. 31, 2022
Financial instruments carried at fair value (asset positions):    
Prepaid expenses and other current assets, foreign currency forward contracts $ 37.8 $ 47.5
Other assets, foreign currency forward contracts 3.4 0.8
Total financial assets 8,195.9 7,807.9
Financial instruments carried at fair value (liability positions):    
Other current liabilities, foreign currency forward contracts (0.7) (14.3)
Other current liabilities, contingent consideration (15.0) (14.6)
Other long-term liabilities, foreign currency forward contracts 0.0 (0.9)
Contingent consideration (112.7) (114.4)
Total financial liabilities (128.4) (144.2)
Level 1    
Financial instruments carried at fair value (asset positions):    
Prepaid expenses and other current assets, foreign currency forward contracts 0.0 0.0
Other assets, foreign currency forward contracts 0.0 0.0
Total financial assets 4,865.8 5,378.5
Financial instruments carried at fair value (liability positions):    
Other current liabilities, foreign currency forward contracts 0.0 0.0
Other current liabilities, contingent consideration 0.0 0.0
Other long-term liabilities, foreign currency forward contracts 0.0 0.0
Contingent consideration 0.0 0.0
Total financial liabilities 0.0 0.0
Level 2    
Financial instruments carried at fair value (asset positions):    
Prepaid expenses and other current assets, foreign currency forward contracts 37.8 47.5
Other assets, foreign currency forward contracts 3.4 0.8
Total financial assets 3,330.1 2,429.4
Financial instruments carried at fair value (liability positions):    
Other current liabilities, foreign currency forward contracts (0.7) (14.3)
Other current liabilities, contingent consideration 0.0 0.0
Other long-term liabilities, foreign currency forward contracts 0.0 (0.9)
Contingent consideration 0.0 0.0
Total financial liabilities (0.7) (15.2)
Level 3    
Financial instruments carried at fair value (asset positions):    
Prepaid expenses and other current assets, foreign currency forward contracts 0.0 0.0
Other assets, foreign currency forward contracts 0.0 0.0
Total financial assets 0.0 0.0
Financial instruments carried at fair value (liability positions):    
Other current liabilities, foreign currency forward contracts 0.0 0.0
Other current liabilities, contingent consideration (15.0) (14.6)
Other long-term liabilities, foreign currency forward contracts 0.0 0.0
Contingent consideration (112.7) (114.4)
Total financial liabilities (127.7) (129.0)
Money market funds    
Financial instruments carried at fair value (asset positions):    
Cash equivalents: 3,753.4 5,162.6
Money market funds | Level 1    
Financial instruments carried at fair value (asset positions):    
Cash equivalents: 3,753.4 5,162.6
Money market funds | Level 2    
Financial instruments carried at fair value (asset positions):    
Cash equivalents: 0.0 0.0
Money market funds | Level 3    
Financial instruments carried at fair value (asset positions):    
Cash equivalents: 0.0 0.0
Time deposits    
Financial instruments carried at fair value (asset positions):    
Cash equivalents: 1,550.0 2,000.0
Time deposits | Level 1    
Financial instruments carried at fair value (asset positions):    
Cash equivalents: 0.0 0.0
Time deposits | Level 2    
Financial instruments carried at fair value (asset positions):    
Cash equivalents: 1,550.0 2,000.0
Time deposits | Level 3    
Financial instruments carried at fair value (asset positions):    
Cash equivalents: 0.0 0.0
Corporate equity securities    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 46.4 116.8
Corporate equity securities | Level 1    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 46.4 88.8
Corporate equity securities | Level 2    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 0.0 28.0
Corporate equity securities | Level 3    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 0.0 0.0
U.S. Treasury securities    
Financial instruments carried at fair value (asset positions):    
Cash equivalents: 236.8 0.0
Marketable securities: 408.2 0.0
U.S. Treasury securities | Level 1    
Financial instruments carried at fair value (asset positions):    
Cash equivalents: 236.8 0.0
Marketable securities: 408.2 0.0
U.S. Treasury securities | Level 2    
Financial instruments carried at fair value (asset positions):    
Cash equivalents: 0.0 0.0
Marketable securities: 0.0 0.0
U.S. Treasury securities | Level 3    
Financial instruments carried at fair value (asset positions):    
Cash equivalents: 0.0 0.0
Marketable securities: 0.0 0.0
Government-sponsored enterprise securities    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 421.0 127.1
Government-sponsored enterprise securities | Level 1    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 421.0 127.1
Government-sponsored enterprise securities | Level 2    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 0.0 0.0
Government-sponsored enterprise securities | Level 3    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 0.0 0.0
Asset-backed securities    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 237.8 0.0
Asset-backed securities | Level 1    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 0.0 0.0
Asset-backed securities | Level 2    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 237.8 0.0
Asset-backed securities | Level 3    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 0.0 0.0
Certificates of deposit    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 31.7 0.0
Certificates of deposit | Level 1    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 0.0 0.0
Certificates of deposit | Level 2    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 31.7 0.0
Certificates of deposit | Level 3    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 0.0 0.0
Corporate debt securities    
Financial instruments carried at fair value (asset positions):    
Cash equivalents: 0.0 5.8
Marketable securities: 1,214.2 87.0
Corporate debt securities | Level 1    
Financial instruments carried at fair value (asset positions):    
Cash equivalents: 0.0 0.0
Marketable securities: 0.0 0.0
Corporate debt securities | Level 2    
Financial instruments carried at fair value (asset positions):    
Cash equivalents: 0.0 5.8
Marketable securities: 1,214.2 87.0
Corporate debt securities | Level 3    
Financial instruments carried at fair value (asset positions):    
Cash equivalents: 0.0 0.0
Marketable securities: 0.0 0.0
Commercial paper    
Financial instruments carried at fair value (asset positions):    
Cash equivalents: 96.5 204.5
Marketable securities: 158.7 55.8
Commercial paper | Level 1    
Financial instruments carried at fair value (asset positions):    
Cash equivalents: 0.0 0.0
Marketable securities: 0.0 0.0
Commercial paper | Level 2    
Financial instruments carried at fair value (asset positions):    
Cash equivalents: 96.5 204.5
Marketable securities: 158.7 55.8
Commercial paper | Level 3    
Financial instruments carried at fair value (asset positions):    
Cash equivalents: 0.0 0.0
Marketable securities: $ 0.0 $ 0.0
XML 53 R43.htm IDEA: XBRL DOCUMENT v3.23.3
Fair Value Measurements - Fair Value of Contingent Consideration Liabilities (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]        
Beginning balance     $ 129.0  
Decrease in fair value of contingent payments $ 1.2 $ (2.6) (1.3) $ (59.3)
Ending balance $ 127.7   $ 127.7  
XML 54 R44.htm IDEA: XBRL DOCUMENT v3.23.3
Marketable Securities and Equity Investments - Additional Information (Details) - USD ($)
 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Summary of cash, cash equivalents and marketable securities      
Cash $ 5,500,000,000   $ 3,100,000,000
Allowance for credit loss for available-for-sale debt securities 0 $ 0  
Debt securities fair value, unrealized loss position 2,280,000,000    
Unrealized loss 24,200,000    
Unrealized loss position for greater than twelve months 0    
Original cost 72,100,000   $ 104,400,000
Publicly Traded Companies Sale      
Summary of cash, cash equivalents and marketable securities      
Proceeds received 95,100,000 $ 0  
Original cost 57,300,000    
Other Assets      
Summary of cash, cash equivalents and marketable securities      
Equity securities without readily determinable fair value, amount $ 98,600,000    
XML 55 R45.htm IDEA: XBRL DOCUMENT v3.23.3
Marketable Securities and Equity Investments - Summary of Cash Equivalents and Marketable Securities (Details) - USD ($)
$ in Millions
 9 Months Ended 12 Months Ended
Sep. 30, 2023
Dec. 31, 2022
Cash equivalents:    
Amortized Cost $ 5,636.7 $ 7,372.9
Fair Value 5,636.7 7,372.9
Total marketable debt securities    
Gross Unrealized Losses (24.2)  
Fair Value 6,558.3 5,642.8
Corporate equity securities    
Amortized Cost 72.1 104.4
Gross Unrealized Gains 0.5 30.9
Gross Unrealized Losses (26.2) (18.5)
Fair Value 46.4 116.8
Amortized Cost 2,567.8 374.4
Gross Unrealized Gains 0.6 31.1
Gross Unrealized Losses (50.4) (18.8)
Fair Value 2,518.0 386.7
Money market funds    
Cash equivalents:    
Amortized Cost 3,753.4 5,162.6
Fair Value 3,753.4 5,162.6
Time deposits    
Cash equivalents:    
Amortized Cost 1,550.0 2,000.0
Fair Value 1,550.0 2,000.0
U.S. Treasury securities    
Cash equivalents:    
Amortized Cost 236.8 0.0
Fair Value 236.8 0.0
Total marketable debt securities    
Amortized Cost 414.6 0.0
Gross Unrealized Gains 0.1 0.0
Gross Unrealized Losses (6.5) 0.0
Fair Value 408.2 0.0
Government-sponsored enterprise securities    
Total marketable debt securities    
Amortized Cost 422.9 127.0
Gross Unrealized Gains 0.0 0.2
Gross Unrealized Losses (1.9) (0.1)
Fair Value 421.0 127.1
Asset-backed securities    
Total marketable debt securities    
Amortized Cost 239.3 0.0
Gross Unrealized Gains 0.0 0.0
Gross Unrealized Losses (1.5) 0.0
Fair Value 237.8 0.0
Certificates of deposit    
Total marketable debt securities    
Amortized Cost 31.7 0.0
Gross Unrealized Gains 0.0 0.0
Gross Unrealized Losses 0.0 0.0
Fair Value 31.7 0.0
Corporate debt securities    
Cash equivalents:    
Amortized Cost 0.0 5.8
Fair Value 0.0 5.8
Total marketable debt securities    
Amortized Cost 1,228.4 87.2
Gross Unrealized Gains 0.0 0.0
Gross Unrealized Losses (14.2) (0.2)
Fair Value 1,214.2 87.0
Commercial paper    
Cash equivalents:    
Amortized Cost 96.5 204.5
Fair Value 96.5 204.5
Commercial paper    
Total marketable debt securities    
Amortized Cost 158.8 55.8
Gross Unrealized Gains 0.0 0.0
Gross Unrealized Losses (0.1) 0.0
Fair Value 158.7 55.8
Total marketable debt securities    
Total marketable debt securities    
Amortized Cost 2,495.7 270.0
Gross Unrealized Gains 0.1 0.2
Gross Unrealized Losses (24.2) (0.3)
Fair Value $ 2,471.6 $ 269.9
XML 56 R46.htm IDEA: XBRL DOCUMENT v3.23.3
Marketable Securities and Equity Investments - Available-for-Sale Debt Securities at Fair Value (Details) - USD ($)
$ in Millions
Sep. 30, 2023
Dec. 31, 2022
Debt Securities, Available-for-sale [Line Items]    
Debt securities $ 6,558.3 $ 5,642.8
Cash and cash equivalents    
Debt Securities, Available-for-sale [Line Items]    
Debt securities 4,086.7 5,372.9
Marketable securities    
Debt Securities, Available-for-sale [Line Items]    
Debt securities 771.6 157.7
Long-term marketable securities    
Debt Securities, Available-for-sale [Line Items]    
Debt securities $ 1,700.0 $ 112.2
XML 57 R47.htm IDEA: XBRL DOCUMENT v3.23.3
Marketable Securities and Equity Investments - Available-for-Sale Debt Securities by Contractual Maturity (Details) - USD ($)
$ in Millions
Sep. 30, 2023
Dec. 31, 2022
Investments, Debt and Equity Securities [Abstract]    
Matures within one year $ 4,858.3 $ 5,530.6
Matures after one year through five years 1,700.0 112.2
Total $ 6,558.3 $ 5,642.8
XML 58 R48.htm IDEA: XBRL DOCUMENT v3.23.3
Marketable Securities and Equity Investments - Net Unrealized Gains (Losses) (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Investments, Debt and Equity Securities [Abstract]        
Net unrealized (losses) gains $ (6.2) $ 16.7 $ (7.1) $ (143.1)
XML 59 R49.htm IDEA: XBRL DOCUMENT v3.23.3
Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
AOCI Attributable to Parent, Net of Tax [Roll Forward]        
Beginning balance $ 15,470.2 $ 11,933.5 $ 13,912.7 $ 10,100.0
Other comprehensive income (loss) before reclassifications     22.1 183.8
Amounts reclassified from accumulated other comprehensive income (loss)     (25.9) (102.1)
Total other comprehensive income (loss) 36.8 40.1 (3.8) 81.7
Ending balance 16,512.8 13,029.6 16,512.8 13,029.6
Total        
AOCI Attributable to Parent, Net of Tax [Roll Forward]        
Beginning balance (39.8) 57.5 0.8 15.9
Total other comprehensive income (loss) 36.8 40.1 (3.8) 81.7
Ending balance (3.0) 97.6 (3.0) 97.6
Foreign Currency Translation Adjustment        
AOCI Attributable to Parent, Net of Tax [Roll Forward]        
Beginning balance     (25.0) (13.6)
Other comprehensive income (loss) before reclassifications     9.1 (42.8)
Amounts reclassified from accumulated other comprehensive income (loss)     0.0 0.0
Total other comprehensive income (loss)     9.1 (42.8)
Ending balance (15.9) (56.4) (15.9) (56.4)
On Available-For-Sale Debt Securities        
AOCI Attributable to Parent, Net of Tax [Roll Forward]        
Beginning balance     (0.1) (0.5)
Other comprehensive income (loss) before reclassifications     (18.8) (3.6)
Amounts reclassified from accumulated other comprehensive income (loss)     0.0 0.0
Total other comprehensive income (loss)     (18.8) (3.6)
Ending balance (18.9) (4.1) (18.9) (4.1)
On Foreign Currency Forward Contracts        
AOCI Attributable to Parent, Net of Tax [Roll Forward]        
Beginning balance     25.9 30.0
Other comprehensive income (loss) before reclassifications     31.8 230.2
Amounts reclassified from accumulated other comprehensive income (loss)     (25.9) (102.1)
Total other comprehensive income (loss)     5.9 128.1
Ending balance $ 31.8 $ 158.1 $ 31.8 $ 158.1
XML 60 R50.htm IDEA: XBRL DOCUMENT v3.23.3
Hedging - Additional Information (Details) - Foreign currency forward contracts
$ in Millions
 9 Months Ended
Sep. 30, 2023
USD ($)
Not Designated as Hedging Instrument  
Derivative [Line Items]  
Derivative term 1 month
Notional amount of foreign currency forward contract $ 922.8
Cash Flow Hedging | Minimum  
Derivative [Line Items]  
Derivative term 1 month
Cash Flow Hedging | Maximum  
Derivative [Line Items]  
Derivative term 18 months
XML 61 R51.htm IDEA: XBRL DOCUMENT v3.23.3
Hedging - Notional Amount (Details) - Foreign currency forward contracts - Designated as Hedging Instruments - Cash Flow Hedging - USD ($)
$ in Millions
Sep. 30, 2023
Dec. 31, 2022
Derivative [Line Items]    
Notional amount of foreign currency forward contract $ 1,915.7 $ 2,201.5
Euro    
Derivative [Line Items]    
Notional amount of foreign currency forward contract 1,343.3 1,497.7
Canadian dollar    
Derivative [Line Items]    
Notional amount of foreign currency forward contract 192.6 216.3
British pound sterling    
Derivative [Line Items]    
Notional amount of foreign currency forward contract 191.9 247.4
Australian dollar    
Derivative [Line Items]    
Notional amount of foreign currency forward contract 136.2 174.9
Swiss Franc    
Derivative [Line Items]    
Notional amount of foreign currency forward contract $ 51.7 $ 65.2
XML 62 R52.htm IDEA: XBRL DOCUMENT v3.23.3
Hedging - Cash Flow Hedging Instruments (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Derivative Instruments, Gain (Loss) [Line Items]        
Product revenues, net $ 2,483.5 $ 2,334.3 $ 7,351.5 $ 6,628.0
Other (expense) income, net (15.9) 17.2 (13.0) (133.7)
Foreign Currency Forward Contract | Reclassification out of Accumulated Other Comprehensive Income | Foreign currency forward contracts | Designated as hedging instruments        
Derivative Instruments, Gain (Loss) [Line Items]        
Product revenues, net 2.8 65.2 33.0 130.3
Foreign Currency Forward Contract | Reclassification out of Accumulated Other Comprehensive Income | Foreign currency forward contracts | Not designated as hedging instruments        
Derivative Instruments, Gain (Loss) [Line Items]        
Other (expense) income, net $ (22.0) $ (22.1) $ (17.8) $ (38.9)
XML 63 R53.htm IDEA: XBRL DOCUMENT v3.23.3
Hedging - Derivative Fair Value (Details) - Designated as Hedging Instruments - Foreign currency forward contracts - Cash Flow Hedging - USD ($)
$ in Millions
Sep. 30, 2023
Dec. 31, 2022
Derivative [Line Items]    
Total assets $ 41.2 $ 48.3
Total liabilities (0.7) (15.2)
Prepaid expenses and other current assets    
Derivative [Line Items]    
Total assets 37.8 47.5
Other assets    
Derivative [Line Items]    
Total assets 3.4 0.8
Other current liabilities    
Derivative [Line Items]    
Total liabilities (0.7) (14.3)
Other long-term liabilities    
Derivative [Line Items]    
Total liabilities $ 0.0 $ (0.9)
XML 64 R54.htm IDEA: XBRL DOCUMENT v3.23.3
Hedging - Offsetting Derivatives (Details) - Cash Flow Hedging - Designated as Hedging Instruments - Foreign currency forward contracts - USD ($)
$ in Millions
Sep. 30, 2023
Dec. 31, 2022
Offsetting Derivative Assets [Abstract]    
Gross Amounts Recognized $ 41.2 $ 48.3
Gross Amounts Offset 0.0 0.0
Gross Amounts Presented 41.2 48.3
Gross Amounts Not Offset (0.7) (15.2)
Legal Offset 40.5 33.1
Offsetting Derivative Liabilities [Abstract]    
Gross Amounts Recognized (0.7) (15.2)
Gross Amounts Offset 0.0 0.0
Gross Amounts Presented (0.7) (15.2)
Gross Amounts Not Offset 0.7 15.2
Legal Offset $ 0.0 $ 0.0
XML 65 R55.htm IDEA: XBRL DOCUMENT v3.23.3
Inventories (Details) - USD ($)
$ in Millions
Sep. 30, 2023
Dec. 31, 2022
Inventory Disclosure [Abstract]    
Raw materials $ 77.5 $ 38.1
Work-in-process 498.3 260.7
Finished goods 112.9 161.8
Total $ 688.7 $ 460.6
XML 66 R56.htm IDEA: XBRL DOCUMENT v3.23.3
Stock-based Compensation Expense and Share Repurchase Programs - Stock-based Compensation Expense (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Stock-based compensation expense:        
Total stock-based compensation expense included in costs and expenses $ 130.9 $ 135.6 $ 372.6 $ 379.8
Stock-based compensation expense related to inventories (0.8) 0.3 (1.8) 0.4
Total stock-based compensation expense included in “Total costs and expenses” 130.9 135.6 372.6 379.8
Income tax effect (37.1) (38.8) (109.0) (101.3)
Total stock-based compensation expense, net of tax 93.8 96.8 263.6 278.5
Cost of sales        
Stock-based compensation expense:        
Total stock-based compensation expense included in costs and expenses 1.7 2.4 5.4 7.0
Research and development expenses        
Stock-based compensation expense:        
Total stock-based compensation expense included in costs and expenses 81.1 80.0 231.9 229.9
Selling, general and administrative expenses        
Stock-based compensation expense:        
Total stock-based compensation expense included in costs and expenses 48.1 53.2 135.3 142.9
Restricted stock units (including PSUs)        
Stock-based compensation expense:        
Total stock-based compensation expense included in costs and expenses 129.1 130.3 358.6 351.5
Stock options        
Stock-based compensation expense:        
Total stock-based compensation expense included in costs and expenses 0.2 3.1 4.0 14.9
ESPP share issuances        
Stock-based compensation expense:        
Total stock-based compensation expense included in costs and expenses $ 2.4 $ 1.9 $ 11.8 $ 13.0
XML 67 R57.htm IDEA: XBRL DOCUMENT v3.23.3
Stock-based Compensation Expense and Share Repurchase Programs - Additional Information (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2023
Feb. 28, 2023
Share-Based Payment Arrangement [Abstract]      
Number of shares authorized to be repurchased     $ 3,000,000,000
Shares repurchased (in shares)   891,060  
Value of shares repurchased $ 123,000,000.0 $ 284,100,000  
Stock repurchase program, remaining amount $ 2,700,000,000 $ 2,700,000,000  
XML 68 R58.htm IDEA: XBRL DOCUMENT v3.23.3
Income Taxes (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Income Tax Disclosure [Abstract]          
Income before provision for income taxes $ 1,179.2 $ 1,176.4 $ 3,232.2 $ 3,155.6  
Provision for income taxes $ 143.9 $ 245.9 $ 581.4 $ 652.5  
Effective tax rate 12.20% 20.90% 18.00% 20.70%  
Net unrecognized tax benefits which would affect the tax rate if recognized $ 245.4   $ 245.4   $ 208.5
XML 69 R59.htm IDEA: XBRL DOCUMENT v3.23.3
Commitments and Contingencies (Details) - USD ($)
 1 Months Ended
Jul. 31, 2022
Sep. 30, 2023
Dec. 31, 2022
Line of Credit Facility [Line Items]      
Indemnification claims   $ 0  
Contingent liabilities   $ 0 $ 0
SOFR Loan | Minimum      
Line of Credit Facility [Line Items]      
Basis spread on variable rate (as a percent) 1.00%    
SOFR Loan | Maximum      
Line of Credit Facility [Line Items]      
Basis spread on variable rate (as a percent) 1.50%    
Revolving Credit Facility      
Line of Credit Facility [Line Items]      
Line of credit facility, maximum borrowing capacity $ 500,000,000    
Line of credit facility additional borrowing capacity $ 500,000,000    
Debt covenant, consolidated leverage ratio 3.50    
Debt covenant, increase in consolidated leverage ratio 4.00    
Revolving Credit Facility | Base Rate | Minimum      
Line of Credit Facility [Line Items]      
Basis spread on variable rate (as a percent) 0.00%    
Revolving Credit Facility | Base Rate | Maximum      
Line of Credit Facility [Line Items]      
Basis spread on variable rate (as a percent) 0.50%    
Letters of Credit      
Line of Credit Facility [Line Items]      
Line of credit facility, maximum borrowing capacity $ 100,000,000    
XML 70 R60.htm IDEA: XBRL DOCUMENT v3.23.3
Additional Cash Flow Information (Details) - USD ($)
$ in Millions
Sep. 30, 2023
Dec. 31, 2022
Sep. 30, 2022
Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]        
Cash and cash equivalents $ 11,110.2 $ 10,504.0 $ 9,171.5 $ 6,795.0
Prepaid expenses and other current assets 6.4 8.0 5.5 5.1
Cash, cash equivalents and restricted cash per condensed consolidated statement of cash flows $ 11,116.6 $ 10,512.0 $ 9,177.0 $ 6,800.1
XML 71 vrtx-20230930_htm.xml IDEA: XBRL DOCUMENT 0000875320 2023-01-01 2023-09-30 0000875320 2023-10-31 0000875320 2023-07-01 2023-09-30 0000875320 2022-07-01 2022-09-30 0000875320 2022-01-01 2022-09-30 0000875320 2023-09-30 0000875320 2022-12-31 0000875320 us-gaap:CommonStockMember 2022-06-30 0000875320 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0000875320 us-gaap:RetainedEarningsMember 2022-06-30 0000875320 2022-06-30 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-07-01 2022-09-30 0000875320 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0000875320 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0000875320 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0000875320 us-gaap:CommonStockMember 2022-09-30 0000875320 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-09-30 0000875320 us-gaap:RetainedEarningsMember 2022-09-30 0000875320 2022-09-30 0000875320 us-gaap:CommonStockMember 2023-06-30 0000875320 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0000875320 us-gaap:RetainedEarningsMember 2023-06-30 0000875320 2023-06-30 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 2023-09-30 0000875320 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0000875320 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0000875320 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0000875320 us-gaap:CommonStockMember 2023-09-30 0000875320 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0000875320 us-gaap:RetainedEarningsMember 2023-09-30 0000875320 us-gaap:CommonStockMember 2021-12-31 0000875320 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0000875320 us-gaap:RetainedEarningsMember 2021-12-31 0000875320 2021-12-31 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-09-30 0000875320 us-gaap:RetainedEarningsMember 2022-01-01 2022-09-30 0000875320 us-gaap:CommonStockMember 2022-01-01 2022-09-30 0000875320 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-09-30 0000875320 us-gaap:CommonStockMember 2022-12-31 0000875320 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000875320 us-gaap:RetainedEarningsMember 2022-12-31 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-09-30 0000875320 us-gaap:RetainedEarningsMember 2023-01-01 2023-09-30 0000875320 us-gaap:CommonStockMember 2023-01-01 2023-09-30 0000875320 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-09-30 0000875320 vrtx:TRIKAFTAKAFTRIOMember 2023-07-01 2023-09-30 0000875320 vrtx:TRIKAFTAKAFTRIOMember 2022-07-01 2022-09-30 0000875320 vrtx:TRIKAFTAKAFTRIOMember 2023-01-01 2023-09-30 0000875320 vrtx:TRIKAFTAKAFTRIOMember 2022-01-01 2022-09-30 0000875320 vrtx:KalydecoMember 2023-07-01 2023-09-30 0000875320 vrtx:KalydecoMember 2022-07-01 2022-09-30 0000875320 vrtx:KalydecoMember 2023-01-01 2023-09-30 0000875320 vrtx:KalydecoMember 2022-01-01 2022-09-30 0000875320 vrtx:ORKAMBIMember 2023-07-01 2023-09-30 0000875320 vrtx:ORKAMBIMember 2022-07-01 2022-09-30 0000875320 vrtx:ORKAMBIMember 2023-01-01 2023-09-30 0000875320 vrtx:ORKAMBIMember 2022-01-01 2022-09-30 0000875320 vrtx:SYMDEKOSYMKEVIMember 2023-07-01 2023-09-30 0000875320 vrtx:SYMDEKOSYMKEVIMember 2022-07-01 2022-09-30 0000875320 vrtx:SYMDEKOSYMKEVIMember 2023-01-01 2023-09-30 0000875320 vrtx:SYMDEKOSYMKEVIMember 2022-01-01 2022-09-30 0000875320 country:US 2023-07-01 2023-09-30 0000875320 country:US 2022-07-01 2022-09-30 0000875320 country:US 2023-01-01 2023-09-30 0000875320 country:US 2022-01-01 2022-09-30 0000875320 srt:EuropeMember 2023-07-01 2023-09-30 0000875320 srt:EuropeMember 2022-07-01 2022-09-30 0000875320 srt:EuropeMember 2023-01-01 2023-09-30 0000875320 srt:EuropeMember 2022-01-01 2022-09-30 0000875320 vrtx:OtherNonU.S.Member 2023-07-01 2023-09-30 0000875320 vrtx:OtherNonU.S.Member 2022-07-01 2022-09-30 0000875320 vrtx:OtherNonU.S.Member 2023-01-01 2023-09-30 0000875320 vrtx:OtherNonU.S.Member 2022-01-01 2022-09-30 0000875320 us-gaap:NonUsMember 2023-07-01 2023-09-30 0000875320 us-gaap:NonUsMember 2022-07-01 2022-09-30 0000875320 us-gaap:NonUsMember 2023-01-01 2023-09-30 0000875320 us-gaap:NonUsMember 2022-01-01 2022-09-30 0000875320 vrtx:CRISPRTherapeuticsAGMember 2019-01-01 2019-12-31 0000875320 vrtx:CRSIPRJDCAMember 2021-01-01 2021-12-31 0000875320 vrtx:CRSIPRJDCAMember 2021-12-31 0000875320 vrtx:CRSIPRJDCAMember vrtx:CRISPRMember 2021-12-31 0000875320 vrtx:CRSIPRJDCAMember 2023-07-01 2023-09-30 0000875320 vrtx:CRSIPRJDCAMember 2022-07-01 2022-09-30 0000875320 vrtx:CRSIPRJDCAMember 2023-01-01 2023-09-30 0000875320 vrtx:CRSIPRJDCAMember 2022-01-01 2022-09-30 0000875320 vrtx:CRISPRT1DMember 2023-03-01 2023-03-31 0000875320 vrtx:CRISPRT1DMember 2023-07-01 2023-09-30 0000875320 vrtx:CRISPRT1DMember 2023-01-01 2023-09-30 0000875320 vrtx:EntradaTherapeuticsMember 2023-02-01 2023-02-28 0000875320 vrtx:VerveMember 2022-07-01 2022-07-31 0000875320 vrtx:SepternaIncMember 2023-09-01 2023-09-30 0000875320 vrtx:CatalystBiosciencesMember 2022-05-01 2022-05-31 0000875320 us-gaap:EmployeeStockOptionMember 2023-07-01 2023-09-30 0000875320 us-gaap:EmployeeStockOptionMember 2022-07-01 2022-09-30 0000875320 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-09-30 0000875320 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-09-30 0000875320 us-gaap:RestrictedStockUnitsRSUMember 2023-07-01 2023-09-30 0000875320 us-gaap:RestrictedStockUnitsRSUMember 2022-07-01 2022-09-30 0000875320 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-09-30 0000875320 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-09-30 0000875320 us-gaap:EmployeeStockOptionMember 2023-07-01 2023-09-30 0000875320 us-gaap:EmployeeStockOptionMember 2022-07-01 2022-09-30 0000875320 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-09-30 0000875320 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-09-30 0000875320 us-gaap:RestrictedStockUnitsRSUMember 2023-07-01 2023-09-30 0000875320 us-gaap:RestrictedStockUnitsRSUMember 2022-07-01 2022-09-30 0000875320 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-09-30 0000875320 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-09-30 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2023-09-30 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2023-09-30 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2023-09-30 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2023-09-30 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2022-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2022-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2022-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2022-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:BankTimeDepositsMember 2023-09-30 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:BankTimeDepositsMember 2023-09-30 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:BankTimeDepositsMember 2023-09-30 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:BankTimeDepositsMember 2023-09-30 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:BankTimeDepositsMember 2022-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:BankTimeDepositsMember 2022-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:BankTimeDepositsMember 2022-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:BankTimeDepositsMember 2022-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2023-09-30 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2023-09-30 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2023-09-30 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2023-09-30 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2022-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2022-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2022-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2022-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-09-30 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-09-30 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-09-30 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-09-30 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2023-09-30 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2023-09-30 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2023-09-30 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2023-09-30 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2022-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2022-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2022-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2022-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2023-09-30 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2023-09-30 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2023-09-30 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2023-09-30 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2022-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2022-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2022-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2022-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2023-09-30 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2023-09-30 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2023-09-30 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2023-09-30 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2022-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2022-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2022-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2022-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2023-09-30 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2023-09-30 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2023-09-30 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2023-09-30 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2022-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2022-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2022-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2022-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2023-09-30 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2023-09-30 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2023-09-30 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2023-09-30 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2022-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2022-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2022-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2022-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0000875320 us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000875320 us-gaap:EquitySecuritiesMember 2023-09-30 0000875320 us-gaap:FairValueInputsLevel3Member 2023-09-30 0000875320 srt:MinimumMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputDiscountRateMember 2023-09-30 0000875320 srt:MaximumMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputDiscountRateMember 2023-09-30 0000875320 us-gaap:MoneyMarketFundsMember 2023-09-30 0000875320 us-gaap:MoneyMarketFundsMember 2022-12-31 0000875320 us-gaap:BankTimeDepositsMember 2023-09-30 0000875320 us-gaap:BankTimeDepositsMember 2022-12-31 0000875320 us-gaap:USTreasurySecuritiesMember 2023-09-30 0000875320 us-gaap:USTreasurySecuritiesMember 2022-12-31 0000875320 us-gaap:CorporateDebtSecuritiesMember 2023-09-30 0000875320 us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0000875320 us-gaap:CommercialPaperMember 2023-09-30 0000875320 us-gaap:CommercialPaperMember 2022-12-31 0000875320 us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2023-09-30 0000875320 us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2022-12-31 0000875320 us-gaap:AssetBackedSecuritiesMember 2023-09-30 0000875320 us-gaap:AssetBackedSecuritiesMember 2022-12-31 0000875320 us-gaap:CertificatesOfDepositMember 2023-09-30 0000875320 us-gaap:CertificatesOfDepositMember 2022-12-31 0000875320 us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2023-09-30 0000875320 us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2022-12-31 0000875320 vrtx:MarketableSecuritiesAndOtherNoncurrentAssetsMember 2023-09-30 0000875320 vrtx:MarketableSecuritiesAndOtherNoncurrentAssetsMember 2022-12-31 0000875320 2022-01-01 2022-12-31 0000875320 us-gaap:CashAndCashEquivalentsMember 2023-09-30 0000875320 us-gaap:CashAndCashEquivalentsMember 2022-12-31 0000875320 vrtx:MarketableSecuritiesMember 2023-09-30 0000875320 vrtx:MarketableSecuritiesMember 2022-12-31 0000875320 vrtx:MarketableSecuritiesNoncurrentMember 2023-09-30 0000875320 vrtx:MarketableSecuritiesNoncurrentMember 2022-12-31 0000875320 vrtx:PubliclyTradedCompaniesSaleMember 2023-01-01 2023-09-30 0000875320 vrtx:PubliclyTradedCompaniesSaleMember 2023-09-30 0000875320 vrtx:PubliclyTradedCompaniesSaleMember 2022-01-01 2022-09-30 0000875320 us-gaap:OtherAssetsMember 2023-09-30 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2022-12-31 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-12-31 0000875320 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-12-31 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2023-01-01 2023-09-30 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-01-01 2023-09-30 0000875320 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-01-01 2023-09-30 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2023-09-30 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-09-30 0000875320 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-09-30 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2021-12-31 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2021-12-31 0000875320 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-12-31 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2022-01-01 2022-09-30 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-01-01 2022-09-30 0000875320 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-01-01 2022-09-30 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2022-09-30 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-09-30 0000875320 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-09-30 0000875320 srt:MinimumMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember 2023-01-01 2023-09-30 0000875320 srt:MaximumMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember 2023-01-01 2023-09-30 0000875320 currency:EUR us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-09-30 0000875320 currency:EUR us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000875320 currency:CAD us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-09-30 0000875320 currency:CAD us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000875320 currency:GBP us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-09-30 0000875320 currency:GBP us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000875320 currency:AUD us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-09-30 0000875320 currency:AUD us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000875320 currency:CHF us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-09-30 0000875320 currency:CHF us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-09-30 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2023-01-01 2023-09-30 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2023-09-30 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedTranslationAdjustmentMember 2023-07-01 2023-09-30 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedTranslationAdjustmentMember 2022-07-01 2022-09-30 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedTranslationAdjustmentMember 2023-01-01 2023-09-30 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedTranslationAdjustmentMember 2022-01-01 2022-09-30 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedTranslationAdjustmentMember 2023-07-01 2023-09-30 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedTranslationAdjustmentMember 2022-07-01 2022-09-30 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedTranslationAdjustmentMember 2023-01-01 2023-09-30 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedTranslationAdjustmentMember 2022-01-01 2022-09-30 0000875320 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-09-30 0000875320 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-09-30 0000875320 us-gaap:OtherAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-09-30 0000875320 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-09-30 0000875320 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000875320 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000875320 us-gaap:OtherAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000875320 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000875320 us-gaap:RestrictedStockMember 2023-07-01 2023-09-30 0000875320 us-gaap:RestrictedStockMember 2022-07-01 2022-09-30 0000875320 us-gaap:RestrictedStockMember 2023-01-01 2023-09-30 0000875320 us-gaap:RestrictedStockMember 2022-01-01 2022-09-30 0000875320 us-gaap:EmployeeStockMember 2023-07-01 2023-09-30 0000875320 us-gaap:EmployeeStockMember 2022-07-01 2022-09-30 0000875320 us-gaap:EmployeeStockMember 2023-01-01 2023-09-30 0000875320 us-gaap:EmployeeStockMember 2022-01-01 2022-09-30 0000875320 us-gaap:CostOfSalesMember 2023-07-01 2023-09-30 0000875320 us-gaap:CostOfSalesMember 2022-07-01 2022-09-30 0000875320 us-gaap:CostOfSalesMember 2023-01-01 2023-09-30 0000875320 us-gaap:CostOfSalesMember 2022-01-01 2022-09-30 0000875320 us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-01 2023-09-30 0000875320 us-gaap:ResearchAndDevelopmentExpenseMember 2022-07-01 2022-09-30 0000875320 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-09-30 0000875320 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-09-30 0000875320 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-07-01 2023-09-30 0000875320 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-07-01 2022-09-30 0000875320 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-09-30 0000875320 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-01-01 2022-09-30 0000875320 2023-02-28 0000875320 us-gaap:RevolvingCreditFacilityMember 2022-07-31 0000875320 us-gaap:LetterOfCreditMember 2022-07-31 0000875320 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember us-gaap:BaseRateMember 2022-07-01 2022-07-31 0000875320 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember us-gaap:BaseRateMember 2022-07-01 2022-07-31 0000875320 srt:MinimumMember vrtx:SecuredOvernightFinancingRateSOFRMember 2022-07-01 2022-07-31 0000875320 srt:MaximumMember vrtx:SecuredOvernightFinancingRateSOFRMember 2022-07-01 2022-07-31 0000875320 us-gaap:RevolvingCreditFacilityMember 2022-07-01 2022-07-31 0000875320 vrtx:EMorrowMorreyAtkinsonIIIMember 2023-07-01 2023-09-30 0000875320 vrtx:EMorrowMorreyAtkinsonIIIMember 2023-09-30 0000875320 vrtx:ReshmaKewalramaniMember 2023-07-01 2023-09-30 0000875320 vrtx:ReshmaKewalramaniMember 2023-09-30 0000875320 vrtx:JeffreyMLeidenMember 2023-07-01 2023-09-30 0000875320 vrtx:JeffreyMLeidenMember 2023-09-30 0000875320 vrtx:BastianoSannaMember 2023-07-01 2023-09-30 0000875320 vrtx:BastianoSannaMember 2023-09-30 0000875320 vrtx:CharlesFWagnerJrMember 2023-07-01 2023-09-30 0000875320 vrtx:CharlesFWagnerJrMember 2023-09-30 shares iso4217:USD iso4217:USD shares vrtx:segment vrtx:target pure VERTEX PHARMACEUTICALS INC / MA 0000875320 --12-31 2023 Q3 false P1M P252D P370D P650D P350D P357D 10-Q true 2023-09-30 false 000-19319 MA 50 Northern Avenue Boston MA 04-3039129 02210 617 341-6100 Common Stock, $0.01 Par Value Per Share VRTX NASDAQ Yes Yes Large Accelerated Filer false false false 257683184 2483500000 2334300000 7351500000 6628000000 318700000 289400000 894200000 797000000.0 810000000.0 645000000.0 2338300000 1846200000 51700000 29000000.0 509300000 92900000 263800000 246800000 767500000 677300000 1200000 -2600000 -1300000 -59300000 1445400000 1207600000 4508000000 3354100000 1038100000 1126700000 2843500000 3273900000 167900000 46200000 435200000 58600000 -10900000 -13700000 -33500000 -43200000 -15900000 17200000 -13000000.0 -133700000 1179200000 1176400000 3232200000 3155600000 143900000 245900000 581400000 652500000 1035300000 930500000 2650800000 2503100000 4.01 3.63 10.29 9.78 3.97 3.59 10.18 9.68 258000000.0 256500000 257700000 255800000 260600000 259500000 260400000 258700000 1035300000 930500000 2650800000 2503100000 1700000 0 5200000 0 -6200000 -600000 -18800000 -3600000 -13200000 -16000000.0 -1600000 -34300000 48000000.0 58800000 5900000 128100000 -5000000.0 -18100000 9100000 -42800000 36800000 40100000 -3800000 81700000 1072100000 970600000 2647000000 2584800000 11110200000 10504000000 818000000.0 274500000 1538700000 1442200000 688700000 460600000 540200000 553500000 14695800000 13234800000 1124000000 1108400000 1088000000 1088000000 603600000 603600000 1729100000 1246900000 310500000 347400000 1700000000 112200000 475200000 409600000 21726200000 18150900000 375900000 303900000 2907300000 2126700000 316200000 311500000 3599400000 2742100000 390300000 430800000 354400000 379500000 869300000 685800000 5213400000 4238200000 0 0 0.01 0.01 1000000 1000000 0 0 0 0 0 0 0.01 0.01 500000000 500000000 257828508 257828508 257011628 257011628 2600000 2600000 7339600000 7386500000 -3000000.0 800000 9173600000 6522800000 16512800000 13912700000 21726200000 18150900000 256000000.0 2600000 7100000000 57500000 4773400000 11933500000 40100000 40100000 930500000 930500000 200000 0.0 48000000.0 48000000.0 800000 0.0 38200000 38200000 135300000 135300000 256600000 2600000 7225500000 97600000 5703900000 13029600000 257800000 2600000 7369100000 -39800000 8138300000 15470200000 36800000 36800000 1035300000 1035300000 400000 0.0 123000000.0 123000000.0 100000 0.0 53200000 53200000 500000 0.0 15000000.0 15000000.0 131700000 131700000 257800000 2600000 7339600000 -3000000.0 9173600000 16512800000 254500000 2500000 6880800000 15900000 3200800000 10100000000 81700000 81700000 2503100000 2503100000 700000 0.0 169900000 169900000 2800000 100000 135200000 135300000 379400000 379400000 256600000 2600000 7225500000 97600000 5703900000 13029600000 257000000.0 2600000 7386500000 800000 6522800000 13912700000 -3800000 -3800000 2650800000 2650800000 900000 0.0 284100000 284100000 700000 0.0 222900000 222900000 2400000 0.0 85700000 85700000 374400000 374400000 257800000 2600000 7339600000 -3000000.0 9173600000 16512800000 2650800000 2503100000 372600000 379800000 122300000 109900000 -405500000 -424000000.0 -200000 -143100000 -1300000 -59300000 9600000 32800000 99500000 368800000 252900000 58100000 94400000 41900000 80500000 -39100000 786100000 980300000 153400000 -40700000 3302700000 3051500000 2798000000 417800000 621000000.0 435900000 142300000 171100000 95100000 0 31000000.0 47800000 0 295900000 -2255200000 -496700000 88200000 134700000 278100000 0 222900000 169900000 32900000 75100000 3300000 2400000 -442400000 -107900000 -500000 -70000000.0 604600000 2376900000 10512000000 6800100000 11116600000 9177000000 919100000 840100000 32600000 41100000 Basis of Presentation and Accounting Policies<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements are unaudited and have been prepared by Vertex Pharmaceuticals Incorporated (“Vertex,” “we,” “us” or “our”) in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements reflect the operations of Vertex and our wholly-owned subsidiaries. All material intercompany balances and transactions have been eliminated. We have reclassified certain items from the prior year’s condensed consolidated balance sheet to conform to the current year’s presentation. We operate in one segment, pharmaceuticals.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain information and footnote disclosures normally included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 (the “2022 Annual Report on Form 10-K”) have been condensed or omitted. These interim financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the financial position and results of income for the interim periods ended September 30, 2023 and 2022.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full fiscal year. These interim financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2022, which are contained in our 2022 Annual Report on Form 10-K. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in accordance with U.S. GAAP requires us to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of our condensed consolidated financial statements, and the amounts of revenues and expenses during the reported periods. We base our estimates on historical experience and various other assumptions, including in certain circumstances future projections that we believe to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted and Issued Accounting Standards</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of recently adopted accounting pronouncements please refer to Note A, “Nature of Business and Accounting Policies,” in our 2022 Annual Report on Form 10-K. We do not expect any recently issued accounting standards to have a significant impact on our condensed consolidated financial statements.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our significant accounting policies are described in Note A, “Nature of Business and Accounting Policies,” in our 2022 Annual Report on Form 10-K.</span></div> <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements are unaudited and have been prepared by Vertex Pharmaceuticals Incorporated (“Vertex,” “we,” “us” or “our”) in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements reflect the operations of Vertex and our wholly-owned subsidiaries. All material intercompany balances and transactions have been eliminated. We have reclassified certain items from the prior year’s condensed consolidated balance sheet to conform to the current year’s presentation. We operate in one segment, pharmaceuticals.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain information and footnote disclosures normally included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 (the “2022 Annual Report on Form 10-K”) have been condensed or omitted. These interim financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the financial position and results of income for the interim periods ended September 30, 2023 and 2022.</span></div>The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full fiscal year. These interim financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2022, which are contained in our 2022 Annual Report on Form 10-K. 1 <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in accordance with U.S. GAAP requires us to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of our condensed consolidated financial statements, and the amounts of revenues and expenses during the reported periods. We base our estimates on historical experience and various other assumptions, including in certain circumstances future projections that we believe to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.</span></div> Revenue Recognition <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disaggregation of Revenue</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Revenues by Product</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">“Product revenues, net” consisted of the following:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:55.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.887%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TRIKAFTA/KAFTRIO</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,274.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,010.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,611.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,665.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KALYDECO</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ORKAMBI</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SYMDEKO/SYMKEVI</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product revenues, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,483.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,334.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,351.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,628.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Product Revenues by Geographic Location</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">“Product revenues, net” by geographic region, based on the location of the customer, consisted of the following:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:55.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.887%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,554.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,455.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,465.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,238.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outside of the United States</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">766.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">730.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,373.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,018.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">512.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product revenues outside of the United States</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">929.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">878.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,885.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,389.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product revenues, net</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,483.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,334.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,351.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,628.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Liabilities</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had contract liabilities of $157.1 million and $159.6 million as of September 30, 2023 and December 31, 2022, respectively, related to annual contracts with government-owned and supported customers in international markets that limit the amount of annual reimbursement we can receive. Upon exceeding the annual reimbursement amount, products are provided free of charge, which is a material right. These contracts include upfront payments and fees. We defer a portion of the consideration received for shipments made up to the annual reimbursement limit as a portion of “Other current liabilities.” The deferred amount is recognized as revenue when the free products are shipped. Our product revenue contracts include performance obligations that are one year or less.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contract liabilities at the end of each fiscal year relate to contracts with annual reimbursement limits in international markets in which the annual period associated with the contract is not the same as our fiscal year. In these markets, we recognize revenues related to performance obligations satisfied in previous years; however, these revenues do not relate to any performance obligations that were satisfied more than 12 months prior to the beginning of the current year.</span></div> <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">“Product revenues, net” consisted of the following:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:55.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.887%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TRIKAFTA/KAFTRIO</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,274.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,010.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,611.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,665.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KALYDECO</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ORKAMBI</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SYMDEKO/SYMKEVI</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product revenues, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,483.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,334.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,351.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,628.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">“Product revenues, net” by geographic region, based on the location of the customer, consisted of the following:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:55.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.887%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,554.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,455.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,465.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,238.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outside of the United States</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">766.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">730.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,373.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,018.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">512.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product revenues outside of the United States</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">929.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">878.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,885.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,389.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product revenues, net</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,483.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,334.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,351.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,628.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 2274300000 2010500000 6611400000 5665300000 112800000 139400000 363100000 417100000 63000000.0 146200000 281800000 399900000 33400000 38200000 95200000 145700000 2483500000 2334300000 7351500000 6628000000 1554200000 1455600000 4465800000 4238900000 766500000 730500000 2373700000 2018300000 162800000 148200000 512000000.0 370800000 929300000 878700000 2885700000 2389100000 2483500000 2334300000 7351500000 6628000000 157100000 159600000 Acquired In-Process Research and Development and Other Arrangements<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into numerous agreements with third parties to collaborate on research, development and commercialization programs, license technologies, or acquire assets. Our “Acquired in-process research and development expenses” included $51.7 million and $509.3 million for the three and nine months ended September 30, 2023, respectively, and $29.0 million and $92.9 million, for the three and nine months ended September 30, 2022, respectively, related to upfront, contingent milestone, or other payments pursuant to our business development transactions, including collaborations, licenses of third-party technologies, and asset acquisitions that qualify as in-process research and development.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our collaboration, licensing and asset acquisition agreements that had a significant impact on our financial statements for the three and nine months ended September 30, 2023 and 2022, or were new or materially revised during the three and nine months ended September 30, 2023, are described below. Additional agreements were described in Note B, “Acquired In-Process Research and Development and Other Arrangements,” of our 2022 Annual Report on Form 10-K.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In-license Agreements</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into several in-license agreements to advance and obtain access to technologies and services related to our research and early-development activities. We are generally required to make an upfront payment upon execution of our license agreements; development, regulatory and commercialization milestones payments upon the achievement of certain product research, development and commercialization objectives; and royalty payments on future sales, if any, of commercial products resulting from our collaborations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of our in-license agreements, our collaborators typically lead the discovery efforts and we lead all preclinical, development and commercialization activities associated with the advancement of any product candidates and fund all expenses.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We typically can terminate our in-license agreements by providing advance notice to our collaborators. Our license agreements may be terminated by either party for a material breach by the other, subject to notice and cure provisions. Unless earlier terminated, these license agreements generally remain in effect until the date on which the royalty term and all payment obligations with respect to all products in all countries have expired.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">CRISPR Therapeutics AG</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CRISPR-Cas9 Gene-editing Therapies Agreements</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015, we entered into a strategic collaboration, option, and license agreement (the “CRISPR Agreement”) with CRISPR Therapeutics AG and its affiliates (“CRISPR”) to collaborate on the discovery and development of potential new treatments aimed at the underlying genetic causes of human diseases using CRISPR-Cas9 gene-editing technology. We had the exclusive right to license certain targets. In 2019, we elected to exclusively license three targets, including cystic fibrosis, pursuant to the CRISPR Agreement. For each of the three targets that we elected to license, CRISPR has the potential to receive up to an additional $410.0 million in development, regulatory and commercial milestones as well as royalties on resulting net product sales. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, we entered into a joint development and commercialization agreement with CRISPR (the “CRISPR JDCA”), which we amended and restated in 2021, pursuant to the terms of the CRISPR Agreement. Under the CRISPR JDCA, we and CRISPR are co-developing and preparing to co-commercialize exagamglogene autotemcel (“exa-cel”), for the treatment of hemoglobinopathies, including treatments for sickle cell disease and transfusion-dependent beta thalassemia. Pursuant to the CRISPR JDCA, we lead global development, manufacturing, and commercialization of exa-cel, with support from CRISPR. We also conduct all research, development, manufacturing, and commercialization activities relating to other product candidates and products under the CRISPR JDCA throughout the world subject to CRISPR’s reserved right to conduct certain activities. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the CRISPR JDCA, CRISPR has the potential to receive a one-time $200.0 million milestone payment upon receipt of the first marketing approval of exa-cel from the U.S. Food and Drug Administration or the European Commission.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for the CRISPR JDCA as a cost-sharing arrangement, with costs incurred related to exa-cel allocated 60% to us and 40% to CRISPR, subject to certain adjustments. We recognized the net impact of the CRISPR JDCA as “Research and </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development expenses” of $74.9 million and $45.5 million during the three months ended September 30, 2023 and 2022, respectively, and $193.2 million and $120.6 million during the nine months ended September 30, 2023 and 2022, respectively; and as “Selling, general and administrative expenses” of $26.0 million and $13.5 million during the three months ended September 30, 2023 and 2022, respectively, and $66.1 million and $35.3 million during the nine months ended September 30, 2023 and 2022, respectively.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, we entered into a non-exclusive license agreement (“the CRISPR T1D Agreement”) for the use of CRISPR’s CRISPR-Cas9 gene-editing technology to accelerate the development of our hypoimmune cell therapies for type 1 diabetes. Pursuant to the CRISPR T1D Agreement, we made a $100.0 million upfront payment to CRISPR. In the second quarter of 2023, we achieved a research milestone that resulted in a $70.0 million payment to CRISPR in the third quarter of 2023. CRISPR is eligible to receive up to an additional $160.0 million in research, development, regulatory and commercial milestones for any products that may result from the agreement, as well as royalties on resulting net product sales. We determined that substantially all the fair value of the collaboration agreement was attributable to in-process research and development and no substantive processes were acquired that would constitute a business. We concluded that there is no alternative future use for the acquired in-process research and development and recorded the upfront payment and the research milestone to “Acquired in-process research and development expenses” in the first and second quarters of 2023, respectively, resulting in $170.0 million of “Acquired in-process research and development expenses” in the nine months ended September 30, 2023. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Entrada Therapeutics, Inc.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023, we closed a strategic collaboration and license agreement (the “Entrada Agreement”) with Entrada Therapeutics, Inc. (“Entrada”) focused on discovering and developing intracellular Endosomal Escape Vehicle (EEV) therapeutics for myotonic dystrophy type 1 (“DM1”). Upon closing, we made an upfront payment of $225.1 million to Entrada, and purchased $24.9 million of Entrada’s common stock in connection with the Entrada Agreement. Entrada is eligible to receive up to an additional $485.0 million in research, development, regulatory and commercial milestones for any products that may result from the Entrada Agreement, as well as royalties on resulting net product sales. We determined that substantially all the fair value of the collaboration agreement was attributable to in-process research and development and no substantive processes were acquired that would constitute a business. We concluded that there is no alternative future use for the acquired in-process research and development and recorded the upfront payment to “Acquired in-process research and development expenses” in the first quarter of 2023. The investment in Entrada’s common stock is recorded at fair value on our condensed consolidated balance sheet within “Marketable securities.”</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Verve Therapeutics, Inc.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, we entered into a research collaboration with Verve Therapeutics, Inc. (“Verve”) focused on discovering and developing an in vivo gene-editing program for a liver disease. Under the terms of the agreement, we made a $25.0 million upfront payment to Verve and purchased $35.0 million of Verve’s common stock. We concluded that there is no alternative future use for the acquired in-process research and development and recorded the upfront payment to “Acquired in-process research and development expenses.” The investment in Verve’s common stock is recorded at fair value on our condensed consolidated balance sheet within “Marketable securities.”</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Asset Acquisitions</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Septerna, Inc. - Novel G Protein-coupled Receptor Program</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2023, pursuant to an asset purchase agreement, we acquired a novel G protein-coupled receptor (“GPCR”) program from Septerna, Inc. We determined that substantially all the fair value acquired is concentrated in the GPCR in-process research and development asset, which does not constitute a business, and for which we determined there is no alternative future use. As a result, we recorded $47.5 million to “Acquired in-process research and development expenses” in the three and nine months ended September 30, 2023.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Catalyst Biosciences, Inc. - Complement 3 Degrader Program</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, pursuant to an asset purchase agreement, we acquired Catalyst Biosciences, Inc.’s portfolio of protease medicines that target the complement system (the “complement portfolio”) and related intellectual property, including CB 2782-PEG, which is a pre-clinical complement component 3 degrader program for geographic atrophy in dry age-related macular degeneration. We determined that substantially all the fair value acquired is concentrated in the CB-2782 PEG in-</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">process research and development assets, which do not constitute a business, and for which we determined there is no alternative future use. As a result, we recorded our $60.0 million upfront payment to “Acquired in-process research and development expenses” in the three and nine months ended September 30, 2022.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cystic Fibrosis Foundation</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2004, we entered into a collaboration agreement with the Cystic Fibrosis Foundation, as successor in interest to the Cystic Fibrosis Foundation Therapeutics, Inc., to support research and development activities. Pursuant to the collaboration agreement, as amended, we have agreed to pay tiered royalties ranging from single digits to sub-teens on covered compounds first synthesized and/or tested during a research term on or before February 28, 2014, including ivacaftor, lumacaftor and tezacaftor and royalties ranging from low-single digits to mid-single digits on potential net sales of certain compounds first synthesized and/or tested between March 1, 2014 and August 31, 2016, including elexacaftor. We do not have any royalty obligations on compounds first synthesized and tested on or after September 1, 2016. For combination products, such as ORKAMBI, SYMDEKO/SYMKEVI and TRIKAFTA/KAFTRIO, sales are allocated equally to each of the active pharmaceutical ingredients in the combination product. We record expenses related to these royalty obligations to “Cost of sales.”</span></div> 51700000 509300000 29000000 92900000 3 3 410000000 200000000 0.60 0.40 74900000 45500000 193200000 120600000 26000000 13500000 66100000 35300000 100000000 70000000 160000000 170000000 225100000 24900000 485000000 25000000 35000000 47500000 60000000 Earnings Per Share<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted net income per common share for the periods ended:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:55.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.887%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,035.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">930.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,650.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,503.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of potentially dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units (including PSUs)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock purchase program</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net income per common share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.01 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.63 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.78 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net income per common share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.97 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.59 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not include the securities in the following table in the computation of the diluted net income per common share because the effect would have been anti-dilutive during each period:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:55.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.887%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock units (including PSUs)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted net income per common share for the periods ended:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:55.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.887%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,035.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">930.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,650.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,503.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of potentially dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units (including PSUs)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock purchase program</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net income per common share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.01 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.63 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.78 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net income per common share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.97 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.59 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1035300000 930500000 2650800000 2503100000 258000000.0 256500000 257700000 255800000 1200000 1400000 1200000 1400000 1400000 1600000 1500000 1400000 0.0 0.0 0.0 100000 260600000 259500000 260400000 258700000 4.01 3.63 10.29 9.78 3.97 3.59 10.18 9.68 <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not include the securities in the following table in the computation of the diluted net income per common share because the effect would have been anti-dilutive during each period:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:55.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.887%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock units (including PSUs)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 0 0 0.0 0.0 0 0.0 200000 200000 Fair Value Measurements<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following fair value hierarchy is used to classify assets and liabilities based on observable inputs and unobservable inputs used in order to determine the fair value of our financial assets and liabilities:</span></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.392%"><tr><td style="width:1.0%"></td><td style="width:11.189%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.611%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1:</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2:</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 3:</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability.</span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment strategy is focused on capital preservation. We invest in instruments that meet the credit quality standards outlined in our investment policy, which also limits the amount of credit exposure to any one issue or type of instrument. We maintain strategic equity investments separately from the investment policy that governs our other cash, cash equivalents and marketable securities as described in Note F, “Marketable Securities and Equity Investments.” Additionally, we utilize foreign currency forward contracts intended to mitigate the effect of changes in foreign exchange rates on our condensed consolidated statement of income.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth our financial assets and liabilities subject to fair value measurements by level within the fair value hierarchy (and does not include $5.5 billion and $3.1 billion of cash as of September 30, 2023 and December 31, 2022, respectively):</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.899%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="48" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financial instruments carried at fair value (asset positions):</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,753.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,753.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,162.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,162.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Time deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,550.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,550.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,000.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,000.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">236.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">236.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable securities:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">116.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">408.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">408.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government-sponsored enterprise securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">421.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">421.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">237.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">237.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,214.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,214.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:36.75pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total financial assets</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,195.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,865.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,330.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,807.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,378.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,429.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="48" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financial instruments carried at fair value (liability positions):</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:29.25pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(112.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(112.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(114.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(114.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:36.75pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total financial liabilities</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(128.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(127.7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(144.2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15.2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(129.0)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please refer to Note F, “Marketable Securities and Equity Investments,” for the carrying amount and related unrealized gains (losses) by type of investment.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Corporate Equity Securities</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify our investments in publicly traded corporate equity securities as “Marketable securities” on our condensed consolidated balance sheets. Generally, our investments in the common stock of publicly traded companies are valued based on Level 1 inputs because they have readily determinable fair values. However, certain of our investments in publicly traded companies have been or continue to be valued based on Level 2 inputs due to transfer restrictions associated with these investments.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023, one of our investments in publicly traded corporate equity securities was subject to a contractual sales restriction expiring partially in 2024 and partially in 2025 with a total fair value of $25.5 million. We purchased this investment directly from the publicly traded company in the first quarter of 2023, and do not anticipate any circumstances that would cause this restriction to lapse prior to the periods listed above.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please refer to Note F, “Marketable Securities and Equity Investments,” for further information on these investments.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Contingent Consideration</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, we acquired Exonics Therapeutics, Inc. (“Exonics”), a privately-held company focused on creating transformative gene-editing therapies to repair mutations that cause Duchenne muscular dystrophy (“DMD”) and other severe neuromuscular diseases, including DM1. Our Level 3 contingent consideration liabilities are related to $678.3 million of development and regulatory milestones potentially payable to former Exonics equity holders. We base our estimates of the probability of achieving the milestones relevant to the fair value of contingent payments, which could include milestone, royalty and option payments, on industry data attributable to rare diseases and our knowledge of the progress and viability of the programs. The discount rates used in the valuation model for contingent payments, which were between 5.5% and 6.5% as of September 30, 2023, represent a measure of credit risk and market risk associated with settling the liabilities. Significant judgment is used in determining the appropriateness of these assumptions at each reporting period.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents a rollforward of the fair value of our contingent consideration liabilities:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.315%"><tr><td style="width:1.0%"></td><td style="width:73.946%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.854%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in fair value of contingent payments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, we determined that additional pre-clinical studies of the delivery system for our gene-editing components for DMD will be required. Any potential impact on the fair value of our contingent consideration liabilities will be recognized as of December 31, 2023.</span></div> <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth our financial assets and liabilities subject to fair value measurements by level within the fair value hierarchy (and does not include $5.5 billion and $3.1 billion of cash as of September 30, 2023 and December 31, 2022, respectively):</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.899%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="48" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financial instruments carried at fair value (asset positions):</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,753.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,753.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,162.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,162.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Time deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,550.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,550.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,000.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,000.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">236.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">236.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable securities:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">116.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">408.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">408.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government-sponsored enterprise securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">421.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">421.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">237.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">237.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,214.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,214.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:36.75pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total financial assets</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,195.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,865.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,330.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,807.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,378.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,429.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="48" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financial instruments carried at fair value (liability positions):</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:29.25pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(112.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(112.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(114.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(114.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:36.75pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total financial liabilities</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(128.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(127.7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(144.2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15.2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(129.0)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 5500000000 3100000000 3753400000 3753400000 0 0 5162600000 5162600000 0 0 1550000000 0 1550000000 0 2000000000 0 2000000000 0 236800000 236800000 0 0 0 0 0 0 0 0 0 0 5800000 0 5800000 0 96500000 0 96500000 0 204500000 0 204500000 0 46400000 46400000 0 0 116800000 88800000 28000000.0 0 408200000 408200000 0 0 0 0 0 0 421000000.0 421000000.0 0 0 127100000 127100000 0 0 237800000 0 237800000 0 0 0 0 0 31700000 0 31700000 0 0 0 0 0 1214200000 0 1214200000 0 87000000.0 0 87000000.0 0 158700000 0 158700000 0 55800000 0 55800000 0 37800000 0 37800000 0 47500000 0 47500000 0 3400000 0 3400000 0 800000 0 800000 0 8195900000 4865800000 3330100000 0 7807900000 5378500000 2429400000 0 700000 0 700000 0 14300000 0 14300000 0 15000000.0 0 0 15000000.0 14600000 0 0 14600000 0 0 0 0 900000 0 900000 0 112700000 0 0 112700000 114400000 0 0 114400000 128400000 0 700000 127700000 144200000 0 15200000 129000000.0 25500000 678300000 0.055 0.065 <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents a rollforward of the fair value of our contingent consideration liabilities:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.315%"><tr><td style="width:1.0%"></td><td style="width:73.946%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.854%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in fair value of contingent payments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 129000000.0 -1300000 127700000 Marketable Securities and Equity Investments<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our cash equivalents and marketable securities, which are recorded at fair value (and do not include $5.5 billion and $3.1 billion of cash as of September 30, 2023 and December 31, 2022, respectively), is shown below:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:25.874%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.253%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>Unrealized <br/>Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>Unrealized <br/>Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair </span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>Unrealized <br/>Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>Unrealized <br/>Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair </span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,753.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,753.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,162.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,162.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Time deposits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,550.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,550.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,000.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,000.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">236.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">236.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:33pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total cash equivalents</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,636.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,636.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,372.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,372.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">414.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">408.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government-sponsored enterprise securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">422.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">421.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">239.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">237.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,228.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,214.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:33pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,495.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,471.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">270.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">269.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate equity securities </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(26.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">116.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:33pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable securities</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,567.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(50.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,518.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">374.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18.8)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">386.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale debt securities were classified on our condensed consolidated balance sheets at fair value as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.458%"><tr><td style="width:1.0%"></td><td style="width:44.855%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.176%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.236%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,086.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,372.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">771.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,700.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,558.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,642.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale debt securities by contractual maturity were as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.458%"><tr><td style="width:1.0%"></td><td style="width:44.855%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.176%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.236%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Matures within one year</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,858.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,530.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Matures after one year through five years</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,700.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,558.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,642.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not record any allowances for credit losses to adjust the fair value of available-for-sale debt securities or gross realized gains or losses in the three and nine months ended September 30, 2023 and 2022. As of September 30, 2023, we held available-for-sale debt securities with a total fair value of $2.28 billion that were in unrealized loss positions totaling $24.2 million; however, none of these investments had been in an unrealized loss position for greater than twelve months.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record changes in the fair value of our investments in corporate equity securities to “Other (expense) income, net” in our condensed consolidated statements of income. During the three and nine months ended September 30, 2023 and 2022, our net unrealized (losses) gains on corporate equity securities held at the conclusion of each period were as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:55.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.887%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized (losses) gains</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(143.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">        </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2023, we received proceeds of $95.1 million related to the sale of the common stock of a publicly traded company, which had a total original cost basis of $57.3 million. There were no sales of the common stock of publicly traded companies during the nine months ended September 30, 2022.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023, the carrying value of our equity investments without readily determinable fair values, which are recorded in “Other assets” on our condensed consolidated balance sheets, was $98.6 million.</span></div> <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our cash equivalents and marketable securities, which are recorded at fair value (and do not include $5.5 billion and $3.1 billion of cash as of September 30, 2023 and December 31, 2022, respectively), is shown below:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:25.874%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.253%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>Unrealized <br/>Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>Unrealized <br/>Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair </span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>Unrealized <br/>Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>Unrealized <br/>Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair </span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,753.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,753.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,162.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,162.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Time deposits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,550.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,550.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,000.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,000.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">236.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">236.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:33pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total cash equivalents</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,636.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,636.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,372.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,372.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">414.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">408.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government-sponsored enterprise securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">422.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">421.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">239.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">237.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,228.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,214.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:33pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,495.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,471.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">270.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">269.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate equity securities </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(26.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">116.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:33pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable securities</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,567.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(50.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,518.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">374.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18.8)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">386.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale debt securities were classified on our condensed consolidated balance sheets at fair value as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.458%"><tr><td style="width:1.0%"></td><td style="width:44.855%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.176%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.236%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,086.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,372.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">771.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,700.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,558.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,642.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale debt securities by contractual maturity were as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.458%"><tr><td style="width:1.0%"></td><td style="width:44.855%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.176%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.236%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Matures within one year</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,858.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,530.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Matures after one year through five years</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,700.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,558.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,642.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 5500000000 3100000000 3753400000 3753400000 5162600000 5162600000 1550000000 1550000000 2000000000 2000000000 236800000 236800000 0 0 0 0 5800000 5800000 96500000 96500000 204500000 204500000 5636700000 5636700000 7372900000 7372900000 414600000 100000 6500000 408200000 0 0 0 0 422900000 0 1900000 421000000.0 127000000.0 200000 100000 127100000 239300000 0.0 1500000 237800000 0 0 0 0 31700000 0.0 0 31700000 0 0 0 0 1228400000 0.0 14200000 1214200000 87200000 0 200000 87000000.0 158800000 0.0 100000 158700000 55800000 0 0 55800000 2495700000 100000 24200000 2471600000 270000000.0 200000 300000 269900000 72100000 500000 26200000 46400000 104400000 30900000 18500000 116800000 2567800000 600000 50400000 2518000000 374400000 31100000 18800000 386700000 4086700000 5372900000 771600000 157700000 1700000000 112200000 6558300000 5642800000 4858300000 5530600000 1700000000 112200000 6558300000 5642800000 0 0 2280000000 24200000 0 During the three and nine months ended September 30, 2023 and 2022, our net unrealized (losses) gains on corporate equity securities held at the conclusion of each period were as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:55.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.887%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized (losses) gains</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(143.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> -6200000 16700000 -7100000 -143100000 95100000 57300000 0 98600000 Accumulated Other Comprehensive Income (Loss)<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in accumulated other comprehensive income (loss) by component:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.873%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Holding Gains (Losses), Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">On Available-For-Sale Debt Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">On Foreign Currency Forward Contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at September 30, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive (loss) income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at September 30, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in accumulated other comprehensive income (loss) by component:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.873%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Holding Gains (Losses), Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">On Available-For-Sale Debt Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">On Foreign Currency Forward Contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at September 30, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive (loss) income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at September 30, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> -25000000.0 -100000 25900000 800000 9100000 -18800000 31800000 22100000 0 0 25900000 25900000 9100000 -18800000 5900000 -3800000 -15900000 -18900000 31800000 -3000000.0 -13600000 -500000 30000000.0 15900000 -42800000 -3600000 230200000 183800000 0 0 102100000 102100000 -42800000 -3600000 128100000 81700000 -56400000 -4100000 158100000 97600000 Hedging <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign currency forward contracts - Designated as hedging instruments</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a hedging program intended to mitigate the effect of changes in foreign exchange rates for a portion of our forecasted product revenues denominated in certain foreign currencies. The program includes foreign currency forward contracts that are designated as cash flow hedges under U.S. GAAP having contractual durations from <span style="-sec-ix-hidden:f-852">one</span> to eighteen months. We recognize realized gains and losses for the effective portion of such contracts in “Product revenues, net” in our </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">condensed consolidated statements of income in the same period that we recognize the product revenues that were impacted by the hedged foreign exchange rate changes. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We formally document the relationship between foreign currency forward contracts (hedging instruments) and forecasted product revenues (hedged items), as well as our risk management objective and strategy for undertaking various hedging activities, which includes matching all foreign currency forward contracts that are designated as cash flow hedges to forecasted transactions. We also formally assess, both at the hedge’s inception and on an ongoing basis, whether the foreign currency forward contracts are highly effective in offsetting changes in cash flows of hedged items on a prospective and retrospective basis. If we were to determine that a (i) foreign currency forward contract is not highly effective as a cash flow hedge, (ii) foreign currency forward contract has ceased to be a highly effective hedge or (iii) forecasted transaction is no longer probable of occurring, we would discontinue hedge accounting treatment prospectively. We measure effectiveness based on the change in fair value of the forward contracts and the fair value of the hypothetical foreign currency forward contracts with terms that match the critical terms of the risk being hedged. As of September 30, 2023, all hedges were determined to be highly effective.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider the impact of our counterparties’ credit risk on the fair value of the foreign currency forward contracts. As of September 30, 2023 and December 31, 2022, credit risk did not change the fair value of our foreign currency forward contracts.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the notional amount in U.S. dollars of our outstanding foreign currency forward contracts designated as cash flow hedges under U.S. GAAP:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.458%"><tr><td style="width:1.0%"></td><td style="width:44.855%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.176%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.236%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign Currency</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Euro</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,343.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,497.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canadian dollar</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">British pound sterling</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australian dollar</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Swiss Franc</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total foreign currency forward contracts</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,915.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,201.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign currency forward contracts - Not designated as hedging instruments</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also enter into foreign currency forward contracts with contractual maturities of less than one month, which are designed to mitigate the effect of changes in foreign exchange rates on monetary assets and liabilities, including intercompany balances. These contracts are not designated as hedging instruments under U.S. GAAP. We recognize realized gains and losses for such contracts in “Other (expense) income, net” in our condensed consolidated statements of income each period. As of September 30, 2023, the notional amount of our outstanding foreign currency forward contracts where hedge accounting under U.S. GAAP is not applied was $922.8 million. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2023 and 2022, we recognized the following related to foreign currency forward contracts in our condensed consolidated statements of income:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:55.317%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.994%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.994%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.994%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Designated as hedging instruments - Reclassified from AOCI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenues, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Not designated as hedging instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Total reported in the Condensed Consolidated Statements of Income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenues, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,483.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,334.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,351.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,628.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income, net</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(133.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value of our outstanding foreign currency forward contracts designated as cash flow hedges under U.S. GAAP included on our condensed consolidated balance sheets:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td></tr><tr><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:21pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023, we expect the amounts that are related to foreign exchange forward contracts designated as cash flow hedges under U.S. GAAP recorded in “Prepaid expenses and other current assets” and “Other current liabilities” to be reclassified to earnings within twelve months.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We present the fair value of our foreign currency forward contracts on a gross basis within our condensed consolidated balance sheets. The following table summarizes the potential effect of offsetting derivatives by type of financial instrument designated as cash flow hedges under U.S. GAAP on our condensed consolidated balance sheets:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Recognized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Offset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Presented</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Not Offset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Legal Offset</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign currency forward contracts</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Recognized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Offset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Presented</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Not Offset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Legal Offset</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign currency forward contracts</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> P18M <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the notional amount in U.S. dollars of our outstanding foreign currency forward contracts designated as cash flow hedges under U.S. GAAP:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.458%"><tr><td style="width:1.0%"></td><td style="width:44.855%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.176%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.236%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign Currency</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Euro</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,343.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,497.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canadian dollar</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">British pound sterling</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australian dollar</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Swiss Franc</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total foreign currency forward contracts</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,915.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,201.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1343300000 1497700000 192600000 216300000 191900000 247400000 136200000 174900000 51700000 65200000 1915700000 2201500000 P1M 922800000 <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2023 and 2022, we recognized the following related to foreign currency forward contracts in our condensed consolidated statements of income:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:55.317%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.994%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.994%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.994%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Designated as hedging instruments - Reclassified from AOCI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenues, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Not designated as hedging instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Total reported in the Condensed Consolidated Statements of Income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenues, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,483.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,334.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,351.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,628.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income, net</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(133.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 2800000 65200000 33000000.0 130300000 -22000000.0 -22100000 -17800000 -38900000 2483500000 2334300000 7351500000 6628000000 -15900000 17200000 -13000000.0 -133700000 <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value of our outstanding foreign currency forward contracts designated as cash flow hedges under U.S. GAAP included on our condensed consolidated balance sheets:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td></tr><tr><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:21pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div> 37800000 700000 3400000 0 41200000 700000 47500000 14300000 800000 900000 48300000 15200000 The following table summarizes the potential effect of offsetting derivatives by type of financial instrument designated as cash flow hedges under U.S. GAAP on our condensed consolidated balance sheets:<div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Recognized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Offset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Presented</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Not Offset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Legal Offset</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign currency forward contracts</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Recognized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Offset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Presented</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Not Offset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Legal Offset</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign currency forward contracts</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> The following table summarizes the potential effect of offsetting derivatives by type of financial instrument designated as cash flow hedges under U.S. GAAP on our condensed consolidated balance sheets:<div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Recognized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Offset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Presented</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Not Offset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Legal Offset</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign currency forward contracts</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Recognized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Offset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Presented</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Not Offset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Legal Offset</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign currency forward contracts</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 41200000 0 41200000 700000 40500000 700000 0 700000 700000 0 48300000 0 48300000 15200000 33100000 15200000 0 15200000 15200000 0 Inventories<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following:</span></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.458%"><tr><td style="width:1.0%"></td><td style="width:44.855%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.176%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.236%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">688.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">460.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following:</span></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.458%"><tr><td style="width:1.0%"></td><td style="width:44.855%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.176%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.236%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">688.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">460.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 77500000 38100000 498300000 260700000 112900000 161800000 688700000 460600000 Stock-based Compensation Expense and Share Repurchase Programs<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-based compensation expense</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2023 and 2022, we recognized the following stock-based compensation expense:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:55.317%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.994%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.994%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.994%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense by type of award:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units (including PSUs)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP share issuances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense related to inventories</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense included in “Total costs and expenses”</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense by line item:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense included in costs and expenses</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax effect</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense, net of tax</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share repurchase program</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023, our Board of Directors approved a share repurchase program (our “Share Repurchase Program”), pursuant to which we are authorized to repurchase up to $3.0 billion of our common stock. Our Share Repurchase Program does not have an expiration date and can be discontinued at any time. During the nine months ended September 30, 2023, we repurchased 891,060 shares of our common stock under our Share Repurchase Program for an aggregate of $284.1 million. As of September 30, 2023, a total of $2.7 billion remained authorized for future repurchases.</span></div> <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2023 and 2022, we recognized the following stock-based compensation expense:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:55.317%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.994%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.994%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.994%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense by type of award:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units (including PSUs)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP share issuances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense related to inventories</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense included in “Total costs and expenses”</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense by line item:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense included in costs and expenses</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax effect</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense, net of tax</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 129100000 130300000 358600000 351500000 200000 3100000 4000000.0 14900000 2400000 1900000 11800000 13000000.0 800000 -300000 1800000 -400000 130900000 135600000 372600000 379800000 1700000 2400000 5400000 7000000.0 81100000 80000000.0 231900000 229900000 48100000 53200000 135300000 142900000 130900000 135600000 372600000 379800000 37100000 38800000 109000000.0 101300000 93800000 96800000 263600000 278500000 3000000000 891060 284100000 2700000000 Income Taxes<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to U.S. federal, state, and foreign income taxes. During the three and nine months ended September 30, 2023 and 2022, we recorded the following provisions for income taxes and effective tax rates as compared to our income before provision for income taxes:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:55.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.887%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions, except percentages)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before provision for income taxes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,179.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,176.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,232.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,155.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">652.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:55.317%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.994%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.994%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.994%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective tax rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective tax rate for each of the three and nine months ended September 30, 2023 was lower than the U.S. statutory rate primarily due to a benefit from a research and development tax credit study that was completed in the third quarter of 2023 and excess tax benefits related to stock-based compensation, partially offset by changes in uncertain tax positions.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective tax rate was similar to the U.S. statutory rate for each of the three and nine months ended September 30, 2022.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have reviewed the tax positions taken, or to be taken, in our tax returns for all tax years currently open to examination by a taxing authority. As of September 30, 2023 and December 31, 2022, we had $245.4 million and $208.5 million, respectively, of net unrecognized tax benefits, which would affect our tax rate if recognized.</span></div>We file U.S. federal income tax returns and income tax returns in various state, local and foreign jurisdictions. We have various income tax audits ongoing at any time throughout the world. Except for jurisdictions where we have net operating losses or tax credit carryforwards, we are no longer subject to any tax assessment from tax authorities for years prior to 2014 in jurisdictions that have a material impact on our consolidated financial statements. During the three and nine months ended September 30, 2023 and 2022, we recorded the following provisions for income taxes and effective tax rates as compared to our income before provision for income taxes:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:55.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.887%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions, except percentages)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before provision for income taxes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,179.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,176.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,232.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,155.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">652.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:55.317%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.994%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.994%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.994%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective tax rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table> 1179200000 1176400000 3232200000 3155600000 143900000 245900000 581400000 652500000 0.122 0.209 0.180 0.207 245400000 208500000 Commitments and Contingencies<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2022 Credit Facility</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, Vertex and certain of its subsidiaries entered into a $500.0 million unsecured revolving facility (the “Credit Agreement”) with Bank of America, N.A., as administrative agent and the lenders referred to therein (the “Lenders”), which matures on July 1, 2027. The Credit Agreement was not drawn upon at closing and we have not drawn upon it to date. Amounts drawn pursuant to the Credit Agreement, if any, will be used for general corporate purposes. Subject to satisfaction of certain conditions, we may request that the borrowing capacity for the Credit Agreement be increased by an additional $500.0 million. Additionally, the Credit Agreement provides a sublimit of $100.0 million for letters of credit.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any amounts borrowed under the Credit Agreement will bear interest, at our option, at either a base rate or a Secured Overnight Financing Rate (“SOFR”), in each case plus an applicable margin. Under the Credit Agreement, the applicable margins on base rate loans range from 0.000% to 0.500% and the applicable margins on SOFR loans range from 1.000% to 1.500%, in each case based on our consolidated leverage ratio (the ratio of our total consolidated funded indebtedness to our consolidated EBITDA for the most recently completed four fiscal quarter period). </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any amounts borrowed pursuant to the Credit Agreement are guaranteed by certain of our existing and future domestic subsidiaries, subject to certain exceptions. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement contains customary representations and warranties and affirmative and negative covenants, including a financial covenant to maintain subject to certain limited exceptions, a consolidated leverage ratio of 3.50 to 1.00, subject to an increase to 4.00 to 1.00 following a material acquisition. As of September 30, 2023, we were in compliance with the covenants described above. The Credit Agreement also contains customary events of default. In the case of a continuing event of default, the administrative agent would be entitled to exercise various remedies, including the acceleration of amounts due under outstanding loans.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Direct costs related to the Credit Agreement are recorded over its term and were not material to our financial statements. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Guaranties and Indemnifications</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As permitted under Massachusetts law, our Articles of Organization and By-laws provide that we will indemnify certain of our officers and directors for certain claims asserted against them in connection with their service as an officer or director. The maximum potential amount of future payments that we could be required to make under these indemnification provisions is unlimited. However, we have purchased directors’ and officers’ liability insurance policies that could reduce our monetary exposure and enable us to recover a portion of any future amounts paid. No indemnification claims currently are outstanding, and we believe the estimated fair value of these indemnification arrangements is minimal.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We customarily agree in the ordinary course of our business to indemnification provisions in agreements with clinical trial investigators and sites in our product development programs, sponsored research agreements with academic and not-for-profit institutions, various comparable agreements involving parties performing services for us, and our real estate leases. We </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">also customarily agree to certain indemnification provisions in our drug discovery, development and commercialization collaboration agreements. With respect to our clinical trials and sponsored research agreements, these indemnification provisions typically apply to any claim asserted against the investigator or the investigator’s institution relating to personal injury or property damage, violations of law or certain breaches of our contractual obligations arising out of the research or clinical testing of our compounds or product candidates. With respect to lease agreements, the indemnification provisions typically apply to claims asserted against the landlord relating to personal injury or property damage caused by us, to violations of law by us or to certain breaches of our contractual obligations. The indemnification provisions appearing in our collaboration agreements are similar to those for the other agreements discussed above, but in addition provide some limited indemnification for our collaborator in the event of third-party claims alleging infringement of intellectual property rights. In each of the cases above, the indemnification obligation generally survives the termination of the agreement for some extended period, although we believe the obligation typically has the most relevance during the contract term and for a short period of time thereafter. The maximum potential amount of future payments that we could be required to make under these provisions is generally unlimited. We have purchased insurance policies covering personal injury, property damage and general liability that reduce our exposure for indemnification and would enable us in many cases to recover all or a portion of any future amounts paid. We have never paid any material amounts to defend lawsuits or settle claims related to these indemnification provisions. Accordingly, we believe the estimated fair value of these indemnification arrangements is minimal.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Contingencies</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have certain contingent liabilities that arise in the ordinary course of our business activities. We accrue for such contingent liabilities when it is probable that future expenditures will be made, and such expenditures can be reasonably estimated. Other than our contingent consideration liabilities discussed in Note E, “Fair Value Measurements,” there were no material contingent liabilities accrued as of September 30, 2023 or December 31, 2022.</span></div> 500000000 500000000 100000000 0.00000 0.00500 0.01000 0.01500 3.50 4.00 0 0 0 Additional Cash Flow Information<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cash, cash equivalents and restricted cash at the beginning and ending of each period presented in our condensed consolidated statements of cash flows consisted of the following:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.809%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning of period</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">End of period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning of period</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">End of period</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,504.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,110.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,795.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,171.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash per condensed consolidated statement of cash flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,512.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,116.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,800.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,177.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cash, cash equivalents and restricted cash at the beginning and ending of each period presented in our condensed consolidated statements of cash flows consisted of the following:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.809%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning of period</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">End of period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning of period</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">End of period</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,504.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,110.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,795.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,171.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash per condensed consolidated statement of cash flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,512.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,116.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,800.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,177.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 10504000000 11110200000 6795000000 9171500000 8000000.0 6400000 5100000 5500000 10512000000 11116600000 6800100000 9177000000 false false false The following table describes the written plans for the sale of our securities adopted by our executive officers and directors during the third quarter of 2023, each of which is intended to satisfy the affirmative defense conditions of Rule 10b5-1 (each, a “Trading Plan”).<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.757%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.179%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.693%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name and Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Date of Adoption of Trading Plan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Scheduled Expiration Date of Trading Plan (1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maximum Shares Subject to Trading Plan</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">E. Morrow “Morrey” Atkinson III</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">EVP, Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/22/2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/30/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,224</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reshma Kewalramani</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">President, Chief Executive Officer and Director</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/11/2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/15/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,330</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jeffrey M. Leiden</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Executive Chairman</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/4/2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/15/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,454</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bastiano Sanna</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">EVP, Chief of Cell and Genetic Therapies</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/25/2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/9/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,833</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charles F. Wagner, Jr.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">EVP, Chief Financial Officer</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/18/2023</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/9/2024</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,000</span></div></td></tr><tr><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1) A Trading Plan may expire on an earlier date if all contemplated transactions are completed before such Trading Plan’s expiration date, upon termination by broker or the holder of the Trading Plan, or as otherwise provided in the Trading Plan.<br/>(2) The maximum shares listed has not been reduced by the number of shares of common stock that will be withheld to satisfy tax withholding obligations at future vesting dates because such number of shares is not yet determinable. </span></td></tr></table> E. Morrow “Morrey” Atkinson III EVP, Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations true 8/22/2023 9224 Reshma Kewalramani President, Chief Executive Officer and Director 8/11/2023 true 27330 Jeffrey M. Leiden Executive Chairman 8/4/2023 true 40454 Bastiano Sanna EVP, Chief of Cell and Genetic Therapies true 8/25/2023 32833 Charles F. Wagner, Jr. EVP, Chief Financial Officer 8/18/2023 true 6000 EXCEL 72 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( !F"9U<'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " 9@F=7C/NY&^T K @ $0 &1O8U!R;W!S+V-O&ULS9+! M2L0P$(9?17)OIVEAA=#-1?&D(+B@> O)[&ZP:4(RTN[;F\;=+J(/X#$S?[[Y M!J;706@?\3GZ@)$LIIO9#6,2.FS9D2@(@*2/Z%2J,V!R65B M.,U##U? B.,+GT7T*S$4OT36SK SLDYV34U35,]=267=^#P]O3X4M:M[)A( MC1KSKV0%G0)NV67R:W=WOWM@LFW:KN*\:FYW+1=\([KN?7']X7<5=M[8O?W' MQA=!V<.ONY!?4$L#!!0 ( !F"9U>97)PC$ 8 )PG 3 >&PO=&AE M;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X? MA1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@ MV2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?+&A T%116F]?(+3E'S/X%/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1 MTDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP M' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?= MTXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP M=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%, M4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']I MJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZ MY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A M6$G:A/@01AKBG'/F<]%L^P>E1M'V5;SC MFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B"P#E_ M+GW/I>^Y]#VATK\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE" M0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KT ML@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K3 M4I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.' M>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\ M3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^ M:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON>;G*YZ(G;ZEW?! M8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83 M+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL' M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5 MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$% @ M&8)G5X$%.P/1!0 T!X !@ !X;"]W;W)KG1T>27UMUQ\2U>,2?041TEZW5I)N7YG6:F_8C%-S_F: M)?!FP45,)=R*I96N!:-!'A1'%K'MGA73,&D-^OFSL1CT>2:C,&%C@=(LCJEX MOF$1WUZW<&O_8!(N5U(]L ;]-5VR*9.?UF,!=U:I$H0Q2]*0)TBPQ77+Q>\\ MAZB _(O/(=NF+ZZ10IES_DW=C(+KEJU*Q"+F2R5!X=^&>2R*E!*4XY^=:*O\ M317X\GJO?IO# \R7O MXF^*>%(3?X7N>2)7*1HF 0M>QUM0EK) 9%^@&V(4G++U.7+L,T1LXFC*XYG# M'WT)X5@7_JHX3ED_3J[G&.OG+W>>2@%-[F]=#14*';V"ZH?OTC7UV74+.EK* MQ(:U!C_]@'OVKSJ\[R3V"K93PG9,ZH/WW,^@BTHT>UXS':DY'-OMCSHD8U1# MI&Z)U#T.Z6-&A60B>D83MN9"ZO#,4E)DNDKQC%$-\7HE7N\XO#$3(0]4+T0P M#FB39U8J^UUMQS/&-^2\*#DOCFR9@L(4DL\ ]7DT:RUHE&H3:0QK"'A9 EX: M"S5,9"B?T6T8,?20Q7,F=&!F#=NVV_C*P5UJ^"!N=R'^X/74';7K&MXF6V2QWP\'J MZ@(]0$1JA M/\-U_?AD5K0)P;:6]!26"5>>"9NM3MY475CTUH.9!7KX0HMU"H>$*XN$S;[F MCON0K_&*)R8+<4#$Z>!V#]OZM)W"(.'*(6&SO9F%$LP17R!,?I[_@J;,SP1D M4@MI5O)X',.$-)7<_W:&?K3/;8S&5*#/-,J8LM)HJI;#VCHXA8_"E9'"9@<$ M]C<(DR6:/L=S'FG1#UBHR>R+ENL41HE41HF8K]J5Z'FP*:$E2\B1_DB+Q-"K6.*Q4N>2IA0,NW.RP'%K]K]&L\S1J04IW8-K.6:8> M[Q0^B%0^B)@MS'ZD?37)YQ-ZBAXS":XV47.HEO@[.9Q=/11JW5Q-G:=L!J1[ MT;MT\&6G;VUTD)49(D?M%WDPI IP?:,D8$_H=Z;/X\%M(_ORHNL0K>DS!S=- M9F5XB-FO[.?+VS!5[O8K YMFVN0\(-=N8])VL!;T% [(J1R08S8NY0[G2]); M>*@=8@^(U6WAFL.:,E8>R#$[EK>,NTWK>DJSW$<]XRG\CU/Y'\?L5EP # K( MB&H'F0,"M<.J.>[_@EDOS@S5C)&PO=V]R:W-H965T M&ULK5E;;]LV&/TKA%<,+=#*(JEKEAA(+ WK0[>@6;>'80^* M1-M")=$3:2?[]Z,ND63RL]!TSD,LV8>?>+X;#\7K)UY_%3O&)'HNBTK<+'92 M[J^62Y'N6)D(B^]9I7[9\+I,I+JMMTNQKUF2M8/*8DELVUN625XM5M?M=_?U MZIH?9)%7[+Y&XE"62?WO'2OXT\T"+UZ^^)QO=[+Y8KFZWB=;]L#DE_U]K>Z6 M@Y4L+UDEZ&)X9C-P>OUB_>>6O"+SF BVYL6?>29W-XM@@3*V M20Z%_,R??F$](;>QE_)"M/_14X^U%R@]",G+?K":09E7W6?RW#MB,D#9@0>0 M?@#1!SAG!M!^ /W6)SC] .=;G^#V UKJRXY[Z[@HD95IL+.,J2N!"_R+)'JYD&J#Y4/4B"^01^KE)<, M?4!?'B+T]LT[)'9)S03**_0I+PH5O9G>7B^EFESSB&7:3^2NFP@Y,Q&* M/O%*[@2*U80R8'PT/SZ<&;]43AD\0UX\(*XNM>,O3\%,<6+Z69E MZ,/YY@\L_5F6GY7?DCK=M2F7J3(K^+[M?2_I!S'WC7D$V-9XFQC/T0HH\DW? M4!KHY1B;,!PXWL0[)\R#@7DPR_PV_>>0UTH&Y-6'?E)[-J^U[M&45JY.B]462 M*5F6-XMA(WEGW1&:0?6H%6C^ % JI!HJ,E&^YQM]V$1YOC]QW(D;L#V*1GN^ M >R2:LL:P;=)\AH=D^+ FH:0*@FF'-2DA;H4><8:K_ *E(.VF;MZ6:\!T =B M>9HO(!0VT@-"N>%99TP4-)YUQN]&([9O,L5$\ MCFL'.G/3&J6N8YTI!TQ&ZF26>B\+-S4OD=J[=L&&B1.3D*T:&M:) SA,/+UI M1 ".!(XA:V( 1XE/K? ,]5$0XUEUIZA+IGJB5$70^ #D3$TNJD9#G;().VGA M/6$ 15UC'01@;C!)FU.VH]C$\VIS8-LG-TC7 :K0-NE",&H&&(!1(+X 3*7! MF040CUH3SPJHU6]RQVKTMJ?[KH_R69'=6SLEY9K<31CVS5"[1E$K#^G$H2?2 MJ1]/F8_:#L^+N[ZF']F&UPRIY?^8MV^%U&WO!223YS/MS11K&/NAV=9!G&=H M/P!'"25FUD."TW7/YOTH ?&\!KQ_'7U CCG4S ) W#E&LD0 S VP[J,8@'DN MF13**?51 ^)Y$?@KF^UM@;$15/W7[X?0/SD\RBDPR+S*CO#@T+V9?X0@,4 SUS1>(G0 L MM+PSKWW(J#()F:W-A^YM\T&T.]*1-DJ3(CT4G>@$JY3,RM?75NE%K447M19? MRMIIB$8U3.;5\%BEW=$ G)'4W.F[^NZ7F *6N)ZQ8( P7U>1,0ASK7,I.>IA M,J^'I^4XQ]A4I\2S]5W<&H*IG:G!&;:F"P+06F (P^7DT*AD];8]K1-JY3M4 MLCL8&+X=3@1OVW,P[?L[?+7&P/<1OHJ[\[[1?'?\^"FIMWDE4,$VZE&VY:N4 MJ+L3O>Y&\GU[9/7(I>1E>[EC2<;J!J!^WW N7VZ:!PSGJJO_ %!+ P04 M" 9@F=7%;0,R2$$ #^#@ & 'AL+W=O;O"*S(EZW#P(Z'D-2EZ4A,F",R3(SP-<. MQN+W@NSD01MI*D^;4CH?M M/?HG0Q[(/&%))IS^4>1J/7(R!^5DB;=4?>&[GTE-*-%X"TZE>:)=;>L[:+&5 MBI>U,T10%JQZX]=:B ,'P+$[A+5#V':(WW&(:H?HHS/$M4/\T1F2VL%0]RKN M1K@I5G@\%'R'A+8&--TPZAMOT*M@NE#F2L#7 OS4>,)9#FDG.8*6Y+3(L8+. M7,$+ZD%)Q)?PJ80J7.OR>"'H,UOPDJ!K]#B?HLN+*W2!"H;N"THA\W+H*0A+ M@WN+.H2[*H3PG1 B=,^96DLT@U!RB__TM/_@A+\'?LDE8 __B]; M[BOTV(ZNE\$;N<$+,G( 6!+Q0ISQCS\$J?^33?AS@DW/"38[$]A1BN(F1?$I M]/$OL)\4)A>V!%2^J?'5V\;+./"CQ(72>CF4MFLVB'PW.;::=JW"-/'=[-AL M9C%+_,@-&K,CGDG#,SE9BK^J-1%H<52#%6]T2;F45S<%62.>#P.;!8+,2ST3A)TJ0)(NM*%1! M9 \Q8E84A5_UZR)P^SWTE0C>0Q>)&R+,\KH+X6Z(.4[0-UM^J]"R@UJ[3MVP M5=T6(]]-6\5M,0JR3FU;K*(#J",!^XV _8\*N(+#G=$-#H%PRF%P"!""L,6; M'MAAD<,/P,QRVQ7Q,HC<\*JG&ZGK5PTWO3)B7EQ&L1M=?5_/*M+D@%_0'G7BB MM)W52=<( P M+PD !@ !X;"]W;W)K?^1L@GE0)H\ISQ7 V<5.NBY[HJ3B&CJB4*R/'+0LB,:IS*I:L*"32QH(R[ M@>=UW8RRW(GZ=FTJH[Y8:C'8BIQYM8L"\9?]B<\=*Z'=@5HG^NA4P%LZFZ9NQ5N3#6-^E)LB#36R&8&5GV+1KU8;NID MIB5^98C3T4CD">XZ) 1'2G"64(V3F<87EH-61"SP4X9%F)KJ6 .YRV.1 ;F8 M4HD&*6@64WY)KLGC;$PNWE^2]X3EY)YQCI6@^J[&,(TS-ZY"&I8A!4=""LF] M0%Y%)AA:TH ?G\9_.H%W49Y:HV"KT3 X23B#HD5"[XH$7A VQ#,Z'QXTI?-_ MWB?_['U/C+ NF-#RA*F@, P>) M%<@U.-&'=W[7^]PD_%N2C=^2;/)&9'M;U*ZWJ'V*/7K,L6-P]AO_XU3PA.5+ MPH52@/]RCF>'? )-YQR(@G@EF6:@KHBFSTV[53KJ6D>FY:PCOW73=]>[FU#: MW.S8>/L6X]D\RJ9:S\\3&?4>97.M=\]D*6)J75@-&DP"MNM\$ ; M=Z<#9""7MO4JS&:5Z_+?KE?K[GYKF]K!^M#OC?R&]3'>!LKF_9>^O$K<4[DT M\G)8H"NO=8,1R[(]EQ,M"MM_YD)C-[/#%&\T((T!?E\(H;<3XZ"^(T5_ %!+ M P04 " 9@F=7KA.D)F8& #T&@ & 'AL+W=OJ[)6%[.UUIO3Y5)E M:U%QM9 ;4<,WM[*IN(;;YFZI-HW@>=NH*I<4XVA9\:*>K<[;SZZ:U;G//T493RX6)&9L\??"ONUMI\L%R=;_B=N!;Z^^:J@;OEWDM>5*)6 MA:Q1(VXO9A_(Z24+3(/6XI]"/*C!-3*AW$CYP]Q\SB]FV"@2IL#>L3UWQUWL@'U!AK\&8NVKYI6T,T16V&\5HW\&T![?3J4M8Y#(K( M$5PI618YUW#SD9>\S@2Z-HX5.D'?KS^A=V_>HS>HJ-&7HBQA#-3Y4H,$XVB9 M[1[WL7LSD'@=F FV:G:\$QR>*\L]BJ[:L2&%SD2CQNS M_J@V-:5>BP:6O>&L=.F.+45A8">GPRID4T.?['4G7MU_2\W+%TA,'.,9I>'B M,#\==HRR8& WDIGN9:9'NA=(W^BGMEO-9-\ >_5DDJ;63"*$!@=24ULJP[7^(67^ $AQX@3;RG!RV(G'K,;"!FPD1V:/YO5=81:BZ8'>^1A- M(LP&TV,G\9C96&-/,.*%!B#Q5D NYDCS1Y]*:@]>3-,%.93IL*-!M$@G=/;T M(7[\?(5TY+JH[U IH.SR2666! ;H"0^5.LR">#(;>_@0/WW^DO7=B19-!676 M"SE$;!"1&.-#P3:*8))-K?"D9Q'QP^AKNVAZ^M-&2Q"'UFKI,L/I9(+V!")^ M!'4+ID>>C1<*J1G9 FU#DI 03^9FCR(2OZ@,+ M^4Y3M,#MK0>)%VJ\6@Z_E M;1QTSS'B!]F^AMGP)Y/CSH!M.C%(G?1P9!QFL+9-C4O/,.*'&$ALMJ*O$9P2 M;2K1%,<+=JC184<@RV*W2-K3B_KI]754LPQ2R+F;P(ZUS4YUIQF9*EUH#S3J M!]JX>#FFU286"]-T<5@6..R@Q*8#M(S5#C9G?K3U*_%M4;?;T0X=QW3;"&,I MMA+"818P/%5WT1YTU ^Z7K4\0-XQW0Z@A8'=W0ZS.)W,C9Y[U,^]+H_+O?IC M:FV:)5%J][)M%B7A9"_WT*-^Z'69?$RCC;20$F9WJ0-]%/9H$VBF/?NHGWV7 MLJH*;2KO;G^3R=KD@ZBS*<6154DD['.'H#4#\#K-6_$6I:Y:-3;WQ+@ M[UF[:=!/[C.15^7@:WD;Q]YSD/HY"!O1706MM,Q^S-$;O, $J-B@>UYNQ1DB MQ6*]@UY##,SJY+C@^PSV0< M9$]2ZB>I24193T88=O&Y8YPC&L;SA";S$"=MC.8>$S*/:/)L[NZ!.8+O-J(] MJBV?G/WAP+*U=SIB-#X.Z\'-_.#^D.>%.4J&=<2<1)P4-E=*I=ZCHH:/ MG<7V1<)V$OYB M&(%UWNO>@SD,W7NPY>"5A'D?](4W=T6MH!*ZA99X$4,:-MTKENY&RTW[EN)& M:BVK]G(M.,@W!O#]K93Z^<:\^-B_Z%K]#U!+ P04 " 9@F=7 CZ$HO\" M !?"@ & 'AL+W=O!^[X,C5VP(U& M!5O"#,R78JJPYS8L"<\@UUSF1,%B[%QYEQ./6D 9\97#1F^UB;4RE_+>=CXE M8X=:12 @-I:"X6,-$Q#",J&.GS6ITZQI@=OM1_;;TCR:F3,-$RF^\<2D8R=T M2 (+MA+F3FX^0FTHL'RQ%+K\)YLJMC]P2+S21F8U&!5D/*^>[*%.Q!; Z[T M\&N ?RR@6P.ZI=%*66GKAAD6C93<$&6CD0QD9HDU.9LR!;E)P?"8B7/RGKPE+M$ICNJ1:U"' M97/C>LWK:DW_A35G4'1(EUX0G_K=%OAD/_P&8H1[)=S?A;OHODF!WZ3 +_FZ M+\DQ:!DKTQ"Y(+<\1^.<"3*5FI>5]OUJKHW">OO19K7B[K5SVT-XJ0L6P]C! M4Z9!K<&)WKWQ^O1#F_'_1+:3AFZ3ANX^]FB*YP>4PLW'HHOO+TC!%%DSL0)R MQG.22"&8TJ0 56W\>5LVJB6&Y1+V#;*.:(=Z(W>][?) T([Z7J.^=YKZJC@) M6YE4*OX;)ZR+:K15>L4?;*GR:/E[HOYPW(Z!H#$0O,H UWIU6'SP3-13V?LB M=@3W&\']5PG&;X4V+$]XOCRDNG]0];Z('=6#1O5@K^J)S#(\T_]0XH-C2OQ MT([TL)$>GB#]Y/H.GZ4RH+2UPH^)W'$P;!P,3W=P7($/GVGR@T'HAP$-GZAO MC:2>U_?#=O4>_?NMI*?K/Z'>:_IC7+2'MMIPM[[^]NKUF:DESS41L$ L[0R0 M1%6WF:IC9%%>".;2X/6B;*9X P1E W!^(:5Y[-@[1G.GC/X 4$L#!!0 ( M !F"9U?OCE&T' H +=8 8 >&PO=V]R:W-H965T&UL MO5QM<]NX$?XK'/6FO9F$NGUV;B7ON9D6"+$TK4B92=_/N" M%",2Q&HEQJOX@TW)BV>!?0 0^Q#$S4N^^URLE"J=+^ML4]R.5F6Y?3N=%HN5 M6B?%)-^JC?[/8[Y;)Z7^N'N:%MN=2I9UH74VY:X;3-=)NAG=W=3??=C=W>3[ M,DLWZL/.*?;K=;+[^DYE^5/G']L-.?YH> M49;I6FV*--\X._5X._J5O96^J K4%O]-U4O1N7:JIGS*\\_5A_?+VY%;U4AE M:E%6$(G^\ZSF*LLJ)%V//QO0T=%G5;![_0U=UHW7C?F4%&J>9_]+E^7J=A2- MG*5Z3/99^3%_^4TU#?(KO$6>%?5OYZ6Q=4?.8E^4^;HIK&NP3C>'O\F7)A"= M DR<*,"; OS2 J(I('H%>'BB@-<4\'H%O.!$ ;\IX/>K%)TH$#0%@CKVAV#5 MD;Y/RN3N9I>_.+O*6J-5%S5==6D=X'13]:R'98NDU)_>"CU']V!RL+)'YV'5;)3JSQ;JEWQ-R?^9IGN*L7-M-35JL"GBZ8*[PY5X">J\)^\3#*@V!PO-L_7:]TU'\I\ M\1DH?8^7_G6Y3*NNG63.AR1=CG4+YLDVA6L2G\%:+/;K?58'[M_E2NUT+-=Z MG*^J ?BLG/>;1;Y6SL__S(OB#0 O8WIG+2:.8+\XW.4,XA3%K^;# MM\4V6:C;D0Y$H7;/:G3WU[^PP/T[Q/0!S*_!JKGP^8[[GN]6/S?3YRZKE&YC M2C!)!&;0*8YTBH%T7D+A 3/L1)VYK!_Q^<$JZ'(S\7NLV#9!%+F3R#2+;3/F M3V:FD;2-A+Y-=K","'G'"'EU.7$B0GH,ZAMOH?NY#DM]]:::M>K9HS>S0:'R M*'L[)=@])5A,"2:)P RZ_2/=/CH@#M/PPIB&TV8:SJII^!=GHY=M^MY6)E\@ MP@_P4:<71FP2]H8&6H>A1%*"Q9=47Q)Y- @*C@0%*$'_TM$_$ )%/["JSWU7 M3%@O_JB+H?&G!(LIP>39:!@,A$<&0I2!9OU45#.@7G26JY7*EH[.51RUWF;Y M5Z6JL>'DG[+T*:F62D5WC0"QAOH;.DF&UI)@'$(+ DJG,268) (SR(V.Y$;$ MY$*$1E;'&[-@UK]CSR-K'=$GZ3*@&&W3T/ 3@1GAGQW#/T/#_[XH]O4R3-]@ M%ETJ]CK;TJFPVJC'M'2V>JUV=E2AGH:.JIF]T(Z@447I-*8$DT1@!JW,;;-E MEXQ8,!-VK9' A#\1O1'5F'47P6[_[G=_ HOW!A7>HJ'AIT(SX]]1*Q@:_WJ] M/JZDI&6]NM-+NWKZGE_X 1?Q0KZMG M\+J:M5(#0U/;\^+:/_:;,S$DU1L:M-Y0<,&A0"HGD*))*C23U5918+BD &IL MYYFT,W'&9D+T._"\,3PS&GR+R=!2[&+ IQ_V'4K R@M#T;E%F8%J,WL67%-J M8Y2Y\YP4[9X4+29%DU1H)NNMFL!P.>'5BEN#;_1':]$[QVLQF$]2]>"B%D@J MGR9/K3# <&4 %]Z8G:G/A&M/5I29^CTI6DR*)L\&Q*2A%0@8KA#0JV^XP\'S MIJT4C#FX8B"5"DC1)!6:^8BU%0LX+A;0B'"-$X,)K_=D;=X881K<)3@QWJ+! MCT2O(1;P5BS@N%A J<+AK@8_[V86%Z ,1^HU)D635&@FN9T-#+C8\%HEKH$W M!)JH+Y[-&RMT7%T"%..M&1S[:Z@"O%4%.*X*?(\*QR%9P%8^<<]#5Q:7.8U) MG4HJ-).<5GW@N/KP2A4.1Q\\T8'2 ZC"D3J.2=$D%9I):2L]<%QZ^ X5CMMR M JS" 8:V[L!MK0!4X0"[73W(S;)OX"3_QQC4W8#_=YX%N3QQQW,I0& M4K28%$T*>R=#+R(F$:T"(' %X*/:[G>+5351]M/$,_F^L#/T<31C;F!MCP8, M9]!]'Z_J8 )("Y_FB:0&FZ-GS&//.M1@3B?NPL[=X>@8KS^ M@Z-]E5<%.N\*X-D[O?2,.QRZG&C0SF_])'4;DZ))*C23XU8$$+@(0",]-T[, MX:&7K_T-H(T=.M(N@XKQ=@UFX1IYNVCS=H'G[90"-.YJ\!BS-Q)P#QQCI*\E MD*))*C23W59@$+C \%H%6MC[^B/?2EH;*W1L70(4XZT9'/MK* 6B50H$KA1\ MCP(M[/1?A)ZU#Q3W/'C9;2L @-.8U*FD0C/):<4)@6\QN%R!%B!/$:2E13SR M72M%@DW!B8Q45B!%DU1H)E^MK"!P60&7EV&.9K;F%OB,VTFL;6AK;L).ZD,A M+*TZ%L"FA-ZS' E@S5@H.ECF^Z-M4N_A2?V@79U@T' '@]\BM9_GG^K[I(YC M4C1)A6:RVBH$'JX0G-W5"3-I[^YGOA>ZUO/CQA#O_@!:*(*9E84"=F,]2OKB M%V 6,1%UGGJ:L6K3=(]?4W3V2/?WDZ+=DZ+%I&B2"LUDO94+/%PN>+7H[-D/ MX45@W2CP6@SFDU0:N*@%DLJGR5/G@ ,\Y<=%9\_.OYD+[+_ G0RF@?29/BF: M/!\1DX@VZ_?PK/_[16<<>/ ,:>?X8S#')W4;DZ))*C23RS;']_ #1Q-P( $#1Q/I.P6D:)(* MS>2X%0:\'W$J@0><)N +>^E]_EB"RY!BO%6#.;A&LN^UR;[WXXXFP%T-'F%V M=@\> 4;J-29%DU1HYJ%'K4;A7_=X M_6%%C_W1___*L&%\#$>$N&QIT*S8Q[ MJR+X],<2^+8TP 1PQA3IL00^(%S83F-2IY(*S22GE2U\JF,)0*W'APX2@.7H M$Z;0)(;7>>@D1HHFJ=!,OEK!P7_-F0,P1\#)@J <#1C:>AQ@!,K1OGV HB5' M UB@'#WM'.%:'>G[>[)[2O4=.%./NJ ["76GVAU.R3U\*/-M?:KKI[PL\W5] MN5*)GN4K _W_QSPOOWVH#HH]GE5\]W]02P,$% @ &8)G5R*]1FO4!P M "( !@ !X;"]W;W)K6BX?K23AY?O"% MW^^4?C!;7>WI/;MCZNO^MH*[63M+Q@M62BY*5+'M]>1]>+F.S C\8VS!]F[ M1EJ5C1#?]+"QCM5P;<4. M?8(5E^@"?;W[B'[^\1?T(^(E^LSS'%9#7LT4@-%3SM+FQ1_J%^.1%R?HLRC5 M3J+? $ V'#\#)5I-\+,F'[!WPCNVGR(2O$,XP,2!9WW^<.R!0UK#$C,?&3.L MMMG6V&Q;B0)!X%54\?*^]ERN.).7+K/5TT;N:7547\H]3=GU!,)6LNK()JN? M?@CGP:\NG=]HLH$%HM8"D6_VU9^0A'B9BH*YU*S'SLU8G6N.*SR/@^GR:G;L M*^ 0BP,R#5NQ ;2XA19[%^=]]@^$5NW?2D Z2D69\IRALL6LG^N[5*_COA)' M#FZ*-D_G+V3\E@OY1I,-K#5OK37W+N2=$NGW"YTL,P2F 0:1U.1@]JBOG*65168\]G7Z"-SYM"E]?:+*(BG\0G(6BP>B.'(C3%I,29>C'\( M*1FD?[#AOP>NGI!DZ:$R[NY"FEA(@RD^@6G+A-%H+(=!1V'!"]9,H8*13!/2 MEO(*'6E^8)JX(*QUI$* L MD$QIF:&AGY!ORB-$@JA&(K@9/7@OCG$OUS7X''+QY00=.VP:3:.@]PE/%7",B<*QG!YV-!GZ>;+U MA3U]TH[@Q&M3WC*P7<"6NB#)J(D[9@S]U @(JP/K3.Q$:#/>8CF?6D:TQ1+0 M9"P1=LP8^JFQ3H2]'.+$:/-B&)-I=(K129_3Q0C&CAE#/S7^>6Y=Z,1NLR A M >ZA:L [Y((X[/G*L$WJZ!('K^I,.*0%>4Y!B[TT_-K$_5:S#:W0$2[V$^[M MH4IWU%0X6T2/E."QUXHY&L9]&!ZL!406Q M!!6G5DT7GWO=J3DQ.Z@RC.PBWBFW",<2*NXH%?LI52^!AGQ6B8QMXDSB:9#T M/Z? (VM1@A','<]B/\_>F'C7)M4EG(7<6+T4BO5K&JW^Q'(8%]>.^W[' MM=C/M;?TR6@ 73I-086*H6^QR):7 MM$S/81$O_[^:1=YHMJ$5NDH ^RN!&RD/H':=MZ"5+Z!=EGJ[!!U*:#;1AI5L MRQ7:Y]2]28IMEE\N[55T=,XD&EM$TI4"Q-\Y?V'[?N+M*^#F-EA06*3 M\WO3_SN7@CAX&F.[_W')A?/1/2'2\3GQ\WFK(NA2AQ-#N=[8<,.UJ5BW]Q9: MA]ABE'6&R'M[W7[ZKHMV5PIP(K?9F%B4[1#"TY$M+=+Q-7EY3WJ0<,_&[&AZ MHPA;+8=++@P6H\[1L3;QL_9OVRVXO(G2;O^%/=8W"#J/>J].*^?$[^!AN^\D M#DI?C(5NQ]7$S]7-04"[1Z!Y$ MUNZ70PR3Q7QT(3K.)G[.7I^-_JGO%JY.C2X3.WU\K>OT["Q1B[=>1, M$F^)*M96A;IZ 7^LS\*!%=S'<=X"X-7G<6\TV_! MKN/[R,_WIF@SFVR:'%\Z?(ALND_"Q&)[A]@R&G7(J&/\R,_XIV 5TW[H!!I: MIX3$/FQR2$5V"SCKG:47K+HW/S&0R.SLU8?1[=/V9PSOS>']R?,/X>6Z_C%" M-TW]VXC/M(*,((';MS!E,%V XU?USPWJ&R7VYL1^(Y02A;G<,0KUI!: [[<" MVK/F1K^@_=''ZC]02P,$% @ &8)G5W-[\5DV!@ /1 !@ !X;"]W M;W)K/?<32;/QZ74 M9C _C6,7;GYJZU!H0Q=.^+HLI;L]I\)NSP;303OP26_RP /C^6DE-[2D<%E= M.+R-.Y1,EV2\MD8X6I\-%M-7Y\<\/T[XHFGK>\^"/5E9>\4O[[.SP80-HH)4 M8 2)GVMZ347!0##C>X,YZ+;DA?WG%OU=]!V^K*2GU[;XJK.0GPU>#D1&:UD7 MX9/=_DJ-/\\83]G"Q[]BF^8>/Q\(5?M@RV8Q+"BU2;_RIN&AM^#EY,""6;-@ M%NU.&T4KW\@@YZ?.;H7CV4#CA^AJ7 WCM.&@+(/#5XUU87XNO?;"KL6%(T\F MR,25R<1"*5N;H,U&7-A"*TW^=!RP)2\"@ES_W M.9SPCO?C<0Z]\I54=#:HF%%W38/YXT?3YY.3>ZP][JP]O@_]WT?K/X07^V=_ MS@FIIFQ927/+\Y5%Z(VGC)\\%F?!".A*UD76F>0IO MG,MK$BLB(T!GA>^96-V*+^0"W8B+7"(Q%=5!*UEX\=XHZRKKX@9/'C]Z.9M- M3M+<87R;GHAF=$M_'ZE].V!=.V9KUPS^)+2)?KD,9A.R-.3QO6&E5 5X MV9 A)XOBEK]3Q;9@;0 OER;ZM62'(W.+DAQ,[VR]'"U'XI?%XJ+==13Y? B% M*&I<\>)^*-TN1B5NUI#&K,(OL$.*RA4Y<32-)6\F MGO#$1BYQX#!N)]U=;':$8DM;ZA"C!(UY2H'6Y5Y9#5L)VTH;]A]Z*J5!VTZ< MM:J#YPT#''*$@7-#9M_0R)(\#1SR'NT_.BW%6FIW)S2,G+AHK:BLUQWGF(E^ M&_4,@FU)'7FM^8BJMIEO"%QR B8&FZ8189BYE%L]P%ZZ' +E H60=V[H&.@, M0N'#16O[?DR(8,K"/5I;RBKM)09P$''X6H+JLF*+F$:M?KMF2ZZ XPAYE-(2PLM5[J '!NH7>8WOG SX-)S:$W:A7V,Z@"+#R!@F,HN!W9G MG:-K,G5C#ZL+6%YD=4R].RXU(H[%CT^RQ>+'ZJF];S+!M2"R!>D?+ZS!LVH2 ><,CA_,9XJL^,A=:#%L^\)' M&1I%GM<>&>O]H4-<=PCZT92&=#(;2V J9()/!9WE.KG<,]QW+L/,V(>D\'IC M.;U*>OC? M2-UW,1CWKG0X)&[BQ36*W81TN^M&N[OQ(ET)=]/3Q?J#=!N-C"MHC:63T8MG M ^'2936]!%O%"^+*!EPWXV..KD*.)^ [GW/:%]Z@^X_!_"]02P,$% @ M&8)G5Y6U7%R@!0 H T !D !X;"]W;W)K&UL MQ5=K;]LV%/TKA%<4&^#)UL.O/ SDU2U(LP1)VJ(8]H&6KBVBDJB15-SLU^^0 ME!RG<+P.&+ O%A_W'AZ>>R])'ZVE^J)S(L.^ED6ECWNY,?7!8*#3G$JN UE3 MA9FE5"4WZ*K50->*>.:*Z:8LN7HZ MI4*NCWMAKQNX$ZO@--BB9**G20E9,T?*X=Q(>G";6 MWAE\%+366VUF=[*0\HOM7&;'O:$E1 6EQB)P?![IC(K" H'&GRUF;[.D==QN M=^COW-ZQEP77=":+3R(S^7%OVF,9+7E3F#NY_I7:_8PL7BH+[7[9VMLFDQY+ M&VUDV3J#02DJ_^5?6QVV'*;#5QRBUB%RO/U"CN4Y-WQ^I.2:*6L---MP6W7> M("7=ZP-RSJ1Y,DB%UK& Z# M$5KC_C@,@P2M47\\'F'VZN3]Y_.+LQL6AE$P96$\PW0\CH.0)>$$OS=W5R?7 MIY<,0T,6)N, )*8A3./9+)BQ^\_7YQ=7-P-\KRX^7K(XMOY36,U&^ F343!A M#]+P@M6[]'/TDFGLZ$7]./:4)_UX%':4HRF6[M3?#M O)%>*U[E(V7N9^EA^ M3[#@NGIV11K L>_..(2O.B?9G\DH^DJIP]9N?Y;J" MI87535U+9?VZ)-0,*2$J UN7I #"P^(+ <;DW&ZK%,9ISDO95,9R;A=4),I% MHS391=@:BJ.0.WL;@U>UY_;A^N41[ MLOA22!NEO.DF@X+N>,&F/$5E(^@C@-TK?P']90=UE]40A_R)XU1[(:@E75,6 MH'K5M]6P0[.:E'NK5BG47Q3"7VYM2E@\B;/GB;AB$*0@K3WPSF+@/GVHW(6$SY%M@*"S0AIA=(R%:YH''X;9D\8FE;2 M$]6\)%>O!K[;!S:3C^"P8KY[V1VI--O2;M4J)+B8J%D;HN)NCAC:JR^ % MKJ^JLN6ZN:I\:CH!=KW"!ENO9IPF*_??0$-7)*I_0&]&-W\_3ORK^]G<_W>Y M1H4+,"]H"==A,!GU?&EW'2-K]P9?2(.CRS5S_(4B90TPOY32=!V[P.9/V?QO M4$L#!!0 ( !F"9U?]E5PHTPX 'PQ 9 >&PO=V]R:W-H965T M/.+?KNR31Z:N,EVH*RM?2KLY59FX?'TP.FA^N]6)9T0^'3QZ5J.I= M>67Q[;"EDNI<%4Z;0E@U?WQP-OGE_)C6\X+W6MVZZ+,@36;&?* O+]+'!V,2 M2&4JJ8B"Q)\;=:&RC A!C#\#S8.6)6V,/S?4G['NT&4FG;HPV>\ZK9:/#^X? MB%3-99U5U^;V'RKHRDD\>67,K+*T&-?K JO)N"*<+>Z;3'4P?B%>FJ)9.7!:I2OO[#Z% J\6TT>)\^DF";U0Y$D?C@9B.IT>? MH'?46N6(Z1WMH/?:+F2A_Y(4. -Q80IG,IU*'T0&.MPM J?B+*V6B'A^4Q,O>J(,G?_]IZ6HIJ MJ6TJ2FDKK9S 2B1+)F?&PD6",<5S'R"-^ZP3DX,F.30$@2BM65B9NX'(= ), M4J)2R;(PF5F ^$ 8"X!A!85T3@$HQ>O:BK__='\Z'3]L==?%L RZVUCW6 #U ML20&CO=.'F)/DM7($W'G9#*Z!Q#(LB8.[YR,'XR.VI^ T5 :HBUA"%Y0P DB M]\FF*-D$4@4!.H-EFWP9D"BE8GC,5@-/>/I@-.ZS>C =/6A^&7P=J^DZ*ZLR M^"(EW]3EW&+S +8O*@V/PQ+@IH" A6+[&HZ'4JZ\B\O:NEIB%38;F'I6.T@ MP\:V1/X53G(!@).\)4$\B@3_)#C543)SV PI;%9K3B8UV;O>UT[S;FR0E?BS M1K#,5WB^CY-]=/2D:(0@\;8RBN.;62XE5@FG%X6>ZX1,H7-@1D6Q31:9MZCD M.E3ZNACAA=Z#V'^+Y!,%*BX^HS J"Q[9"LK>:(?M:6U)B:^)1 G"J7*)U3.L MF%'/,!)G:6EV(WPSR^GRPD71?#SB#)@<1%F11LH X*PKX&J1* M8]G6U!Z(R7CX'Q"!+2"FM6,D/FMTP)5^NJAF&!BLT3$64; JD?7DIPS= M.!-*M4L,PFHEU!R)7OG0N%5^!=9"3)6@,M/&?:S3A0?AD<$C"JU07543HHT? M8);6!\"CE%JF$)[SNO "--6-PZU3 *;F&'F01IA%6G.Q6B 68;#AU@' M(=B.%"TLIO,.?U=DE+>4?AKT.Z8#(@;!M@@8IR%-5X1P\"IQJU$A,^_PT,K< M+G7B7=+$+_'P=82\'I+5S#*]\%'HG1C*,<--%@4Q80V^)P:L+'G?X]?'DN!@ M)"ZN7[RYNA9O80-9*F1^XL39\_#S\$*Z!^(YQ!\J FXXRB\D.A$JOBB IY.3 M <5G#QE1TRKJT18Z62^1IO1_2;$-FXF[9(" _D'$EE] \I^]WCL4(+*:LF8^ MUYGFX+W;H]=2V>PF^_FWWM0A.TJ4)S@.H42ELT(X5=X0$E,N_%0Q">2) DB3 MU2@"*K*!K$-KLJQSY FX*$F_U-PLQ%9?Q%9O:\1JY$N0!PGU$5V0 ^()2R,K MJ=*8L@'22MH%][#>1P^\CVB2]L6@)4'@T_3#7.K#SEZOM7*DQ5S/K'$:C\HU M^%MWU8@JJN!LXW9LC;9O?OH"!2$&#:VE=+RQLSD6 ?H4J5V7'.\(\:ZQN',\ M&4<=+VRP7[F*ZY2DI@19@[\^"RG@_9P1*@+\V0(D5Y/&PO>V9<$?!A_V >DV M >+8WI(,OSZ].&LB>! P VQE[ALR+G^*>T7NI]#M3#:]U1:K[:Y[1_$;/R.F MK!V1#[]1FY&8IA%I.E[4)B O1RYEUS#6E,)6+F2^0#@CQH6L*[@V3U369B@6 M#/&]4[!M=9M4XQ12N0&1F2Y,*='JJUZL1EE)NYU./F24%O!JR#J6E,>*>4WH M#B5*,A^HSU0E*3@S:MUS+3<+_;I)N"R3- BD7KPAS>LYBB]WTH-=K;(H 7''>'ZU@9I3ZY12\"M9O!7F,ZV5_^VKM3;HH/2 MV]2+I:D]!-X:FZ5Q:>VP=W+OH1^J[ UBM,6O1K<&O^*N%@F&QT4X!6Q;EYXK M]D$-B516PPI8C>EX'(-%"P']II@WEE63*G-M'49::3\HMIDLJ4, C\Z-WG&T M^-WH#:&@\4GYU-8+3$'H&3171G:^-^-E;4VI@&47<)1V%)'>Y0G7[C8'8G-# M2PF;N&KHEC[?9#?SA%"BQ]0&H)4A1(J&BD96Q)%)^,?3\=]X@O>^/O;?/,-> MA]1Z)_VC=C[+6%88RF"&_4OY^D0@V0RR\VW"AWR_WO< !53NW#ON3B_\><;Q MR>BD_65C9-U_'MYR>#)Y<#2:]KE-IN/1Z39V7SA]Q]P>AG."QB!O %.'/%3:+:P'H M[CJA+;UD,&H4?V\G3[?TDTV&H4?$ODVPPPOQ?SWN!)BWSTT7GN&L=V M&-&($DPW>I:ISS9[D].U9F]'0=RK[>,YL9M\0W]*\Z77LD-UV5G^JWK%WRDR M_/#(6 DV@%8O0FYC,I7MZ$I531&A0T!=;C&X)>EJZ.IK&_0]V1H;@ M.D70AB>(].0#Q<&VEGG#_%T0? GX'M\_^1'@NR']_T'XOQ6$OP?2;K0-0 FL MN%%^$J'%G\X)U\D,V\3.+<*Q,YT"4+(E[?L"=*HL,SZC]J_84"Z!4]#N%0^# M['$4 72^/+$VXK^G(7<'O/Y:9ZO0]VZVMJV!^O'&>;R3:(-%O. +\5%R&M_H M&]/O<<.E>3A)SQ [MCE&B0^*>B=*7YUT5T' MM)%.U69-C:\I&%U$.8Y+57#3E#:81LSWBS92NSGK38VB<*ZVEP#?,U!,MR?# M/;D_EPXCN-2C#XHGF[6-J#O']Z(#A6\+[U_VB@'&15G)#)V8.-?&)5K!N*X- MN N3P]O,[D@\5? I@5049:]D@[M?%5^[F;=I22>X<^27X3LCBD*BEP-3$W)3 M ">^"@E-12NR V65]UKFZ&E+N(U:#T59"*P*K1!:OMI?9I?*5JOX:/SB7$SO MW9\.KRZ?-_&DR=^E5Q7ZYY;KD^B&I1=A\Y_0S9S<_ M*MVF2#=_^_\<\'$[ MU#BD'@;&Z=[;BAI(?HG 7S;,%,)717/]??+PY#B&"'TC$SE'D1R(K,[#9W^D MHOZ*O^Y0*#.WPPVEIC,XA>!]M=YIJI;6"P<%D^\3BSC6;VH ML?7(_W8:ZZDR]3&HXZ'(I[YW((;1YAV,^'4+\UFI&I&\O4$=>=1E5!##WXV# MTHQ>( EOIO+D2U?;J_,5 O/GGJZ>7+U\?XN_+R_EH^AUQHR/IN-[>/\.O2B7TL*]G";\!AN"-M5\ M:QI08HN [56/35MLB>^5_(LPVTS7 =B%<7SNX4?Q@$S;7H@^C-Z(SQ5J);WW M[_S[+/[E^/;7]K\6G/DWZKOE_O\E(#(0H4YD:HZMX]&]DP-_\=A\J4S)[]?/ M3%69G#\N%54[6H#G??C[XYW)!<'I>],A6CAH1;2+(/*VF8>1::HL&8F5 U*FMDI73-+7;V/3*.1 ME=ZH%E$:Q^.H9EP&JX4?6^O50K56<(EK#::M:Z8?KU"HPS)(@J>!&[ZOK!N( M5HN&[7&#]K99:^I% TK):Y2&*PD:=\O@,IE?C9R^5_B3X\$ \V2IUYSJ_ ME\L@=H108&$= J/F'K^@$ Z(:/S38P;#DL[P6'Y"_]7[3KYLF<$O2OS@I:V6 MP32 $G>L%?9&'7[#WI_;Q0$4K;&J[HV)0IY=PMYEE^99:N%5@?03IO0G.!=]=9$CDNW*1NK:9:3G5U=,RVYW!M8 MHX9-Q30N(DNX;C8J>HRK#B/]"<8,OBEI*P/7LL3RI7U$? 92Z1.IJ_0LX :; M$++X M(XS<[@98.3F?SY =#61'Y]#?N"-G,4XS/!&%/RJ$G1)4F30!EFT%@D%K:%#; M"BQ-%ZIN6LM\":F=JP!> ),EE%RT%DN0=')P26H(#0&34).J\?@$XT%H@JO2 M +H$F=.R&O%%T@!MN<5Z2P!NW[^3/^?F75ZX7WHD_<(E%8@01-1< #X49.$9 M=518K5IIS4?X_LSW/207<9:'&4FS+ YS:M.+<1Z'4R_E<18F<.5=/OCZQO(3 MNT=-Q]4+1PW0>6 MNSC2R42!+UK-+4W)*KGLQIBHOW\)?"UW^+_XOLX MI@73?.9\)WGDHS'I@W@N5][#*(P3:K)P[#8DB<-TYC8FG$P')N/K_+MP[MIFJ2?A_8I)V[E M/64>P>LW)N!+@-1_IX[(Z.@"JU'O_35M*)14LMU=-HP.+X'+[@)\5N^>$=^8 MWG/R0>".3.-PD@>@NZNYZUC5^.MPJRQ=KEZLZ#6#VBG0_$Y1\=QG M>_7*%#[1F?ILA2O25-K-&Y68]>O.H%--_*X72T\3IU>O#]_'K3I\84HF*/%&0 M^+=2-RI)B!#8^%[2[-1'TL;FA"G):=12>A-(#1\@-"%^& ROW3B;1:KN+W_%$S5G TKSMX,'R7X M1>4],>IWQ; _'#U";U1+.F)ZHZKX1^*>P6V:Q2+2<2&(=V&RB"-*MM5\"'>=S'6DP M)N96?2]4%FU8S)5)BE21EG)K5F"=92/+Z2R ,Z$< 1W]+@R]@4TTQ A*&5Z* M3WLF,."(V,*F4G7EFYYX>R_3/('RH/R20K5+9U%2@(/OSU"RTZE.I#VL8I:L M3>49AJ&3JB/ NA?2*I$97QY?"3RZ%-\.>-W648O E7,4#R1F:9XBS8/)F'AI MU%Q:L*1S2:&S-D42D_\2*Y4=#ANW)S[A')VME/-\#L&-5PMVF;F)BI*;2.;: M0^(22=B5?)@VX8)KD5\%P;'JG$&"EQSG C(NLG@6M?(3SB7==\?-/T^&P__+#=M.7 MQB:0>QLX?[_EO,=[!B_%=0P-P5XR24BA2A0>MO\/P:M%7@#C%M9R)&-B#<.( M")VAQ=[!,170Y%: 68% MCB7J//'VF, K\.].Q+M:QIIT!V?#WEGK:7_=5V3EB"'FPXE!=S+I M]_KUV]WQL-OO/S;^UOL"9[3L,YMFH Y'9[UI^5LM?N[_&V-S0Z$!/F>^2?6I MG9/&:'P&>_'/ M+J^# >EF.B4U39^CTG%_VAN6OS^JTE\8>LD_7[B!IWIV>D%4*[T:@/1VNBV'EWVC_G=9/NZ'P*WH^ 2>/A10L5 M?PB7MXE\$YL_M?3>JE*>H9 MPSS^CWOC@^]Y?M>WFJD.*18@.SYLD6,"M/)IC)#?-GV$KXCW1:!W@S1;Y2CX:W"';KSL$[4*#\]:\F"&+1X8/^\>\,YG BMA'K3%4L[^H#&["^?D!]EAQP&!#I8J)[DC:?993%'_,(*H@ M#OUX6TRVJV3JJSXXG-F2E%'A6--9P77:[.'^*TK^C@LY(8%.24R9(^R-I3!,*M!0)!: MN4+#(,-)-#?0W M+:!_3U8;7'"I+2,<3KGHVWN3Z8C;FA8Y%$KPR'6Q-.J)XU*"_AQ5(E6_,T&S.(7,\U,@='D "!!K[4"VJ-E+T?'$KZ@-XX"[,B+;QL])&" M@6Z+:*DRQ$1:N*B@QEB\@;5,3B5PR>;MA]N*Q48&YP@HNCR-#B'*P+M&XZT<[]P=R-:I(QF,UVJV M?T'*R)4:R/]5Q MV-+T5LKHXZU9K#MT@?$$[(_4%A;EV!Q=QI^ PQ+FQ'*D! M^@[VO[;R43/?XF65N);&V/\B\9S0NA0?Z9-&\_O8H693NS'TILQ?(,!^_^E( M<"));RQ#-G4&G_)V9)]4�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

-5*_=E9;(:JJ#4G7PYA$- MVC2C);*:&6%I1OB_$Z\]RG><%M[.^;2%<=#3+!*>2%06UF?.WFM,56UU^9E[PW#VMQB[8,:8FM M;LC3^.,U#A0O"6S!$%6S&+GN06"+JNI?ON?YMG^06*KEBJ"(70NC'A1FIRU>H\3]02P,$ M% @ &8)G5S2AR"6M @ O 8 !D !X;"]W;W)K&ULK55-3]M $/TK*Q=55(+8L>,0T<02)*W* 0F1TAZJ'C;.)%ZQ]IK= M<4+^?6?7QC)@$(=>[/V8]_;-&^]XNE?ZWF0 R!YS69B9ER&6Y[YOT@QR;@:J MA()V-DKG'&FJM[XI-?"U ^72#X-@[.=<%%XR=6LW.IFJ"J4HX$8S4^4YUX=+ MD&H_\X;>T\*MV&9H%_QD6O(M+ 'ORAM-,[]E68L<"B-4P31L9M[%\'P>VW@7 M\$O WG3&S&:R4NK>3J[6,R^P@D!"BI:!TVL'"7Q5NU_0)./$Y@J:=R3[9O8P&-I95#E#9@4 MY**HW_RQ\:$#&([> (0-(/PH(&H D4NT5N;26G#DR52K/=,VFMCLP'GCT)2- M*&P5EZAI5Q .DVNN[P'Y2@);0EII@0(,X\6:?7NH!![85;$#@U0W-.R47>RX MD#;ZE#Z@TR4GV )6V,6N#FRN"M14H(I+=LW1[AS8\8+.$=)\(9J[Y8(='WUA M1TP4[%I(214U4Q\I(2O+3QOQE[7X\ WQ2R@'+ I.6!B$40]\_CY\ 2G!APX> M/H?[9&/K9=AZ&3J^Z V^CE4GM2T='SL._;E8&>?/W[Z4ZS-&_6?82WUN2I[" MS*-;:T#OP$L^?QJ.@Z]]!OPGLF=V1*T=T7OLB:L\I;L7F%&950'L %SWY5P3 MC1V1[3N[9#2))P.JZ:Z;S>NP.(Z"P;@->Z9SU.HZ*Z#)MV@83@(^V7'K>SX7=D_%7+9)RE^Y=(X[C'S M=5@\'H6#R0M5?J>WV+Y.#6,K"L,D; @8#,Z(1]>]LIZ@*EV[62FDYN6&&?U> M0-L VM\HA4\3V\':'U;R#U!+ P04 " 9@F=7$-BJR\$" 6" &0 M 'AL+W=OI\3@U?++@J?\FVMG4L$A=*B[0&8P0IRZHGO:_KT (@3S? JP'>4T#P#,"O M ?Y+/00U('BIA],:4*9N5[F7A8NHIN%(BBV1QAK9S**L?HG&>K',Z&2N);YE MB-/A)96WH.F" YE#7$BF&2A"LX3,[@JF'\A%M@&E41E:D1/R#95[DZ$@.?L- M"?F,0E2D]U4H!>H=Z45(Q3BN3LC-/"*]HW?DB+",7#+.419J9&N,V7BVXSJ^ M216?]TQ\/KD4F5XK,LL22#KPT6'\AP-X&VO5%,S;%6SB'22<0]XGOG-,/,?S M.^*9OASN=:7S?]YG_^Q]KQA^HQZ_Y/.?X6N)XYA$L-!MY;3T]/-\H;3$IO"K M2P&5CZ#;AVF40Y73&,86=D(%<@-6^/:-.W ^=I7_-@&)9V9-9OP9-!'R6S:M?[;R!WTS_:-H@ZF ML[Z[;S3K,'(#OV5696VW&ET* MX="K9M0C?34QL5&N3+/CL$173O\,^["LIE"UT2(OV^Q":&S:Y7*-@QND,<#W M2R'T;F,<-'\%PC]02P,$% @ &8)G5[%S?O>L!@ Y2\ !D !X;"]W M;W)K&ULO5I=;]LV%/TKA%<,+5#;(FGY(TL,)):& M!5C7H&FWAV$/M$S'6B71D^BX_?>C/F*))DU+#9,^-+)\>'7O/18O]RS] MFFTHY>!;'"7956_#^?9B.,R"#8U)-F!;FHAOUBR-"14?]G>I>+3\("R"F.:9"%+0$K75[UK>.'C43Z@L/@SI/NL<0UR5Y:, M?DZ^(AK1@.<01/QYI L:13F26,=_%6CO,&<^L'G]A/YKX;QP9DDR MNF#17^&*;ZYZTQY8T3791?P3V_]&*X?<'"]@45;\#_:5K=,#P2[C+*X&BQ7$ M85+^)=\J(AH#!(Y^ *H&H.,!HQ,#<#4 MYUA5 T8M9W!K084K@]+WPOB/,+) M_#)E>Y#FU@(MORC8+T8+OL(D#Y1[GHIO0S&.SZ^#8!?O(L+I"GSD&YJ"!8M% MR&WR6'BDX#8)6$S!V]]9EKT#;SW*21B)JS[X@3<@3,"',(K$OF>7 M0RX6E4,/@VH!-^4"T(D%8/"!)7R3 3]9T95FO&<>/S.,'PHR#HR@)T9ND!'P MGFX' #OO 7(0UJQGT7XXTKGSO-G]'YY=(@,?P@,7>/A4>'Q-D M&5' &;@C*4WX>_"'R&-L#3Z3;^#O3RR*@'AT]R1=_:.+@G*>D7Z>/!U>9%L2 MT*N>"+Z,IH^T-__Y)SAV?M%M@4TPSR:8;PE,VJS18;-&)O3Y#7T(DR1,'D3J MC$@24-T^E!#C B*O(H]SZ(XFSD!$RV.38HT=G&$\<&4[3V.'9Q -)K*=7]I- MFG8.=)R#E>2Q>_#8-7I<9JQ REAAE;&B(F,MJ2BF5)2T(")9%J[#@/!3B 1PZH1G.+!5,_P^,#PV,CP=KC8R1?-9K"QF,O>3\]>#\U>B^*^)G\-56C?.R* M?'/LI\8..V@V&!^YVA+//X\G.3P[.#P[O]TZ/XW#NCX=-L$\FV"^)3")>^C4 MS:_S2NU--9&E_;**YEE%\VVAR5O6T"OP^4U.A2$GL)F2(S1F[D3I<#16CI(> M-$:P63)D;U'M+7JI:E AGRD'&BM-/=!8:0J"QNIT18"U!('&IKE%3:@ 7&EY MQXYB97$SL=>SYK]CK\_#^IU@90+JMAZ:^WJ1=VCXD(#%+A69*?@./JU4($NJ]52:S*$*MHGE4TWQ:: MO&6ULH%F:=.NDEA5*5;1O I-RD_(/4Y0.IF"3[6ML)8IT*Q3[$IO\V2=:;:) MYD%5Z,P4\:TQZH_0*?4-:ST$S8+H!?6W>>;.G-M$\RJT9F@[QXR;3&2V:S$& M6ZBQ'V33JF"SBN95:&6A<[,'0]&1UU; M.S3_+)KL;JU/D%F??!0MV2,)H[P'Z(LZW[\GHAGPZ)*#>QKLTI"'5)L"S;A= M \@JFF<5S;>%)N]0K:D0>J56#1G%6^C6CB?E?634K&CY1TG"M'?$9[6BU43-/UIED MJX(2JZ_+,%2*G,8*X>91)9GG6@%B\UNU%VS4S#-W)MVJ),2:MWBZT-:8&0ZV MX,990K.*>T;'9D;N3*O=\X.J:M.0JAI!-#W)::WML%G;G6_8L'I"3WW4%AHK MZ$Z5AJT5F'\6K'1VV#BV'-/TH3@OGHG0$ ]G>43U4'SK;%H>DEXYS%Q>6& MDA5-

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end XML 73 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 74 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 75 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 317 255 1 false 77 0 false 6 false false R1.htm 0000001 - Document - Cover Sheet http://www.vrtx.com/role/Cover Cover Cover 1 false false R2.htm 0000002 - Statement - Condensed Consolidated Statements of Income Sheet http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome Condensed Consolidated Statements of Income Statements 2 false false R3.htm 0000003 - Statement - Condensed Consolidated Statements of Comprehensive Income Sheet http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncome Condensed Consolidated Statements of Comprehensive Income Statements 3 false false R4.htm 0000004 - Statement - Condensed Consolidated Statements of Comprehensive Income (Parenthetical) Sheet http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParenthetical Condensed Consolidated Statements of Comprehensive Income (Parenthetical) Statements 4 false false R5.htm 0000005 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 5 false false R6.htm 0000006 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.vrtx.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 6 false false R7.htm 0000007 - Statement - Condensed Consolidated Statements of Shareholders' Equity Sheet http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity Condensed Consolidated Statements of Shareholders' Equity Statements 7 false false R8.htm 0000008 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows Condensed Consolidated Statements of Cash Flows Statements 8 false false R9.htm 0000009 - Disclosure - Basis of Presentation and Accounting Policies Sheet http://www.vrtx.com/role/BasisofPresentationandAccountingPolicies Basis of Presentation and Accounting Policies Notes 9 false false R10.htm 0000010 - Disclosure - Revenue Recognition Sheet http://www.vrtx.com/role/RevenueRecognition Revenue Recognition Notes 10 false false R11.htm 0000011 - Disclosure - Acquired In-Process Research and Development and Other Arrangements Sheet http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangements Acquired In-Process Research and Development and Other Arrangements Notes 11 false false R12.htm 0000012 - Disclosure - Earnings Per Share Sheet http://www.vrtx.com/role/EarningsPerShare Earnings Per Share Notes 12 false false R13.htm 0000013 - Disclosure - Fair Value Measurements Sheet http://www.vrtx.com/role/FairValueMeasurements Fair Value Measurements Notes 13 false false R14.htm 0000014 - Disclosure - Marketable Securities and Equity Investments Sheet http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestments Marketable Securities and Equity Investments Notes 14 false false R15.htm 0000015 - Disclosure - Accumulated Other Comprehensive Income (Loss) Sheet http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLoss Accumulated Other Comprehensive Income (Loss) Notes 15 false false R16.htm 0000016 - Disclosure - Hedging Sheet http://www.vrtx.com/role/Hedging Hedging Notes 16 false false R17.htm 0000017 - Disclosure - Inventories Sheet http://www.vrtx.com/role/Inventories Inventories Notes 17 false false R18.htm 0000018 - Disclosure - Stock-based Compensation Expense and Share Repurchase Programs Sheet http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchasePrograms Stock-based Compensation Expense and Share Repurchase Programs Notes 18 false false R19.htm 0000019 - Disclosure - Income Taxes Sheet http://www.vrtx.com/role/IncomeTaxes Income Taxes Notes 19 false false R20.htm 0000020 - Disclosure - Commitments and Contingencies Sheet http://www.vrtx.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 20 false false R21.htm 0000021 - Disclosure - Additional Cash Flow Information Sheet http://www.vrtx.com/role/AdditionalCashFlowInformation Additional Cash Flow Information Notes 21 false false R22.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 22 false false R23.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 23 false false R24.htm 9954471 - Disclosure - Basis of Presentation and Accounting Policies (Policies) Sheet http://www.vrtx.com/role/BasisofPresentationandAccountingPoliciesPolicies Basis of Presentation and Accounting Policies (Policies) Policies http://www.vrtx.com/role/BasisofPresentationandAccountingPolicies 24 false false R25.htm 9954472 - Disclosure - Revenue Recognition (Tables) Sheet http://www.vrtx.com/role/RevenueRecognitionTables Revenue Recognition (Tables) Tables http://www.vrtx.com/role/RevenueRecognition 25 false false R26.htm 9954473 - Disclosure - Earnings Per Share (Tables) Sheet http://www.vrtx.com/role/EarningsPerShareTables Earnings Per Share (Tables) Tables http://www.vrtx.com/role/EarningsPerShare 26 false false R27.htm 9954474 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.vrtx.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.vrtx.com/role/FairValueMeasurements 27 false false R28.htm 9954475 - Disclosure - Marketable Securities and Equity Investments (Tables) Sheet http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsTables Marketable Securities and Equity Investments (Tables) Tables http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestments 28 false false R29.htm 9954476 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables) Sheet http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossTables Accumulated Other Comprehensive Income (Loss) (Tables) Tables http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLoss 29 false false R30.htm 9954477 - Disclosure - Hedging (Tables) Sheet http://www.vrtx.com/role/HedgingTables Hedging (Tables) Tables http://www.vrtx.com/role/Hedging 30 false false R31.htm 9954478 - Disclosure - Inventories (Tables) Sheet http://www.vrtx.com/role/InventoriesTables Inventories (Tables) Tables http://www.vrtx.com/role/Inventories 31 false false R32.htm 9954479 - Disclosure - Stock-based Compensation Expense and Share Repurchase Programs (Tables) Sheet http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsTables Stock-based Compensation Expense and Share Repurchase Programs (Tables) Tables http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchasePrograms 32 false false R33.htm 9954480 - Disclosure - Income Taxes (Tables) Sheet http://www.vrtx.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://www.vrtx.com/role/IncomeTaxes 33 false false R34.htm 9954481 - Disclosure - Additional Cash Flow Information (Tables) Sheet http://www.vrtx.com/role/AdditionalCashFlowInformationTables Additional Cash Flow Information (Tables) Tables http://www.vrtx.com/role/AdditionalCashFlowInformation 34 false false R35.htm 9954482 - Disclosure - Basis of Presentation and Accounting Policies (Details) Sheet http://www.vrtx.com/role/BasisofPresentationandAccountingPoliciesDetails Basis of Presentation and Accounting Policies (Details) Details http://www.vrtx.com/role/BasisofPresentationandAccountingPoliciesPolicies 35 false false R36.htm 9954483 - Disclosure - Revenue Recognition - Disaggregation of Revenue (Details) Sheet http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails Revenue Recognition - Disaggregation of Revenue (Details) Details 36 false false R37.htm 9954484 - Disclosure - Revenue Recognition - Additional Information (Details) Sheet http://www.vrtx.com/role/RevenueRecognitionAdditionalInformationDetails Revenue Recognition - Additional Information (Details) Details 37 false false R38.htm 9954485 - Disclosure - Acquired In-Process Research and Development and Other Arrangements - Additional Information (Details) Sheet http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsAdditionalInformationDetails Acquired In-Process Research and Development and Other Arrangements - Additional Information (Details) Details 38 false false R39.htm 9954486 - Disclosure - Earnings Per Share - Schedule of Computation (Details) Sheet http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails Earnings Per Share - Schedule of Computation (Details) Details 39 false false R40.htm 9954487 - Disclosure - Earnings Per Share - Anti-dilutive Securities (Details) Sheet http://www.vrtx.com/role/EarningsPerShareAntidilutiveSecuritiesDetails Earnings Per Share - Anti-dilutive Securities (Details) Details 40 false false R41.htm 9954488 - Disclosure - Fair Value Measurements - Additional Information (Details) Sheet http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails Fair Value Measurements - Additional Information (Details) Details 41 false false R42.htm 9954489 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Subject to Fair Value Measurements (Details) Sheet http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails Fair Value Measurements - Financial Assets and Liabilities Subject to Fair Value Measurements (Details) Details 42 false false R43.htm 9954490 - Disclosure - Fair Value Measurements - Fair Value of Contingent Consideration Liabilities (Details) Sheet http://www.vrtx.com/role/FairValueMeasurementsFairValueofContingentConsiderationLiabilitiesDetails Fair Value Measurements - Fair Value of Contingent Consideration Liabilities (Details) Details 43 false false R44.htm 9954491 - Disclosure - Marketable Securities and Equity Investments - Additional Information (Details) Sheet http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails Marketable Securities and Equity Investments - Additional Information (Details) Details 44 false false R45.htm 9954492 - Disclosure - Marketable Securities and Equity Investments - Summary of Cash Equivalents and Marketable Securities (Details) Sheet http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails Marketable Securities and Equity Investments - Summary of Cash Equivalents and Marketable Securities (Details) Details 45 false false R46.htm 9954493 - Disclosure - Marketable Securities and Equity Investments - Available-for-Sale Debt Securities at Fair Value (Details) Sheet http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesatFairValueDetails Marketable Securities and Equity Investments - Available-for-Sale Debt Securities at Fair Value (Details) Details 46 false false R47.htm 9954494 - Disclosure - Marketable Securities and Equity Investments - Available-for-Sale Debt Securities by Contractual Maturity (Details) Sheet http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails Marketable Securities and Equity Investments - Available-for-Sale Debt Securities by Contractual Maturity (Details) Details 47 false false R48.htm 9954495 - Disclosure - Marketable Securities and Equity Investments - Net Unrealized Gains (Losses) (Details) Sheet http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsNetUnrealizedGainsLossesDetails Marketable Securities and Equity Investments - Net Unrealized Gains (Losses) (Details) Details 48 false false R49.htm 9954496 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details) Sheet http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails Accumulated Other Comprehensive Income (Loss) (Details) Details http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossTables 49 false false R50.htm 9954497 - Disclosure - Hedging - Additional Information (Details) Sheet http://www.vrtx.com/role/HedgingAdditionalInformationDetails Hedging - Additional Information (Details) Details 50 false false R51.htm 9954498 - Disclosure - Hedging - Notional Amount (Details) Sheet http://www.vrtx.com/role/HedgingNotionalAmountDetails Hedging - Notional Amount (Details) Details 51 false false R52.htm 9954499 - Disclosure - Hedging - Cash Flow Hedging Instruments (Details) Sheet http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails Hedging - Cash Flow Hedging Instruments (Details) Details 52 false false R53.htm 9954500 - Disclosure - Hedging - Derivative Fair Value (Details) Sheet http://www.vrtx.com/role/HedgingDerivativeFairValueDetails Hedging - Derivative Fair Value (Details) Details 53 false false R54.htm 9954501 - Disclosure - Hedging - Offsetting Derivatives (Details) Sheet http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails Hedging - Offsetting Derivatives (Details) Details 54 false false R55.htm 9954502 - Disclosure - Inventories (Details) Sheet http://www.vrtx.com/role/InventoriesDetails Inventories (Details) Details http://www.vrtx.com/role/InventoriesTables 55 false false R56.htm 9954503 - Disclosure - Stock-based Compensation Expense and Share Repurchase Programs - Stock-based Compensation Expense (Details) Sheet http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails Stock-based Compensation Expense and Share Repurchase Programs - Stock-based Compensation Expense (Details) Details 56 false false R57.htm 9954504 - Disclosure - Stock-based Compensation Expense and Share Repurchase Programs - Additional Information (Details) Sheet http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsAdditionalInformationDetails Stock-based Compensation Expense and Share Repurchase Programs - Additional Information (Details) Details 57 false false R58.htm 9954505 - Disclosure - Income Taxes (Details) Sheet http://www.vrtx.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.vrtx.com/role/IncomeTaxesTables 58 false false R59.htm 9954506 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.vrtx.com/role/CommitmentsandContingenciesDetails Commitments and Contingencies (Details) Details http://www.vrtx.com/role/CommitmentsandContingencies 59 false false R60.htm 9954507 - Disclosure - Additional Cash Flow Information (Details) Sheet http://www.vrtx.com/role/AdditionalCashFlowInformationDetails Additional Cash Flow Information (Details) Details http://www.vrtx.com/role/AdditionalCashFlowInformationTables 60 false false All Reports Book All Reports vrtx-20230930.htm vrtx-20230930.xsd vrtx-20230930_cal.xml vrtx-20230930_def.xml vrtx-20230930_lab.xml vrtx-20230930_pre.xml vrtx-20230930_g1.gif http://fasb.org/srt/2023 http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 http://xbrl.sec.gov/ecd/2023 true true JSON 78 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "vrtx-20230930.htm": { "nsprefix": "vrtx", "nsuri": "http://www.vrtx.com/20230930", "dts": { "inline": { "local": [ "vrtx-20230930.htm" ] }, "schema": { "local": [ "vrtx-20230930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" ] }, "calculationLink": { "local": [ "vrtx-20230930_cal.xml" ] }, "definitionLink": { "local": [ "vrtx-20230930_def.xml" ] }, "labelLink": { "local": [ "vrtx-20230930_lab.xml" ] }, "presentationLink": { "local": [ "vrtx-20230930_pre.xml" ] } }, "keyStandard": 237, "keyCustom": 18, "axisStandard": 22, "axisCustom": 1, "memberStandard": 52, "memberCustom": 23, "hidden": { "total": 12, "http://xbrl.sec.gov/ecd/2023": 5, "http://xbrl.sec.gov/dei/2023": 6, "http://fasb.org/us-gaap/2023": 1 }, "contextCount": 317, "entityCount": 1, "segmentCount": 77, "elementCount": 521, "unitCount": 6, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 940, "http://xbrl.sec.gov/dei/2023": 29, "http://xbrl.sec.gov/ecd/2023": 34, "http://fasb.org/srt/2023": 1 }, "report": { "R1": { "role": "http://www.vrtx.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome", "longName": "0000002 - Statement - Condensed Consolidated Statements of Income", "shortName": "Condensed Consolidated Statements of Income", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "unique": true } }, "R3": { "role": "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncome", "longName": "0000003 - Statement - Condensed Consolidated Statements of Comprehensive Income", "shortName": "Condensed Consolidated Statements of Comprehensive Income", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "unique": true } }, "R4": { "role": "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParenthetical", "longName": "0000004 - Statement - Condensed Consolidated Statements of Comprehensive Income (Parenthetical)", "shortName": "Condensed Consolidated Statements of Comprehensive Income (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true } }, "R5": { "role": "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets", "longName": "0000005 - Statement - Condensed Consolidated Balance Sheets", "shortName": "Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "srt:ScheduleOfCondensedCashFlowStatementTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:MarketableSecuritiesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "unique": true } }, "R6": { "role": "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "longName": "0000006 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity", "longName": "0000007 - Statement - Condensed Consolidated Statements of Shareholders' Equity", "shortName": "Condensed Consolidated Statements of Shareholders' Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-35", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-35", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows", "longName": "0000008 - Statement - Condensed Consolidated Statements of Cash Flows", "shortName": "Condensed Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "unique": true } }, "R9": { "role": "http://www.vrtx.com/role/BasisofPresentationandAccountingPolicies", "longName": "0000009 - Disclosure - Basis of Presentation and Accounting Policies", "shortName": "Basis of Presentation and Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.vrtx.com/role/RevenueRecognition", "longName": "0000010 - Disclosure - Revenue Recognition", "shortName": "Revenue Recognition", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangements", "longName": "0000011 - Disclosure - Acquired In-Process Research and Development and Other Arrangements", "shortName": "Acquired In-Process Research and Development and Other Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.vrtx.com/role/EarningsPerShare", "longName": "0000012 - Disclosure - Earnings Per Share", "shortName": "Earnings Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.vrtx.com/role/FairValueMeasurements", "longName": "0000013 - Disclosure - Fair Value Measurements", "shortName": "Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestments", "longName": "0000014 - Disclosure - Marketable Securities and Equity Investments", "shortName": "Marketable Securities and Equity Investments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLoss", "longName": "0000015 - Disclosure - Accumulated Other Comprehensive Income (Loss)", "shortName": "Accumulated Other Comprehensive Income (Loss)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.vrtx.com/role/Hedging", "longName": "0000016 - Disclosure - Hedging", "shortName": "Hedging", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.vrtx.com/role/Inventories", "longName": "0000017 - Disclosure - Inventories", "shortName": "Inventories", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchasePrograms", "longName": "0000018 - Disclosure - Stock-based Compensation Expense and Share Repurchase Programs", "shortName": "Stock-based Compensation Expense and Share Repurchase Programs", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.vrtx.com/role/IncomeTaxes", "longName": "0000019 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.vrtx.com/role/CommitmentsandContingencies", "longName": "0000020 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.vrtx.com/role/AdditionalCashFlowInformation", "longName": "0000021 - Disclosure - Additional Cash Flow Information", "shortName": "Additional Cash Flow Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true } }, "R22": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true }, "uniqueAnchor": null }, "R23": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.vrtx.com/role/BasisofPresentationandAccountingPoliciesPolicies", "longName": "9954471 - Disclosure - Basis of Presentation and Accounting Policies (Policies)", "shortName": "Basis of Presentation and Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.vrtx.com/role/RevenueRecognitionTables", "longName": "9954472 - Disclosure - Revenue Recognition (Tables)", "shortName": "Revenue Recognition (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.vrtx.com/role/EarningsPerShareTables", "longName": "9954473 - Disclosure - Earnings Per Share (Tables)", "shortName": "Earnings Per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.vrtx.com/role/FairValueMeasurementsTables", "longName": "9954474 - Disclosure - Fair Value Measurements (Tables)", "shortName": "Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsTables", "longName": "9954475 - Disclosure - Marketable Securities and Equity Investments (Tables)", "shortName": "Marketable Securities and Equity Investments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossTables", "longName": "9954476 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)", "shortName": "Accumulated Other Comprehensive Income (Loss) (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.vrtx.com/role/HedgingTables", "longName": "9954477 - Disclosure - Hedging (Tables)", "shortName": "Hedging (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.vrtx.com/role/InventoriesTables", "longName": "9954478 - Disclosure - Inventories (Tables)", "shortName": "Inventories (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsTables", "longName": "9954479 - Disclosure - Stock-based Compensation Expense and Share Repurchase Programs (Tables)", "shortName": "Stock-based Compensation Expense and Share Repurchase Programs (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.vrtx.com/role/IncomeTaxesTables", "longName": "9954480 - Disclosure - Income Taxes (Tables)", "shortName": "Income Taxes (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.vrtx.com/role/AdditionalCashFlowInformationTables", "longName": "9954481 - Disclosure - Additional Cash Flow Information (Tables)", "shortName": "Additional Cash Flow Information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "srt:ScheduleOfCondensedCashFlowStatementTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "srt:ScheduleOfCondensedCashFlowStatementTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.vrtx.com/role/BasisofPresentationandAccountingPoliciesDetails", "longName": "9954482 - Disclosure - Basis of Presentation and Accounting Policies (Details)", "shortName": "Basis of Presentation and Accounting Policies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails", "longName": "9954483 - Disclosure - Revenue Recognition - Disaggregation of Revenue (Details)", "shortName": "Revenue Recognition - Disaggregation of Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-68", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "unique": true } }, "R37": { "role": "http://www.vrtx.com/role/RevenueRecognitionAdditionalInformationDetails", "longName": "9954484 - Disclosure - Revenue Recognition - Additional Information (Details)", "shortName": "Revenue Recognition - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:ContractWithCustomerLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:ContractWithCustomerLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsAdditionalInformationDetails", "longName": "9954485 - Disclosure - Acquired In-Process Research and Development and Other Arrangements - Additional Information (Details)", "shortName": "Acquired In-Process Research and Development and Other Arrangements - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-97", "name": "us-gaap:AssetAcquisitionConsiderationTransferred", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "unique": true } }, "R39": { "role": "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails", "longName": "9954486 - Disclosure - Earnings Per Share - Schedule of Computation (Details)", "shortName": "Earnings Per Share - Schedule of Computation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "unique": true } }, "R40": { "role": "http://www.vrtx.com/role/EarningsPerShareAntidilutiveSecuritiesDetails", "longName": "9954487 - Disclosure - Earnings Per Share - Anti-dilutive Securities (Details)", "shortName": "Earnings Per Share - Anti-dilutive Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-107", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-107", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "longName": "9954488 - Disclosure - Fair Value Measurements - Additional Information (Details)", "shortName": "Fair Value Measurements - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:Cash", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": [ "span", "div", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-196", "name": "vrtx:BusinessCombinationRemainingMilestonePayment", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "unique": true } }, "R42": { "role": "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails", "longName": "9954489 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Subject to Fair Value Measurements (Details)", "shortName": "Fair Value Measurements - Financial Assets and Liabilities Subject to Fair Value Measurements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-187", "name": "us-gaap:DerivativeAssetsCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-187", "name": "us-gaap:DerivativeAssetsCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.vrtx.com/role/FairValueMeasurementsFairValueofContingentConsiderationLiabilitiesDetails", "longName": "9954490 - Disclosure - Fair Value Measurements - Fair Value of Contingent Consideration Liabilities (Details)", "shortName": "Fair Value Measurements - Fair Value of Contingent Consideration Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails", "longName": "9954491 - Disclosure - Marketable Securities and Equity Investments - Additional Information (Details)", "shortName": "Marketable Securities and Equity Investments - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:Cash", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": [ "span", "div", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "unique": true } }, "R45": { "role": "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails", "longName": "9954492 - Disclosure - Marketable Securities and Equity Investments - Summary of Cash Equivalents and Marketable Securities (Details)", "shortName": "Marketable Securities and Equity Investments - Summary of Cash Equivalents and Marketable Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-6", "name": "vrtx:CashEquivalentsAndDebtSecuritiesAvailableForSale", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "vrtx:CashEquivalentsAndDebtSecuritiesAvailableForSale", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesatFairValueDetails", "longName": "9954493 - Disclosure - Marketable Securities and Equity Investments - Available-for-Sale Debt Securities at Fair Value (Details)", "shortName": "Marketable Securities and Equity Investments - Available-for-Sale Debt Securities at Fair Value (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-220", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "unique": true } }, "R47": { "role": "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails", "longName": "9954494 - Disclosure - Marketable Securities and Equity Investments - Available-for-Sale Debt Securities by Contractual Maturity (Details)", "shortName": "Marketable Securities and Equity Investments - Available-for-Sale Debt Securities by Contractual Maturity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsNetUnrealizedGainsLossesDetails", "longName": "9954495 - Disclosure - Marketable Securities and Equity Investments - Net Unrealized Gains (Losses) (Details)", "shortName": "Marketable Securities and Equity Investments - Net Unrealized Gains (Losses) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:UnrealizedGainLossOnInvestments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:UnrealizedGainLossOnInvestments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "longName": "9954496 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)", "shortName": "Accumulated Other Comprehensive Income (Loss) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-26", "name": "us-gaap:StockholdersEquity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "unique": true } }, "R50": { "role": "http://www.vrtx.com/role/HedgingAdditionalInformationDetails", "longName": "9954497 - Disclosure - Hedging - Additional Information (Details)", "shortName": "Hedging - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-262", "name": "us-gaap:DerivativeTermOfContract", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-262", "name": "us-gaap:DerivativeTermOfContract", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "longName": "9954498 - Disclosure - Hedging - Notional Amount (Details)", "shortName": "Hedging - Notional Amount (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-260", "name": "us-gaap:DerivativeNotionalAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-260", "name": "us-gaap:DerivativeNotionalAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails", "longName": "9954499 - Disclosure - Hedging - Cash Flow Hedging Instruments (Details)", "shortName": "Hedging - Cash Flow Hedging Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-264", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "unique": true } }, "R53": { "role": "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "longName": "9954500 - Disclosure - Hedging - Derivative Fair Value (Details)", "shortName": "Hedging - Derivative Fair Value (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-260", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-272", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "unique": true } }, "R54": { "role": "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails", "longName": "9954501 - Disclosure - Hedging - Offsetting Derivatives (Details)", "shortName": "Hedging - Offsetting Derivatives (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-260", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-260", "name": "us-gaap:DerivativeAssetFairValueGrossLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "unique": true } }, "R55": { "role": "http://www.vrtx.com/role/InventoriesDetails", "longName": "9954502 - Disclosure - Inventories (Details)", "shortName": "Inventories (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails", "longName": "9954503 - Disclosure - Stock-based Compensation Expense and Share Repurchase Programs - Stock-based Compensation Expense (Details)", "shortName": "Stock-based Compensation Expense and Share Repurchase Programs - Stock-based Compensation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsAdditionalInformationDetails", "longName": "9954504 - Disclosure - Stock-based Compensation Expense and Share Repurchase Programs - Additional Information (Details)", "shortName": "Stock-based Compensation Expense and Share Repurchase Programs - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-300", "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-300", "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.vrtx.com/role/IncomeTaxesDetails", "longName": "9954505 - Disclosure - Income Taxes (Details)", "shortName": "Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "unique": true } }, "R59": { "role": "http://www.vrtx.com/role/CommitmentsandContingenciesDetails", "longName": "9954506 - Disclosure - Commitments and Contingencies (Details)", "shortName": "Commitments and Contingencies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-6", "name": "vrtx:IndemnificationClaims", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "vrtx:IndemnificationClaims", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.vrtx.com/role/AdditionalCashFlowInformationDetails", "longName": "9954507 - Disclosure - Additional Cash Flow Information (Details)", "shortName": "Additional Cash Flow Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "srt:ScheduleOfCondensedCashFlowStatementTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-21", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "srt:ScheduleOfCondensedCashFlowStatementTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20230930.htm", "unique": true } } }, "tag": { "us-gaap_EquitySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesMember", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate equity securities", "label": "Equity Securities [Member]", "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants." } } }, "auth_ref": [ "r44", "r654", "r655", "r656", "r818" ] }, "vrtx_CharlesFWagnerJrMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vrtx.com/20230930", "localname": "CharlesFWagnerJrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Charles F. Wagner, Jr. [Member]", "documentation": "Charles F. Wager, Jr. [Member]" } } }, "auth_ref": [] }, "us-gaap_DerivativeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLineItems", "presentation": [ "http://www.vrtx.com/role/HedgingAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Line Items]", "label": "Derivative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r405" ] }, "vrtx_CatalystBiosciencesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vrtx.com/20230930", "localname": "CatalystBiosciencesMember", "presentation": [ "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Catalyst Biosciences", "label": "Catalyst Biosciences [Member]", "documentation": "Catalyst Biosciences" } } }, "auth_ref": [] }, "us-gaap_DerivativeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeTable", "presentation": [ "http://www.vrtx.com/role/HedgingAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Table]", "label": "Derivative [Table]", "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item." } } }, "auth_ref": [ "r14", "r52", "r53", "r55", "r57", "r60", "r64", "r66", "r67", "r69", "r405" ] }, "us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OciBeforeReclassificationsNetOfTaxAttributableToParent", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss) before reclassifications", "label": "OCI, before Reclassifications, Net of Tax, Attributable to Parent", "documentation": "Amount after tax, before reclassification adjustments, of other comprehensive income (loss), attributable to parent." } } }, "auth_ref": [ "r21", "r33" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par value (in dollars per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r74", "r305" ] }, "vrtx_DebtandEquitySecuritiesUnrealizedLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.vrtx.com/20230930", "localname": "DebtandEquitySecuritiesUnrealizedLoss", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails_1": { "parentTag": "vrtx_DebtandEquitySecuritiesCost", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Gross Unrealized Losses", "label": "Debt and Equity Securities, Unrealized Loss", "documentation": "Debt and Equity Securities, Unrealized Loss" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective tax rate", "label": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r377" ] }, "us-gaap_StockRepurchasedDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchasedDuringPeriodValue", "crdr": "debit", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity", "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repurchase of common stock", "verboseLabel": "Value of shares repurchased", "label": "Stock Repurchased During Period, Value", "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": [ "r13", "r74", "r75", "r106", "r506", "r567", "r593", "r658" ] }, "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Amounts reclassified from accumulated other comprehensive income (loss)", "label": "Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent", "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent." } } }, "auth_ref": [ "r21", "r33" ] }, "vrtx_ContingentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.vrtx.com/20230930", "localname": "ContingentLiabilities", "crdr": "credit", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent liabilities", "label": "Contingent Liabilities", "documentation": "Contingent Liabilities" } } }, "auth_ref": [] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r303", "r323", "r324", "r325", "r326", "r327", "r328", "r411", "r435", "r436", "r437", "r627", "r628", "r637", "r638", "r639" ] }, "vrtx_CollaborativeArrangementAllocationOfNetProfitsAndLossesPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.vrtx.com/20230930", "localname": "CollaborativeArrangementAllocationOfNetProfitsAndLossesPercent", "presentation": [ "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Allocation of net profits and net losses, percent", "label": "Collaborative Arrangement, Allocation Of Net Profits And Losses, Percent", "documentation": "Collaborative Arrangement, Allocation Of Net Profits And Losses, Percent" } } }, "auth_ref": [] }, "vrtx_IndemnificationClaims": { "xbrltype": "monetaryItemType", "nsuri": "http://www.vrtx.com/20230930", "localname": "IndemnificationClaims", "crdr": "credit", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indemnification claims", "label": "Indemnification Claims", "documentation": "Amount of indemnification claims currently outstanding" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "terseLabel": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract]", "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareAntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities [Axis]", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r40" ] }, "vrtx_PubliclyTradedCompaniesSaleMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vrtx.com/20230930", "localname": "PubliclyTradedCompaniesSaleMember", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Publicly Traded Companies Sale", "label": "Publicly Traded Companies Sale [Member]", "documentation": "Publicly Traded Companies Sale" } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.vrtx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Other current liabilities", "label": "Other Liabilities, Current", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r27", "r643" ] }, "vrtx_TRIKAFTAKAFTRIOMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vrtx.com/20230930", "localname": "TRIKAFTAKAFTRIOMember", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "TRIKAFTA/KAFTRIO", "label": "TRIKAFTA/KAFTRIO [Member]", "documentation": "TRIKAFTA/KAFTRIO [Member]" } } }, "auth_ref": [] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value by Measurement Frequency [Axis]", "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r410", "r411", "r413", "r414", "r416" ] }, "vrtx_CollaborativeArrangementsByAgreementDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.vrtx.com/20230930", "localname": "CollaborativeArrangementsByAgreementDomain", "presentation": [ "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangements by Agreement [Domain]", "label": "Collaborative Arrangements by Agreement [Domain]", "documentation": "Collaborative Arrangements by Agreement [Domain]" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareAntidilutiveSecuritiesDetails", "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r28", "r146", "r185", "r268", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r393", "r395", "r396", "r419", "r643", "r782", "r801", "r802" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Other long-term liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r29" ] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MoneyMarketFundsMember", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Money market funds", "label": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": [ "r786" ] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total financial assets", "label": "Assets, Fair Value Disclosure", "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r70" ] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.vrtx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r663" ] }, "vrtx_CollaborativeArrangementRightToLicenseNumberOfTargets": { "xbrltype": "integerItemType", "nsuri": "http://www.vrtx.com/20230930", "localname": "CollaborativeArrangementRightToLicenseNumberOfTargets", "presentation": [ "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative arrangement, right to exclusively license, number of targets", "label": "Collaborative Arrangement, Right To License, Number Of Targets", "documentation": "Collaborative Arrangement, Right To License, Number Of Targets" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareAntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive securities excluded from computation of earnings per share (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r211" ] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r673", "r684", "r694", "r719" ] }, "vrtx_PaymentToAcquireCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://www.vrtx.com/20230930", "localname": "PaymentToAcquireCommonStock", "crdr": "credit", "presentation": [ "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase of common stock", "label": "Payment To Acquire Common Stock", "documentation": "Payment To Acquire Common Stock" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Net income per common share:", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://www.vrtx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r696" ] }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Provision for (Benefits from) Income Taxes and Effective Tax rates", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years." } } }, "auth_ref": [ "r107" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term operating lease liabilities", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r428" ] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Financial Assets Subject to Fair Value Measurements", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r410", "r411" ] }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:", "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockRepurchasedDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchasedDuringPeriodShares", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity", "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Repurchase of common stock (in shares)", "terseLabel": "Shares repurchased (in shares)", "label": "Stock Repurchased During Period, Shares", "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": [ "r13", "r74", "r75", "r106", "r503", "r567", "r593" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Potential Gross Common Equivalent Shares", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r40" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.vrtx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r735" ] }, "us-gaap_DerivativeLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLiabilities", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails": { "parentTag": "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Gross Amounts Presented", "label": "Derivative Liability", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r156", "r158", "r418", "r509", "r510", "r511", "r512", "r515", "r516", "r517", "r518", "r519", "r542", "r544", "r545", "r580", "r581", "r582", "r585", "r586", "r588", "r589", "r618", "r814" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareAntidilutiveSecuritiesDetails", "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities." } } }, "auth_ref": [ "r40" ] }, "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Cash Equivalents and Marketable Securities", "label": "Cash, Cash Equivalents and Investments [Table Text Block]", "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://www.vrtx.com/role/InventoriesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Inventories by Type", "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r23", "r81", "r82", "r83" ] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfOperatingSegments", "presentation": [ "http://www.vrtx.com/role/BasisofPresentationandAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of operating segments", "label": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r762" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.vrtx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r661" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.vrtx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "us-gaap_DerivativeFairValueOfDerivativeAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeFairValueOfDerivativeAsset", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails": { "parentTag": "us-gaap_DerivativeAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Total assets", "terseLabel": "Gross Amounts Recognized", "label": "Derivative Asset, Subject to Master Netting Arrangement, before Offset", "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement." } } }, "auth_ref": [ "r19", "r61", "r85", "r155", "r618" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r95" ] }, "us-gaap_RestrictedCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashAndCashEquivalents", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/AdditionalCashFlowInformationDetails": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.vrtx.com/role/AdditionalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Restricted Cash and Cash Equivalents", "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r38", "r111", "r147", "r184", "r475" ] }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpensesMember", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative expenses", "label": "Selling, General and Administrative Expenses [Member]", "documentation": "Primary financial statement caption encompassing selling, general and administrative expense." } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legal Entity [Axis]", "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Income Statement Location [Domain]", "label": "Income Statement Location [Domain]", "documentation": "Location in the income statement." } } }, "auth_ref": [ "r287", "r552" ] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Entity [Domain]", "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Issuances of common stock under benefit plans", "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised", "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised." } } }, "auth_ref": [ "r6", "r15" ] }, "us-gaap_FinanceLeasePrincipalPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeasePrincipalPayments", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments on finance leases", "label": "Finance Lease, Principal Payments", "documentation": "Amount of cash outflow for principal payment on finance lease." } } }, "auth_ref": [ "r429", "r430" ] }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax", "crdr": "debit", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized holding losses on marketable securities, tax", "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax", "documentation": "Amount, after adjustment, of tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": [ "r159", "r160", "r163" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.vrtx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsMember", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesatFairValueDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents [Member]", "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [] }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeFairValueOfDerivativeLiability", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails": { "parentTag": "us-gaap_DerivativeLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Total liabilities", "negatedTerseLabel": "Gross Amounts Recognized", "label": "Derivative Liability, Subject to Master Netting Arrangement, before Offset", "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement." } } }, "auth_ref": [ "r19", "r61", "r85", "r155", "r618" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.vrtx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r661" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r672", "r683", "r693", "r718" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.vrtx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiability", "crdr": "credit", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract liabilities", "label": "Contract with Customer, Liability", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r308", "r309", "r320" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.vrtx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "crdr": "credit", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net unrecognized tax benefits which would affect the tax rate if recognized", "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate", "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate." } } }, "auth_ref": [ "r379" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r75" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.vrtx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, net", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization", "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset." } } }, "auth_ref": [ "r737", "r777" ] }, "us-gaap_InterestIncomeExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestIncomeExpenseNet", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense", "label": "Interest Income (Expense), Net", "documentation": "The net amount of operating interest income (expense)." } } }, "auth_ref": [ "r116" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r701" ] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 }, "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncome", "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome", "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity", "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net income", "terseLabel": "Net income", "verboseLabel": "Net income", "netLabel": "Net income", "label": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r89", "r98", "r115", "r144", "r165", "r168", "r172", "r185", "r190", "r192", "r193", "r194", "r195", "r198", "r199", "r207", "r216", "r222", "r226", "r228", "r268", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r408", "r419", "r482", "r549", "r565", "r566", "r623", "r657", "r782" ] }, "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpenseNetOfTax", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total stock-based compensation expense, net of tax", "label": "Share-Based Payment Arrangement, Expense, after Tax", "documentation": "Amount, after tax, of expense for award under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r149" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails": { "parentTag": "vrtx_DebtandEquitySecuritiesCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Amortized Cost", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r237", "r276", "r472" ] }, "srt_EuropeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "EuropeMember", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Europe", "label": "Europe [Member]", "documentation": "Continent of Europe." } } }, "auth_ref": [ "r817", "r819", "r820", "r821" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.vrtx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r661" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r700" ] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.vrtx.com/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r186", "r373", "r378", "r380", "r381", "r384", "r386", "r387", "r388", "r505" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r672", "r683", "r693", "r718" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "presentation": [ "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Research and development expenses", "label": "Research and Development Expense", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r73", "r372", "r809" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.vrtx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails": { "parentTag": "us-gaap_FinancialLiabilitiesFairValueDisclosure", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Other current liabilities, contingent consideration", "label": "Business Combination, Contingent Consideration, Liability, Current", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r2", "r51" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.vrtx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.vrtx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails": { "parentTag": "us-gaap_FinancialLiabilitiesFairValueDisclosure", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Contingent consideration", "label": "Business Combination, Contingent Consideration, Liability, Noncurrent", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r2", "r51" ] }, "us-gaap_DerivativeNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeNotionalAmount", "presentation": [ "http://www.vrtx.com/role/HedgingAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Notional amount of foreign currency forward contract", "label": "Derivative, Notional Amount", "documentation": "Nominal or face amount used to calculate payment on derivative." } } }, "auth_ref": [ "r792", "r793" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.vrtx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss):", "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "auth_ref": [] }, "vrtx_SecuredOvernightFinancingRateSOFRMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vrtx.com/20230930", "localname": "SecuredOvernightFinancingRateSOFRMember", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SOFR Loan", "label": "Secured Overnight Financing Rate (SOFR) [Member]", "documentation": "Secured Overnight Financing Rate (SOFR)" } } }, "auth_ref": [] }, "us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "USGovernmentSponsoredEnterprisesDebtSecuritiesMember", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Government-sponsored enterprise securities", "terseLabel": "Government-sponsored enterprise securities", "label": "US Government-sponsored Enterprises Debt Securities [Member]", "documentation": "Debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae)." } } }, "auth_ref": [ "r786", "r810" ] }, "us-gaap_Cash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Cash", "crdr": "debit", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash", "label": "Cash", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r122", "r475", "r507", "r536", "r643", "r659", "r747" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://www.vrtx.com/role/BasisofPresentationandAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r41", "r42", "r43", "r124", "r126", "r127", "r128" ] }, "us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeAssetNotOffsetPolicyElectionDeduction", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails": { "parentTag": "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Gross Amounts Not Offset", "label": "Derivative Asset, Subject to Master Netting Arrangement, Deduction of Financial Instrument Not Offset", "documentation": "Fair value of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and contract can be net settled by means outside contract or delivery of asset, subject to master netting arrangement or similar agreement and not elected or qualified to offset, deducted from derivative asset." } } }, "auth_ref": [ "r17", "r20", "r129" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementGeographicalAxis", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Axis]", "label": "Geographical [Axis]", "documentation": "Information by geographical components." } } }, "auth_ref": [ "r133", "r142", "r230", "r231", "r511", "r514", "r516", "r571", "r574", "r578", "r592", "r594", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r610", "r631", "r648", "r785", "r811" ] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Shareholders\u2019 equity:", "label": "Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Sales and maturities of available-for-sale debt securities", "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale", "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r176", "r177", "r765" ] }, "vrtx_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.vrtx.com/20230930", "localname": "ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of cash, cash equivalents and marketable securities", "label": "Schedule of Cash, Cash Equivalents and Available-for-sale Securities [Line Items]", "documentation": "-- None. No documentation exists for this element. --" } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments [Domain]", "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r304", "r306", "r405", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r484", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r769", "r770", "r771", "r772" ] }, "us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock", "presentation": [ "http://www.vrtx.com/role/HedgingTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Foreign Exchange Contracts", "label": "Schedule of Foreign Exchange Contracts, Statement of Financial Position [Table Text Block]", "documentation": "Tabular disclosure of the presentation of foreign exchange contracts on the statement of financial position, including the fair value amounts and location of such amounts." } } }, "auth_ref": [ "r62" ] }, "us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "presentation": [ "http://www.vrtx.com/role/HedgingTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Cash Flow Hedging Instruments", "label": "Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]", "documentation": "Tabular disclosure of the notional amounts of outstanding derivative positions." } } }, "auth_ref": [ "r54" ] }, "us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommercialPaperNotIncludedWithCashAndCashEquivalentsMember", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commercial paper", "label": "Commercial Paper, Not Included with Cash and Cash Equivalents [Member]", "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds that is excluded from cash and cash equivalents." } } }, "auth_ref": [ "r786", "r795" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "SegmentGeographicalDomain", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Domain]", "label": "Geographical [Domain]", "documentation": "Geographical area." } } }, "auth_ref": [ "r133", "r134", "r135", "r136", "r137", "r138", "r139", "r140", "r141", "r230", "r231", "r511", "r514", "r516", "r571", "r574", "r578", "r592", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r610", "r631", "r648", "r785", "r811" ] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Disaggregation of Revenue", "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r785" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r672", "r683", "r693", "r718" ] }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "debit", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Common stock withheld for employee tax obligations", "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation", "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.vrtx.com/role/EarningsPerShare" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r200", "r211", "r212", "r213" ] }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Other liabilities", "label": "Increase (Decrease) in Other Operating Liabilities", "documentation": "Amount of increase (decrease) in operating liabilities classified as other." } } }, "auth_ref": [ "r8" ] }, "us-gaap_HedgingRelationshipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HedgingRelationshipDomain", "presentation": [ "http://www.vrtx.com/role/HedgingAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Relationship [Domain]", "label": "Hedging Relationship [Domain]", "documentation": "Nature or intent of a hedge." } } }, "auth_ref": [ "r14" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]", "documentation": "Information by product and service, or group of similar products and similar services." } } }, "auth_ref": [ "r229", "r463", "r489", "r490", "r491", "r492", "r493", "r494", "r609", "r630", "r644", "r738", "r780", "r781", "r785", "r811" ] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r698" ] }, "us-gaap_CommercialPaperMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommercialPaperMember", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commercial paper", "label": "Commercial Paper [Member]", "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds." } } }, "auth_ref": [ "r105", "r650", "r651", "r652", "r653" ] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueLineItems", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Line Items]", "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r319", "r630", "r631", "r632", "r633", "r634", "r635", "r636" ] }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses", "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities", "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other." } } }, "auth_ref": [ "r754" ] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]", "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTable", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Table]", "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r319", "r630", "r631", "r632", "r633", "r634", "r635", "r636" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]", "documentation": "Product or service, or a group of similar products or similar services." } } }, "auth_ref": [ "r229", "r463", "r489", "r490", "r491", "r492", "r493", "r494", "r609", "r630", "r644", "r738", "r780", "r781", "r785", "r811" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r30", "r71", "r474", "r527" ] }, "us-gaap_UnrealizedGainLossOnInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrealizedGainLossOnInvestments", "crdr": "credit", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsNetUnrealizedGainsLossesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net unrealized (losses) gains", "label": "Unrealized Gain (Loss) on Investments", "documentation": "Amount of unrealized gain (loss) on investment." } } }, "auth_ref": [ "r9" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Shares used in per share calculations:", "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments in connection with common stock withheld for employee tax obligations", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [ "r178" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement [Abstract]", "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r731" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive income", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r34", "r167", "r169", "r174", "r467", "r485" ] }, "us-gaap_MarketableSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecuritiesCurrent", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Marketable securities", "label": "Marketable Securities, Current", "documentation": "Amount of investment in marketable security, classified as current." } } }, "auth_ref": [ "r748" ] }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNoteTextBlock", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss)", "label": "Comprehensive Income (Loss) Note [Text Block]", "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income." } } }, "auth_ref": [ "r86", "r173", "r466", "r483" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingencies" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r104", "r288", "r289", "r597", "r779" ] }, "us-gaap_OtherNoncashIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNoncashIncomeExpense", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Other non-cash items, net", "label": "Other Noncash Income (Expense)", "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other." } } }, "auth_ref": [ "r98" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r732" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease assets", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r427" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r731" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r721" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Recurring Basis", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r409", "r416" ] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of credit facility, maximum borrowing capacity", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r25" ] }, "us-gaap_MeasurementInputDiscountRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputDiscountRateMember", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discount Rate", "label": "Measurement Input, Discount Rate [Member]", "documentation": "Measurement input using interest rate to determine present value of future cash flows." } } }, "auth_ref": [ "r796" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r733" ] }, "us-gaap_OtherAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsMember", "presentation": [ "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Other Assets", "terseLabel": "Other assets", "label": "Other Assets [Member]", "documentation": "Primary financial statement caption encompassing other assets." } } }, "auth_ref": [ "r58", "r68" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r664", "r734" ] }, "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "presentation": [ "http://www.vrtx.com/role/BasisofPresentationandAccountingPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation and Accounting Policies", "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]", "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles." } } }, "auth_ref": [ "r99", "r100", "r101", "r108" ] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of changes in exchange rates on cash", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r420" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r703" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net increase in cash, cash equivalents and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r3", "r96" ] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "US", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "United States", "label": "UNITED STATES" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityTable", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit Facility [Table]", "label": "Line of Credit Facility [Table]", "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line." } } }, "auth_ref": [ "r25", "r755" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r664", "r734" ] }, "us-gaap_IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements", "calculation": { "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee stock purchase program (in shares)", "label": "Incremental Common Shares Attributable to Dilutive Effect of Equity Unit Purchase Agreements", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of equity unit purchase agreements using the treasury stock method." } } }, "auth_ref": [ "r204", "r205", "r210" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1", "crdr": "debit", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total stock-based compensation expense included in \u201cTotal costs and expenses\u201d", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount", "documentation": "Amount of cost expensed and capitalized for award under share-based payment arrangement." } } }, "auth_ref": [ "r362" ] }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "calculation": { "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based payment arrangements (in shares)", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method." } } }, "auth_ref": [ "r204", "r205", "r206", "r210", "r334" ] }, "us-gaap_DerivativeTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeTermOfContract", "presentation": [ "http://www.vrtx.com/role/HedgingAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative term", "label": "Derivative, Term of Contract", "documentation": "Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityLineItems", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit Facility [Line Items]", "label": "Line of Credit Facility [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r755" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/AdditionalCashFlowInformationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.vrtx.com/role/AdditionalCashFlowInformationDetails", "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash, cash equivalents and restricted cash\u2014beginning of period", "periodEndLabel": "Cash, cash equivalents and restricted cash\u2014end of period", "totalLabel": "Cash, cash equivalents and restricted cash per condensed consolidated statement of cash flows", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r38", "r96", "r184" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r664", "r734" ] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome", "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails", "http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product revenues, net", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r217", "r218", "r221", "r224", "r225", "r229", "r230", "r232", "r318", "r319", "r463" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Unrealized loss", "negatedTerseLabel": "Gross Unrealized Losses", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r241" ] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails", "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r75" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross Unrealized Gains", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r240" ] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationDomain", "presentation": [ "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesatFairValueDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Domain]", "label": "Balance Sheet Location [Domain]", "documentation": "Location in the balance sheet (statement of financial position)." } } }, "auth_ref": [ "r58", "r63" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome", "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Diluted (in dollars per share)", "terseLabel": "Diluted net income per common share (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r175", "r192", "r193", "r194", "r195", "r196", "r203", "r208", "r209", "r210", "r214", "r407", "r408", "r468", "r486", "r621" ] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeDomain", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input Type [Domain]", "label": "Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets", "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "totalLabel": "Total shareholders\u2019 equity", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r75", "r78", "r79", "r102", "r530", "r547", "r568", "r569", "r643", "r659", "r756", "r774", "r797", "r815" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r703" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r674", "r685", "r695", "r720" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Common stock, $0.01 par value; 500,000,000 shares authorized, 257,828,508 and 257,011,628 shares issued and outstanding, respectively", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r75", "r477", "r643" ] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r698" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r75", "r528" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent consideration, measurement input (as a percent)", "label": "Business Combination, Contingent Consideration, Liability, Measurement Input", "documentation": "Value of input used to measure contingent consideration liability from business combination." } } }, "auth_ref": [ "r414" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares outstanding (in shares)", "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r13", "r75", "r528", "r547", "r815", "r816" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r698" ] }, "us-gaap_PaymentsToAcquireEquitySecuritiesFvNi": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireEquitySecuritiesFvNi", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Investment in equity securities and notes receivable", "label": "Payments to Acquire Equity Securities, FV-NI", "documentation": "Amount of cash outflow to acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity." } } }, "auth_ref": [ "r120", "r180" ] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsAdditionalInformationDetails", "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative expenses", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r92" ] }, "us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleOfEquitySecuritiesFvNi", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of equity securities", "label": "Proceeds from Sale of Equity Securities, FV-NI", "documentation": "Amount of cash inflow from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity." } } }, "auth_ref": [ "r120", "r180" ] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Income Statement Location [Axis]", "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r286", "r287", "r552" ] }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsGainLossLineItems", "presentation": [ "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]", "label": "Derivative Instruments, Gain (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r397" ] }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "presentation": [ "http://www.vrtx.com/role/HedgingAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Relationship [Axis]", "label": "Hedging Relationship [Axis]", "documentation": "Information by type of hedging relationship." } } }, "auth_ref": [ "r14", "r59", "r64" ] }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "presentation": [ "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments, Gain (Loss) [Table]", "label": "Derivative Instruments, Gain (Loss) [Table]", "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments." } } }, "auth_ref": [ "r14", "r59", "r64", "r65", "r68", "r69", "r397" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r699" ] }, "us-gaap_CashAndCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAbstract", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash equivalents:", "label": "Cash and Cash Equivalents [Abstract]" } } }, "auth_ref": [] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r699" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r670", "r681", "r691", "r716" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r703" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 }, "http://www.vrtx.com/role/AdditionalCashFlowInformationDetails": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.vrtx.com/role/AdditionalCashFlowInformationDetails", "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r38", "r147", "r611" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r721" ] }, "us-gaap_BankTimeDepositsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BankTimeDepositsMember", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Time deposits", "label": "Bank Time Deposits [Member]", "documentation": "Certificates of deposit (CD) or savings accounts with a fixed term or understanding the customer can only withdraw by giving advanced notice with a bank or other financial institution. A CD is a short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest." } } }, "auth_ref": [ "r117" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r721" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.vrtx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialInstrumentAxis", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instrument [Axis]", "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r271", "r272", "r273", "r274", "r275", "r277", "r280", "r281", "r304", "r306", "r405", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r484", "r625", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r769", "r770", "r771", "r772" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r703" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.vrtx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r703" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r703" ] }, "us-gaap_InvestmentIncomeInterestAndDividend": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentIncomeInterestAndDividend", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Interest income", "label": "Investment Income, Interest and Dividend", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities." } } }, "auth_ref": [ "r93" ] }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "crdr": "debit", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Equity securities without readily determinable fair value, amount", "label": "Equity Securities without Readily Determinable Fair Value, Amount", "documentation": "Amount of investment in equity security without readily determinable fair value." } } }, "auth_ref": [ "r266" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r723" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level\u00a02", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r303", "r323", "r328", "r411", "r436", "r627", "r628", "r637", "r638", "r639" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r725" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r721" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level\u00a01", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r303", "r323", "r328", "r411", "r435", "r637", "r638", "r639" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r112", "r150", "r185", "r216", "r223", "r227", "r268", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r392", "r395", "r419", "r473", "r541", "r643", "r659", "r782", "r783", "r801" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r669", "r680", "r690", "r715" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Equity [Abstract]", "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherDeferredLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherDeferredLiability", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred income taxes", "label": "Increase (Decrease) in Other Deferred Liability", "documentation": "Amount of increase (decrease) in deferred obligations classified as other." } } }, "auth_ref": [ "r8" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r675", "r683", "r693", "r710", "r718", "r722", "r730" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r721" ] }, "us-gaap_OffsettingLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OffsettingLiabilitiesTableTextBlock", "presentation": [ "http://www.vrtx.com/role/HedgingTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Offsetting Liabilities", "label": "Offsetting Liabilities [Table Text Block]", "documentation": "Tabular disclosure of derivative and other financial liabilities that are subject to offsetting, including master netting arrangements." } } }, "auth_ref": [ "r84", "r157" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level\u00a03", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r303", "r323", "r324", "r325", "r326", "r327", "r328", "r411", "r437", "r627", "r628", "r637", "r638", "r639" ] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-sale [Line Items]", "label": "Debt Securities, Available-for-Sale [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247" ] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r675", "r683", "r693", "r710", "r718", "r722", "r730" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r721" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.vrtx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r722" ] }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repurchases of common stock", "label": "Payments for Repurchase of Common Stock", "documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth_ref": [ "r37" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental disclosure of cash flow information:", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r668", "r679", "r689", "r714" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r721" ] }, "us-gaap_DeferredIncomeTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxAssetsNet", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax assets", "label": "Deferred Income Tax Assets, Net", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting." } } }, "auth_ref": [ "r374", "r375" ] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses and other assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r8" ] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount", "crdr": "debit", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Stock-based compensation expense related to inventories", "label": "Share-Based Payment Arrangement, Amount Capitalized", "documentation": "Amount of cost capitalized for award under share-based payment arrangement." } } }, "auth_ref": [ "r364" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails": { "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total stock-based compensation expense included in costs and expenses", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r363", "r371" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r722" ] }, "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss", "crdr": "credit", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Allowance for credit loss for available-for-sale debt securities", "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss", "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r239", "r276", "r282", "r283" ] }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails": { "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Income tax effect", "label": "Share-Based Payment Arrangement, Expense, Tax Benefit", "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement." } } }, "auth_ref": [ "r363" ] }, "us-gaap_ForeignExchangeForwardMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignExchangeForwardMember", "presentation": [ "http://www.vrtx.com/role/HedgingAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency forward contracts", "label": "Foreign Exchange Forward [Member]", "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate." } } }, "auth_ref": [ "r534", "r539", "r544", "r557", "r563", "r583", "r584", "r585", "r648" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r668", "r679", "r689", "r714" ] }, "us-gaap_EmployeeStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockMember", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "ESPP share issuances", "label": "Employee Stock [Member]", "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock." } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": { "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Matures within one year", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r244", "r470" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": { "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Matures after one year through five years", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r245", "r471" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r726" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation expense", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r8" ] }, "us-gaap_CertificatesOfDepositMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CertificatesOfDepositMember", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Certificates of deposit", "label": "Certificates of Deposit [Member]", "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured." } } }, "auth_ref": [ "r10", "r650", "r651", "r652", "r653" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r724" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r697" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares authorized (in shares)", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r74", "r528" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Accounts receivable, net", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r8" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares outstanding (in shares)", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r74", "r528", "r547", "r815", "r816" ] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r145", "r154", "r185", "r268", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r392", "r395", "r419", "r643", "r782", "r783", "r801" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares issued (in shares)", "label": "Preferred Stock, Shares Issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r74", "r305" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r673", "r684", "r694", "r719" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.vrtx.com/role/BasisofPresentationandAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r671", "r682", "r692", "r717" ] }, "us-gaap_AssetAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionAxis", "presentation": [ "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Acquisition [Axis]", "label": "Asset Acquisition [Axis]", "documentation": "Information by asset acquisition." } } }, "auth_ref": [ "r788" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Domain]", "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [] }, "us-gaap_LetterOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LetterOfCreditMember", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Letters of Credit", "label": "Letter of Credit [Member]", "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit)." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r303", "r323", "r324", "r325", "r326", "r327", "r328", "r435", "r436", "r437", "r627", "r628", "r637", "r638", "r639" ] }, "us-gaap_OffsettingDerivativeAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OffsettingDerivativeAssetsAbstract", "presentation": [ "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Offsetting Derivative Assets [Abstract]", "label": "Offsetting Derivative Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OffsettingAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OffsettingAssetsTableTextBlock", "presentation": [ "http://www.vrtx.com/role/HedgingTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Offsetting Assets", "label": "Offsetting Assets [Table Text Block]", "documentation": "Tabular disclosure of derivative and other financial assets that are subject to offsetting, including master netting arrangements." } } }, "auth_ref": [ "r84", "r157" ] }, "us-gaap_AssetAcquisitionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionDomain", "presentation": [ "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Acquisition [Domain]", "label": "Asset Acquisition [Domain]", "documentation": "Asset acquisition." } } }, "auth_ref": [ "r788" ] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for income taxes", "label": "Income Taxes Paid, Net", "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes." } } }, "auth_ref": [ "r39" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r170", "r171", "r421", "r422", "r423", "r424", "r425", "r426" ] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeContractTypeDomain", "presentation": [ "http://www.vrtx.com/role/HedgingAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Contract [Domain]", "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r517", "r519", "r533", "r534", "r535", "r537", "r538", "r539", "r540", "r542", "r543", "r544", "r545", "r555", "r556", "r557", "r558", "r561", "r562", "r563", "r564", "r579", "r580", "r585", "r588", "r646", "r648" ] }, "us-gaap_MarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecurities", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Marketable securities:", "label": "Marketable Securities", "documentation": "Amount of investment in marketable security." } } }, "auth_ref": [ "r72", "r748" ] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareAntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name [Domain]", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r40" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchasePrograms" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based Compensation Expense and Share Repurchase Programs", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r330", "r335", "r365", "r366", "r367", "r641" ] }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryFinishedGoodsNetOfReserves", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/InventoriesDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.vrtx.com/role/InventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finished goods", "label": "Inventory, Finished Goods, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale." } } }, "auth_ref": [ "r103", "r614" ] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Schedule of Fair Value of Our Contingent Consideration Liabilities", "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]", "documentation": "Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments." } } }, "auth_ref": [] }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CollaborativeArrangementDisclosureTextBlock", "presentation": [ "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Acquired In-Process Research and Development and Other Arrangements", "label": "Collaborative Arrangement Disclosure [Text Block]", "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants." } } }, "auth_ref": [ "r123", "r125", "r132" ] }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryWorkInProcessNetOfReserves", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/InventoriesDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.vrtx.com/role/InventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Work-in-process", "label": "Inventory, Work in Process, Net of Reserves", "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing." } } }, "auth_ref": [ "r103", "r615" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DesignatedAsHedgingInstrumentMember", "presentation": [ "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Designated as Hedging Instruments", "terseLabel": "Designated as hedging instruments", "label": "Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": [ "r14" ] }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryRawMaterialsNetOfReserves", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/InventoriesDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.vrtx.com/role/InventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Raw materials", "label": "Inventory, Raw Materials, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process." } } }, "auth_ref": [ "r103", "r616" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareAntidilutiveSecuritiesDetails", "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails", "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "verboseLabel": "Stock options", "terseLabel": "Stock options", "label": "Employee Stock Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Retained earnings", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r77", "r106", "r479", "r499", "r501", "r504", "r529", "r643" ] }, "us-gaap_HedgingDesignationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HedgingDesignationAxis", "presentation": [ "http://www.vrtx.com/role/HedgingAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation [Axis]", "label": "Hedging Designation [Axis]", "documentation": "Information by designation of purpose of derivative instrument." } } }, "auth_ref": [ "r14", "r397" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r187", "r188", "r189", "r215", "r463", "r502", "r508", "r520", "r521", "r522", "r523", "r524", "r525", "r528", "r531", "r532", "r533", "r534", "r535", "r537", "r538", "r539", "r540", "r542", "r543", "r544", "r545", "r546", "r548", "r550", "r551", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r567", "r649" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r672", "r683", "r693", "r710", "r718" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFairValueofContingentConsiderationLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 }, "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncome", "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "totalLabel": "Total other comprehensive income (loss)", "terseLabel": "Other comprehensive income (loss), net of tax", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": [ "r7", "r11", "r109", "r166", "r169" ] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome", "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Basic (in dollars per share)", "terseLabel": "Basic net income per common share (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r175", "r192", "r193", "r194", "r195", "r196", "r201", "r203", "r208", "r209", "r210", "r214", "r407", "r408", "r468", "r486", "r621" ] }, "us-gaap_MarketableSecuritiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecuritiesNoncurrent", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term marketable securities", "label": "Marketable Securities, Noncurrent", "documentation": "Amount of investment in marketable security, classified as noncurrent." } } }, "auth_ref": [ "r748" ] }, "us-gaap_AssetAcquisitionConsiderationTransferred": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionConsiderationTransferred", "crdr": "credit", "presentation": [ "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset acquisition, consideration transferred", "label": "Asset Acquisition, Consideration Transferred", "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer." } } }, "auth_ref": [ "r642", "r789", "r790", "r791" ] }, "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AOCIAttributableToParentNetOfTaxRollForward", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation adjustment", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity." } } }, "auth_ref": [ "r7", "r11", "r109" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive (loss) income", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r32", "r33", "r87", "r152", "r478", "r500", "r501" ] }, "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized holding losses on marketable securities, net of tax of $1.7, zero, $5.2 and zero, respectively", "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent", "documentation": "Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent." } } }, "auth_ref": [ "r7", "r11", "r109" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r181" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r646", "r647", "r648", "r650", "r651", "r652", "r653", "r758", "r759", "r794", "r813", "r815" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome", "http://www.vrtx.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Income before provision for income taxes", "terseLabel": "Income before provision for income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r0", "r88", "r114", "r216", "r222", "r226", "r228", "r469", "r481", "r623" ] }, "us-gaap_NondesignatedMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NondesignatedMember", "presentation": [ "http://www.vrtx.com/role/HedgingAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Not Designated as Hedging Instrument", "terseLabel": "Not designated as hedging instruments", "label": "Not Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": [ "r14" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities:", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r181" ] }, "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfSalesMember", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of sales", "label": "Cost of Sales [Member]", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth_ref": [] }, "us-gaap_DerivativeLiabilityFairValueGrossAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLiabilityFairValueGrossAsset", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails": { "parentTag": "us-gaap_DerivativeLiabilities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross Amounts Offset", "label": "Derivative Liability, Subject to Master Netting Arrangement, Asset Offset", "documentation": "Fair value of asset associated with financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r16", "r22", "r61", "r586", "r587", "r617" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities:", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r96", "r97", "r98" ] }, "us-gaap_DerivativeAssetFairValueGrossLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeAssetFairValueGrossLiability", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails": { "parentTag": "us-gaap_DerivativeAssets", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Gross Amounts Offset", "label": "Derivative Asset, Subject to Master Netting Arrangement, Liability Offset", "documentation": "Fair value of liability associated with financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r16", "r22", "r61", "r586", "r587" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities:", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r26", "r185", "r268", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r393", "r395", "r396", "r419", "r526", "r622", "r659", "r782", "r801", "r802" ] }, "us-gaap_CostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostsAndExpenses", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome" ], "lang": { "en-us": { "role": { "totalLabel": "Total costs and expenses", "label": "Costs and Expenses", "documentation": "Total costs of sales and operating expenses for the period." } } }, "auth_ref": [ "r90" ] }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payment to acquire ViaCyte, Inc., net of cash acquired", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase." } } }, "auth_ref": [ "r36" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r749" ] }, "us-gaap_CashFlowHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashFlowHedgingMember", "presentation": [ "http://www.vrtx.com/role/HedgingAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Cash Flow Hedging", "label": "Cash Flow Hedging [Member]", "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk." } } }, "auth_ref": [ "r56" ] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryDisclosureTextBlock", "presentation": [ "http://www.vrtx.com/role/Inventories" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories", "label": "Inventory Disclosure [Text Block]", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": [ "r284" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r672", "r683", "r693", "r718" ] }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term finance lease liabilities", "label": "Finance Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent." } } }, "auth_ref": [ "r428" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, net", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r233", "r234" ] }, "us-gaap_NonUsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonUsMember", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total product revenues outside of the United States", "label": "Non-US [Member]", "documentation": "Countries excluding the United States of America (US)." } } }, "auth_ref": [ "r817", "r819", "r820", "r821" ] }, "us-gaap_CostsAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostsAndExpensesAbstract", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Costs and expenses:", "label": "Costs and Expenses [Abstract]" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.vrtx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities and Shareholders\u2019 Equity", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Inventories", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r8" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and shareholders\u2019 equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r80", "r113", "r480", "r643", "r756", "r774", "r797" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r170", "r171", "r421", "r422", "r423", "r424", "r425", "r426" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock-based Compensation Expense by Line Item", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r48" ] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash equivalents:", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 3.0 }, "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome", "http://www.vrtx.com/role/FairValueMeasurementsFairValueofContingentConsiderationLiabilitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Change in fair value of contingent consideration", "netLabel": "Decrease in fair value of contingent consideration", "terseLabel": "Decrease in fair value of contingent payments", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement." } } }, "auth_ref": [ "r390", "r754" ] }, "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestments" ], "lang": { "en-us": { "role": { "terseLabel": "Marketable Securities and Equity Investments", "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]", "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss)." } } }, "auth_ref": [ "r763" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r24", "r643" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.vrtx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r660" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.vrtx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://www.vrtx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r661" ] }, "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "On Foreign Currency Forward Contracts", "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent." } } }, "auth_ref": [ "r164", "r171", "r172", "r394", "r619", "r750" ] }, "us-gaap_FinancialLiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialLiabilitiesFairValueDisclosure", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Total financial liabilities", "label": "Financial Liabilities Fair Value Disclosure", "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities." } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurements" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r409" ] }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Investments, Debt and Equity Securities [Abstract]", "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesAbstract", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total marketable debt securities", "label": "Debt Securities, Available-for-Sale [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 3.0 }, "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesatFairValueDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value", "verboseLabel": "Debt securities", "totalLabel": "Total", "label": "Debt Securities, Available-for-Sale", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r238", "r276", "r465", "r764" ] }, "us-gaap_USTreasurySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "USTreasurySecuritiesMember", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. Treasury securities", "label": "US Treasury Securities [Member]", "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)." } } }, "auth_ref": [ "r620", "r637", "r639", "r810" ] }, "us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueEmployeeBenefitPlan", "crdr": "credit", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock under benefit plans", "label": "Stock Issued During Period, Value, Employee Benefit Plan", "documentation": "Value of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan." } } }, "auth_ref": [] }, "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalFinancialInformationDisclosureTextBlock", "presentation": [ "http://www.vrtx.com/role/AdditionalCashFlowInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Cash Flow Information", "label": "Additional Financial Information Disclosure [Text Block]", "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesEmployeeBenefitPlan", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock under benefit plans (in shares)", "label": "Stock Issued During Period, Shares, Employee Benefit Plan", "documentation": "Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://www.vrtx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r661" ] }, "srt_CurrencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CurrencyAxis", "presentation": [ "http://www.vrtx.com/role/HedgingNotionalAmountDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Currency [Axis]", "label": "Currency [Axis]", "documentation": "Information by currency." } } }, "auth_ref": [ "r800" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gains on foreign currency forward contracts, net of tax of $(13.2), $(16.0), $(1.6) and $(34.3), respectively", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent", "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent." } } }, "auth_ref": [ "r162" ] }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss)", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r33", "r798", "r799" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.vrtx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent", "crdr": "debit", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gains (losses) on foreign currency forward contracts, tax", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax, Parent", "documentation": "Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent." } } }, "auth_ref": [ "r163" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://www.vrtx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r661" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.vrtx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r662" ] }, "us-gaap_DerivativeLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails": { "parentTag": "us-gaap_FinancialLiabilitiesFairValueDisclosure", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other long-term liabilities, foreign currency forward contracts", "label": "Derivative Liability, Noncurrent", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r156" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Preferred stock, $0.01 par value; 1,000,000 shares authorized; none issued and outstanding", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r74", "r476", "r643" ] }, "us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsAdditionalInformationDetails", "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Acquired in-process research and development expenses", "label": "Research and Development Asset Acquired Other than Through Business Combination, Writeoff", "documentation": "The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination." } } }, "auth_ref": [ "r46", "r787" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.vrtx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r661" ] }, "us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrealizedGainLossOnInvestmentsTableTextBlock", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Company's Net Unrealized (Losses) Gains on Corporate Equity Securities", "label": "Unrealized Gain (Loss) on Investments [Table Text Block]", "documentation": "Tabular disclosure of unrealized gains and losses on investments." } } }, "auth_ref": [] }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Common stock withheld for employee tax obligations (in shares)", "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation", "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_CorporateDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CorporateDebtSecuritiesMember", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate debt securities", "label": "Corporate Debt Securities [Member]", "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment." } } }, "auth_ref": [ "r637", "r639", "r812" ] }, "vrtx_SepternaIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vrtx.com/20230930", "localname": "SepternaIncMember", "presentation": [ "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Septerna, Inc", "label": "Septerna, Inc [Member]", "documentation": "Septerna, Inc" } } }, "auth_ref": [] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.vrtx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses", "label": "Accrued Liabilities, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r27" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails", "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]", "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r290", "r291", "r292", "r293", "r322", "r329", "r358", "r359", "r360", "r438", "r462", "r495", "r518", "r519", "r570", "r573", "r575", "r576", "r590", "r607", "r608", "r624", "r629", "r640", "r645", "r648", "r778", "r784", "r804", "r805", "r806", "r807", "r808" ] }, "vrtx_CollaborativeArrangementMilestonePayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.vrtx.com/20230930", "localname": "CollaborativeArrangementMilestonePayment", "crdr": "credit", "presentation": [ "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Milestone payment", "label": "Collaborative Arrangement, Milestone Payment", "documentation": "Collaborative Arrangement, Milestone Payment" } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentRiskAxis", "presentation": [ "http://www.vrtx.com/role/HedgingAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instrument [Axis]", "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": [ "r59", "r62", "r64", "r65", "r517", "r519", "r533", "r534", "r535", "r537", "r538", "r539", "r540", "r542", "r543", "r544", "r545", "r555", "r556", "r557", "r558", "r561", "r562", "r563", "r564", "r579", "r580", "r585", "r588", "r618", "r646", "r648" ] }, "vrtx_MarketableSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vrtx.com/20230930", "localname": "MarketableSecuritiesMember", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesatFairValueDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Marketable securities", "label": "Marketable Securities [Member]", "documentation": "Marketable Securities [Member]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": [ "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r391" ] }, "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome" ], "lang": { "en-us": { "role": { "verboseLabel": "Research and development expenses", "label": "Research and Development Expense (Excluding Acquired in Process Cost)", "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept." } } }, "auth_ref": [ "r787" ] }, "vrtx_CollaborativeArrangementUpFrontLicenseFee": { "xbrltype": "monetaryItemType", "nsuri": "http://www.vrtx.com/20230930", "localname": "CollaborativeArrangementUpFrontLicenseFee", "crdr": "credit", "presentation": [ "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Up-front payment", "label": "Collaborative Arrangement Up-front License Fee", "documentation": "Collaborative Arrangement Up-front License Fee" } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails", "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]", "documentation": "Upper limit of the provided range." } } }, "auth_ref": [ "r290", "r291", "r292", "r293", "r329", "r462", "r495", "r518", "r519", "r570", "r573", "r575", "r576", "r590", "r607", "r608", "r624", "r629", "r640", "r645", "r784", "r803", "r804", "r805", "r806", "r807", "r808" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome" ], "lang": { "en-us": { "role": { "totalLabel": "Income from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r216", "r222", "r226", "r228", "r623" ] }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": [ "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r391" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails", "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]", "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r290", "r291", "r292", "r293", "r322", "r329", "r358", "r359", "r360", "r438", "r462", "r495", "r518", "r519", "r570", "r573", "r575", "r576", "r590", "r607", "r608", "r624", "r629", "r640", "r645", "r648", "r778", "r784", "r804", "r805", "r806", "r807", "r808" ] }, "currency_AllCurrenciesDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2023", "localname": "AllCurrenciesDomain", "presentation": [ "http://www.vrtx.com/role/HedgingNotionalAmountDetails" ], "lang": { "en-us": { "role": { "terseLabel": "All Currencies [Domain]", "label": "All Currencies [Domain]" } } }, "auth_ref": [] }, "vrtx_CRISPRMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vrtx.com/20230930", "localname": "CRISPRMember", "presentation": [ "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "CRISPR", "label": "CRISPR [Member]", "documentation": "CRISPR" } } }, "auth_ref": [] }, "vrtx_CollaborativeArrangementsByAgreementAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.vrtx.com/20230930", "localname": "CollaborativeArrangementsByAgreementAxis", "presentation": [ "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangements by Agreement [Axis]", "label": "Collaborative Arrangements by Agreement [Axis]", "documentation": "Significant terms of collaboration arrangements, by individual agreement." } } }, "auth_ref": [] }, "vrtx_CollaborativeArrangementDevelopmentAndRegulatoryPotentialMilestonePaymentsMaximum": { "xbrltype": "monetaryItemType", "nsuri": "http://www.vrtx.com/20230930", "localname": "CollaborativeArrangementDevelopmentAndRegulatoryPotentialMilestonePaymentsMaximum", "crdr": "debit", "presentation": [ "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative arrangement, development and regulatory potential milestone payments maximum", "label": "Collaborative Arrangement Development And Regulatory Potential Milestone Payments Maximum", "documentation": "Represents the potential milestone amount to be paid by the entity under the collaboration agreement if drug candidates are approved and commercialized." } } }, "auth_ref": [] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 }, "http://www.vrtx.com/role/InventoriesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets", "http://www.vrtx.com/role/InventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories", "totalLabel": "Total", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r153", "r612", "r643" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails", "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]", "documentation": "Lower limit of the provided range." } } }, "auth_ref": [ "r290", "r291", "r292", "r293", "r329", "r462", "r495", "r518", "r519", "r570", "r573", "r575", "r576", "r590", "r607", "r608", "r624", "r629", "r640", "r645", "r784", "r803", "r804", "r805", "r806", "r807", "r808" ] }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of potentially dilutive securities:", "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareAntidilutiveSecuritiesDetails", "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted stock units (including PSUs)", "verboseLabel": "Unvested restricted stock units (including PSUs)", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "vrtx_CRISPRTherapeuticsAGMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vrtx.com/20230930", "localname": "CRISPRTherapeuticsAGMember", "presentation": [ "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "CRISPR Therapeutics", "label": "CRISPR Therapeutics AG [Member]", "documentation": "CRISPR Therapeutics AG" } } }, "auth_ref": [] }, "srt_ScheduleOfCondensedCashFlowStatementTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScheduleOfCondensedCashFlowStatementTableTextBlock", "presentation": [ "http://www.vrtx.com/role/AdditionalCashFlowInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Additional Cash Flow Information", "label": "Condensed Cash Flow Statement [Table Text Block]", "documentation": "Tabular disclosure of condensed cash flow statement, including, but not limited to, cash flow statements of consolidated entities and consolidation eliminations." } } }, "auth_ref": [ "r746", "r757" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r410", "r411", "r415" ] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of sales", "label": "Cost of Goods and Services Sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r91", "r463" ] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "terseLabel": "Revenue from Contract with Customer [Abstract]", "label": "Revenue from Contract with Customer [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://www.vrtx.com/role/RevenueRecognition" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Recognition", "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r131", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r321" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for interest", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r179", "r182", "r183" ] }, "vrtx_SYMDEKOSYMKEVIMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vrtx.com/20230930", "localname": "SYMDEKOSYMKEVIMember", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SYMDEKO/SYMKEVI", "label": "SYMDEKO/SYMKEVI [Member]", "documentation": "SYMDEKO/SYMKEVI [Member]" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome", "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in shares)", "totalLabel": "Diluted weighted-average common shares outstanding (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r202", "r210" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basis spread on variable rate (as a percent)", "label": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation expense", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r49", "r50", "r332" ] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation expense", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r9", "r219" ] }, "vrtx_EntradaTherapeuticsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vrtx.com/20230930", "localname": "EntradaTherapeuticsMember", "presentation": [ "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Entrada Therapeutics", "label": "Entrada Therapeutics [Member]", "documentation": "Entrada Therapeutics" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsFairValueDisclosureAbstract", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial instruments carried at fair value (asset positions):", "label": "Assets, Fair Value Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r700" ] }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevolvingCreditFacilityMember", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revolving Credit Facility", "label": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": [] }, "us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLiabilityNotOffsetPolicyElectionDeduction", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails": { "parentTag": "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross Amounts Not Offset", "label": "Derivative Liability, Subject to Master Netting Arrangement, Deduction of Financial Instrument Not Offset", "documentation": "Fair value of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and contract can be net settled by means outside contract or delivery of asset, subject to master netting arrangement or similar agreement and not elected or qualified to offset, deducted from derivative liability." } } }, "auth_ref": [ "r17", "r20", "r129" ] }, "us-gaap_AssetBackedSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetBackedSecuritiesMember", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset-backed securities", "label": "Asset-Backed Securities [Member]", "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans." } } }, "auth_ref": [ "r637", "r766", "r767", "r768" ] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateAxis", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Axis]", "label": "Variable Rate [Axis]", "documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "currency_AUD": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2023", "localname": "AUD", "presentation": [ "http://www.vrtx.com/role/HedgingNotionalAmountDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Australian dollar", "label": "Australia, Dollars" } } }, "auth_ref": [] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "verboseLabel": "Statement", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r187", "r188", "r189", "r215", "r463", "r502", "r508", "r520", "r521", "r522", "r523", "r524", "r525", "r528", "r531", "r532", "r533", "r534", "r535", "r537", "r538", "r539", "r540", "r542", "r543", "r544", "r545", "r546", "r548", "r550", "r551", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r567", "r649" ] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityAxis", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Axis]", "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "us-gaap_BaseRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BaseRateMember", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Base Rate", "label": "Base Rate [Member]", "documentation": "Minimum rate investor will accept." } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r727" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r702" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome", "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Basic (in shares)", "terseLabel": "Basic weighted-average common shares outstanding (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r201", "r210" ] }, "us-gaap_DerivativeAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeAssetsCurrent", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets, foreign currency forward contracts", "label": "Derivative Asset, Current", "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r156" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-in Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r368", "r369", "r370", "r506", "r758", "r759", "r760", "r794", "r815" ] }, "us-gaap_OtherCurrentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherCurrentLiabilitiesMember", "presentation": [ "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other current liabilities", "label": "Other Current Liabilities [Member]", "documentation": "Primary financial statement caption encompassing other current liabilities." } } }, "auth_ref": [] }, "vrtx_MarketableSecuritiesAndOtherNoncurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vrtx.com/20230930", "localname": "MarketableSecuritiesAndOtherNoncurrentAssetsMember", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total marketable debt securities", "label": "Marketable Securities And Other Noncurrent Assets [Member]", "documentation": "Marketable Securities And Other Noncurrent Assets" } } }, "auth_ref": [] }, "vrtx_DebtandEquitySecuritiesUnrealizedGain": { "xbrltype": "monetaryItemType", "nsuri": "http://www.vrtx.com/20230930", "localname": "DebtandEquitySecuritiesUnrealizedGain", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails_1": { "parentTag": "vrtx_DebtandEquitySecuritiesCost", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross Unrealized Gains", "label": "Debt and Equity Securities, Unrealized Gain", "documentation": "Debt and Equity Securities, Unrealized Gain" } } }, "auth_ref": [] }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNoncurrentLiabilitiesMember", "presentation": [ "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other long-term liabilities", "label": "Other Noncurrent Liabilities [Member]", "documentation": "Primary financial statement caption encompassing other noncurrent liabilities." } } }, "auth_ref": [] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r728" ] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityDomain", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Domain]", "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateDomain", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Domain]", "label": "Variable Rate [Domain]", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital, Common Stock", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r76" ] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r729" ] }, "us-gaap_RestrictedInvestmentsAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedInvestmentsAtFairValue", "crdr": "debit", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investments with restrictions", "label": "Restricted Investments, at Fair Value", "documentation": "The aggregate value of all restricted investments." } } }, "auth_ref": [ "r572", "r577", "r591", "r595", "r596" ] }, "vrtx_DebtandEquitySecuritiesFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.vrtx.com/20230930", "localname": "DebtandEquitySecuritiesFairValue", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails_1": { "parentTag": "vrtx_DebtandEquitySecuritiesCost", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value", "label": "Debt and Equity Securities, Fair Value", "documentation": "Debt and Equity Securities, Fair Value" } } }, "auth_ref": [] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeAxis", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input Type [Axis]", "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r412" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleTable", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-sale [Table]", "label": "Debt Securities, Available-for-Sale [Table]", "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r728" ] }, "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Legal Offset", "label": "Derivative Asset, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election", "documentation": "Fair value, after effects of master netting arrangements, deduction of assets not subject to a master netting arrangement and elected not to be offset, of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, offset against an obligation to return collateral." } } }, "auth_ref": [ "r18", "r20" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r45", "r47" ] }, "vrtx_CRISPRT1DMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vrtx.com/20230930", "localname": "CRISPRT1DMember", "presentation": [ "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "CRISPR T1D", "label": "CRISPR T1D [Member]", "documentation": "CRISPR T1D" } } }, "auth_ref": [] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r708" ] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r701" ] }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "crdr": "debit", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt securities fair value, unrealized loss position", "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss." } } }, "auth_ref": [ "r118", "r278", "r625" ] }, "vrtx_ORKAMBIMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vrtx.com/20230930", "localname": "ORKAMBIMember", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ORKAMBI", "label": "ORKAMBI [Member]", "documentation": "ORKAMBI [Member]" } } }, "auth_ref": [] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r710" ] }, "vrtx_CashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://www.vrtx.com/20230930", "localname": "CashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails": { "parentTag": "vrtx_CashEquivalentsAndDebtSecuritiesAvailableForSale", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value", "label": "Cash Equivalents And Debt Securities, Available for Sale, Fair Value Disclosure", "documentation": "Cash Equivalents And Debt Securities, Available for Sale, Fair Value Disclosure" } } }, "auth_ref": [] }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger", "crdr": "debit", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized loss position for greater than twelve months", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [ "r119", "r279", "r625" ] }, "us-gaap_OffsettingDerivativeLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OffsettingDerivativeLiabilitiesAbstract", "presentation": [ "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Offsetting Derivative Liabilities [Abstract]", "label": "Offsetting Derivative Liabilities [Abstract]" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r708" ] }, "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Legal Offset", "label": "Derivative Liability, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election", "documentation": "Fair value, after effects of master netting arrangements, deduction of liabilities not subject to a master netting arrangement and elected not to be offset, of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, offset against the right to receive collateral." } } }, "auth_ref": [ "r18", "r20" ] }, "vrtx_MarketableSecuritiesNoncurrentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vrtx.com/20230930", "localname": "MarketableSecuritiesNoncurrentMember", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term marketable securities", "label": "Marketable Securities, Noncurrent [Member]", "documentation": "Marketable Securities, Noncurrent" } } }, "auth_ref": [] }, "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpensesAndOtherCurrentAssetsMember", "presentation": [ "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expenses and Other Current Assets [Member]", "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets." } } }, "auth_ref": [] }, "vrtx_EMorrowMorreyAtkinsonIIIMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vrtx.com/20230930", "localname": "EMorrowMorreyAtkinsonIIIMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "E. Morrow \"Morrey\" Atkinson III [Member]", "documentation": "Morrey Atkinson [Member]" } } }, "auth_ref": [] }, "us-gaap_DerivativeAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeAssets", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails": { "parentTag": "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Gross Amounts Presented", "label": "Derivative Asset", "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r156", "r158", "r418", "r509", "r510", "r511", "r512", "r513", "r515", "r516", "r517", "r518", "r519", "r534", "r535", "r579", "r582", "r585", "r586", "r588", "r589", "r618", "r648", "r814" ] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Abstract]", "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "vrtx_ShareBasedCompensationAllocationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.vrtx.com/20230930", "localname": "ShareBasedCompensationAllocationAbstract", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation expense:", "label": "Share-based Compensation Allocation [Abstract]", "documentation": "-- None. No documentation exists for this element. --" } } }, "auth_ref": [] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r707" ] }, "vrtx_KalydecoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vrtx.com/20230930", "localname": "KalydecoMember", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "KALYDECO", "label": "KALYDECO [Member]", "documentation": "KALYDECO inventories, net" } } }, "auth_ref": [] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r728" ] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r701" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r8" ] }, "vrtx_DebtCovenantIncreaseInConsolidatedLeverageRatio": { "xbrltype": "pureItemType", "nsuri": "http://www.vrtx.com/20230930", "localname": "DebtCovenantIncreaseInConsolidatedLeverageRatio", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt covenant, increase in consolidated leverage ratio", "label": "Debt Covenant, Increase In Consolidated Leverage Ratio", "documentation": "Debt Covenant, Increase In Consolidated Leverage Ratio" } } }, "auth_ref": [] }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "presentation": [ "http://www.vrtx.com/role/HedgingTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Foreign Exchange Contracts, Condensed Consolidated Statements of Operations", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]", "documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss)." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails", "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361" ] }, "vrtx_CRSIPRJDCAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vrtx.com/20230930", "localname": "CRSIPRJDCAMember", "presentation": [ "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "CRISPR JDCA", "label": "CRSIPR JDCA [Member]", "documentation": "CRISPR Amended and restated the Original CTX001 JDCA" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r331", "r333", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationLiability", "crdr": "credit", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFairValueofContingentConsiderationLiabilitiesDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Business Combination, Contingent Consideration, Liability", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination." } } }, "auth_ref": [ "r1", "r51", "r389" ] }, "us-gaap_EquitySecuritiesFvNi": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesFvNi", "crdr": "debit", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value", "label": "Equity Securities, FV-NI, Current", "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current." } } }, "auth_ref": [ "r151", "r417", "r613" ] }, "currency_CAD": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2023", "localname": "CAD", "presentation": [ "http://www.vrtx.com/role/HedgingNotionalAmountDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Canadian dollar", "label": "Canada, Dollars" } } }, "auth_ref": [] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r701" ] }, "us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValueAbstract", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate equity securities", "label": "Equity Securities, FV-NI and without Readily Determinable Fair Value [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r331", "r333", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361" ] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "label": "Goodwill", "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r148", "r285", "r464", "r626", "r643", "r775", "r776" ] }, "currency_CHF": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2023", "localname": "CHF", "presentation": [ "http://www.vrtx.com/role/HedgingNotionalAmountDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Swiss Franc", "label": "Switzerland, Francs" } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of available-for-sale debt securities", "label": "Payments to Acquire Debt Securities, Available-for-Sale", "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r35", "r176", "r235" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r729" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity", "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "verboseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r13", "r31", "r143", "r170", "r171", "r172", "r187", "r188", "r189", "r191", "r197", "r199", "r215", "r269", "r270", "r307", "r368", "r369", "r370", "r382", "r383", "r399", "r400", "r401", "r402", "r403", "r404", "r406", "r421", "r422", "r423", "r424", "r425", "r426", "r431", "r496", "r497", "r498", "r506", "r567" ] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationAxis", "presentation": [ "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesatFairValueDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Axis]", "label": "Balance Sheet Location [Axis]", "documentation": "Information by location on balance sheet (statement of financial position)." } } }, "auth_ref": [] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r665", "r676", "r686", "r711" ] }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "crdr": "debit", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds received", "label": "Proceeds from Sale and Maturity of Marketable Securities", "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period." } } }, "auth_ref": [] }, "vrtx_CashEquivalentsAndDebtSecuritiesAvailableForSale": { "xbrltype": "monetaryItemType", "nsuri": "http://www.vrtx.com/20230930", "localname": "CashEquivalentsAndDebtSecuritiesAvailableForSale", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Amortized Cost", "label": "Cash Equivalents And Debt Securities, Available for Sale", "documentation": "Cash Equivalents And Debt Securities, Available for Sale" } } }, "auth_ref": [] }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchaseProgramAuthorizedAmount1", "crdr": "credit", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares authorized to be repurchased", "label": "Stock Repurchase Program, Authorized Amount", "documentation": "Amount of stock repurchase plan authorized." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Retained Earnings", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r143", "r187", "r188", "r189", "r191", "r197", "r199", "r269", "r270", "r368", "r369", "r370", "r382", "r383", "r399", "r401", "r402", "r404", "r406", "r496", "r498", "r506", "r815" ] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r702" ] }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "crdr": "credit", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock repurchase program, remaining amount", "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount", "documentation": "Amount remaining of a stock repurchase plan authorized." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r761" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r729" ] }, "vrtx_VerveMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vrtx.com/20230930", "localname": "VerveMember", "presentation": [ "http://www.vrtx.com/role/AcquiredInProcessResearchandDevelopmentandOtherArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Verve", "label": "Verve [Member]", "documentation": "Verve" } } }, "auth_ref": [] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r705" ] }, "vrtx_LineOfCreditFacilityAdditionalBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://www.vrtx.com/20230930", "localname": "LineOfCreditFacilityAdditionalBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of credit facility additional borrowing capacity", "label": "Line Of Credit Facility Additional Borrowing Capacity", "documentation": "Amount of increased borrowing capacity available in the future." } } }, "auth_ref": [] }, "us-gaap_DerivativeAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other assets, foreign currency forward contracts", "label": "Derivative Asset, Noncurrent", "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r156" ] }, "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "On Available-For-Sale Debt Securities", "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]", "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent." } } }, "auth_ref": [ "r159", "r160", "r161", "r164", "r171", "r172", "r750" ] }, "us-gaap_EquitySecuritiesFvNiCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesFvNiCost", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails": { "parentTag": "vrtx_DebtandEquitySecuritiesCost", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Original cost", "terseLabel": "Amortized Cost", "label": "Equity Securities, FV-NI, Cost", "documentation": "Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value." } } }, "auth_ref": [ "r472" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Disclosure [Abstract]", "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "vrtx_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.vrtx.com/20230930", "localname": "ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Cash, Cash Equivalents and Available-for-sale Securities [Table]", "label": "Schedule of Cash, Cash Equivalents and Available-for-sale Securities [Table]", "documentation": "Schedule of the cash and cash equivalents and available-for-sale investments held by the entity." } } }, "auth_ref": [] }, "vrtx_JeffreyMLeidenMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vrtx.com/20230930", "localname": "JeffreyMLeidenMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Jeffrey M. Leiden [Member]", "documentation": "Jeffrey M. Leiden [Member]" } } }, "auth_ref": [] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r729" ] }, "vrtx_DebtandEquitySecuritiesCost": { "xbrltype": "monetaryItemType", "nsuri": "http://www.vrtx.com/20230930", "localname": "DebtandEquitySecuritiesCost", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Amortized Cost", "label": "Debt and Equity Securities, Cost", "documentation": "Debt and Equity Securities, Cost" } } }, "auth_ref": [] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r706" ] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r702" ] }, "us-gaap_DerivativeLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails": { "parentTag": "us-gaap_FinancialLiabilitiesFairValueDisclosure", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other current liabilities, foreign currency forward contracts", "label": "Derivative Liability, Current", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r156" ] }, "us-gaap_HedgingDesignationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HedgingDesignationDomain", "presentation": [ "http://www.vrtx.com/role/HedgingAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation [Domain]", "label": "Hedging Designation [Domain]", "documentation": "Designation of purpose of derivative instrument." } } }, "auth_ref": [ "r14" ] }, "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesFvNiUnrealizedGainLoss", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Losses on equity securities", "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)", "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": [ "r487", "r773" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r729" ] }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedTranslationAdjustmentMember", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Currency Translation Adjustment", "verboseLabel": "Foreign Currency Forward Contract", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent." } } }, "auth_ref": [ "r5", "r12", "r33", "r171", "r172", "r422", "r423", "r424", "r425", "r426", "r750" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r710" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r703" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity", "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r13", "r143", "r170", "r171", "r172", "r187", "r188", "r189", "r191", "r197", "r199", "r215", "r269", "r270", "r307", "r368", "r369", "r370", "r382", "r383", "r399", "r400", "r401", "r402", "r403", "r404", "r406", "r421", "r422", "r423", "r424", "r425", "r426", "r431", "r496", "r497", "r498", "r506", "r567" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r702" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r704" ] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "presentation": [ "http://www.vrtx.com/role/Hedging" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts." } } }, "auth_ref": [ "r110", "r398", "r405" ] }, "currency_EUR": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2023", "localname": "EUR", "presentation": [ "http://www.vrtx.com/role/HedgingNotionalAmountDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Euro", "label": "Euro Member Countries, Euro" } } }, "auth_ref": [] }, "vrtx_ReshmaKewalramaniMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vrtx.com/20230930", "localname": "ReshmaKewalramaniMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Reshma Kewalramani [Member]", "documentation": "Reshma Kewalramani [Member]" } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r672", "r683", "r693", "r718" ] }, "us-gaap_EquitySecuritiesFvNiUnrealizedLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesFvNiUnrealizedLoss", "crdr": "debit", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Gross Unrealized Losses", "label": "Equity Securities, FV-NI, Unrealized Loss", "documentation": "Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": [ "r267" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss)", "verboseLabel": "Total", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r4", "r12", "r33", "r400", "r403", "r431", "r496", "r497", "r750", "r751", "r752", "r758", "r759", "r760" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r410", "r411", "r415" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosures [Abstract]", "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r730" ] }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Other financing activities", "label": "Proceeds from (Payments for) Other Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities classified as other." } } }, "auth_ref": [ "r736", "r753" ] }, "currency_GBP": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2023", "localname": "GBP", "presentation": [ "http://www.vrtx.com/role/HedgingNotionalAmountDetails" ], "lang": { "en-us": { "role": { "terseLabel": "British pound sterling", "label": "United Kingdom, Pounds" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Inventory Disclosure [Abstract]", "label": "Inventory Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockMember", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "verboseLabel": "Restricted stock units (including PSUs)", "label": "Restricted Stock [Member]", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": [ "r40" ] }, "vrtx_OtherNonU.S.Member": { "xbrltype": "domainItemType", "nsuri": "http://www.vrtx.com/20230930", "localname": "OtherNonU.S.Member", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other, Non U.S. [Member]", "documentation": "Other, Non U.S. [Member]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesFairValueDisclosureAbstract", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial instruments carried at fair value (liability positions):", "label": "Liabilities, Fair Value Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome", "http://www.vrtx.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Provision for income taxes", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r121", "r130", "r198", "r199", "r220", "r376", "r385", "r488" ] }, "us-gaap_EquitySecuritiesFvNiUnrealizedGain": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesFvNiUnrealizedGain", "crdr": "credit", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross Unrealized Gains", "label": "Equity Securities, FV-NI, Unrealized Gain", "documentation": "Amount of unrealized gain on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": [ "r267" ] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r709" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r730" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development expenses", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [ "r665", "r676", "r686", "r711" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r710" ] }, "vrtx_DebtCovenantConsolidatedLeverageRatio": { "xbrltype": "pureItemType", "nsuri": "http://www.vrtx.com/20230930", "localname": "DebtCovenantConsolidatedLeverageRatio", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt covenant, consolidated leverage ratio", "label": "Debt Covenant, Consolidated Leverage Ratio", "documentation": "Consolidated leverage ratio that must be maintained in order to be in compliance with debt covenants." } } }, "auth_ref": [] }, "vrtx_BastianoSannaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vrtx.com/20230930", "localname": "BastianoSannaMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Bastiano Sanna [Member]", "documentation": "Bastiano Sanna [Member]" } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r702" ] }, "vrtx_BusinessCombinationRemainingMilestonePayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.vrtx.com/20230930", "localname": "BusinessCombinationRemainingMilestonePayment", "crdr": "credit", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining milestone payment", "label": "Business Combination, Remaining Milestone Payment", "documentation": "Business Combination, Remaining Milestone Payment" } } }, "auth_ref": [] }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income", "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]", "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r172" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r667", "r678", "r688", "r713" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r702" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r730" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome", "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other (expense) income, net", "verboseLabel": "Other (expense) income, net", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r94" ] }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain", "presentation": [ "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]", "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]", "documentation": "Item reclassified out of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r172" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r710" ] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r666", "r677", "r687", "r712" ] }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis", "presentation": [ "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]", "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]", "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r172" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "b", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a),(b),(c)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481047/942-405-50-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "SubTopic": "20", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)(1)(i)", "SubTopic": "20", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "SubTopic": "20", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(c)(2)", "SubTopic": "20", "Topic": "860", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4D" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13", "SubTopic": "20", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-13" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "SubTopic": "20", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-8" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "320", "Publisher": "FASB", "URI": "https://asc.fasb.org//320/tableOfContent" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "((a)(1),(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-6" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a),(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-5" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-8" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "55", "Paragraph": "182", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480401/815-10-55-182" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "25", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480238/815-25-50-1" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-7" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//220/tableOfContent" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7(a),(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "250", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//250/tableOfContent" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//275/tableOfContent" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-12A" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "9", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//815/tableOfContent" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.10)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "b.", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481160/942-230-45-1" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-7" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "10", "Topic": "321", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479567/321-10-45-1" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "210", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-20" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)(1)(ii)", "SubTopic": "20", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//606/tableOfContent" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org//808/tableOfContent" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Footnote": "2", "Publisher": "SEC" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column B", "Publisher": "SEC" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column C", "Publisher": "SEC" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column D", "Publisher": "SEC" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column E", "Publisher": "SEC" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column F", "Publisher": "SEC" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column G", "Publisher": "SEC" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column H", "Publisher": "SEC" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column I", "Publisher": "SEC" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "29", "Footnote": "4", "Publisher": "SEC" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-4" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-10" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-12" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-11" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-19" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//260/tableOfContent" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-22" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-23" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-28A" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-4" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-5" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//330/tableOfContent" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480454/718-10-45-1" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-4" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4E" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-5C" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-1A" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3A" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3A" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(d)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-21" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-12" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5A", "Subparagraph": "(SX 210.12-13A(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 5)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-4" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480602/954-210-50-2" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r610": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r611": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-20" }, "r618": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r619": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15" }, "r620": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r622": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r623": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r624": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r625": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8" }, "r626": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24" }, "r627": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r628": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r629": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r630": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r631": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r632": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r633": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r634": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r635": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r636": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r637": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r640": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r641": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r642": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479908/805-50-55-1" }, "r643": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r644": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r645": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r646": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r647": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r648": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r649": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r650": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r651": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r652": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r653": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r654": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r655": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r656": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r657": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r658": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r659": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r660": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r661": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r662": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r663": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r664": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r665": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r666": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r667": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r668": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r669": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r670": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r671": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r672": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r673": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r674": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r675": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii", "Section": "6" }, "r676": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r677": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r678": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r679": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r680": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r681": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r682": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r683": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r684": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r685": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r686": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r687": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r688": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r689": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r690": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r691": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r692": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r693": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r694": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r695": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r696": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r697": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r698": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r699": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r700": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r701": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r702": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r703": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r704": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r705": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r706": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r707": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r708": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r709": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r710": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r711": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r712": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r713": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r714": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r715": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r716": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r717": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r718": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r719": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r720": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r721": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r722": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r723": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r724": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r725": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r726": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r727": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r728": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r729": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r730": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r731": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r732": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r733": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r734": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r735": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r736": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r737": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r738": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r739": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r740": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(1)", "Publisher": "SEC" }, "r741": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(2)", "Publisher": "SEC" }, "r742": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(3)", "Publisher": "SEC" }, "r743": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r744": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r745": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r746": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "04", "Paragraph": "(a)", "Publisher": "SEC" }, "r747": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r748": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r749": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r750": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r751": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r752": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r753": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r754": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r755": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r756": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r757": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r758": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r759": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r760": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r761": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r762": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18" }, "r763": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//320/tableOfContent" }, "r764": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1" }, "r765": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11" }, "r766": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r767": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r768": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r769": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r770": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r771": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r772": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r773": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-4" }, "r774": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r775": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r776": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r777": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r778": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r779": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r780": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r781": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r782": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r783": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r784": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r785": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r786": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r787": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r788": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480123/805-50-15-3" }, "r789": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480060/805-50-25-1" }, "r790": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-1" }, "r791": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-2" }, "r792": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r793": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B" }, "r794": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r795": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r796": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r797": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r798": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r799": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r800": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479424/830-30-S99-1" }, "r801": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r802": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r803": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r804": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r805": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r806": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r807": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r808": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r809": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r810": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2" }, "r811": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r812": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-1" }, "r813": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r814": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r815": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r816": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r817": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r818": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r819": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r820": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r821": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" } } } ZIP 79 0000875320-23-000031-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000875320-23-000031-xbrl.zip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Ʀ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end

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